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Zusammenfassung 
Pre-clinical investigation of carnosine’s anti-neoplastic effect on glioblastoma: uptake, 
signal transduction, gene expression and tumour cell metabolism 
Dr. rer. med. Dipl. Chem. Oppermann, Henry 
Universität Leipzig, Habilitation 
Das Glioblastom ist der häufigste maligne Tumor des zentralen Nervensystems. Trotz 
leitliniengerechter Therapie, bestehend aus mikrochirurgischer Resektion, Strahlentherapie 
und ergänzender Chemotherapie mit Temozolomid, beträgt die 2-Jahres-Überlebensrate nur 
ca. 17%. Daher sind dringend neue Therapieansätze erforderlich. Dem natürlich 
vorkommenden Dipeptid Carnosin, welches vor über 100 Jahren erstmals isoliert wurde, 
konnten viele physiologische Funktionen zugeschrieben werden. Zu Beginn unserer Arbeiten 
war bekannt, dass das Dipeptid das Wachstum von Krebszellen inhibiert, wobei die genauen 
Mechanismen der antineoplastischen Wirkungsweise weitgehend unbekannt waren. Die 
Untersuchungen im Rahmen der vorliegenden Habilitationsarbeit setzten sich mit möglichen 
Wirkmechanismen des Dipeptides auseinander, wobei ebenfalls Fragestellungen zur 
klinischen Anwendung von Carnosin bearbeitet wurden. Im ersten Abschnitt werden die 
Transportmechanismen von Carnosin in Glioblastom-Zellen beschrieben. Weiterhin wird die 
Frage beantwortet, ob das Dipeptid die biologisch aktive Verbindung ist oder ob L-Histidin 
von Carnosin abgespalten werden muss, um die antineoplastische Wirkung zu entfalten. Der 
zweite Abschnitt beschäftigt sich mit den Einflüssen von Carnosin auf die Signaltransduktion 
und Genexpression. Im dritten Abschnitt wird unter anderem mit einem Metabolomics-Ansatz 
der Stoffwechsel von Glioblastom-Zellen charakterisiert und der Einfluss von Carnosin auf 
diesen bestimmt. Im vierten Abschnitt wird ein neuartiges Ko-Kultur Modell zur Untersuchung 
von Carnosins Einfluss auf Glioblastom-Zell-Migration und Koloniebildung vorgestellt. 
Weiterhin untersuchten wir die möglichen Interaktionen des Dipeptides mit der 
Standardtherapie von Glioblastomen. 
Zusammenfassend zeigten wir, dass Carnosin durch drei verschiedene Transporter 
aufgenommen werden kann. Das Dipeptid hemmt sowohl Proliferation und Migration von 
Glioblastom-Zellen. Die Spaltung des Dipeptides ist für seine antineoplastische Wirkung 
nicht notwendig. In die Zelle aufgenommen, wirkt Carnosin inhibitorisch auf den 
Pentosephosphatweg. Eine mögliche Erklärung dafür lieferte die beobachte nicht-
enzymatische Reaktion von Glycerinaldehyd-3-phosphat mit dem Dipeptid. Weiterhin zeigten 
unsere Experimente zum ersten Mal eine Carnosin-bedingte Veränderung der 
Histonacetylierung und eine damit einhergehende Beeinflussung der Genexpression. Da das 
Dipeptid den Effekt der Radio-/Chemotherapie verstärkt, sollte die Wirkung von Carnosin in 
einer klinischen Studie an Glioblastom-Patienten untersucht werden. 
 
Abstract 
Pre-clinical investigation of carnosine’s anti-neoplastic effect on glioblastoma: uptake, 
signal transduction, gene expression and tumour cell metabolism 
Dr. rer. med. Dipl. Chem. Oppermann, Henry 
Universität Leipzig, Habilitation 
Glioblastoma is the most common malignant tumour of the central nervous system. Only 
~17% of patients undergoing standard therapy, including microsurgical resection, 
radiotherapy and adjuvant chemotherapy using temozolomide survive two years after 
diagnosis. Hence, new therapeutic approaches are urgently needed. The naturally occurring 
dipeptide carnosine was discovered more than 100 years ago. Since then, many 
physiological functions and beneficial effects have been ascribed to it. Previous studies 
demonstrated that carnosine inhibits growth of cancer cells. However, at the beginning of our 
investigations were the mechanisms behind carnosine’s anti-neoplastic effect mostly 
unknown. The present work addresses possible modes of action of carnosine and issues 
regarding the clinical application of the dipeptide. In the first paragraph we describe the 
transport mechanisms of carnosine in glioblastoma cells. Furthermore, we deal with the 
problem whether carnosine is the biological active compound or release of L-histidine from 
the dipeptide is required to deploy its anti-neoplastic effect. The second paragraph 
addresses the influence of carnosine on glioblastoma cell signal transduction and gene 
expression. In the third paragraph we characterise the metabolism of glioblastoma cells and 
how it is influenced by carnosine by using a metabolomics approach. The fourth paragraph 
introduces a novel co-culture model which allows the analysis of carnosine’s impact on 
glioblastoma cell migration and colony formation. Furthermore, the possible interaction of the 
dipeptide with the glioblastoma standard therapy is investigated. 
In conclusion, we demonstrated that three different transporters are capable for the uptake of 
carnosine in glioblastoma cells. The dipeptide inhibited in addition to proliferation also 
migration of glioblastoma cells. Moreover, cleavage of carnosine was not required for its anti-
neoplastic effect. After taken up by the cell, carnosine inhibits the pentose phosphate 
pathway. The observed non-enzymatic reaction of glyceraldehyde-3-phosphate with the 
dipeptide could possibly explain this effect. Furthermore, our experiments showed for the first 
time that carnosine influences gene expression by an effect on histone acetylation. As the 
administration of carnosine arguments the effects of radio-/chemotherapy, we encourage the 
clinical evaluation of the dipeptide for glioblastoma patients. 
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1 Introduction 
 
1.1 Glioblastoma 
 
Tumours of the central nervous system (CNS) are categorized by the World Health 
Organisation (WHO) into four grades. The grades are based on histological and molecular 
properties of the tumours, on prognosis and on the response to therapy. In general, WHO 
grade I tumours are benign and patients have a good prospect of cure. WHO grade II to IV 
are malignant tumours. The median overall survival of patients suffering from these tumours 
is more than five years (Grade II), between two and three years (Grade III) and less than one 
year (Grade IV) (Louis et al. 2007). The most common malignant brain tumour of the CNS is 
glioblastoma with an incident of 3.21 new cases per inhabitants in the United States (Ostrom 
et al. 2018) and 3.91 new cases per inhabitants in Europe (Sant et al. 2012). Glioblastoma 
belongs to the astrocytic tumours and is categorised together with oligodendrogliomas and 
astrocytomas as glioma. Although it can manifest in patients of any age, persons with a 
median age at diagnosis of 62 years are more often diagnosed with glioblastoma. 
Furthermore, males are more frequently affected than females (male/female ratio: 1.26). 
Several risk factors for glioblastoma have been suggested, such as viral infections and 
environmental carcinogens (e.g. formaldehyde) but due to inconclusive and contradictory 
results these factors could not be validated (Ohgaki and Kleihues 2005). Deeply discussed is 
a possible influence of non-ionizing radiation (e.g. from cell phones) (Morgan 2015; Ostrom 
et al. 2014). At least, it is confirmed that ionizing radiation (IR) of head and neck increases 
the risk and that individuals who exhibit allergies or atopic diseases in the past have a 
reduced risk (Ohgaki and Kleihues 2005). Furthermore, single nucleotide polymorphisms of 
alleles of the genes telomerase reverse transcriptase (TERT), regulator of telomere 
elongation helicase 1 (RTEL1), epidermal growth factor receptor (EGFR) and tumour 
suppressor protein 53 (p53) have been associated with an increased risk (Ostrom et al. 
2014). Approximately 5% of patients suffering from malignant glioma have a family history of 
gliomas. Among this family cases some rare genetic syndromes were reported, including 
neurofibromatosis type 1 (loss-of-function mutations of the NF1 gene which is a suppressor 
of Ras) and type 2, the Li−Fraumeni syndrome (germline mutations in the p53 and/or CHEK2 
gene) and Turcot’s syndrome (mutations in the APC gene which leads to aberrant Wnt 
signalling activity) (Farrell and Plotkin 2007). Glioblastomas emerging de novo exhibit 
different localisations. The incidence in the temporal lobe is 31%, 24% in the parietal lobe, 
23% in the frontal lobe and 16% in the occipital lobe (Louis et al. 2016). Typical symptoms of 
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patients suffering from glioblastoma are caused by increased intracranial pressure resulting 
in nausea, vomiting, seizure and occasionally severe pulsing headache. Based on tumour 
localisation, further symptoms can occur, such as focal neurologic deficits, confusion, 
memory loss, and personality changes (Wen and Kesari 2008). Glioblastomas exhibit a 
comparable large size when first symptoms occur. In rare cases a small tumour can increase 
its size by several fold after two months (Ohgaki et al. 2014). Due to its rapid and infiltrative 
growth, supply of nutrients and oxygen of the central tumour mass is reduced, resulting in 
typical necrotic areas which may comprise more than 80% of the tumour. Histopathologically, 
glioblastomas exhibit a high cellular density, consist of poorly differentiated, pleomorphic 
cells, exhibit a high mitotic activity, vascular endothelial proliferation and necrosis (Kleihues 
et al. 1995). Furthermore, glioblastomas are composed of different cell types, including cells 
resembling diffuse astrocytoma, oligodendroglioma and granular components and also of 
small, giant and lipidized cells (Louis et al. 2016). Accompanying the histopathological 
heterogeneity, glioblastomas contain multiple genetic changes. Among the most important 
alterations are mutations of the isocitrate-dehydrogenase (IDH) 1/2 genes. With 89.3% the 
most common of them is the gain of function variant IDH1R132H (Reitman and Yan 2010). 
IDH1/2 mutations are exclusively found in secondary glioblastomas and are almost (~5%) 
absent in de novo formed primary glioblastomas. Therefore, glioblastomas are now also 
classified according to their IDH1/2 mutation status (Louis et al. 2016). IDH-mutant 
glioblastomas account for ~10% of all glioblastomas, generally develop from diffuse (WHO 
grade II) or anaplastic (WHO grade III) astrocytoma and manifest in younger patients (mean 
age at diagnosis: 45 years) (Ohgaki et al. 2016). IDH-wild type and -mutant glioblastoma can 
both exhibit mutations in the TERT (frequency: 70% and 30%, respectively) and the p53 
(frequency: 30% and 80%, respectively) gene (TP53) and loss of heterozygosity (LOH) on 
chromosome 10q (frequency: 70% and 60%, respectively). EGFR amplification (frequency: 
35%) and mutations in the PTEN gene (frequency: 25%) only occur in IDH-wild type 
glioblastoma, whereas mutations in the ATRX Chromatin Remodeler gene (frequency: 65%) 
appear only in IDH-mutant glioblastoma (Ohgaki and Kleihues 2013).  
The prognosis of patients diagnosed with glioblastoma is devastating. Without therapy the 
median overall survival of patients with IDH-wild type glioblastoma is 4.7 months and that of 
patients with IDH-mutant glioblastoma 7.8 months (Ohgaki et al. 2004). Surgical removal of 
the tumour and subsequent radiotherapy increases median overall survival to 11.3 (IDH-wild 
type) and 27.1 (IDH-mutant) months (Nobusawa et al. 2009). Current standard therapy of 
newly diagnosed IDH-mutant and IDH-wild type glioblastoma patients consists of 5-
aminolevulinic acid supported microsurgical total gross resection (Stummer et al. 2006), 
followed by radiotherapy with up to 60 Gy and adjuvant chemotherapy with temozolomide 
(TMZ). This treatment increases the median overall survival of glioblastoma patients 
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(including both IDH-wild type and IDH-mutant) to 16 months (Stupp et al. 2017). An important 
prognostic marker, especially for the treatment with TMZ, is the methylation status of the O-
6-Methylguanine-DNA methyltransferase (MGMT) promoter. Patients with tumours carrying a 
methylated MGMT promoter have a better prognosis compared to patients with an 
unmethylated MGMT promoter (median overall survival: 15.3 and 11.8 months, respectively) 
after resection of the tumour and radiotherapy (Hegi et al. 2005). In the same study, patients 
with MGMT promoter methylation have an even better prognosis when treated with TMZ 
(21.7 months median overall survival) compared to patient with the unmethylated promoter 
(12.7 months) (Hegi et al. 2005). Among the currently tested novel therapeutic approaches 
only treatment with alternating electric fields (tumour-treating fields) which interfere with the 
spindle apparatus during mitosis, appear to slightly improve median overall survival from 16 
to 20.9 months (Stupp et al. 2017). In addition, new molecular and cell-therapeutic 
approaches have been investigated or are under investigation. 
As enhanced angiogenesis is a prominent feature of glioblastoma, inhibition of the vascular 
endothelial growth factor receptor (VEGF) seemed to be a rational approach. Unfortunately, 
bevacizumab, a VEGF inhibitory antibody, only increased progression free survival and not 
overall survival of glioblastoma patients (Gilbert et al. 2014). Due to amplification of the 
epidermal growth factor receptor (EGFR) in some glioblastomas, nimotuzumab, an EGFR 
inhibiting antibody, was investigated in a clinical trial. Again and unfortunately, this antibody 
also revealed no benefit for glioblastoma patients (Westphal et al. 2015). 
Recently, exploiting the human immune system became a promising approach in treating 
various types of cancer. Noteworthy, the discovery of checkpoint inhibitors for cancer therapy 
was 2018 awarded with the Nobel Prize. For example, nivolumab, a programmed death-1 
inhibitor (affects T-lymphocyte activity against target cell), received marketing authorization in 
the United States and Europe for treatment of metastatic renal cell cancer (Ross and Jones 
2017). Unfortunately, the interim analysis of a phase 3 clinical trial investigating nivolumab 
for treatment of recurrent glioblastoma revealed no benefits on median overall survival over 
bevacizumab. Nevertheless, some promising effects for long time survivors were reported 
(Reardon et al. 2017). 
Cancer vaccine therapy, either using patient derived tumour lysates or conjugated peptides, 
have also been clinically evaluated for glioblastoma patients. In the DC-Vax-L clinical trial, 
whole tumour lysates were used to pulse dendritic cells. After surgery and radiotherapy, 
patients with newly diagnosed glioblastoma received TMZ and the vaccine or TMZ and 
placebo. Albeit the data of this study is still blinded, the median overall survival of all patients 
was reported to be 23.1 months (Liau et al. 2018). The adoptive cellular immunotherapy with 
chimeric antigen receptor (CAR) T-cells has revolutionised the treatment options for patients 
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suffering from B-cell non-Hodgkin’s lymphoma and leukaemia (Chavez et al. 2019). In brief, 
this strategy utilizes genetically modified T-cells which recognize a unique extracellular 
tumour associated antigen which results in specific cancer cell lysis. For glioblastoma 
treatment interleukin-13 receptor alpha 2 (IL-13Ra2), EGFR mutation variant III (EGFRvIII) 
and human epidermal growth factor receptor 2 are investigated in several ongoing clinical 
trials as possible antigens for CAR T-cells (for a review see (Bagley et al. 2018)). In a case 
report of a patient with recurrent multifocal glioblastoma, injection of CAR T-cells targeting IL-
13Ra2 resulted in a dramatic response, completely eliminating initial intracranial and spinal 
tumours. However, the disease of the patient recurred 228 days after the start of the therapy 
(Brown et al. 2016). 
Rapid growth is a main feature of glioblastoma; requiring specific metabolic pathways which 
are less active in non-proliferating cells in order to build up biomass (see 1.4 Cancer 
metabolism). As cancer cells intensively metabolise glucose and as the enzyme expression 
profile of malignant gliomas does not favour growth depended on ketone bodies (Chang et 
al. 2013), a ketogenic diet (diet with a ratio of fat to carbohydrate and protein of 4:1) was 
suggested to be beneficial for glioblastoma patients. Although, the ketogenic diet can be 
safely applied to glioblastoma patients, no benefits in the progression free survival were 
observed in a pilot study (Rieger et al. 2014). However, in one case report a ketogenic diet 
combined with calorie restriction demonstrated the absence of recurrence after standard 
therapy of a glioblastoma patient until strict diet was quitted (recurrence after ten weeks). 
Noteworthy, due to the nutritional protocol, therapy was tolerated without using steroids 
(suppression of oedema resulting from radiation and chemotherapy) (Zuccoli et al. 2010). 
Hence, dietary treatment for glioblastoma is under further investigation with promising results 
after a 24-month follow-up of one patient (Elsakka et al. 2018). 
Although promising approaches are under investigation to improve the outcome of 
glioblastoma patients, standard therapy is still restricted to neurosurgery and radio-
/chemotherapy. Therefore, new therapeutic options are urgently needed to treat malignant 
gliomas. A potential approach to treat glioblastoma may be provided by the natural occurring 
dipeptide carnosine, as it was shown to inhibit aggressive tumour growth (see 1.3.2 
Carnosine and cancer). 
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1.2 Distribution and physiology of carnosine 
 
In 1843 the chemist Justus Liebig started to analyse the composition of meat from different 
animals. Over the course of his investigations he developed an extract which Liebig believed 
could be used as meat substitute. One decade later Liebig administered his extract to the 
daughter of his friend, suffering from typhus getting progressively weaker, as she couldn’t 
take up food. Due to Liebig’s meat extract the daughter of his friend was able to recover. In 
1861 Georg Gilbert gained interest in Liebig’s meat extract as he was looking for a use for 
the meat of livestock which were raised in Uruguay only for the production of pelt, animal fat, 
bones and horn. In cooperation with Justus Liebig, Gilbert started 1863 to sell his produced 
meat extract under the name: “Extractum Carnis Liebig” (Judel 2003). 
In 1900 Gulewitsch and Amiradžibi analysed the composition of Liebig’s meat extract and 
identified an organic base with the chemical formula C9H14N4O3 which they named carnosine 
(Gulewitsch and Amiradžibi 1900). Carnosine revealed to be a dipeptide which consists of 
the amino acids β-alanine and L-histidine (Gulewitsch 1911). 
 
1.2.1 Distribution of histidine containing dipeptides in mammals 
 
After the discovery of the dipeptide several other animal tissues were analysed for their 
carnosine levels. It turned out that bird muscle tissue contains mostly a methylated derivate 
of carnosine, anserine (β-alanyl-N3-methyl-histidine) which was named after goose (Latin: 
anser) wherein it was first discovered (Ackermann et al. 1929). In snake and whale muscle 
tissue β-alanyl-N1-methyl-histidine was abundantly found which is also known as ophidine 
and balenine, respectively (Suyama and Maruyama 1969). In general, skeletal muscle tissue 
contains an abundant amount of carnosine, anserine and/or ophidine (preference name). 
Therefore, carnosine, anserine and ophidine are often collectively called imidazole or 
histidine containing dipeptides, whereby the ratio of each dipeptide strongly varies across 
different species (for a comprehensive review covering the distribution, physiology and 
pathophysiology of carnosine see (Boldyrev et al. 2013)). 
Histidine containing dipeptides are not exclusively present in skeletal muscle. In mice, 
carnosine reaches a concentration of ~1.8 mmol/kg tissue in the olfactory bulb which is 
comparable to mouse skeletal muscle (~1.15 mmol/kg tissue). Significantly lower amounts of 
carnosine were determined in the choroid plexus (~0.2 mmol/kg tissue), the cerebral cortex 
(~0.075 mmol/kg tissue), the kidney (~0.05 mmol/kg tissue) and the spleen (~0.03 mmol/kg 
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tissue). Blood plasma and cerebrospinal fluid exhibit with ~2.5 µM and ~8.6 µM the lowest 
carnosine concentrations (Kamal et al. 2009). Cardiac muscle of mammalians exhibits similar 
to skeletal muscle imidazole containing compounds in the millimolar range. In the case of 
guinea pigs, cardiac muscle contains 0.14±0.04 mmol carnosine per kg wet weight, 
1.21±0.05 mmol N-acetylcarnosine and 2.31±0.01 mmol N-acetylanserine (O'Dowd et al. 
1988). Unfortunately, a comprehensive profiling of the concentrations of histidine containing 
dipeptides in human tissue has not been performed, yet. However, multiple studies report 
concentrations of carnosine and its derivatives in different human tissues and body fluids. 
High carnosine concentrations were determined in skeletal muscle and olfactory bulb with 
20.0±4.7 mmol per kg dry weight (Mannion et al. 1992) and 2.2 mmol per kg dry weight 
(Margolis 1974), respectively. In contrast to mice, carnosine (1.8±0.9 mmol per kg tissue) 
and anserine (4±2.7 mmol per kg tissue) reach concentrations in the millimolar range in 
human kidney tissue (Peters et al. 2015). In human brain tissue ~0.03 mmol carnosine per kg 
dry weigh were detected, whereas it’s isomer homocarnosine (γ-aminobutyryl-L-histidine) is 
present at a much higher concentration with ~0.16 mmol per kg dry weight (Abraham et al. 
1962). Accordingly, homocarnosine and not carnosine was detected in the human 
cerebrospinal fluid. Interestingly, children exhibited a higher concentration (7.9±2.6 µM) than 
adults (0.1±0.4 µM) (Perry et al. 1968). Regarding human blood plasma, carnosine and 
anserine were detected with a concentration of ~6.5 µM and ~0.27 µM, respectively (Fonteh 
et al. 2007). Albeit anserine is ~25-fold lower concentrated in blood plasma, carnosine and 
anserine are in comparable amounts present in the urine (5.5 µmol/ per mmol creatinine and 
7.0 µmol/ per mmol creatinine, respectively) (Bouatra et al. 2013). 
 
1.2.2 Transport and metabolism of histidine containing dipeptides 
 
Tissue and plasma concentrations of carnosine are controlled by different enzymes. The 
central metabolism is summarized in Figure 1. The synthesis of carnosine from β-alanine and 
L-histidine is carried out by an ATP-consuming enzyme called carnosine synthase (CS) 
which is encoded by the ATPGD1 gene (ATP-Grasp domain containing protein 1). CS (EC 
6.3.2.11) features a broad substrate specificity which allows among others the synthesis of 
homocarnosine, anserine and ophidine (Kalyankar and Meister 1959). The synthesis of 
histidine containing dipeptides occurs mainly in brain, skeletal and cardiac muscle (Drozak et 
al. 2010). Furthermore, only specific cell types of the corresponding tissue, such as 
oligodendrocytes in brain (Hoffmann et al. 1996) or podocytes in kidney (Peters et al. 2015), 
express CS. Alongside with the cellular expression of CS, substrate availability is the rate-
limiting factor for histidine containing dipeptide synthesis. It turned out that the supply of the 
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non-proteinogenic amino acid β-alanine and not the supply of L-histidine is curial for 
carnosine-synthesis (Dunnett and Harris 1999).  
 
Figure 1 Metabolism of carnosine. Synthesis of carnosine, homocarnosine and anserine is catalysed by 
carnosine synthase (CS), whereas cleavage is carried out by carnosinase (CN). β-Alanine (substrate for 
carnosine and anserine synthesis) can be formed by decarboxylation of aspartate via glutamate decarboxylase 
like 1 (GADL1) or by the degradation of uracil via dihydropyrimidine dehydrogenase (DPYD), dihydropyrimidinase 
(DPYS) and beta-ureidopropionase 1 (UPB1). 4-Aminobutyrate aminotransferase (ABAT) converts β-alanine to 3-
oxopropanoate which is further processed via the propanoate metabolism pathway. For homocarnosine 
synthesis, γ-aminobutyrate is required which is formed by decarboxylation of glutamate via glutamate 
decarboxylase 1 (GAD1). Histidine is decarboxylated by histidine decarboxylase (HDC) forming histamine. 
Anserine can either be formed from 3-methylhistidine which is produced by protein arginine methyltransferase 3 
(PRMT3) via methylation of histidine or by direct methylation of carnosine via carnosine N-methyltransferase 1 
(CARNMT1). ?: It is currently unknown whether acetylcarnosine and acetylanserine are formed by a specific 
enzyme or non-enzymatically. The formation of ophidine has not been detected in humans (dashed line). 
Furthermore, it is unknown whether ophidine is formed by a specific methyltransferase. 
β-Alanine is an intermediate of the pyrimidine degradation pathway which occurs manly in 
liver (Wasternack 1978). In this pathway uracil is converted by dihydropyrimidine 
dehydrogenase (DPYD), dihydropyrimidinase (DPYS) and beta-ureidopropionase 1 (UPB1) 
to β-alanine which is further degraded in the propanoate pathway yielding acetyl-CoA. As β-
alanine production by liver is comparable low, carnosine biosynthesis depends primarily on 
nutritional uptake of β-alanine (Artioli et al. 2010). The transport of the amino acid though cell 
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membranes is performed by the taurine transporter (Artioli et al. 2010). Noteworthy, β-
alanine can also be generated by decarboxylation of aspartate via glutamate decarboxylase 
like 1 (Liu et al. 2012). In order to synthesise homocarnosine, γ-aminobutyrate is required 
which can be formed from glutamate by the enzyme glutamate decarboxylase 1. Due to the 
abundant availability of the neurotransmitter γ-aminobutyrate (GABA) in nervous tissue, 
homocarnosine is presumably exclusively present in the brain (Bauer 2005). The formation of 
anserine in the human body was unclear for a long time. Albeit its precursor 3-methylhistidine 
can be synthesised by protein arginine methyltransferase 3, the direct methylation of 
carnosine by the recently discovered human carnosine N-methyltransferase 1 which is 
restricted to kidney, seems to be its primary source (Drozak et al. 2015). In contrast, a 
specific methyltransferase which is required to produce ophidine has not been identified in 
humans, yet. Furthermore, the formation of ophidine in humans is unlikely, as ophidine has 
not been detected in human tissues and/or body fluids. 
Carnosine and its related compounds contain non-proteinogenic amino acids which prevent 
these dipeptides from degradation by regular aminopeptidases (aminopeptidases have in 
general a broad substrate specificity, as these enzymes are involved in the degradation of 
proteins and peptide hormones – for a review see (Sanderink et al. 1988)). Nevertheless, two 
enzymes which belong to the M20 metalloprotease family are known to degrade carnosine in 
humans (for a review see (Bellia et al. 2014)). The first enzyme (EC 3.4.13.20), a 
homodimeric dipeptidase, is encoded by the carnosine dipeptidase 1 (CNDP1) gene and is 
exclusively present in serum of primates and the syrian golden hamster and hence, named 
serum carnosinase (CN1) (Jackson et al. 1991). CN1 is mainly produced in brain and liver. 
Noteworthy, patients suffering from liver cirrhosis (Peters et al. 2011) or glioblastoma 
(Gautam et al. 2012) exhibit reduced amounts of CN1 in plasma. The second enzyme (EC 
3.4.13.18.) is encoded by the by the carnosine dipeptidase 2 (CNDP2) gene and has 
formerly been designated tissue carnosinase, as it is ubiquitously expressed in human 
tissue. Due to its broad specificity towards many dipeptides it is now named cytosolic 
nonspecific dipeptidase (CN2) (Teufel et al. 2003). Both dipeptidases are capable to cleave 
various different histidine containing dipeptides but differ with regard to specificity and 
activity. CN1 is able to degrade carnosine, anserine, homocarnosine and other β-alanine 
containing dipeptides (Jackson et al. 1991). In contrast, CN2 is not able to cleave 
homocarnosine. Additionally, CN2 cleaves carnosine only with low activity compared to other 
histidine containing dipeptides such as Met-His, Leu-His or Ala-His (Okumura and Takao 
2017). Noteworthy, albeit not expressed in humans, a third dipeptidase named anserinase 
(EC 3.4.13.5) is known to be capable to hydrolyse carnosine, anserine and homocarnosine 
(Oku et al. 2012).  
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In order to be taken up by the cell, carnosine needs to be actively transported through 
biological membranes. This can be performed by membrane proteins of the proton-coupled 
oligopeptide transporters (POT) family. In mammals, four members of the POT family namely 
peptide transporter 1 (PEPT1, encoded by the SLC15A1 gene), peptide transporter 2 
(PEPT2, encoded by the SLC15A2 gene), peptide/histidine transporter 1 (PHT1, encoded by 
the SLC15A4 gene) and peptide/histidine transporter 2 (PHT2, encoded by the SLC15A3 
gene) have been identified (for a review see (Smith et al. 2013)). In general, POTs use an 
inwardly-directed proton gradient to transport a wide range of di- and tripeptides, which are 
especially formed upon protein breakdown and peptide-like drugs. While PEPT1 and PEPT2 
are able to transport 400 different dipeptides and 8000 different tripeptides, it is only 
assumed but not confirmed that PHT1 and PHT2 are capable to transport the same range of 
di- and tripeptides. Nevertheless, PHT’s also transport free histidine, whereas PEPT’s are 
not able to transport amino acids (for a review see (Daniel and Kottra 2004)). PEPT1 is 
abundantly expressed in the small intestine, but also detected in kidney, liver, pancreas and 
prostate tissue (Herrera-Ruiz et al. 2001; Ogihara et al. 1996). In brain, PEPT2 is responsible 
for peptide uptake from of the cerebrospinal fluid (Ocheltree et al. 2004) which is of 
importance for fluorescence-guided neuro surgery of brain tumours (Hou et al. 2019). In 
contrast to PEPT’s, PHT’s are ubiquitously expressed across different tissues (Fagerberg et 
al. 2014). PHT’s are supposed to perform the transport of histidine and peptides from the 
lysosome to the cytoplasm (Sasawatari et al. 2011) and in brain the contribution of PHT1 on 
cellular uptake has been demonstrated (Hu et al. 2014). 
 
1.2.3 Molecular properties of carnosine 
 
Since its discovery in 1900, several physiological properties of carnosine have been 
described. Nevertheless, the biological role of carnosine is still not completely understood. 
Due to the multiple functions observed, carnosine is still an enigmatic compound (Bauer 
2005). The first biochemical property was discovered in 1938 by Smith (Smith 1938) 
observing that carnosine and anserine account for a substantial amount of the buffering 
capacity in muscle. This effect is due to the pKa (6.72) of the imidazole ring. As this pKa is 
close to a pH of 7 it offers a high proton sequestering capacity under physiological conditions 
(Sale et al. 2010). Later, it was reported that carnosine acts as a metal ion chelator as it 
forms complexes in the presence of Cu2+ (Dobbie and Kermack 1955). Subsequently, 
several other stable complexes consisting of carnosine and Ni2+, Zn2+, Co2+, Ca2+ and Cd2+ 
were reported (Baran 2000). The metal ion chelating effect of carnosine is based on its 
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imidazole moiety and most complexes are present in its N1-H tautomeric form (Gaggelli and 
Valensin 1990). It has been demonstrated that the complexes containing Ni2+ (Ueda et al. 
1993), Zn2+ (Yoshikawa et al. 1991) or Cu2+ (Baran et al. 1995) exhibit antioxidant properties. 
More importantly, histidine containing dipeptides alone possess an antioxidant activity by 
metal ion chelation and scavenging of reactive oxygen species (Pavlov et al. 1993) and 
peroxyl radicals (Kohen et al. 1988) at physiological concentrations. Furthermore, carnosine 
is also a protective agent against hypochlorite and reactive nitrogen species (Hipkiss 1998a). 
In detail, the imidazole moiety of carnosine interacts witch reactive oxygen species such as 
hydroxyl radicals, forming resonance-stabilized radicals (Tamba and Torreggiani 1998). 
These products exhibit a lower toxicity, as resonance-stabilized radicals are less reactive 
compared to hydroxyl radicals. Additionally, it has been reported that histidine containing 
dipeptides inhibit the formation of advanced glycation end-products (AGEs) and advanced 
lipoxidation end-products (ALEs) by scavenging their precursors such as reducing sugars 
and reactive carbonyls (Hipkiss 2010). For these effects both moieties of carnosine (β-
alanine and L-histidine) are required. As demonstrated for the toxic aldehyde trans-2,3-
nonenal the first reaction step is the formation of an α,β-unsaturated imine via the primary 
amine of the β-alanyl moiety followed by ring closure through an intra-molecular Michael 
addition proceeding from the N3-H of the imidazole ring. Therefore, carnosine and anserine 
exhibit a better aldehyde quenching effectivity compared to L-histidine alone (~30% of 
carnosine’s effect). Blocking the primary amine inhibits the scavenging effect 
(acetylcarnosine exhibits ~20% of carnosine’s effect) which emphasizes the importance of 
the β-alanyl moiety for reactive aldehyde quenching (Aldini et al. 2002). Moreover, in addition 
to serve as sacrificial molecule to prevent glycation, carnosine and anserine can also reverse 
glycation of proteins. This mechanism is supposed to be similar to that reported for reactive 
aldehydes (Szwergold 2005). Carnosine was also reported to interact with nitric oxide. 
Interestingly, the dipeptide can both stimulate nitric oxide production (Takahashi et al. 2009) 
and scavenge free nitric oxide. L-histidine alone is also capable to scavenge nitric oxide, but 
the addition of the β-alanyl moiety (carnosine) strongly increases nitric oxide adduct 
formation (Nicoletti et al. 2007). 
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1.3 Carnosine in health and disease 
 
As carnosine was initially discovered and is highly abundant in muscle tissue, its 
physiological role in skeletal muscle has thoroughly been investigated. High intensity muscle 
contractions are accompanied with anaerobic glycolysis which leads to the production of L-
lactate, drop of pH values and ultimately acidosis which decreases the ability of the muscle 
to generate force. Carnosine’s role as physiological pH-buffer was confirmed by increasing 
its muscular concentration via β-alanine supplementation which reduced acidosis during high 
intensity training (Baguet et al. 2010). Nevertheless, the average contribution of carnosine to 
total human muscle pH buffering amounts to only 7% (Mannion et al. 1992). Hence, it is 
supposed that carnosine may have additional functions in muscle. The dipeptide reduces the 
formation of ALEs which can be formed during exercise (Dawson et al. 2002). Furthermore, 
carnosine stimulates Ca2+ release from the sarcoplasmic reticulum and increases Ca2+ 
sensitivity for muscle contraction (Dutka et al. 2012). 
In the mammalian brain, homocarnosine is the predominant histidine containing dipeptide. 
This is possibly due to the fact that the concentrations of γ-aminobutyrate are ~20-fold higher 
as those of β-alanine in different brain structures (del Rio et al. 1977). As γ-aminobutyrate is 
the most important inhibitory neurotransmitter in mammalian brain, β-alanine and also 
carnosine have been proposed to exhibit similar properties (Tiedje et al. 2010). It is assumed 
that carnosine interacts with glutamatergic neurotransmission as both compounds are co-
localised in synaptic terminals of olfactory neurons (Sassoè-Pognetto et al. 1993). 
Furthermore, carnosine can stimulate glia cells to secrete neurotrophins which promotes 
neurite outgrowth of neurons activating cognitive function (Yamashita et al. 2018). 
Nevertheless, definitive evidence for carnosine’s role as a neuromodulator is lacking 
(Marchis et al. 2000). However, unquestioned is the homoeostatic role of histidine containing 
dipeptides in brain due to their antioxidant properties (Bonfanti et al. 1999). Consequently, it 
was investigated whether treatment with carnosine could mitigate ischaemic brain damage, 
as oxidative stress is known to be involved in cell damage during ischaemia. In a mouse 
model of permanent focal cerebral ischemia, pre- or post-treatment with carnosine reduced 
infarct size which was also accompanied with the reduction of reactive oxygen species in 
ischaemic brain areas (Rajanikant et al. 2007). 
Accumulation of amyloid-β is one hallmark of Alzheimer’s disease. Supplementation of 
carnosine reduced amyloid-β induced cell toxicity in a transgenic mouse model which 
emphasises the neuroprotective role of the dipeptide (Corona et al. 2011). Furthermore, 
carnosine also inhibits the oligomerisation of α-synuclein which is known to be involved in 
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Parkinson’s disease (Kang and Kim 2003). Using a senescence accelerated mouse model 
Boldyrev and co-workers impressively demonstrated the anti-ageing effect of carnosine, 
wherein the dipeptide increases average life span and decreased properties of the senescent 
phenotype such as skin ulcers and lowered reactivity (Boldyrev et al. 1999). This effect was 
associated with its antioxidant property, inhibited formation of AGEs and ALEs and extension 
of the cell division capacity (Hayflick limit) possibly by increasing telomerase activity (Ait-
Ghezala et al. 2016; Hipkiss 1998b). Nevertheless, the underlying mechanism of the anti-
ageing effect of carnosine are still not understood (Hipkiss 2009). 
There is also a growing body of evidence that carnosine is involved in the prevention of 
diabetes. Due to the dipeptide’s ability to scavenge reactive carbonyls, to protect from protein 
glycation and to chelate metal ions, it could mitigate the secondary complications of diabetes 
such as nephropathy and ocular damage (Hipkiss 2005). Additionally, it was demonstrated 
that carnosine can control blood glucose levels (Nagai et al. 2012) and insulin response 
(Forsberg et al. 2015). Moreover, patients suffering from diabetes mellitus type I exhibit 
reduced carnosine levels in erythrocytes and urine (Gayova et al. 1999). In this context, 
carnosine also improved wound healing in a type 2 diabetes mouse model (Ansurudeen et 
al. 2012). It is supposed that the activation of fibroblast proliferation is involved in its positive 
effect on wound healing (Perel'man et al. 1989). Histamine is known to accelerate wound 
healing by increasing expression of fibroblast growth factor (Numata et al. 2006). As 
carnosine can serve as a histamine precursor and as it is known to bind to the histamine H1-
receptor, though with low affinity (O'Dowd and Miller 1998), a histamine related mechanism 
of carnosine on wound healing has been proposed (Nagai et al. 1986). With regard to 
treatment of gastric ulcer it has been demonstrated that the Zn2+ complex of carnosine 
(polaprezinc) is more effective than zinc or carnosine alone, possibly due to the longer 
persistence of polaprezinc in the stomach (Furuta et al. 1995). 
 
1.3.1 Clinical application / trials of histidine containing dipeptides 
 
In the previous sections several functions of carnosine and its related compounds were 
described. Due to its multifunctional role several applications of carnosine have been 
discussed. In over fifteen studies the effect of increased intramuscular carnosine on exercise 
performance was investigated. A meta-analysis concluded that exercise capacity (volunteer 
individual point of volitional exhaustion) is significantly improved, when a median total of 179 
g of β-alanine is supplemented over four weeks (Hobson et al. 2012). The same study also 
revealed that effect size consisting of different exercise performance measures such as 
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running and rowing performance, was especially increased when the exercise lasts between 
one and four minutes. 
Carnosine has also been clinically evaluated for the treatment of different neurological 
disorders (for a review see (Schön et al. 2019)). Chengappa and co-workers reported the 
improved performance of carnosine treated (2 g per day for three months) adults suffering 
from chronic schizophrenia in some cognitive tests (Chengappa, K N Roy et al. 2012). 
Cognitive function was also improved by carnosine treatment (1.5 g per day for twelve 
weeks) of Persian Gulf War veterans who suffered of a neurological dysfunction termed Gulf 
War illness (Baraniuk et al. 2013). Boldyrev and co-workers suggested carnosine as adjuvant 
to L-DOPA therapy of Parkinson’s disease patients, as combined treatment with the 
dipeptide (1.5 g per day) mitigated neurological symptoms such as reduced leg agility and 
rigidity of hands and legs (Boldyrev et al. 2008). Three clinical trials investigated the effect of 
carnosine on neurological symptoms of children with autistic spectrum disorder. In a pilot 
study the daily intake of 0.8 g carnosine improved receptive speech, social attention and 
behaviour (Chez et al. 2002). Employing a dose of 0.5 g carnosine per day, a later study 
could not confirm the results of Chez and co-workers, but a significantly reduced sleep 
disturbance was reported (Mehrazad-Saber et al. 2018). In a third randomized placebo-
controlled trial, the daily dose of 0.8 g carnosine was combined with risperidone (atypical 
antipsychotic) for ten weeks. Compared to risperidone alone (placebo), carnosine 
significantly reduced hyperactivity and noncompliance (Hajizadeh-Zaker et al. 2018). The 
daily supplementation of a combination of carnosine and anserine was also reported to 
improve cognitive functioning in healthy elderly people (Szcześniak et al. 2014). 
Furthermore, carriers of the ε4 allele of apolipoprotein E, who bear a greater risk of 
developing Alzheimer’s disease, exhibited a benefit on carnosine/anserine supplementation 
with regard to age related memory decline and alteration of brain blood flow (Ding et al. 
2018). 
It was demonstrated that polaprezinc (also known as Z-103 and promac) is able to prevent 
and improve healing of gastric ulcers (Seiki et al. 1990). Polaprezinc is clinically used in 
Japan to treat gastric ulcers since 1994 (Matsukura and Tanaka 2000) and therefore, the first 
approved carnosine like drug. Due to its antioxidant properties, polaprezinc was clinically 
evaluated to mitigate radiotherapy induced toxicity/adverse effects. As the effect of IR 
evolves by the formation of reactive oxygen and nitrogen species (Spitz and Hauer-Jensen 
2014), the zinc carnosine complex significantly supressed the formation of radiotherapy 
induced oral mucositis in patients with head and neck cancer (Watanabe et al. 2010). In 
contrast to other antioxidant vitamins (Bairati et al. 2006), polaprezinc did not negatively 
affect the outcome of patients suffering from head and neck cancer (Watanabe et al. 2010) 
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and non-small cell lung cancer (Yanase et al. 2015). Just recently, Yehia and co-workers 
demonstrated in a pilot study including 65 patients that oral supplementation of carnosine 
(0.5 g per day for three months) protects against oxaliplatin-induced peripheral neuropathy in 
colorectal cancer patients (Yehia et al. 2019). Additionally to the antioxidant activity of 
carnosine, a large body of evidence exists on the inhibitory effect of the dipeptide on tumour 
growth (for reviews see (Gaunitz and Hipkiss 2012; Hipkiss and Gaunitz 2014)). 
 
1.3.2 Carnosine and cancer 
 
The first experimental evidence of carnosine’s anti-neoplastic effect was provided by Nagai 
and Suda in 1986 (Nagai and Suda 1986). In their experiments they implanted tumour cells 
subcutaneously into mice and administered every second day carnosine by a subcutaneous 
injection. Carnosine treated animals exhibited reduced tumour growth and prolonged survival 
compared to control animals. As this work was published in Japanese, it took less attention. 
Ten years later, Holliday and McFarland demonstrated that carnosine selectively eliminated 
cervix carcinoma cells from a co-culture with fibroblasts (Holliday and McFarland 1996). After 
another decade, Renner and co-workers treated cells isolated from human glioblastoma with 
carnosine and confirmed the anti-proliferative effect of the dipeptide (Renner et al. 2008). 
Afterwards, the same group investigated the effect of carnosine in a nude mouse model with 
subcutaneously implanted NIH3T3 cells (mouse fibroblast cell line) which expressed the 
human epidermal growth factor receptor 2 (Renner et al. 2010b). Tumours grown in animals 
which received daily peritoneal injections of carnosine displayed growth retardation, were 
less pleomorphic and exhibited a reduced number of mitotic figures compared to tumours in 
mice which received NaCl. Horii and co-workers used an athymic nude mouse model with 
implanted human colon cancer cells to demonstrate that carnosine exerts an anti-proliferative 
effect also when the dipeptide is administered orally (Horii et al. 2012). In several cell culture 
experiments the anti-proliferative effect of carnosine was confirmed by different groups using 
proliferating cells originating from different tissues, namely pheochromocytoma cells 
(Rybakova and Boldyrev 2012), rat mesangial cells (Huijie Jia et al. 2009), human gastric 
cancer cells (Zhang et al. 2014), cervical gland carcinoma cells (Bao et al. 2018) and 
hepatocellular carcinoma cells (Tehrani et al. 2018). Furthermore, in vitro experiments also 
suggest that carnosine inhibits cancer cell invasion via inhibiting matrix metalloproteinases 
(Chuang and Hu 2008; Hsieh et al. 2019). Consequently, the possible use of carnosine as an 
anti-cancer (Gaunitz and Hipkiss 2012) agent and possible mechanisms (Hipkiss and 
Gaunitz 2014) had been discussed. 
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Due to mutations cancer cells exhibit aberrant activities of various signalling molecules which 
act in different signalling pathways that are important to control homeostasis, proliferation 
and differentiation. Different experimental observations suggest that carnosine influences 
such aberrant signalling pathways in cancer. Son and co-workers observed that carnosine 
inhibited H2O2 induced interleukin 8 protein synthesis which was accompanied by reduced 
phosphorylation of eukaryotic initiation factor (eIF) 4E, protein kinase B (Akt) and 
extracellular signal regulated kinase 1/2 (Erk1/2) (Son et al. 2008). The aforementioned 
signal molecules play key roles in the regulation of mechanistic target of rapamycin complex 
1 (mTORC1) signalling which coordinates eukaryotic cell growth and metabolism and which 
is frequently hyper-activated in cancer (for a review see (Saxton and Sabatini 2017) and 
Figure 2). Further evidence of carnosine’s influence on mTORC1 signalling was provided by  
 
Rybakova and co-workers who demonstrated the inhibitory effect of the dipeptide on Erk1/2 
(Rybakova et al. 2013). More important, Zhang and co-workers suggested carnosine as a 
mimic of rapamycin, as the dipeptide inhibited Akt/mTORC1/S6K signalling in gastric 
carcinoma cells (Zhang et al. 2014). 
Figure 2 Signal transduction pathways related to the 
mechanistic target of rapamycin complex 1 (mTORC1). 
When receptor tyrosine kinases (RTK) are activated, binding 
of growth factor receptor binding protein 2 (GRB2) occurs, 
which can activate son of sevenless 1 (SOS). SOS activates 
rat sarcoma (Ras) by inducing the exchange of GDP with 
GTP, followed by the activation of Raf1. Active Raf1 directly 
phosphorylates mitogen-activated protein kinase 1/2 
(Mek1/2) which in turn phosphorylates extracellular signal 
regulated kinase 1/2 (Erk1/2), leading to the interaction of 
several downstream targets including the activation of 
ribosomal protein S6 (S6) kinase A1 (p90RSK) and 
inactivation of tuberous sclerosis 2 (TSC2). GRB2 is also 
able to interact with the GRB2 associated binding protein 1 
(GAB1) which results in the activation of the phospho-
inositide 3-kinase (PI3K). PI3K catalyse the conversion of 
PIP2 to PIP3. Phosphatase and tensin homolog (PTEN) 
reverse this process. PIP3 recruits phosphoinositide-
dependent protein kinase 1 (PDK1) and protein kinase B 
(Akt) which results in the activation of Akt. Phosphorylated 
Akt interacts with multiple downstream targets, including 
p90RSK and TSC2. As the active TSC1/2 complex inhibits 
phosphorylation of GDP bound to Ras homolog enriched in 
brain (Rheb) to GTP, inhibition of TSC1/2 results in 
production of Rheb:GTP, which in turn activates mTORC1. 
Afterwards, mTOCR1 can phosphorylate the eukaryotic 
initiation factor 4E (eIF4E) binding protein (eIF4BP1), S6 
kinase B1 (S6K) and signal transducer and activator of 
transcription 3 (STAT3). STAT3 influences the transcription 
of several genes, including hypoxia-inducible factor 1α (HIF) 
which is also a key signal transducer. After phosphorylation, 
eIF4BP1 detaches from eIF4E, enabling cap-dependent 
translation. Translation is also initiated after phosphorylation 
of S6 by S6K, whereby S6K can also affect transcription by 
interfering with other signal transducers. mTORC1 initiated 
translation positively affects HIF activity. Red: activating 
nodes; green: inhibitory nodes; : activation; : inhibition 
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Hypoxia-inducible factor 1α (HIF) is activated during oxygen deprivation and induces the 
expression of genes that enable the cell to cope with the reduced supply of oxygen and 
nutrients. HIF overexpression is observed in many types of cancer and thus discussed as a 
pharmaceutical target to supress tumour growth (for a review see (Masoud and Li 2015)). 
Bharadwaj and co-workers reported that carnosine inhibited HIF protein expression in cardio 
myoblasts (Bharadwaj et al. 2002). This observation was confirmed in colon carcinoma cells, 
in which the dipeptide increased the degradation of HIF (Iovine et al. 2014). At this point it 
should be noted that active mTORC1 signalling increases translation of HIF mRNA which in 
turn promotes HIF signalling. Furthermore, mTORC1 also activates the signal transducer and 
activator of transcription 3 (STAT3) which enhances HIF transcription and hence, strongly 
connects mTORC1 with HIF signalling (Dodd et al. 2015). A proteomic analysis of 
glioblastoma cells treated with carnosine revealed a reduction of the Hippel–Lindau binding 
protein 1 (VBP1) (Asperger et al. 2011) which transports the Hippel-Lindau protein (pVHL) 
from perinuclear granules to the nucleus or cytoplasm. pVHL itself is a tumour suppressor 
which initiates the degradation of HIF. Therefore, reduced expression of VBP1 may result in 
lower amounts of pVHL in the nucleus and the cytoplasm, which in turn will lead to 
decreased degradation of HIF (Kim et al. 2018). Indeed, Ditte and co-workers demonstrated 
that the reduced growth of cervix carcinoma xenografts under the influence of carnosine was 
accompanied with increased HIF protein expression (Ditte et al. 2014). In addition to 
carnosine’s influence on cancer cell signalling, multiple studies report its impact on the cell 
cycle. Jia and co-workers investigated the influence of carnosine on high glucose-induced rat 
mesangial cell proliferation and observed cell cycle arrest in G1 phase (Huijie Jia et al. 
2009). Furthermore, treatment of HCT116 human colon carcinoma cells with 50 or 100 mM 
carnosine also resulted in arrest in G1 phase (Iovine et al. 2012). In contrast to that, 
Rybakova and co-workers reported cell cycle arrest in G2 phase of U118MG glioblastoma 
cells, after treatment with carnosine or anserine (Rybakova et al. 2015). 
Alongside with aberrant cell signalling, changes of cell metabolism are now also considered 
to be a hallmark of cancer (Hanahan and Weinberg 2011). In brief, a common observation in 
cancer and proliferating cells is the enhanced uptake of glucose and the release of L-lactate 
even in the presence of sufficient oxygen. This fermentation of glucose not only provides 
ATP. Glycolytic intermediates also serve as precursors to fuel metabolic pathways yielding 
nucleotides, amino acids and lipids which are building blocks for proliferation (see 1.4 Cancer 
metabolism). Consequently, inhibiting or diminishing glycolysis is considered as strategy to 
reduce tumour growth (Patra et al. 2013). As carnosine does not further reduce intracellular 
amounts of ATP in glioblastoma cells after inhibition of the L-lactate producing enzyme 
lactate dehydrogenase, it was suggested that the dipeptide inhibits glycolytic ATP production 
(Renner et al. 2010a). Carnosine has been shown to react non-enzymatically with glucose 
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and dihydroxyacetone phosphate (Hipkiss et al. 1995). Experiments with yeast cells further 
support carnosine’s impact on glycolysis. When yeast cells grow dependent on glycolytic 
ATP production carnosine lowers proliferation and increases apoptosis, whereas yeast cells 
depending on oxidative phosphorylation become resistant to carnosine’s effect (Cartwright et 
al. 2012). Nevertheless, two studies also demonstrate that carnosine is able to inhibit 
mitochondrial respiration in neoplastic cells (Bao et al. 2018; Shen et al. 2014). The pyruvate 
dehydrogenase complex (PDC) plays a decisive role in glucose oxidation by catalysing the 
formation of acetyl-CoA from pyruvate. In cancer cells PDC is frequently inhibited due to the 
over activation of pyruvate dehydrogenase kinases (PDK; not to be confused with 
phosphoinositide-dependent protein kinase) which leads to an increased formation of L-
lactate (McFate et al. 2008). As carnosine was shown to induce the expression of mRNA 
encoding PDK4, modulation of PDC by carnosine could be responsible for its influence on 
oxidative metabolism (Letzien et al. 2014). Furthermore, mRNA expression of PDK4 is 
controlled by signalling molecules which are known to be relevant for cancer cell growth such 
as Akt and estrogen-related receptors (for further details see (Gaunitz et al. 2015)). 
Moreover, is was also demonstrated that PDK4 can affect mTORC1 signalling (Liu et al. 
2014). 
In conclusion, the anti-neoplastic effect of carnosine was demonstrated by independent 
groups and in different cancer types both in vitro and in vivo. However, albeit different 
mechanisms regarding the dipeptide’s anti-tumour activity were suggested, neither the 
precise mode of action nor a primary target is known. 
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1.4 Cancer metabolism 
 
One century ago Otto Warburg, a student of Emil Fischer (developed the Fischer-projection 
of sugars), observed that cancer cells primarily produce L-lactate instead of CO2 from 
glucose (fermentation). In general, glucose fermentation takes place under anaerobe 
conditions. However, Warburg detected increased L-lactate concentrations in venous 
compared to arterial blood of rats with Jensen sarcoma (Warburg et al. 1927). As this effect 
was absent in the venous blood of heathy organs, he concluded that fermentation in cancer 
cells is performed even when sufficient amounts of oxygen are available. This effect is also 
known as Warburg effect or aerobe glycolysis (Warburg 1956). As Warburg detected that two 
molecules of L-lactate are produced per molecule glucose, he assumed that cancer cells are 
forced to ferment glucose due to mitochondrial defects in cancer cells. Albeit his theory was 
disproved by later investigations, the discovery of the enhanced uptake of glucose remains 
as a major feature of cancer cells (Hanahan and Weinberg 2011). Increasing the glycolytic 
rate renders several advantages to support cell growth. First, glycolysis is not only used for 
energy production. Glycolytic intermediates also serve as precursors for important building 
blocks required for proliferation such as nucleotides, lipids and amino acids (for a review see 
(Lunt and Vander Heiden 2011)). Second, fermentation of glucose provides an enhanced 
ATP production rate compared to glucose oxidation, albeit only two instead of 32 moles of 
ATP are produced per mole glucose (Pfeiffer et al. 2001). Hence, increasing the glycolytic 
rate seems to be a reliable strategy for proliferating cells, as less than 7% of consumed 
glucose are exploited for macromolecule synthesis (DeBerardinis et al. 2007). In order to 
proliferate, a cell has to synthesise macromolecules which are comparable to the own 
biomass composition. Simplified, cells consist of carbohydrates, protein, DNA/RNA and lipids 
which can be synthesised from sugars, amino acids, nucleotides and fatty acids (Watson et 
al. 2014). As a main nitrogen source for amino acids and nucleotides serves glutamine which 
is the most abundant amino acid in the human plasma (Stein and Moore 1954). It turned out 
that glutamine possess a comparable importance for proliferating cells as glucose. 
Consequently, enhanced glutamine uptake and breakdown was observed to be a common 
feature of cancer cells (for a review see (Altman et al. 2016)). Most of the metabolic 
demands for proliferation can be satisfied by glycolysis and glutaminolysis. The metabolic 
pathways of glucose and glutamine breakdown are illustrated in Figure 3. At this point should 
be noted that certain cancer cells are able to overcome glutamine restriction by inducing 
glutamine synthetase expression (Tardito et al. 2015). Several aberrantly regulated signalling 
pathways have been connected to altered cancer metabolism. For example, PI3K/Akt 
signalling (Figure 2) increases the expression of glucose transporter GLUT1 and hexokinase 
2 (catalyses the phosphorylation of glucose), whereby the latter was connected to tumour  
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Figure 3 Metabolism of glucose and glutamine in proliferating cells. This simplified diagram shows the 
metabolic pathways of glucose and glutamine breakdown which are required to produce precursors of 
macromolecules needed for cell growth. In general, biomass is composed of proteins (yellow), lipids (green), 
nucleotides (blue) and carbohydrates (violet). Precursors are coloured according to their group of 
macromolecules. Glucose is taken up by the cell and metabolised via glycolysis yielding pyruvate. Pyruvate can 
be converted to alanine, lactate or further metabolised in the tricarboxylic acid (TCA) cycle which conduces to the 
synthesis of several amino acids. After taken up by the cell, glutamine contributes to the anaplerotic flux after 
conversion to glutamate. Furthermore, glutamine serves as a precursor for carbamoyl phosphate (P) and is 
needed for the synthesis of purines. Glucose-6-P can alternatively be consumed for carbohydrate (glycogen, 
maltose, etc.) synthesis via Glucose-1-P or metabolised via the oxidative pentose phosphate pathway (PPP) 
yielding ribulose-5-P. Fructose-6-P and glyceraldehyde-3-P (GA3P) are also metabolised in the reductive PPP to 
synthesise ribose-5-P which is further converted to 5-phosphoribosyl-α-pyrophosphate (PRPP). PRPP serves as 
an important backbone of DNA and RNA. 3-P-glycerate is an important precursor for serine synthesis which is 
needed for synthesis of proteins, phospholipids and one-carbon units. The latter is generated by a reaction with 
tetrahydrofolate (THF) yielding glycine and 5,10-methylene-THF (5,10-me-THF). 5,10-me-THF is used for 
pyrimidine synthesis, whereby it can also be converted to 5,10-methenyl-THF (5,10-m-THF) and further to 10-
formyl-THF (10-f-THF) which is needed for purine synthesis. To generate glycerol-3-P which serves as backbone 
for lipids, dihydroxyacetone phosphate (DHAP) is used. Acetyl-CoA synthesised from pyruvate is conducted in the 
mitochondria and cannot be used for lipid biosynthesis. Therefore, citrate generated in mitochondria is cleaved by 
ATP-citrate lyase in the cytoplasm to produce cytoplasmic acetyl-CoA. 
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initiation (Patra et al. 2013). Furthermore, P53 which is frequently mutated in cancer, inhibits 
the transcription of several glycolytic genes, whereas HIF and protooncogene MYC induce 
them (Yeung et al. 2008). Aberrant activity of MYC is also associated with increased 
glutaminolysis via induced expression of glutaminase 1 (Wise et al. 2008). Moreover, specific 
expression of splice variants of pyruvate kinase muscle type (catalyses the reaction of 
phosphoenolpyruvate to pyruvate) can strongly influence the metabolic program of 
proliferating and quiescent cells (Morita et al. 2018). 
Increased uptake of serine was demonstrated to accelerate cell growth. Noteworthy, the 
serine uptake rate can reach the level of glucose consumption (pmoles per cell per hour) 
(Labuschagne et al. 2014). Serine is an important intermediate for protein, phospholipid and 
nucleotide synthesis (for a review see (Mattaini et al. 2016)). For the latter, serine is 
metabolised in the folate cycle to generate one-carbon units (one-carbon metabolism), 
whereby an excess of glycine is generated. Albeit glycine can be converted to serine, 
replacement of serine by glycine inhibits proliferation (Labuschagne et al. 2014). 
Nevertheless, de novo synthesis of serine also plays a crucial role, as overexpression of 
enzymes required for serine synthesis is accompanied with a poor prognosis of breast and 
lung cancer patients (Antonov et al. 2014). 
Lipids are the main components of biological membranes, which account for ~20% of total 
glioblastoma biomass (Yates et al. 1979). Most lipids are generated from fatty acids which 
require acetyl-CoA and NADPH for de novo synthesis. Cytosolic acetyl-CoA can be 
generated from citrate via ATP-citrate lyase, acetate via acetyl-CoA synthetase 2 (Schug et 
al. 2015) or from branched-chain amino acids catabolism (Crown et al. 2015). Biosynthesis 
of fatty acids and subsequently of lipids demands large amounts of NADPH (e.g. 26 
molecules for cholesterol biosynthesis). Hence, production of NADPH was suggested to be 
rate limiting for cell proliferation (Vander Heiden et al. 2009). Malic enzyme, IDH1, the 
oxidative pentose phosphate pathway (PPP) and the serine/one-carbon metabolism serve as 
sources for NADPH, whereby the latter two pathways are the largest contributors of NADPH 
for proliferating cells (Fan et al. 2014). In general, fatty acid biosynthesis is restricted to liver, 
adipose tissue and lactating breast, but proliferating cells, such as cancer cells, reactivate 
expression of the required enzyme fatty acid synthase (FASN) (Kuhajda et al. 1994; 
Kusakabe et al. 2000). Hence, FASN was suggested as a target for cancer therapy. 
Interestingly, the effect of the FASN inhibitor TVB-2640 on the outcome of patients suffering 
from breast cancer is investigated in a clinical trial (ClinicalTrials.gov ID: NCT03179904). 
Although activation of de novo fatty acid synthesis is a common feature of cancer cells 
(Kinlaw et al. 2016), uptake of lipids by tumour cells during growth is strongly connected to 
cancer cachexia (Argilés et al. 2014). Depending on the environmental condition, fatty acids 
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are stored or directly used for ATP production via β-oxidation, synthesis of biological 
membranes or signalling molecules such as PIP3 (for a review see (Rohrig and Schulze 
2016)). Especially during invasion, cancer cells can change from de novo fatty acid synthesis 
to uptake of specific fatty acids in order to adjust cell membrane fluidity for migration (Zhao et 
al. 2016). The rearrangement of membrane lipids of cancer cells is also highlighted by a 
study which identified a specific phosphatidylcholine profile in human colorectal cancer tissue 
using a mass spectrometry based imaging method (Kurabe et al. 2013). 
In conclusion, insight into the metabolic reprograming during cancer initiation/progression 
offers new potential approaches to treat cancer. Additionally, cancer specific metabolism can 
be exploited to image tumours using specific radionuclides, such as [18F]fluoro-2-deoxy-D-
glucose, 11C-acetate and 11C-methionine for positron emission tomography (Momcilovic and 
Shackelford 2018). 
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2 Publications 
 
The following chapters summarise the own experimental efforts to elucidate the mechanisms 
responsible for the anti-tumour activity of carnosine. This includes the analysis of the cellular 
uptake and subsequent metabolism of carnosine in glioblastoma cells. Furthermore, the 
impact of the dipeptide on glioblastoma cell signalling, gene expression and metabolism was 
investigated. Using a novel co-culture system, we analysed the migratory behaviour of 
glioblastoma cells under the influence of carnosine. Finally, the interaction of chemo-
radiotherapy and carnosine on glioblastoma cell viability was evaluated. 
 
2.1 Uptake and possible cleavage of carnosine in glioblastoma 
 
Previously, it was hypothesized that carnosine develops some of its effects via degradation 
followed by synthesis of histamine from L-histidine (Figure 1) leading to stimulation of 
histamine receptors (Zhang et al. 2012). As in cell cultures glioblastoma cells can degrade 
carnosine only intracellularly (Letzien et al. 2014; Oppermann et al. 2019c), cellular uptake of 
the dipeptide would be required. Although Son and co-workers demonstrated that carnosine 
is taken up by epithelial cells (Son et al. 2008), it was unknown which transport mechanism is 
responsible for uptake in glioblastoma cells. For example, adsorptive-mediated transcytosis 
is an alternative mechanism to transporters for drug delivery in brain (Lu 2012). As a 
dipeptide, carnosine could be transported across biological membranes by proton-coupled 
oligopeptide transporters (POTs). Four members of the POT family are known in 
mammalians (see 1.2.2 Transport and metabolism of histidine containing dipeptides). In a 
corresponding study (Oppermann et al. 2019e) we tested the hypothesis whether POTs 
contribute to the cellular uptake of carnosine in glioblastoma cells. Therefore, we first 
analysed whether mRNA encoding PEPT1, PEPT2, PHT1 or PHT2 is expressed in 
glioblastoma tissue and cell cultures. Furthermore, we analysed the mRNA expression of the 
corresponding genes (SLC15A1/2/3/4) in healthy brain tissue. In order to study the functional 
uptake of carnosine in glioblastoma cells, we used high performance liquid chromatography 
coupled with mass spectrometry (LC-MS) to determine the dipeptides uptake in the presence 
of the competitive inhibitors β-alanyl-L-alanine (taken up by all four POTs) and L-histidine 
(not taken up by PEPT1/2). Finally, we tested the contribution of PEPT2, PHT1 and PHT2 to 
carnosine uptake after transient transfection of small interfering RNA.  
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Abstract
The previous studies demonstrated that carnosine (β-alanyl-L-histidine) inhibits the growth of tumor cells in vitro and in vivo. 
Considering carnosine for the treatment of glioblastoma, we investigated which proton-coupled oligopeptide transporters 
(POTs) are present in glioblastoma cells and how they contribute to the uptake of carnosine. Therefore, mRNA expression 
of the four known POTs (PEPT1, PEPT2, PHT1, and PHT2) was examined in three glioblastoma cell lines, ten primary 
tumor cell cultures, in freshly isolated tumor tissue and in healthy brain. Using high-performance liquid chromatography 
coupled to mass spectrometry, the uptake of carnosine was investigated in the presence of competitive inhibitors and after 
siRNA-mediated knockdown of POTs. Whereas PEPT1 mRNA was not detected in any sample, expression of the three other 
transporters was significantly increased in tumor tissue compared to healthy brain. In cell culture, PHT1 expression was 
comparable to expression in tumor tissue, PHT2 exhibited a slightly reduced expression, and PEPT2 expression was reduced 
to normal brain tissue levels. In the cell line LN405, the competitive inhibitors β-alanyl-L-alanine (inhibits all transporters) 
and L-histidine (inhibitor of PHT1/2) both inhibited the uptake of carnosine. SiRNA-mediated knockdown of PHT1 and 
PHT2 revealed a significantly reduced uptake of carnosine. Interestingly, despite its low expression at the level of mRNA, 
knockdown of PEPT2 also resulted in decreased uptake. In conclusion, our results demonstrate that the transporters PEPT2, 
PHT1, and PHT2 are responsible for the uptake of carnosine into glioblastoma cells and full function of all three transport-
ers is required for maximum uptake.
Keywords Carnosine · Glioblastoma · Peptide Transport · siRNA
Introduction
More than 100  years ago, Gulewitsch and Amiradžibi 
isolated and characterized the first dipeptide carnosine 
(β-alanyl-L-histidine) (Gulewitsch and Amiradzibi 1900). 
The formation of this naturally occurring dipeptide is 
catalyzed by carnosine synthase (CARNS1), whereas the 
degradation of carnosine is performed by serum carnosi-
nase (CNDP1) and with a minor rate by the intracellularly 
expressed non-specific dipeptidase CNDP2 (Bellia et al. 
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2014). Carnosine is highly abundant in the human skele-
tal muscle with around 20 ± 4.7 mmol per kg dry weight 
(Mannion et al. 1992). The human brain mostly contains 
its isomer homocarnosine (γ-aminobutyry-L-histidine) with 
around 0.16 mmol per kg dry weight, as mostly γ-amino-
butyric acid rather than β-alanine is present in brain (Abra-
ham et al. 1962).
Since the discovery of carnosine, several physiological 
properties have been ascribed to it, such as pH-buffering, 
scavenging of reactive oxygen species and heavy metal ions, 
protection from lipid peroxidation, and ischemic brain dam-
age [for a comprehensive review see (Boldyrev et al. 2013)]. 
Furthermore, an anti-neoplastic effect of carnosine has been 
demonstrated in vitro and in vivo in different types of cancer, 
such as human colon carcinoma (Horii et al. 2012), gastric 
carcinoma (Shen et al. 2014), cervix carcinoma (Ditte et al. 
2014), and glioblastoma (GBM) (Oppermann et al. 2016; 
Renner et al. 2008, 2010). Therefore, the dipeptide has been 
considered as a possible anti-cancer drug (Gaunitz and Hip-
kiss 2012; Hipkiss and Gaunitz 2013; Gaunitz et al. 2015).
Especially, with regard to GBM, carnosine’s inhibitory 
effect on tumor cell growth is highly interesting, as this brain 
tumor is still incurable. With an incidence rate of 3.91 per 
100,000 persons in Europe and 3.19 per 100,000 persons in 
the United States, GBM is the most common malignant pri-
mary tumor of the central nervous system (Sant et al. 2012; 
Ostrom et al. 2016). According to the world health organi-
zation (WHO), GBM, which relates to astrocytic tumors, is 
classified based on its malignancy with the highest WHO 
grade IV. With the current standard therapy, consisting of 
surgical removal of the tumor and radiotherapy with adju-
vant chemotherapy using temozolomide, the 5-year overall 
survival of GBM patients is only 2.7% (Sant et al. 2012).
In recent years, we investigated which molecular targets 
and physiological mechanisms are affected by carnosine, to 
evaluate, whether it could be employed for the therapy of 
GBM. Unfortunately, the exact mechanisms by which carno-
sine exerts its anti-neoplastic effect are still not fully under-
stood, although we could demonstrate that its action is asso-
ciated with epigenetic regulation (Oppermann et al. 2019a) 
and an influence on glycolytic ATP production (Oppermann 
et al. 2016). In addition, we demonstrated that carnosine is 
also able to prevent migration of GBM cells (Oppermann 
et al. 2018), which is important for the high malignancy of 
GBM tumors.
Just recently, we could also show that the anti-neoplas-
tic effect of carnosine is independent from its intracellular 
cleavage (Oppermann et al. 2019b). However, we did not 
know how carnosine is taken up by GBM cells which trans-
porters are responsible.
As a dipeptide, carnosine is transported across biologi-
cal membranes via proton-coupled oligopeptide transport-
ers (POTs). In mammals, four members of the POT family 
including PEPT1 (encoded by SLC15A1), PEPT2 (encoded 
by SCL15A2), PHT1 (encoded by SLC15A4), and PHT2 
(encoded by SLC15A3) have been identified [for a review, 
see (Smith et al. 2013)]. PEPT1 and PEPT2 are known to 
mediate the uptake of a wide range of di- and tri-peptides 
and peptide-like drugs, such as β-lactam antibiotics, angi-
otensin-converting enzyme inhibitors, the antiviral agent 
valaciclovir, 5-aminolevulinic acid, or the aminopeptidase 
inhibitor bestatin, in a proton gradient-dependent manner 
(Brandsch et  al. 2008; Rubio-Aliaga and Daniel 2008). 
Although PHT1 and PHT2 are able to transport di- and trip-
eptides, L-histidine is preferably transported by these POTs, 
due to a high affinity for the amino acid (Yamashita et al. 
1997; Sakata et al. 2001). Regarding distribution in tissue, 
mRNA encoding PHT1 and PHT2 is expressed in various 
cell types, whereas PEPT1 is mainly expressed in the small 
intestine, kidney, liver, pancreas, and prostate (Ogihara et al. 
1996; Herrera-Ruiz et al. 2001) and PEPT2 in kidney, brain, 
mammary gland, and lung (Daniel and Kottra 2004).
With regard to tumor specificity, it is important to know 
which of the aforementioned transporters are responsible for 
carnosine uptake into GBM cells. In addition, this knowl-
edge becomes therapeutically relevant when carnosine is 
considered to be combined with other substances that may 
affect a transporter system. Therefore, we investigated the 
four POTs known to be able to transport carnosine with 
regard to their significance for the dipeptides’ uptake into 
GBM cells.
Materials and methods
Reagents
If not stated otherwise, all chemicals were purchased from 
Sigma-Aldrich (Taufkirchen, Germany), Merck (Darmstadt, 
Germany) or Carl Roth (Karlsruhe, Germany). Carnosine 
was kindly provided by Flamma s.p.a. (Chignolo d’Isola, 
Italy) and β-alanyl-L-alanine was purchased from Bachem 
(Bubendorf, Switzerland). cDNA samples from healthy 
brain tissue were obtained from BioCat (“PCR Ready First 
Strand cDNA”; Cat.no.: HD-201-ZY; BioCat, Heidelberg, 
Germany).
Cell culture and tissue samples
U87 and T98G cells were purchased from the ATCC 
(Manassas, USA) and LN405 cells were obtained from the 
DMSZ (Braunschweig, Germany). All cell lines were geno-
typed (Genolytic GmbH, Leipzig, Germany) to confirm their 
identity.
Primary GBM cell cultures were established from 
tumor tissue obtained after surgery as described previously 
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(Oppermann et  al. 2018). All patients provided written 
informed consent according to the German law as confirmed 
by the local ethics committee. Surgery was performed at the 
Neurosurgery Department of the University Hospital Leip-
zig between 2014 and 2017. All samples were diagnosed 
as GBM and have been approved by the Neuropathology 
Department of the Leipzig University Hospital (Table 1).
All cells were cultivated in 75 cm2 or 175 cm2 culture 
flasks (Sarstedt AG & Co., Nümbrecht, Germany) using 
10 mL or 20 mL of standard culture medium (SCM: DMEM 
4.5 g/L glucose, without pyruvate, supplemented with 2 mM 
GlutaMAX™, 1% penicillin streptomycin (all Thermo 
Fisher Scientific, Darmstadt, Germany) and 10% fetal bovine 
serum (FBS superior, Biochrom, Berlin, Germany) at 37 °C 
and 5%  CO2 in humidified air in an incubator.
Transient transfection
Transient transfection was performed using 0.5 μL INTER-
FERin™/pmol siRNA (Polyplus, Illkirch, France) accord-
ing to the manufacturer’s recommendation. For transfection, 
1 × 105 LN405 cells were seeded in 2 mL of SCM in six-
well plates. After an overnight incubation, old medium was 
removed and replaced by fresh SCM containing the transfec-
tion mix (2 mL with an equivalent of 5 pmol siRNA). 96 h 
later, total RNA was extracted as described below or cells 
were used for uptake experiments. SiRNAs used in this study 
were purchased from Qiagen (Hilden, Germany): siPEPT2 
(Hs_SLC15A2_5; #SI04234608), siPHT1 (Hs_SLC15A4_9; 
#SI04960207), siPHT2 (Hs_SLC15A3_10; #SI04362078), 
and negative control siRNA (#1022076).
qRT‑PCR
Total cellular RNA was extracted from  106 cells or from 
40 to 80 mg of surgically obtained tumor tissue transferred 
to RNA later (Qiagen, Hilden, Germany) immediately after 
surgical removal of tissue. Extraction was performed using 
a miRNeasy mini kit (Qiagen) according to manufactur-
er’s instructions. The RNA concentration and purity were 
assessed photometrically using a NanoDrop spectrometer 
(Thermo Fisher Scientific, Wilmington, DE, USA). The 
RNA was stored at − 80 °C until further use. For cDNA syn-
thesis, the ImProm-II™ Reverse Transcription System (Pro-
mega, Mannheim, Germany) according to manufacturer’s 
instructions was used, employing 500 ng of total RNA and 
random primer sets. DNA amplification was performed on 
a Rotor-Gene Q system (Qiagen), using SYBR Green (Max-
ima SYBR Green/ROX qPCR Master Mix, Thermo Fisher 
Scientific). Beta-actin was used as reference gene. Data 
analysis was performed using the RotorGene 6 software and 
Table 1  Samples used for the 
experiments
The table shows the samples used in the experiments with age and gender of the patients and donors. In 
addition, the diagnosis of patients and whether tissue (T) and cell culture (C) were available is indicated. 
From “donors” only cDNA from healthy brain tissue (obtained from BioCat) was available which was 
derived from the brain regions indicated. In the last row the passage number is indicated in case cell cul-
tures were available and the Lot Numbers of the samples purchased from BioCat
Age (years) Gender Diagn/Locat Type Passage/lot no
Patient 1 55 Male GBM wt T/C 2
Patient 2 59 Male GBM wt T/C 2
Patient 3 41 Male GBM wt T/C 3
Patient 4 73 Male GBM wt T/C 5
Patient 5 79 Female GBM wt T/C 3
Patient 6 63 Female GBM wt T/C 3
Patient 7 54 Male GBM wt T/C 5
Patient 8 56 Female GBM wt T/C 3
Patient 9 74 Male GBM wt T n.a.
Patient 10 57 Male GBM wt T n.a.
Patient 11 75 Male GBM wt C 4
Patient 12 74 Male GBM wt C 4
Donor 1 28 Male Frontal lobe cDNA Lot no.: B811001
Donor 2 26 Male Temporal lobe cDNA Lot no.: B811001
Donor 3 28 Male Occipital lobe cDNA Lot no.: B811001
Donor 4 41 Male Parietal lobe cDNA Lot no.: B811001
Donor 5 66 Male Frontal lobe cDNA Lot no.: B209070
Donor 6 26 Male Temporal lobe cDNA Lot no.: B509032
Donor 7 28 Male Parietal lobe cDNA Lot no.: A403022
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data were processed as described previously (Letzien et al. 
2014). Primer sequences are listed in Supplemental Table 1.
Uptake experiments
Ninety-six hours after transient transfection, cells were 
washed once with pre-warmed (37  °C) washing buffer 
(137 mM NaCl, 5.4 mM HCl, 0.41 mM  MgSO4, 0.49 mM 
 MgCl2, 0.126 mM  CaCl2, 0.33 mM  Na2HPO4, 0.44 mM 
 KH2PO4, 2 mM HEPES, pH 7.4). Afterwards, 1 mL of 
pre-warmed (37 °C) transport medium (Hanks balanced 
salt solution, calcium, magnesium, 1 g/L glucose, pH 7.4, 
Thermo Fisher Scientific, Darmstadt, Germany), contain-
ing carnosine and competitive inhibitors as indicated, was 
added. After 10 min of incubation, cells were washed briefly 
for three times with 1 mL of ice cold washing buffer and 
extraction was performed by the addition of ice cold metha-
nol (1 mL per well of a six-well plate was used). The extracts 
were collected in 1.5 mL reaction vials after 10 min of incu-
bation under constant shaking at 4 °C and evaporated to 
dryness using a SpeedVac (Thermo Fisher Scientific, Darm-
stadt, Germany). Extracts were stored at − 80 °C until fur-
ther analysis.
The use of 1 mM carnosine and 50 mM of competitive 
inhibitor in transport medium resulted in maximal suppres-
sion of carnosine uptake (data not shown). Therefore, this 
experimental setting was used for all uptake studies. At this 
point, it should also be emphasized that in the uptake experi-
ments, the cells were exposed to the compounds for only 
10 min. The recently described effect of L-histidine (50 mM) 
on cell viability, however, was observed after 24 and 48 h 
exposure (Letzien et al. 2014; Oppermann et al. 2019b). In 
addition, β-Ala-L-Ala (50 mM) does not affect cell viability 
even after 48 h exposure (Oppermann et al. 2019a).
Derivatization and HPLC–MS analysis
To quantify carnosine, a modified method of Csámpai et al. 
was used (Csámpai et al. 2004). Extracts were dissolved in 
100 µL high-quality water (Milli-Q) followed by the addi-
tion of 100 µL of 0.5% (w/v) ortho-phthalaldehyde (dis-
solved in methanol). Derivatization was performed at 37 °C 
and 1000 rpm in a thermomixer for 45 min. After adding 
800 µL 0.1% formic acid (in HPLC grade water) to each 
sample, 200 µL of the obtained solution was transferred 
into 250 µL conic glass inserts of 2 mL ND10 vials (BGB 
Analytik, Rheinfelden, Germany), followed by high-perfor-
mance liquid chromatography coupled to mass spectrometry 
(HPLC–MS) with 100 µL of sample.
The system used for the detection was an Agilent HPLC 
1100 (Agilent, Waldbronn, Germany) consisting of a vari-
able wave length detector (VWD), a well plate autosampler 
and a binary pump, coupled with a Bruker Esquire 3000 
plus electrospray-ionization ion trap mass spectrometer. 
The employed column was a Phenomenex Gemini 5 µ C18 
110 Å, 150 mm × 2 mm with a 2 mm guard column of the 
same material (Phenomenex Ltd., Aschaffenburg, Germany). 
The eluent system consisted of two solvents, with eluent 
A: 0.1% formic acid in acetonitrile and eluent B: 0.1% 
formic acid in HPLC grade water. Mobile phase flow rate 
was 0.5 mL/min with the following gradient for separation: 
0–10 min 90% B, 90%–0% B within 15 min, 25–35 min 0% 
B, 0%–90% B within 5 min, and 40–47 min 90% B for col-
umn equilibration. Mass spectrometer was operated in posi-
tive mode (target mass: m/z 300; scan range: m/z 70–400), 
the dry gas temperature was set to 360 °C at a flow rate of 
11 L/min and the nebulizer to 70 psi (both nitrogen). Car-
nosine was quantified by the integration of the peak area of 
the selective mass trace of the corresponding derivative (m/z 
343) using Xcalibur 1.4 (Thermo Fisher Scientific, Darm-
stadt, Germany). The intracellular amount of carnosine was 
quantified using a carnosine calibration curve with concen-
trations from 0.1 µM to 1 mM (corresponding to an amount 
of  10−10 to  10−7 mol carnosine). For inter-batch correction, 
a carnosine reference standard  (10−8 mol) was determined 
in duplicate. For normalization, protein was extracted by 
adding 200 µL lysis buffer (77.05 mM  K2HPO4, 22.9 mM 
 KH2PO4, 0.2% TritonX-100, pH 7.8) to the remaining cell 
layer in the six-well plate (which still contains the proteins), 
followed by incubation for 45 min on an orbital shaker. Pro-
tein concentration was determined using the Pierce 660 nm 
assay (Thermo Fisher Scientific) according to manufactur-
er’s instructions. Each experiment was performed as sixfold 
replication.
Database analysis
Comparison of POT expression in human tissues was per-
formed using the data provided by Fagerberg et al. which is 
available as fragments per kilobase of exon model per mil-
lion mapped reads (FPKM) (Fagerberg et al. 2014). In addi-
tion, we also analyzed data available from the GTEx con-
sortium (in reads per kilobase million; RPKM) (The GTEx 
Consortium 2015) and from “The Human Protein Atlas” (in 
transcripts per million; TPM) (Uhlén et al. 2015).
Statistical analysis
Statistical analysis was carried out using SPSS (IBM, 
Armonk, USA; Version: 24.0.0.2 64-bit). For multiple com-
parisons, a one-way ANOVA with the Games–Howell post 
hoc test was used. A significance level of p < 0.05 data was 
considered to be significant. Relative data resulting from 
two or more parameters (normalization to reference) with 
a separate mean and standard deviation are presented using 
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Gaussian error propagation as described before (Letzien 
et al. 2014).
Results
mRNA expression of peptide transporters in primary 
GBM cell cultures, GBM cell lines, GBM tumor tissue, 
and healthy brain
First, we asked whether the transporters, which are possibly 
responsible for the uptake of carnosine in GBM cells, are 
expressed on the level of mRNA. Therefore, we extracted the 
mRNA from ten primary GBM cell cultures and three GBM 
cell lines followed by the determination of the expression of 
PEPT1 (SLC15A1), PEPT2 (SLC15A2), PHT1 (SLC15A4), 
and PHT2 (SLC15A3) via qRT-PCR. In this experiment, we 
also included commercially available cDNA from healthy 
donors and RNA from tumor tissue directly isolated after 
surgery. As illustrated in Fig. 1, expression of PEPT1 was 
neither detectable in healthy brain nor in cell culture and also 
not in freshly isolated tumor tissue. Compared to healthy 
brain tissue, all other three transporters, PEPT2, PHT1, and 
PHT2 were significantly upregulated in the tumor tissue 
(PEPT2: 21-fold; PHT1: 13-fold; PHT2:11-fold). Whereas 
no statistically significant difference between GBM tis-
sue and cell culture was seen with regard to expression of 
PHT1 (1.6-fold lower), PHT2 exhibited a significantly lower 
expression in cell culture (2.3-fold lower). Most strikingly, 
PEPT2 expression appears to be strongly reduced during 
cultivation of the cells (24.8-fold lower than in GBM tis-
sue) and statistical analysis identified no difference between 
expression in cell culture and healthy tissue. Comparing the 
mRNA expression of the detected transporters in cell cul-
tures, PHT2 exhibited a significant 15.4-fold higher mRNA 
expression than PEPT2 (p < 0.005) and PHT1 a significant 
96.2-fold higher expression than PEPT2 (p < 0.005). Over-
all, primary GBM cultures and GBM cell lines exhibited a 
comparable mRNA expression for each transporter.
Carnosine uptake is decreased by competitive 
inhibitors of peptide transporters
In the previous section, we observed that GBM cells express 
mRNA of the transporters encoding PEPT2, PHT1, and 
PHT2. To investigate whether these transporters play a role 
in carnosine uptake in the cultured cells, we asked whether 
the dipeptide β-alanyl-L-alanine (β-Ala-L-Ala), which is a 
substrate of all three transporters, competitively inhibits the 
uptake of carnosine. In addition, we used L-histidine, which 
is a substrate of PHT1/2 but not of PEPT2, as a competitive 
inhibitor to discriminate between uptake mediated by PEPT2 
and/or PHT1/2. For the experiments, LN405 cells were incu-
bated in the presence of 1 mM carnosine and 50 mM β-Ala-
L-Ala, 50 mM L-histidine, or no inhibitor. After 10 min of 
incubation, intracellular amounts of carnosine were deter-
mined. The result of the experiment is illustrated in Fig. 2. 
Without any inhibitor, carnosine was taken up at a rate of 
0.71 ± 0.15 nmol per mg protein and minute. The presence 
of 50 mM β-Ala-L-Ala significantly decreased the uptake 
of carnosine to 0.22 ± 0.04 nmol per mg protein and minute 
(p < 0.0005). In the presence of 50 mM L-histidine, carnos-
ine uptake was decreased to 0.15 ± 0.04 nmol per mg protein 
and minute (p < 0.0005). Statistical analysis revealed only 
a p = 0.051 comparing the effect of both inhibitors which 
each other.
Carnosine uptake is decreased by knockdown 
of PEPT2, PHT1, and PHT2
From the experiments presented above, it is obvious that 
PHT1 and/or PHT2 contribute to the uptake of carnos-
ine, as L-histidine, which does not inhibit PEPT2, signifi-
cantly attenuated the uptake of the dipeptide. However, 
this experiment does not unequivocally tell that PEPT2 
does not contribute to uptake, as it may be deduced from 
Fig. 1  mRNA expression of peptide transporters in healthy brain, 
GBM tissue, and cell cultures. Total mRNA from ten primary GBM 
cell cultures (C/dark grey boxes/dark diamonds), three cell lines (C/
dark grey boxes/white diamonds), ten GBM tissues (GBM/light grey 
boxes), and healthy brain (N/white boxes) was analyzed for expres-
sion of PEPT1, PEPT2, PHT1, and PHT2 using qRT-PCR. Relative 
expression represents the expression of the gene of interest normal-
ized to the expression of beta-actin. All individual measurements 
were performed in triplicate. Mean is shown as a small square in the 
box, the median is illustrated by a horizontal line, first and third quar-
tiles are shown as box, and whiskers indicate outliers with factor 1.5. 
Asterisks indicate level of significance between the indicated groups 
as determined by one-way ANOVA with the Games–Howell post hoc 
test with *p < 0.05; **p < 0.005; ns not significant. Arrows indicate 
the three individual cell lines used
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the low expression of its corresponding mRNA. Therefore, 
we analyzed the uptake of carnosine after siRNA-mediated 
knockdown of PEPT2, PHT1, and PHT2 in LN405 cells. 
As can be seen in Fig. 3a, transfection of siRNA against 
PHT1 reduced the corresponding mRNA expression by 
86.4% ± 4.1%; p < 0.0005. Utilizing a specific siRNA tar-
geting PHT2 resulted in a 63.4% ± 6.2% reduction of mRNA 
expression (p < 0.0005) and expression of PEPT2 was 
reduced by 28.1% ± 3.5% after transfection with siPEPT2 
(p < 0.05). Interestingly, we also identified increases of 
mRNA expression of transporters not targeted by the corre-
sponding siRNA in the single experiments: Targeting PHT1 
we observed a significant increase of PEPT2 expression to 
156% ± 15%; (p < 0.0005) and a non-significant increase 
of PHT2 (124% ± 21%). In the case of siRNA directed 
against PHT2, both PHT1 and PEPT2 mRNA expressions 
were significantly increased [131% ± 12%; (p < 0.005) and 
128% ± 14%; (p < 0.05), respectively]. When PEPT2 was tar-
geted by the specific siRNA, a significant increase of expres-
sion was observed regarding PHT2 121% ± 11%; (p < 0.05) 
but no effect on expression of PHT1 101% ± 8%.
More important, as illustrated in Fig. 3b, employing all 
three siRNAs resulted in a significant decrease of carno-
sine uptake [siPHT1: 0.45 ± 0.08 nmol/(mg protein × min) 
(50.9% ± 9.4%) and PHT2: 0.30 ± 0.08  nmol/(mg  pro-
tein × min) (33.9% ± 9.7%), both p < 0.0005] compared 
to negative control: 0.87 ± 0.06 nmol/(mg protein × min), 
indicating that both PHT1 and PHT2 are responsible for 
uptake of carnosine in GBM cells. However, despite the 
low expression of mRNA encoding PEPT2, the knockdown 
of this transporter also resulted in a significant decrease 
of carnosine uptake [0.40 ± 0.16 nmol/(mg protein × min) 
(44.4% ± 17.8%), p < 0.005].
Fig. 2  Influence of competitive inhibitors on the uptake of carnosine 
in GBM cells from the line LN405. Uptake of carnosine in the pres-
ence of an extracellular concentration of 1  mM of the dipeptide in 
cells from the line LN405 was quantified by HPLC–MS in the pres-
ence of β-alanyl-L-alanine (50 mM) and L-histidine (50 mM) as com-
petitors (Ctrl: control cells without inhibitors). All experiments were 
performed in sextuplicate and mean and standard deviations are pre-
sented. Statistical analysis was performed by one-way ANOVA with 
the Games–Howell post hoc test: ***p < 0.0005
Fig. 3  Carnosine uptake after siRNA-mediated knockdown of 
PEPT2, PHT1, and PHT2. Cells from the GBM line LN405 were 
transfected using negative control siRNA (siRC) and specific siRNAs 
targeting PEPT2 (siPEPT2), PHT1 (siPHT1), and PHT2 (siPHT2). 
96  h after transfection, total mRNA was isolated and analyzed by 
qRT-PCR and uptake of carnosine was determined by HPLC–MS. a 
Relative expression of mRNA encoding PEPT2, PHT1 and PHT2 in 
cells transfected with siRNA targeting PEPT2, PHT1 or PHT2 was 
determined by normalization using expression of beta-actin mRNA as 
reference. Then, the relative expression of each gene under the influ-
ence of the siRNAs was compared to expression in cells transfected 
with negative control siRNA (set to 1). Experiments were performed 
in sextuplicate. b Quantification of intracellular carnosine 96 h after 
transfection followed by a 10 min incubation in the presence of 1 mM 
carnosine. Intracellular amounts of carnosine were normalized to the 
amounts of protein. Experiments were performed in sextuplicate. Sta-
tistical analysis was performed by one-way ANOVA with the Games–
Howell post hoc test: *p < 0.05; **p < 0.005; ***p < 0.0005
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Discussion
Here, we investigated the uptake of carnosine by cells 
derived from glioblastoma asking which transporter 
systems are responsible for this dipeptide. In humans 
and other mammals, four peptide transporters have 
been described. The transporters PEPT1 (encoded 
by SLC15A1), PEPT2 (encoded by SLC15A2), PHT1 
(encoded by SLC15A4), and PHT2 (encoded by SLC15A3) 
are members of the evolutionary well-conserved family 
of proton-coupled transport systems (POTs) (Parker et al. 
2017). All POTs are supposed to be able to transport 
carnosine, being responsible for either its uptake or its 
release. At the brush border membrane of intestinal epi-
thelial cells, it is suggested that PEPT1 is the responsible 
transporter for luminal uptake (Son et al. 2004), but less is 
known about transporters mediating its observable portal 
release (Bauchart et al. 2007). In the kidney, PEPT2 is the 
most important transporter for tubular reabsorption of car-
nosine into epithelial cells at their apical side (Kamal et al. 
2009), but a further transport into blood is very limited 
and probably mediated via a facilitative carrier (Jappar 
et al. 2009). PEPT2 is also present in the apical membrane 
of epithelial cells of the choroid plexus, where it is respon-
sible for carnosine uptake from cerebrospinal fluid (CSF) 
(Teuscher et al. 2004) and it appears to be responsible 
for carnosine uptake in astrocytes (Xiang et al. 2006) and 
cardiomyocytes (Lin and King 2007). The physiological 
importance of PHT1 and PHT2 with regard to carnosine 
transport is less clear, although their ability to transport 
carnosine has been confirmed for PHT1 (Yamashita et al. 
1997) as well as for PHT2 (Sakata et al. 2001). In addition, 
Everaert et al. suggested that PHT1 could have a role in 
carnosine transport in the muscle, which lacks expression 
of PEPT1/2 but significantly expresses mRNA encoding 
PHT1 (Everaert et al. 2013). As all transporters have been 
shown to be able to transport carnosine, the dipeptides 
tissue-specific transport appears to be dependent on the 
presence of the individual transporters.
Using the data set provided by Fagerberg et al. (2014), 
we compared the relative expression of the four transport-
ers in different tissues. The analysis, which is presented 
in Supplemental Fig. 1, shows that according to this data 
set almost no expression of PEPT1 is observed in healthy 
brain, which is in agreement with observations made in 
the rat brain by Fujita et al. (2004). However, regarding 
to the relative expression in normal tissue, our data are in 
contrast to the data obtained by Fagerberg et al. (2014): 
In the data set of Fagerberg et al. expression of PHT1 
(24.6%) and PHT2 (21.1%) almost sums up to expression 
of PEPT2 (54.3%), whereas in our data set, PHT1 has the 
highest expression in healthy brain tissue (PEPT2: 10.4%; 
PHT1: 74.4%; PHT2: 15.2%). Unfortunately, the analysis 
of other mRNA expression data sets available, such as 
those provided by the GTEx consortium (The GTEx Con-
sortium 2015) or “The Human Protein Atlas” (Uhlén et al. 
2015), did not resolve this riddle, as they also revealed 
quite different levels of expression. At this point, it also 
has to be noted that in the mRNA expression data sets 
from “The GTEx Consortium” and “The Human Protein 
Atlas”, high individual differences in the levels of the 
transporters become obvious [e.g., “The Human Protein 
Atlas”; Brain-Frontal Cortex, 108 samples, data in RPKM: 
SLC15A2 (PEPT2): range 0.9–14.6; 4.2 ± 2.6; SLC15A3 
(PHT2): range 0.5–18.8; 1.4 ± 2.0; SLC15A4 (PHT1): 
range 1.7–10.8; 3.4 ± 1.0). Although we also encountered 
high deviations between our samples of RNA derived from 
healthy brain (PEPT2: deviation: 65.9%; PHT1: deviation: 
30%; and PHT2: 25.4%), it is interesting to note that in our 
data, the relation between the different levels of expression 
was comparable between healthy brain (see above) and 
tumor tissue (PEPT2: 16.4%; PHT1: 71.2% and PHT2: 
12.4%) despite the fact that the increase of PEPT2 expres-
sion (21-fold) was slightly higher than that of the two other 
transporters (PHT1: 13-fold; PHT2: 11-fold). Unfortu-
nately, cultivation of tumor tissue-derived cells results in 
a small decrease of PHT1 and PHT2 expression (1.6-fold 
and 2.3-fold, respectively) and a high decrease in PEPT2 
expression (24.8-fold) which may lead to an underestima-
tion of PEPT2’s role in carnosine uptake in intact tumor 
tissue as discussed below. In fact, a decrease of PEPT2 
expression during cultivation has previously been reported 
by Zimmermann et al. investigating its expression in a 
primary GBM cell culture (Zimmermann and Stan 2010). 
It is tempting to speculate, whether a better supply with 
amino acids and peptides in culture compared to tumor tis-
sue with a restricted supply, especially in bad vascularized 
areas of the tumor, is responsible for decreased expression 
in culture. This could be tested by further experiments in 
which the nutritional supply in culture has to be modified. 
However, this is beyond the scope of the present work, as 
these experiments would require using culture media with 
modified compositions of single components.
Although no kinetic data are available to discuss the 
individual uptake rates of carnosine by PEPT2, PHT1, 
or PHT2, at a first glance PEPT2 appears to be of minor 
importance for the uptake of carnosine into cultured glio-
blastoma cells, as its expression in culture is significantly 
lower than that of PHT1 and PHT2 (Fig. 1). However, we 
were able to measure uptake of carnosine in the presence 
of L-histidine, which competitively inhibits the transport 
of carnosine by PHT1 and PHT2 but not the transport by 
PEPT2 (Fig. 2). Therefore, we conclude that PEPT2 also 
contributes to the overall uptake of carnosine in the cul-
tures. This notion is also confirmed by siRNA knockdown 
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of PEPT2 resulting in a significantly reduced expression of 
the corresponding mRNA and a significantly reduced uptake 
of carnosine (Fig. 3). Given the fact that PEPT2 mRNA 
expression decreases in cell culture compared to tumor tis-
sue, this transporter’s relevance for carnosine uptake into 
tumor tissue may certainly be underestimated by our uptake 
experiments. Unfortunately, uptake experiments with freshly 
isolated human cells are almost impossible to perform, as 
tissue material obtained by surgery is limited. Nonetheless, 
PHT1 and PHT2 are obviously able to transport significant 
amounts of carnosine. At this point, it is interesting to note 
that Sakata et al. reported that at least PHT2 is confined 
to lysosomal membranes and not present on the cell sur-
face (Sakata et al. 2001). However, their experiments were 
performed with ectopic expression of rPHT2 protein in 
HEK-293T cells, and to our knowledge, no further data are 
available that shows, where this transporter is expressed in 
cells of human tissue. Unfortunately, as recently pointed out 
by Hu et al. there are currently no antibodies available to 
detect human PHT1 and PHT2 (Hu et al. 2018). In fact, we 
also tested a number of commercially available antibodies 
without any success (data not shown). Therefore, it is not 
possible to compare healthy brain tissue with GBM tissue 
to evaluate whether tumor cells translocate these transport-
ers from an intracellular localization to the cell membrane.
Another aspect detected by the experiments and the 
analysis presented is the observation that the expression of 
PEPT2, PHT1, and PHT2 is increased in GBM tissue com-
pared to healthy tissue. Of course, it should be taken into 
account that samples from healthy tissue have to be con-
sidered as a mixture of neurons and glia cells. Therefore, a 
transporter which is only present in glia cells but not in neu-
rons may appear to be overexpressed in a tumor tissue origi-
nating from astrocytes compared to healthy brain. Unfortu-
nately, aside from experiments with rat brain-derived cell 
cultures, in which PEPT2 appeared to be restricted to glial 
cultures (Dieck et al. 1999), to our knowledge, nothing is 
known about differential expression of the transporters dis-
criminating between glia and neurons. Given the magnitude 
in the difference of expression between healthy tissue and 
GBM tissue, we think that the observed difference deserves 
attention because of possible pharmacological implications. 
At least for PEPT1 and PEPT2, it is known that they are not 
only responsible for proton-coupled intake of peptides con-
sisting of 2–4 amino acids, with a preference for dipeptides; 
in addition, they are also able to transport other compounds, 
especially pharmaceutically relevant drugs [for comprehen-
sive reviews, see (Brandsch et al. 2008; Smith et al. 2013)]. 
Unfortunately, the substrate specificity of PHT1/2 is less 
well described, but they could be alternative targets for drug 
delivery to target tissues such as glioblastoma. The idea to 
pay more attention to the “less appreciated” transporters has 
already been pointed out by Smith et al. as expression of 
PHT1 was shown to be significantly upregulated in inflamed 
areas of the colon of patients with Crohn’s disease and ulcer-
ative colitis (Lee et al. 2009).
In conclusion, we show that carnosine enters glioblas-
toma cells via PEPT2, PHT1, and PHT2 and knockdown of 
one transporter cannot be compensated by one of the oth-
ers, although we observed increases of mRNA encoding the 
transporters not targeted by a specific siRNA, which can be 
interpreted as a response of the cell trying to compensate 
the loss of one specific transporter. Nonetheless, efficient 
uptake of carnosine into target cells, as required for a phar-
macological intervention using carnosine as an anti-cancer 
drug, should take into consideration that any influence on 
the transport efficiency of any of the transporters will result 
in a reduced uptake of the dipeptide.
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In summary, we detected the mRNA of the genes encoding PEPT2, PHT1 and PHT2 in 
glioblastoma tissue, whereas PEPT1 mRNA was absent. The comparison of tumour tissue 
with normal brain tissue revealed a significantly increased mRNA expression of the three 
POTs in glioblastoma tissue, albeit the enhanced expression of PEPT2 mRNA was lost in 
glioblastoma cell culture. Analysing the uptake of carnosine in glioblastoma cells, we 
detected an initial rate of 0.71 ± 0.15 nmol per mg protein and minute. Finally, using transient 
transfection of small interfering RNA we demonstrated that carnosine enters glioblastoma 
cells by all three POTs. Noteworthy, in contrast to PEPT1/2, PHT1/2 are comparably poorly 
described. As PHT2 was considered to be only present in lysosomal membranes (Sakata et 
al. 2001), our experiments demonstrated for the first time that PHT2 is involved in cellular 
uptake. 
After the mechanism of cellular uptake of carnosine in glioblastoma cells was evaluated, it 
was of interest, whether L-histidine needs to be released from carnosine to deploy the anti-
neoplastic effect of the dipeptide. In the study of Oppermann et al. (Oppermann et al. 2019c) 
this question is addressed. If release of L-histidine from carnosine is required to reduce 
glioblastoma cell viability, the amino acid should be at least as potent as the dipeptide. 
Therefore, we investigated the influence of different concentrations of carnosine and L-
histidine on viability of ten glioblastoma cell lines and 21 primary glioblastoma cell cultures. 
We detected that both carnosine and L-histidine dose-dependently reduced cell viability. 
Furthermore, lower doses of L-histidine achieved the same quantitative effect of carnosine 
on viability. Analysis of CNDP1 mRNA, which encodes the enzyme CN1 capable to cleave 
carnosine, revealed only a minor or undetectable expression in the analysed samples. In 
contrast to that, the mRNA of the intracellular isoenzyme CN2, encoded by CNDP2 was 
expressed in all 31 glioblastoma cell cultures. As CN2 expression was confirmed in 
glioblastoma cell lines, we concluded that carnosine is presumably cleaved intracellularly to 
L-histidine and β-alanine. Using LC-MS we analysed the possible intracellular release of L-
histidine from carnosine in five primary glioblastoma cell cultures and ten glioblastoma cell 
lines. Moreover, the influence of the CN2 inhibitor bestatin on the anti-neoplastic effect of 
carnosine was investigated.  
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Abstract
The naturally occurring dipeptide carnosine (β-alanyl-L-histidine) inhibits the growth of tumor cells. As its component 
L-histidine mimics the effect, we investigated whether cleavage of carnosine is required for its antineoplastic effect. Using 
ten glioblastoma cell lines and cell cultures derived from 21 patients suffering from this malignant brain tumor, we deter-
mined cell viability under the influence of carnosine and L-histidine. Moreover, we determined expression of carnosinases, 
the intracellular release of L-histidine from carnosine, and whether inhibition of carnosine cleavage attenuates carnosine’s 
antineoplastic effect. We observed a significantly higher response of the cells to L-histidine than to carnosine with regard to 
cell viability in all cultures. In addition, we detected protein and mRNA expression of carnosinases and a low but significant 
release of L-histidine in cells incubated in the presence of 50 mM carnosine (p < 0.05), which did not correlate with carno-
sine’s effect on viability. Furthermore, the carnosinase 2 inhibitor bestatin did not attenuate carnosine’s effect on viability. 
Interestingly, we measured a ~ 40-fold higher intracellular abundance of L-histidine in the presence of 25 mM extracellular 
L-histidine compared to the amount of L-histidine in the presence of 50 mM carnosine, both resulting in a comparable decrease 
in viability. In addition, we also examined the expression of pyruvate dehydrogenase kinase 4 mRNA, which was comparably 
influenced by L-histidine and carnosine, but did not correlate with effects on viability. In conclusion, we demonstrate that 
the antineoplastic effect of carnosine is independent of its cleavage.
Keywords Carnosine · L-Histidine · Glioblastoma · Carnosinase · Pyruvate dehydrogenase kinase 4
Introduction
In 1900, Gulewitsch and Amiradzibi investigated the 
chemical components of Liebig’s meat extract (Gul-
ewitsch and Amiradzibi 1900), discovering the first 
peptide, carnosine (β-alanyl-L-histidine). Carnosine is 
one of several imidazole-containing dipeptides such as 
homocarnosine (γ-aminobutyryl-L-histidine) and anserine 
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(β-alanyl-N-π-methyl-L-histidine), which are present in high 
concentrations in the central nervous system and the skeletal 
muscle of vertebrates (Boldyrev et al. 2013). In the human 
body, carnosine levels are controlled by three enzymes. The 
formation of imidazole-containing dipeptides is catalyzed 
by the ATP-requiring Carnosine Synthase 1 [EC 6.3.2.11, 
also known as ATP-Grasp Domain-Containing Protein 1 
(ATPGD1)]. The enzyme is encoded by the CARNS1 gene, 
which is in humans primarily expressed in skeletal muscle, 
heart muscle, and olfactory neurons (Drozak et al. 2013). 
The degradation of carnosine can be carried out by two 
metalloproteases. The extracellular occurring carnosine 
dipeptidase 1 (CN1; EC 3.4.13.20; also known as serum 
carnosinase and encoded by the CNDP1 gene) is supposed to 
be mainly produced in brain (Jackson et al. 1991), although 
it may also be synthesized in the liver (Peters et al. 2011). It 
hydrolyses carnosine with high specificity, but is also able 
to cleave anserine (β-alanyl-3-methyl-L-histidine), L-alanyl-
L-histidine, L-glycyl-L-histidine, and homocarnosine (deam-
ino-3-aminomethyl-alanyl-L-histidine) (reviewed in Bellia 
et al. 2014). The second enzyme (CN2; EC 3.4.13.18; also 
known as cytosolic non-specific dipeptidase or formerly 
known as tissue carnosinase; encoded by the CNDP2 gene), 
is expressed intracellularly and occurs ubiquitously in human 
tissue (Teufel et al. 2003). Although CN2 was shown to have 
optimum activity at pH 9.5 with regard to cleavage of carno-
sine (Lenney et al. 1985), the dipeptide can be hydrolyzed 
intracellularly, but at a much lower rate compared to other 
histidine containing dipeptides, as demonstrated by experi-
ments with HEK293T cells (Okumura and Takao 2017). 
Since the discovery of carnosine, several physiological func-
tions have been ascribed to it, such as  Ca2+ regulation, pH-
buffering, metal ion chelating, scavenging of reactive oxygen 
species, and protection against advanced glycation end prod-
ucts and lipid peroxidation (for a comprehensive review see 
Boldyrev et al. 2013). Furthermore, we and others reported 
the antineoplastic effect of carnosine on cancer cells from 
different origin such as glioblastoma (Renner et al. 2008), 
colon (Horii et al. 2012; Iovine et al. 2014), gastric (Shen 
et al. 2014), and cervix carcinoma (Ditte et al. 2014).
In Europe, glioblastoma is the most common and in the 
United States the second most common primary tumor of 
the central nervous system (Ostrom et al. 2016; Sant et al. 
2012). Under the currently recommended therapy consisting 
of surgical removal of the tumor, radiotherapy, and adju-
vant chemotherapy with temozolomide, median survival of 
patients is only 14.6 months (Stupp et al. 2005). Therefore, 
new therapeutic options are urgently needed. Although car-
nosine has been intensively discussed as a potential anti-
tumor drug (Gaunitz et al. 2015; Gaunitz and Hipkiss 2012; 
Hipkiss and Gaunitz 2014), up to now, the molecular mech-
anisms of carnosine’s antineoplastic effects are not com-
pletely understood. In addition, it is not known whether the 
intact molecule or one of its moieties (β-alanine/L-histidine) 
is responsible for tumor growth inhibition. Previously, we 
reported that L-histidine is able to mimic the antineoplas-
tic effect of carnosine in glioblastoma cell lines (Letzien 
et al. 2014). In these experiments, L-histidine also induced 
expression of pyruvate dehydrogenase kinase 4 (PDK4) 
in a comparable manner to carnosine. L-histidine released 
from the dipeptide may then become a substrate for further 
reactions such as decarboxylation or deamination leading to 
histamine or urocanate formation, respectively. In fact, both 
compounds are known to be able to induce gene expression 
(Romero et al. 2016; Kaneko et al. 2008). Therefore, we 
hypothesized that cleavage of the dipeptide may be required 
to deploy its effect.
Materials and methods
Reagents
Unless stated, otherwise, all chemicals were purchased 
from Sigma-Aldrich (Taufkirchen, Germany). Carnosine 
was kindly provided by Flamma (Flamma s.p.a. Chignolo 
d’Isola, Italy).
Cell lines and primary cell cultures
The glioblastoma cell lines G55T2, 1321N1, and U373 were 
obtained from Sigma-Aldrich (Taufkirchen, Germany), the 
cell lines U87, T98G, and LN229 from the American-Type 
Culture Collection (ATCC; Manassas, USA); MZ54 and 
MZ18 were originally obtained from Donat Kögel (Frank-
furt, Germany) and the lines LN405 and U343 were obtained 
from the “Deutsche Sammlung von Mikroorganismen und 
Zellkulturen” (DMSZ; Braunschweig, Germany). Primary 
cell cultures were established from tissue samples obtained 
during standard surgery performed at the Neurosurgery 
Department of the University Hospital Leipzig during 2011 
and 2015 (see Table 1 for age and gender of patients). All 
patients provided written informed consent according to the 
German laws as confirmed by the local committee. All glio-
blastoma samples were diagnosed and have been approved 
by the Neuropathology Department of the Leipzig Univer-
sity Hospital. Primary cultures from glioblastoma tissue 
were established as described before (Renner et al. 2008). 
Briefly, tissue specimens from the tumor were cut into 
approximately 1 mm3 large pieces and then separately placed 
into 25 mm2 culture flasks (TPP, Trasadingen, Switzerland) 
until tumor cells grew out. When more than 90% confluence 
was reached, specimens were removed and primary cell cul-
tures were transferred into 75 mm2 culture flasks (TPP) for 
further cultivation. Cell cultures were maintained in high 
glucose DMEM (Dulbecco’s Modified Eagle Medium with 
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4.5 g glucose/mL) supplemented with 2 mM GlutamaxTM, 
1% penicillin/streptomycin (all from Gibco Life Technolo-
gies, now Thermo Fisher Scientific, Darmstadt, Germany) 
and 10% Fetal Bovine Serum (FBS; Biochrom GmbH, Ber-
lin, Germany), further referred to as “culture medium”, and 
kept in incubators (37 °C, 5%  CO2/95% air).
Cell based assays
For cell viability assays, cells were counted and seeded 
into sterile 96-well plates (µClear, Greiner Bio-One, Fric-
kenhausen, Germany) at a density of 5000 cells/well in 
200 µL culture medium (for passage number of primary 
cultured cells refer to Table 1). After 24 h of cultivation 
(37 °C, 5%  CO2/95% air), the medium was removed and 
replaced with fresh medium (100 µL/well) containing carno-
sine (10, 25, 50, 75 mM) or L-histidine (10, 25, 50 mM) for 
the determination of viability after 48 h of incubation. For 
testing the effect of the CN2 inhibitor bestatin (also known 
as Ubenimex) on viability of cells from the glioblastoma 
lines G55T2 and LN405, the cells received 0 mM or 50 mM 
carnosine and different concentrations of bestatin (0 µM, 
10 µM, 50 µM, or 100 µM). In these cells viability was deter-
mined after 24, 48, and 72 h of incubation. Cells used for the 
determination of viability after 48 and 72 h received fresh 
medium with the corresponding compounds after 24 h and 
48 h to account for a possible instability of bestatin in the 
medium. After incubation, the CellTiter-Glo Luminescent 
Cell Viability Assay (CTG, Promega, Mannheim, Germany) 
was employed to determine viable cells by measuring ATP 
in cell lysates and the CellTiter-Blue Cell Viability Assay 
(CTB, Promega) was used to quantify the metabolic capac-
ity in living cells. All assays were carried out according to 
manufacturer’s protocols. Luminescence and fluorescence 
were measured using a SpectraMax M5 multilabel reader 
(Molecular Devices, Biberach, Germany).
Real‑time quantitative polymerase chain reaction
Real-time quantitative polymerase chain reaction (qRT-
PCR) experiments were carried out as described (Letzien 
et al. 2014). Briefly,  106 cells were seeded in 10 mL of 
medium into 10-cm cell culture dishes (TPP, Trasadingen, 
Switzerland) with 10 mL culture medium. After 24 h of 
incubation, cells received fresh medium without test com-
pounds or containing 25 mM L-histidine or 50 mM carno-
sine. RNA was isolated after 24 h of incubation using the 
miRNeasy mini kit (Qiagen, Hilden, Germany) according to 
manufacturer’s instructions. The RNA was stored at − 80 °C 
until further use. 500 ng of RNA was used for reverse tran-
scription employing the ImProm-II™ Reverse Transcrip-
tion System (Promega, Mannheim, Germany) according to 
manufacturer’s instructions using random primer sets. DNA 
amplification was performed on a Rotor-Gene 3000 system 
(Qiagen) employing SYBR Green (Maxima SYBR Green/
ROX qPCR Master Mix, Thermo Scientific). Copy num-
bers of individual mRNAs were determined using linearized 
plasmid DNA (described in Letzien et al. 2014) containing 
the corresponding target sequence. The relative expression 
of pyruvate dehydrogenase kinase 4 (PDK4), serum car-
nosinase (CNDP1) and cytosolic non-specific dipeptidase 
(CNDP2) was obtained by normalization to the copy num-
ber of the mRNA encoding the TATA box-binding protein 
(TBP) which was used as reference gene. Data analysis was 
performed using the RotorGene 6 software and all amplifica-
tion reactions were controlled for the appropriate products 
by melting curve analysis. The following primer sequences 
were used: For CNDP1: CNDP1 forward primer: 5ʹ GAA 
GAA TAC CGG AAT AGC AG 3ʹ and CNDP1 reverse 
primer: 5ʹ CGG CCA GGT ATG ACT GTT 3ʹ; for CNDP2: 
Table 1  Patients of primary glioblastoma cell cultures
Primary cultures of glioblastoma cells established from freshly iso-
lated tumor tissue. Table shows the patient ID with the corresponding 
age at time of the operation, gender and cell culture passages used 
for the experiments of this study. Primary cell cultures used for cor-
responding experiment are marked with “x”
qRT-PCR quantitative reverse transcription polymerase chain reac-
tion, CBA cell based assays, HPLC-MS high-performance liquid chro-
matography coupled with mass spectrometry
Patient Age (years) Gender Passage Experiments
CBA/
qRT-
PCR
HPLC-MS
P0052 69 Male 6 x
P0076 51 Female 4 x
P0082 52 Male 5 x
P0086 59 Male 5 x
P0087 76 Male 7 x
P0091 79 Male 21 x
P0109 55 Female 6 x
P0138 80 Female 5–10 x x
P0167 60 Female 4 x
P0174 61 Female 4 x
P0223 64 Male 3 x
P0233 53 Male 3–4 x x
P0240 55 Male 2 x
P0244 63 Female 3–6 x x
P0250 79 Female 3 x
P0258 56 Female 3 x
P0297 77 Female 2–3 x x
P0306 75 Male 3–9 x x
P0310 71 Female 5 x
P0336 54 Male 5 x
P0355 58 Male 4 x
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CNDP2 forward primer: 5ʹ AGA AGC CCT GCA TCA CCT 
AC 3′ and CNDP2 reverse primer: 5ʹ CCA CCA AAG AGC 
CCA TC 3ʹ; for PDK4: PDK4 forward primer: 5′ CTG TGA 
TGG ATA ATT CCC 3′ and PDK4 reverse primer: 5′ GCC 
TTT AAG TAG ATG ATA GCA 3′. For the reference gene 
TBP: TBP forward primer: 5′ TTG ACC TAA AGA CCA 
TTG CAC 3′ and TBP reverse primer: 5′ GCT CTG ACT 
TTA GCA CCT GTT 3′; (all from Biomers, Ulm, Germany).
Western blot
For isolation of protein,  106 glioblastoma cells were seeded 
into 10-cm cell culture dishes (TPP, Trasadingen, Switzer-
land) with 10 mL medium. After 24 h cells received fresh 
media and were subjected to additional 24 h of incubation. 
Then, cells were washed twice with ice-cold washing buffer 
(137 mM NaCl, 5.4 mM HCl, 0.41 mM  MgSO4, 0.49 mM 
 MgCl2, 0.126 mM  CaCl2, 0.33 mM  Na2HPO4, 0.44 mM 
 KH2PO4, 2 mM HEPES, pH 7.4) and finally collected in 
1 mL washing buffer. After a brief centrifugation (5 min, 
500×g, 4 °C), and cells were resuspended in 150 µl of ice-
cold radioimmunoprecipitation assay buffer (RIPA buffer: 
50 mM Tris, 150 mM NaCl, 0.25% sodium deoxy cholate, 
0.1% SDS, 1% Nonidet P40) supplemented with PhosS-
tOP™ and an in-house protease inhibitor cocktail (0.025 g/L 
aprotinin, 0.025 g/L leupeptin, 0.01 g/L pepstatin A, 1 mM 
dithiothreitol, 2.5 mM phenylmethylsulfonylfluoride, and 
2.5 mM benzamidine). After 10 min of incubation on ice, 
cells were lysed by sonification (Bioruptor, Diagenode, Sera-
ing, Belgium; settings: power: high, interval: 0.5, time: 7 
min). The resulting cell fraction was centrifuged (5 min at 
4 °C and 5500×g) and the resulting supernatant was trans-
ferred into a new 1.5 mL reaction vial and stored at − 80 °C 
until further use. Protein concentration was determined using 
the Pierce 660 nm-assay reagent according to manufacturer’s 
instructions. Electrophoresis was performed using a vertical 
electrophoresis unit (Mini-Protean-Cell, Bio-Rad, Munich, 
Germany) and separation was carried out in 12% polyacryla-
mide gels. Before loading onto the gel, 30 µg protein was 
mixed with 4 µL sample buffer (0.5 mM Tris, 40% glycerol, 
275 mM sodium dodecyl sulfate, 0.125% bromophenol blue, 
20% 2-mercaptoethanol, pH 6.8) and volume was adjusted 
to 16 µL with double distilled water, followed by denatura-
tion (5 min, 95 °C). Separated proteins were transferred 
overnight at 4 °C onto a low fluorescence polyvinylidene 
fluoride membrane (ab133411 Abcam, Cambridge, United 
Kingdom) using a wet blot system (Mini Trans-Blot Cell, 
Bio-Rad) with BSN-buffer (48 mM Tris, 39 mM glycine, 
20% methanol). After transfer, membranes were blocked for 
1 h at room temperature under constant shaking in Tris-
buffered saline with Tween20 (TBST: 20 mM Tris, 134 mM 
NaCl, 0.1% Tween 20, pH 7.6) supplemented with 2% (w/v) 
bovine serum albumin. Then, the solution was exchanged, 
adding primary antibodies diluted in TBST (mouse anti 
CNDP2 clone AT15E5 [Abnova; MAB11202] 1:1000; rab-
bit anti ACTB [abcam; ab8227] 1:5000) followed by incu-
bation of 1 h at room temperature under constant shaking. 
The primary antibodies were removed by three washes with 
TBST and a mixture of two secondary antibodies (anti-rab-
bit-IRDye680 [LI-COR; 925-68071] 1:8000; anti-mouse-
IRDye800 [LI-COR; 925-32210] 1:8000) diluted in TBST 
was added to the membrane. After 1 h incubation at room 
temperature and constant shaking, secondary antibodies 
were removed by three washes with TBST. The membrane 
was dried overnight between two Whatman filter papers. 
Membranes were scanned using an Odyssey Imaging Sys-
tem (LI-COR, Bad Homburg, Germany) and band intensities 
were determined by the Image Studio 5 software (LI-COR).
Determination of intracellular L‑histidine
To quantify intracellular amounts of histidine, a modified 
method of Csámpai et al. (2004) was used. Cells from ten 
glioblastoma lines and from five primary cultures were 
seeded at a density of 300,000 cells per well into a 6-well-
plate in 2 mL of culture medium. After 24 h of cultivation, 
the culture medium was removed and replaced with fresh 
medium containing 50 mM carnosine or 25 mM L-histidine 
or no compound (control). Then, cells were incubated for 
additional 24 h before they were washed thrice with 1 mL 
ice-cold washing buffer followed by extraction using 400 µL 
ice-cold methanol. After 10 min of gentle shaking on ice, 
extracts were collected in 1.5 mL Eppendorf-vials, wells 
were rinsed twice with 400 µL high-quality water (Milli-Q) 
and 800 µL obtained were combined with the first 400 µL. 
Samples were evaporated to dryness by lyophilization (Mar-
tin Christ Gefriertrocknungsanlagen, Osterode, Germany). 
For derivatization, the freeze-dried extracts were dissolved 
in 100 µL high-quality water (Milli-Q) and 0.5% (w/v) 
ortho-phthalaldehyde (dissolved in 100 µL methanol) was 
added. Derivatization was carried out at 37 °C for 45 min, 
followed by the addition of 800 µL 0.1% formic acid (in 
HPLC grade water). The obtained solution (200 µL) was 
transferred into 250 µL conic glass inserts of 2 mL ND10 
vials, followed by high-performance liquid chromatography 
coupled to mass spectrometry (HPLC-MS) with 100 µL of 
sample.
HPLC‑MS set up and data analysis
The system used for detection was an Agilent HPLC 1100 
(Agilent, Waldbronn, Germany) consisting of a variable 
wavelength detector (VWD), a well plate auto sampler and a 
binary pump, coupled with a Bruker Esquire 3000 plus elec-
trospray ionization mass spectrometer run by Esquire Con-
trol 5.3 (Bruker, Bremen, Germany). The employed column 
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was a Phenomenex Gemini 5 µ C18 110 Å, 150 mm × 2 mm 
with a 2 mm guard column of the same material (Phenom-
enex Ltd., Aschaffenburg, Germany). The eluent system 
consisted of two solvents, with eluent A: 0.1% formic acid in 
acetonitrile and eluent B: 0.1% formic acid in HPLC grade 
water. Mobile phase flow rate was 0.5 mL/min with the fol-
lowing gradient for separation: 0–10 min 90% B, 90–0% 
B within 15 min, 25–35 min 0% B, 0–90% B within 5 min 
and 40–47 min 90% B for column equilibration. The mass 
spectrometer operated in positive mode (target mass: m/z 
300; scan range: m/z 70–400), the dry gas temperature was 
set to 360°C (with a flow rate of 11 L/min; nebulizer: 70 
psi). Data were analyzed using OpenChrom version 2.0.103.
v20150204-1700 (Wenig and Odermatt 2010). Histidine was 
identified by an authentic standard. The selective ion chro-
matogram of m/z = 272 was used for quantification by peak 
integration.
Data presentation and statistical analysis
If not stated otherwise, data are presented as mean ± stand-
ard deviation (SD). For pairwise comparisons, Welch’s t test 
(unpaired two-sample test with unequal variances) was per-
formed using the algorithm implemented in Excel (Micro-
soft, Redmond, USA; Version: 14.0.7212.5000 32-Bit). For 
multivariate statistical analysis, a Kruskal–Wallis–ANOVA 
was performed, followed by a Welch’s t test for pairwise 
comparisons. To consider the false discovery rate of multiple 
comparisons, p values were adjusted according to Benjamini 
and Hochberg (1995), and a value < 0.05 was presumed to be 
significant. Correlation analysis (Pearson correlation coef-
ficient) and Kruskal–Wallis–ANOVA were carried out by 
OriginPro 2017G (OriginLab Corporation, Northampton, 
USA; Version: 2017G 64-bit SR1).
Results
Cell viability in cultured primary glioblastoma cells 
and cell lines derived from glioblastoma cultivated 
in medium with different concentrations of carnosine 
and L‑histidine
First, we analyzed the viability of ten cell lines and 21 pri-
mary cell cultures derived from glioblastoma after 48 h 
of incubation in the presence of various concentrations of 
carnosine (0, 10, 25, 50, and 75 mM) and L-histidine (0, 
10, 25, and 50 mM). As can be seen in Fig. 1, viability 
of glioblastoma cells was significantly reduced by a con-
centration of 50 (p = 1.45 × 10−9) and 75 (p = 5.19 × 10−22) 
mM carnosine as determined by the CTB and at a concen-
tration of 25 (p = 2.8 × 10−2), 50 (p = 7.44 × 10−8) and 75 
(p = 3.63 × 10−14) mM carnosine as determined by the CTG 
assay (for the individual responses of all cultures see sup-
plemental Fig. 1–e). With regard to L-histidine, even the 
lowest concentration employed (10 mM) was able to signifi-
cantly reduce the relative amount of ATP (p = 2.13 × 10−2) 
and dehydrogenase activity (p = 6.77 × 10−4) in the tested 
glioblastoma cells. In the presence of 25  mM (CTB: 
p = 3.94 × 10−2; CTG: p = 5.53 × 10−3) and 50 mM (CTB: 
Fig. 1  Viability of primary glioblastoma cell cultures and glioblas-
toma cell lines under the influence of carnosine and L-histidine. Pri-
mary glioblastoma cell cultures (21) and glioblastoma cell lines (10) 
were exposed for 48 h to different concentrations of carnosine (0, 10, 
25, 50 or 75 mM) or L-histidine (0, 10, 25, or 50 mM). Viability was 
determined by assessing metabolic activity (CTB; a) and by measur-
ing the amount of ATP in cell lysates (CTG; b). Each dot within the 
boxplot represents the mean obtained from six independent measure-
ments of an individual culture which was normalized to the untreated 
control (set to 100%). Dark gray dots represent cell lines treated with 
carnosine or histidine, and light gray dots represent primary cell cul-
tures treated with carnosine or histidine. Statistical significance com-
pared to untreated control and between equal concentrations of carno-
sine and L-histidine was determined by Welch’s t test with: *p < 0.05; 
**p < 0.005; ***p < 0.0005. The individual results of each cell culture 
are presented in Supplemental Fig. 1a–e
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p = 1.49 × 10−3; CTG: p = 2.54 × 10−3) of L-histidine, cells 
from lines revealed a significantly stronger loss of viability 
than primary cultured cells. Overall, comparing equal con-
centrations, L-histidine was 1.37 ± 0.14-fold (median) more 
effective than carnosine in decreasing cell viability.
Expression of serum carnosinase and cytosolic 
non‑specific dipeptidase in human glioblastoma 
cells
As the experiments presented in the previous section suggest 
that carnosine may need first to be cleaved to L-histidine and 
β-alanine to deploy its effect, we asked whether the glioblas-
toma cells express the mRNA of the required enzymes at all. 
Therefore, we analyzed CNDP1 and CNDP2 expression in 
31 glioblastoma cell cultures by qRT-PCR. As can be seen 
in Fig. 2, CNDP2 was expressed in all analyzed samples 
with a relative expression ranging from 0.59 to 30.24 copy 
numbers per TBP copy (note that TBP mRNA has ~ 100 
copies per ng RNA). In contrast to that, CNDP1 was only 
weakly expressed or not detectable with a relative expres-
sion ranging from 0 to 0.14 copy numbers per TBP copy. 
Next, we asked whether the presence of CNDP2 mRNA in 
glioblastoma cells also results in a corresponding protein 
expression. In the western blot presented in Fig. 3, it can 
be seen that CN2 protein was detectable in all investigated 
samples, suggesting the possibility that carnosine could 
indeed be cleaved intracellularly. Noteworthy, by quanti-
fying CN2 band intensity, we could not find a correlation 
between protein and mRNA expression (Pearson correlation; 
r = − 5.68 × 10−4; p = 0.999).
Cell viability under the influence of carnosine 
and bestatin
Next, we asked, whether the CN2 inhibitor bestatin attenu-
ates the effect of carnosine on cell viability. In Fig. 4, viabil-
ity in the presence of 50 mM carnosine and different con-
centrations of bestatin are presented, relative to viability of 
cells with only the indicated concentrations of bestatin but 
without carnosine (set as 100% for each concentration of 
bestatin). As illustrated, bestatin does not attenuate the effect 
of carnosine in both cell lines, independent of the employed 
concentrations of bestatin and the time of measurement. 
Only at concentrations of 50 µM and 100 µM bestatin and 
in the case of LN405 with regard to ATP in cell lysates after 
72 h of incubation, the effect of carnosine on viability was 
statistically not significant (p = 0.31 and 0.33, respectively). 
However, this was most likely caused by an already strong 
effect of bestatin on viability after 72 h exposure even in 
the absence of carnosine which resulted in a high standard 
deviation (50 µM: 42 ± 17% viability without and 27 ± 13% 
with carnosine, 100 µM: 26 ± 16% viability without, and 
13 ± 7% with carnosine). At this point, it has to be noted that 
we observed a negative effect on viability with increased 
concentrations of bestatin and exposure time, even in the 
absence of carnosine (see supplemental Fig. 2). More impor-
tant, comparing viability in the presence of carnosine and 
different concentrations of bestatin and incubation time does 
Fig. 2  Expression of CNDP1 
and CNDP2 mRNA in primary 
glioblastoma cell cultures 
and glioblastoma cell lines. 
Total RNA from 21 primary 
glioblastoma cell cultures and 
ten glioblastoma cell lines was 
extracted, reverse transcribed 
and analyzed by qRT-PCR. 
CNDP1 and CNDP2 mRNA 
copy numbers were determined 
using standards and relative 
expression was calculated by 
the normalization to the TBP 
mRNA copy number of each 
sample. Data are represented as 
mean and standard deviation of 
three measurements. An x-axis 
break has been used because of 
the high differences between the 
absolute expression of CNDP1 
and CNDP2 mRNA
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not indicate an influence of the CN2 inhibitor on carnosine’s 
effect on viability.
Comparison of intracellular L‑histidine in primary 
cultured glioblastoma cells and cell lines derived 
from glioblastoma exposed to extracellular carnosine
The experiments presented in the previous section indi-
cated that a release of L-histidine may not be required for 
the antineoplastic effect of carnosine. However, as via-
bility was obviously negatively affected by the inhibitor 
bestatin itself, these experiments do not unequivocally 
demonstrate that the antineoplastic effect of carnosine is 
independent of the release of L-histidine in the absence 
of the inhibitor. Therefore, we investigated whether the 
release of L-histidine and the effect of carnosine on viabil-
ity show any correlation. As can be seen in Fig. 5a, except 
for P0297 and G55T2, treatment with 50 mM carnosine 
resulted in a significant 1.22 to 2.5-fold increase of the 
intracellular abundance of histidine (with p values reach-
ing from 3.12 × 10−4 to 7.12 × 10−3). This indicates that the 
dipeptide is cleaved to a certain amount inside the cells. 
However, there was no correlation between the expres-
sion of CN2 (Fig. 3) and the relative release of L-histidine. 
This is seen, for example, in the low expression of CN2 in 
MZ18 compared to its higher expression in LN229, which 
is not reflected by a corresponding difference in L-histidine 
release. More important, we did not see any significant 
correlation between the decrease of viability under the 
influence of 50 mM carnosine and the relative release of 
L-histidine (supplemental Fig. 3). This also indicates that 
the antineoplastic effect is independent of the cleavage 
of the dipeptide. Analyzing the intracellular abundance 
of L-histidine in the presence of 25  mM extracellular 
L-histidine (a concentration resulting in a similar decrease 
of viability as observed in the presence of 50 mM car-
nosine, Fig. 1), we detected a ~ 40-fold higher abundance 
of intracellular L-histidine compared to incubation in the 
presence of 50 mM carnosine (Fig. 5). This observation 
also confirms the notion that cleavage of carnosine is not 
required for its antineoplastic effect.
Expression of PDK4 mRNA under the influence 
of carnosine and L‑histidine and correlation 
between viability and influence on expression
Finally, we investigated whether the effect of L-histidine 
(25 mM) and carnosine (50 mM) on viability correlates 
with their influence on PDK4 expression. As can be seen 
in Fig. 6a, carnosine significantly induced the expression 
of PDK4 mRNA in eight samples, whereas a significantly 
reduced expression was found in four samples. Under the 
influence of L-histidine, PDK4 mRNA expression was sig-
nificantly induced in 21 samples. Comparing the effect of 
the two compounds on PDK4 expression (Fig. 6b), 18 cell 
cultures responded in the same way (both carnosine and 
L-histidine induced or reduced PDK4 mRNA expression 
when treatment of at least one compound was significantly 
different compared to the untreated control), whereas six 
cell cultures responded in an opposite way. Furthermore, 
there was a significant correlation between the influence 
of carnosine and L-histidine on PDK4 mRNA expression 
(Pearson correlation; r = 0.419; p = 0.019). Comparing the 
effect on PDK4 expression with the effect on viability, no 
correlation was found neither for L-histidine (Fig. 6c) nor 
for carnosine (Fig. 6d).
Fig. 3  Expression of CN2 
protein in glioblastoma cell 
lines. Protein from ten glio-
blastoma cell lines was isolated 
and subjected to SDS-PAGE. 
Western blotting was performed 
using antibodies against CN2 
(53 kDa) and β-actin (42 kDa). 
Upper panel: western blot image 
as analyzed by an Odyssey 
Imaging System. Lower panel: 
quantitative analysis of bands 
from the upper panel deter-
mined by Image Studio 5
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Discussion
The antineoplastic effect of carnosine, which was first 
described by Nagai and Suda (1986), has been confirmed 
in vitro (Ditte et al. 2014; Iovine et al. 2014; Renner et al. 
2008; Shen et  al. 2014) and in vivo (Horii et  al. 2012; 
Renner et  al. 2010) by several research groups. Hence, 
its potential as an anti-tumor agent has been discussed in 
a number of review articles (Gaunitz et al. 2015; Gaunitz 
and Hipkiss 2012; Hipkiss and Gaunitz 2014). As we pre-
viously demonstrated that L-histidine is able to mimic the 
antineoplastic effect of the dipeptide (Letzien et al. 2014), 
we wondered whether carnosine has to be cleaved to inhibit 
tumor cell growth. Comparing the viability of 21 primary 
cell cultures and ten cell lines originated from glioblastoma, 
we observed that with regard to the effector concentrations 
required to induce similar losses of viability, L-histidine 
was more effective at lower concentrations than carnosine. 
We also observed increased concentrations of intracellular 
L-histidine when cells were exposed to carnosine. As we 
identified the presence of CN2, we assume that this intra-
cellular L-histidine is produced by cleavage of carnosine 
catalyzed by the enzyme. Comparing CN2 expression with 
the amount of intracellular L-histidine, we found no correla-
tion. However, at this point, it has to be taken into account 
that because of different cell sizes, it is almost impossible 
to precisely compare the exact changes of intracellular con-
centrations of L-histidine between different cells. However, 
Fig. 4  Viability of G55T2 and LN405 glioblastoma cells under the 
influence of carnosine and the dipeptidase-inhibitor bestatin. Via-
bility of cells from the lines G55T2 and LN405 in the presence of 
50 mM carnosine and different concentrations of bestatin (0, 10, 50, 
or 100 µM) was compared to the viability of cells with the inhibitor 
bestatin but without carnosine, setting the viability without carnosine 
for each concentration of bestatin to 100 percent. After 24, 48, and 
72  h of incubation, viability was determined by determining meta-
bolic activity [dehydrogenase (DH) activity] and by measuring the 
amount of ATP in cell lysates (ATP in cell lysates). Data are repre-
sented as mean and standard deviation of six independent measure-
ments. Statistical significance was determined by Welch’s t test with: 
*p < 0.05; **p < 0.005; ***p < 0.0005
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cleavage appears to be weak as the intracellular concentra-
tion of L-histidine in the presence of 25 mM L-histidine in 
the medium is ~ 40-times higher than the amount of L-histi-
dine in cells incubated in the presence of 50 mM carnosine. 
At this point, it also has to be noted that Teufel et al. (2003) 
claimed that the intracellular pH is far from the optimal pH 
required for effective cleavage of carnosine by CNDP2. A 
very low release of L-histidine from carnosine has also been 
demonstrated by Son et al. (2008), investigating the intracel-
lular concentration of amino acids of Caco-2 cells cultivated 
in the presence of 50 mM carnosine for 6 and 27 h. In these 
experiments, the intracellular amount of L-histidine in the 
presence of carnosine was more than 50 times lower than 
that observed in the presence of 50 mM L-ala-L-his.
Obviously, carnosine does not need to be cleaved into its 
single amino acids to deploy its antineoplastic effect, but the 
question remains, whether L-histidine bound to the β-alanine 
moiety in carnosine is sufficient to induce the antineoplastic 
effect of carnosine and whether β-alanine may be substi-
tuted by another moiety. This question has to be elaborated 
by further experiments, as it bears the interesting aspect 
that it could lead to the development of anti-cancer drugs 
which may have an advantage over carnosine. It also has to 
be asked whether L-histidine could be used as a supplement 
instead of carnosine. As demonstrated by cell injury assays 
with cultivated rat hepatocytes, this appears to be no good 
choice (Rauen et al. 2007). In these experiments, highly 
increased lactate dehydrogenase (LDH) release, as an indica-
tor of cellular necrosis, was seen in the presence of 198 mM 
(92 ± 1%), 76  mM (91 ± 1%), and 50  mM L-histidine 
(74 ± 18%), whereas a concentration of 198 mM carnosine 
resulted in only 39 ± 3% LDH release compared to 20 ± 5% 
LDH release in untreated control cells. This also points to 
the possibility that other mechanisms are responsible for the 
increased toxicity of L-histidine than those responsible for 
the specific antineoplastic effect of carnosine. At this point, 
it should also be noted that we recently demonstrated that 
in co-cultures of tumor cells with non-tumor cells, carnos-
ine selectively eliminated the tumor cells (Oppermann et al. 
2018). In these experiments, in which the cells were incu-
bated up to several weeks, lower concentrations of carnosine 
have been employed than those that were used in the experi-
ments presented in the present study. This has to be noted, as 
we are aware that it may be difficult to achieve the compound 
concentrations employed in the present investigation in vivo. 
On the other hand, it is also difficult to estimate, which intra-
cellular concentrations may be achievable when carnosine 
is delivered orally, as we do not know whether carnosine 
can efficiently be protected from degradation by CN1 (see 
below). We also do not know whether it can be transported 
to the target cells, whether it may be resynthesized from 
the single amino acids, and whether it may accumulate in 
cells which could take it up. Anyway, the most frequently 
discussed obstacle using carnosine as an orally given drug is 
its rapid degradation by serum carnosinase in humans (Len-
ney et al. 1982). Despite the observation that the dipeptide 
is effective as a drug in different diseases (Baraniuk et al. 
2013; Boldyrev et al. 2008; Chengappa et al. 2012; Chez 
et al. 2002) and despite the fact that it may be protected 
by deposition in liver (Gardner et al. 1991) or erythrocytes 
Fig. 5  Intracellular abundance of histidine in glioblastoma cells incu-
bated in the presence of 50  mM carnosine and 25  mM histidine. a 
Cells from ten lines (dark gray) and five primary glioblastoma 
cell cultures (light gray) were exposed for 24  h to 50  mM carnos-
ine. Then, amino acids were extracted and analyzed by HPLC-MS. 
Changes of the relative intracellular abundances of L-histidine are 
shown as mean percent and standard deviation (using error propa-
gation) compared to untreated control cells from six independent 
experiments. Statistical significance was determined by Welch’s t test 
with: *p < 0.05; **p < 0.005; ***p < 0.0005. b Relative intracellular 
abundance of L-histidine in cells from 10 cell lines incubated in the 
presence of 50  mM carnosine or 25  mM L-histidine. Each dot rep-
resents the mean obtained from six independent measurements of an 
individual culture
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(Chaleckis et al. 2016), the high activity of CN1 in human 
serum will certainly strongly affect the effective concentra-
tion achievable in a patient’s tumor tissue when given orally. 
In addition, it has to be asked whether cleavage of carnosine 
by CN1 may increase serum concentrations of L-histidine to 
hepatotoxic concentrations. Therefore, it would be interest-
ing to analyze whether other L-histidine- or imidazole-con-
taining compounds which are not degradable by CN1 and 
are not toxic to other cells, may be useful alternatives. How-
ever, it has to be taken into account that these compounds 
need to be able to be taken up by tumor cells, can pass the 
blood–brain barrier in case of brain tumors, and are selec-
tive in preventing cancer cell proliferation. For the purpose 
of further drug development, it is also of major importance 
to understand the molecular mechanisms responsible for the 
antineoplastic effect.
Aside from a plethora of reports on carnosine’s influ-
ence on signaling molecules in different models (for review, 
see Gaunitz et al. 2015), the currently best described effect 
of carnosine on transcription in glioblastoma cells is its 
influence on transcription of PDK4 (Letzien et al. 2014). 
Therefore, we also investigated whether we could see any 
Fig. 6  Expression of PDK4 mRNA after exposure to carnosine or 
L-histidine. 21 primary glioblastoma cell cultures and ten glioblas-
toma cell lines were incubated in the presence of 50 mM carnosine, 
25 mM L-histidine, or vehicle control for 24 h. Then, total RNA was 
extracted, reverse transcribed and analyzed by qRT-PCR. PDK4 
mRNA copy numbers were determined using standards and relative 
expression was calculated by the normalization to the TBP mRNA 
copy number of each sample. a Fold enhancement of PDK4 expres-
sion compared to untreated control cells. Data are represented as 
mean and standard deviation of three measurements compared to the 
untreated control (set to 1). Statistical significance was determined by 
Welch’s t test with: *p < 0.05; **p < 0.005; ***p < 0.0005. b Com-
parison of PDK4 mRNA expression under the influence of carnosine 
and L-histidine. The data presented in a are here depicted with fold 
increase of relative PDK4 mRNA expression under the influence car-
nosine on the x-axis, and with fold increase under the influence of 
L-histidine on the y-axis. c Comparison between viability and PDK4 
mRNA expression under the influence of 25 mM L-histidine. d Com-
parison between viability and PDK4 mRNA expression under the 
influence of 50 mM carnosine
44
Carnosine’s inhibitory effect on glioblastoma cell growth is independent of its cleavage 
1 3
correlation between carnosine and L-histidine regarding 
their effect on PDK4 mRNA expression (Fig. 6). As we 
could demonstrate that carnosine and L-histidine influence 
PDK4 mRNA expression in 18 out of 31 cell cultures in the 
same way, this may indicate that at least in some cultures 
L-histidine and carnosine share similarities with regard to 
their influence on transcription. Although this only moder-
ate correlation may be tempered by a limited sample size, 
it is at least obvious that there is no correlation between 
carnosine’s and L-histidine’s effect on viability and expres-
sion of PDK4 mRNA. Therefore, we conclude that changes 
of PDK4 expression may not be responsible for carnosine’s 
antineoplastic effect.
In summary, we demonstrate that the cleavage of car-
nosine and the release of L-histidine is not required for the 
antineoplastic effect of the dipeptide, which can be deduced 
from three observations: (1) The CN2 inhibitor bestatin does 
not attenuate the effect of carnosine on tumor cell viability. 
(2) Intracellular cleavage of carnosine is observable, but 
has a low efficiency. (3) Roughly 40-times higher amounts 
of intracellular free L-histidine in the presence of 25 mM 
extracellular L-histidine have the same effect on tumor cell 
viability as concentrations of free L-histidine observed in the 
presence of 50 mM extracellular carnosine.
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In summary, we observed that lower doses of L-histidine are sufficient to achieve a 
comparable effect on glioblastoma cell viability as carnosine. Using LC-MS we detected 
increased intracellular amounts of L-histidine after carnosine treatment in 13 out of 15 
glioblastoma cell cultures. Nevertheless, intracellular amounts of L-histidine after carnosine 
treatment were ~40 times lower compared to cells treated with an L-histidine dose which 
leads to a comparable decrease in cell viability. Furthermore, bestatin, a CN2 inhibitor, failed 
to attenuate the anti-neoplastic effect of carnosine. Thus, we concluded that carnosine is the 
biological active compound and does not need to be cleaved or further processed to deploy 
its effects as it is the case for other drugs such as temozolomide.  
In further studies it should be evaluated whether L-histidine or another moiety than β-alanine 
bound to L-histidine might have an advantage over carnosine. However, cell injury assays 
with cultivated rat hepatocytes demonstrated the induction of cellular necrosis after treatment 
with 198 mM L-histidine (92%), whereas a concentration of 198 mM carnosine resulted only 
in a 39% loss of viability (Rauen et al. 2007). Keeping in mind that carnosine after oral 
ingestion is rapidly degraded to L-histidine and β-alanine by CN1 in plasma (Park et al. 
2005), it also has to be analysed whether treatment with carnosine could rise serum 
concentrations of L-histidine to hepatotoxic concentrations. Nevertheless, the oral 
administration of carnosine was demonstrated to have beneficial effects for patients with 
neurological disorders (see 1.3.1 Clinical application / trials of histidine containing dipeptides) 
and to reduce side effects of chemotherapy (Yehia et al. 2019). Considering the short half-life 
of carnosine in blood, Gardner and co-workers who observed release of carnosine with the 
urine even 3-hours after oral administration, assumed an unknown compartment which could 
sequester carnosine and thus, protect the dipeptide from rapid degradation in plasma 
(Gardner et al. 1991). Interestingly, Chaleckis and co-workers detected significant amounts 
of carnosine in erythrocytes (Chaleckis et al. 2016). This is an interesting observation, as red 
blood cells may therefore act as a protecting compartment which could also explain the 
delivery of the dipeptide to the brain. Therefore, we analysed whether human erythrocytes 
are capable of carnosine uptake using LC-MS. In these unpublished experiments the uptake 
of the dipeptide followed a biphasic kinetic without visible saturation in the presence of 
extracellular concentrations of carnosine ranging from 0.1 mM to 100 mM. Furthermore, we 
were also able to detect intracellular carnosine, when erythrocytes were incubated for 4 
hours in the presence of human serum which otherwise completely degraded extracellular 
carnosine. Taken together, these observations strongly support the notion that red blood 
cells could serve as a depot and as a carrier for carnosine. 
Nevertheless, the rapid degradation of carnosine by CN1 considerably reduces tissue 
availability (Qiu et al. 2019) and thus hampers the delivery of the dipeptide to the target cells. 
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In order to overcome this obstacle different approaches were suggested. Garofalo and co-
workers used an oncolytic adenovirus as carrier to increase the delivery of carnosine. This 
approach resulted in an enhanced anti-tumour activity in vivo compared to the treatment with 
each component alone (Garofalo et al. 2016). Another approach would be the design of a 
drug which exhibits carnosine’s effects but is not cleaved by CN1. Anderson and co-workers 
demonstrated such a carnosine derivate, carnosinol which possesses the dipeptides property 
to scavenge reactive aldehydes without being cleaved by CN1 (Anderson et al. 2018). 
However, whether carnosinol exhibits a comparable anti-cancer activity as carnosine still 
needs to be addressed by further experiments. Hipkiss suggested the intra-nasal 
administration of carnosine to overcome degradation by CN1 in plasma which would be 
applicable for the treatment of neurodegenerative diseases and brain tumours (Hipkiss et al. 
2013). Interestingly, Bermúdez and co-workers compared the intra-nasal and oral 
administration of carnosine in a Thy1-aSyn mouse model (Parkinson's disease model). They 
found that intra-nasal application of carnosine increases mitochondrial function and restores 
genetic alterations caused by aSyn overexpression and thus, recommended the intra-nasal 
route of administration of the dipeptide (Bermúdez et al. 2018). In order to increase the 
serum concentration of carnosine, Qiu and co-workers performed a screening of 6080 
different protease-directed small-molecules to discover a selective inhibitor against human 
CN1 (Qiu et al. 2019). They identified carnostatine (SAN9812) which inhibits human 
recombinant CN1 with a Ki of 11 nM. Most importantly, subcutaneous injection of 
carnostatine reduced CN1 activity and increased carnosine concentration in renal tissue after 
administration of the dipeptide in transgenic mice overexpressing human CN1 (Qiu et al. 
2019). 
 
2.2 The influence of carnosine on glioblastoma cell signalling and gene 
expression 
 
Previously, we demonstrated that the anti-neoplastic effect of carnosine is accompanied by 
the induction of mRNA expression of the gene encoding PDK4 (Letzien et al. 2014). As the 
expression of PDK4 has intensively been studied in different tissues and organisms, several 
pathways and transcription factors are known which regulate its expression (for a review see 
(Jeong et al. 2012)). Analysing the influence of carnosine on the transcription of PDK4 may 
reveal possible molecular targets of the dipeptide. Among the factors known to interact with 
specific elements within the ~ 850 bp long 5’-upstream region of the human PDK4 gene are 
the estrogen-related receptor (Wende et al. 2005) and the forkhead box proteins FOXO1 and 
FOXO3a (Kwon et al. 2004). Induction of PDK4 expression by FOXO1 and FOXO3a is 
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reversed by Akt (Puthanveetil et al. 2010), which plays a central role in stimulation of growth 
and evasion of apoptosis in cancer (Peng et al. 2016). Additionally, the downstream target of 
Akt, mTORC1, conduces the suppression of transcription of PDK4 via peroxisome 
proliferator-activated receptors (Laplante and Sabatini 2013; Muoio et al. 2002). As it was 
demonstrated that carnosine is able to reduce phosphorylation of Akt and mTORC1 (Son et 
al. 2008; Zhang et al. 2014), the dipeptide could induce PDK4 expression via inhibition of the 
PI3K/Akt/mTORC1 signalling pathway. In the study of Oppermann et al. (Oppermann et al. 
2019b) we evaluated the relevance of the PI3K/Akt/mTORC1 signalling pathway for the 
carnosine-dependent induction of the PDK4 gene and the anti-neoplastic effect of the 
dipeptide. To do this, we treated T98G and U87 glioblastoma cells with rapamycin (inhibitor 
of mTORC1), Ly-294,002 (inhibitor of PI3K), carnosine or a combination of these compounds 
and determined PDK4 mRNA expression. Furthermore, we investigated which transcription 
factors possibly lead to the induction of PDK4 expression using a reporter gene whose 
activity is controlled by the PDK4 promoter. To test whether the PI3K/Akt/mTORC1 signalling 
pathway is affected at the level of phosphorylation of Akt and mTORC1 by carnosine, we 
treated T98G and U87 cells with the dipeptide and a combination of rapamycin and Ly-
294,002 and performed Western blot experiments. Finally, we analysed the impact of the 
inhibitors on carnosine-dependent reduction of glioblastoma cell viability, to estimate the 
contribution of the PI3K/Akt/mTORC1 signalling pathway on the anti-neoplastic effect of the 
dipeptide. 
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Abstract
Glioblastoma is a high-grade glioma with poor prognosis even after surgery and standard
therapy. Here, we asked whether carnosine (β-alanyl-L-histidine), a naturally occurring
dipeptide, exert its anti-neoplastic effect on glioblastoma cells via PI3K/Akt/mTOR signal-
ing. Therefore, glioblastoma cells from the lines U87 and T98G were exposed to carnosine,
to the mTOR inhibitor rapamycin and to the PI3K inhibitor Ly-294,002. Pyruvate dehydroge-
nase kinase (PDK4) expression, known to be a target of PI3K/Akt/mTOR, and which is also
affected by carnosine, was analyzed by RT-qPCR, and reporter gene assays with the
human PDK4 promoter were performed. Cell viability was assessed by cell-based assays
and mTOR and Akt phosphorylation by Western blotting. Rapamycin and Ly-294,002
increased PDK4 mRNA expression in both cell lines but significance was only reached in
U87. Carnosine significantly increased expression in both lines. A significant combinatorial
effect of carnosine was only detected in U87 when the dipeptide was combined with Ly-
294,002. Reporter gene assays revealed no specific effect of carnosine on the human
PDK4 promoter, whereas both inhibitors increased reporter gene expression. Rapamycin
reduced phosphorylation of mTOR, and Ly-294,002 that of Akt. A significant reduction of
Akt phosphorylation was observed in the presence of carnosine in U87 but not in T98G,
and carnosine had no effect on mTOR phosphorylation. Cell viability as determined by
ATP in cell lysates was reduced only in the presence of carnosine. We conclude that carno-
sine’s anti-neoplastic effect is independent from PI3K/Akt/mTOR signaling. As the dipep-
tide reduced viability in tumor cells that do not respond to PI3K or mTOR inhibitors, it
appears to be worth to further investigate the mechanisms by which carnosine exerts its
anti-tumor effect and to consider it for therapy, especially as it is a naturally occurring com-
pound that has already been used for the treatment of other diseases without indication of
side-effects.
Introduction
The most common and aggressive primary tumor of the brain is designated Glioblastoma
(GBM). It is classified by the WHO (World Health Organization) as grade IV glioma. In the
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United States it accounts for 46.6 percent of all malignant tumors of the central nervous sys-
tem (CNS) and for 55.4 percent of gliomas. Its incidence is 3.21 per 100.000 population
which accounts for 13,010 cases projected in 2018 and 13,310 cases projected in 2019 [1].
Current standard of medical treatment after maximal safe resection is radiotherapy and adju-
vant chemotherapy with the alkylating agent temozolomide. Unfortunately, in patients with
newly diagnosed GBM the median survival under this treatment is only 12 to 15 month [2,3]
and there is urgent need for new strategies for treatment including targeted and immuno-
therapy strategies (for recent reviews see [4,5]). Among the intracellular pathways, which are
intensively investigated as potential targets for treatment strategies, is the PI3K/AKT/mTOR
pathway (Phosphoinositide 3-kinase/Ak strain transforming/mechanistic target of rapamy-
cin pathway) (for review see [6]). The more than 50 PI3K inhibitors that have been designed
for cancer treatment are classified into pan-PI3K, isoform selective or dual PI3K/mTOR
inhibitors (for a recent review see [7]). The drugs MK-2206 and perifosine (KRX-0401) are
used as inhibitors of Akt and there is a number of inhibitors of mTOR currently investigated,
including temsirolimus, sirolimus (rapamycin), everolimus and ridaforolimus (for review
see: [5]).
In recent years our group investigated whether the dipeptide carnosine (β-alanyl-L-histi-
dine) is a candidate for glioblastoma therapy. Carnosine has originally been isolated from
Liebig’s meat extract almost 120 years ago by Gulewitsch and Amiradzibi [8]. The dipeptide
is highly abundant in skeletal muscle with around 20±4.7 mmol per kg dry weight [9], and
since its discovery several physiological properties have been ascribed to it, such as pH-buff-
ering, scavenging of reactive oxygen species and heavy metal ions, protection from lipid
peroxidation and ischemic brain damage (for a comprehensive review see [10]). Further-
more, an anti-neoplastic effect of carnosine has been demonstrated in vitro and in vivo in a
number of cancer models, such as human colon carcinoma [11], gastric carcinoma [12], cer-
vix carcinoma [13], and GBM [14,15]. Interestingly, the dipeptides effect is not limited to
proliferation and cell cycle control, but it is also able to decrease the migration of glioblas-
toma cells [16]. In fact, migration and invasive behavior are hallmarks of glioblastoma, lead-
ing to recurrence of tumors only a few months after surgical removal of the primary tumor
mass.
Unfortunately, not much is known about the molecular targets of carnosine in cancer
cells. Among the mechanisms discussed are an influence on ATP production from glucose
[17], and there are observations that depending on the model investigated, hypoxia inducible
factor 1 (HIF1) [18], the signal transducer and activator of transcription 3 (STAT3) [19], the
mitogen-activated protein kinase (MAPK) [20], and the Kirsten rat sarcoma viral oncogene
(KRAS) [21] might be influenced. In addition, there have been hints that the Akt/mTOR/
Ribosomal protein S6 kinase beta-1 pathway is involved in carnosine’s anti-neoplastic effect
[22]. At this point, it is noteworthy, that other observations also point towards the possibility
that carnosine may be a mimic of rapamycin, which is an inhibitor of mTORC1 (mTOR
complex 1) [23]. In addition, carnosine’s anti-neoplastic effect in glioblastoma cells was
shown to be accompanied by increased expression of pyruvate dehydrogenase kinase 4
(PDK4) [24]. As PDK4 expression is regulated by transcription factors, such as FOXO1a and
FOXO3a (Forkhead box protein O1a and O3a) [25], which are downstream effectors of
PI3K/AKT/mTOR signaling, we hypothesized that carnosine’s anti-neoplastic effect may be
mediated by an influence on this pathway. Therefore, we compared the effect of carnosine on
glioblastoma cell viability, PDK4 expression and signaling molecule phosphorylation with
the PI3K inhibitor Ly294,002 and the mTOR inhibitor rapamycin in two cell lines derived
from glioblastoma.
Carnosine and PI3K/Akt/mTOR signaling
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Materials andmethods
Reagents
If not stated otherwise, all chemicals were purchased from Sigma Aldrich (Taufkirchen, Ger-
many) including the PI3K inhibitor Ly-294,002, and the carnosine employed in this study
(Cat.-Nr.: C9625/ Lot: BCBK4678V). The mTOR inhibitor rapamycin was purchased from
Santa Cruz Biotechnology (Heidelberg, Germany).
Cell culture
U87 (ATCC HTB-14) and T98G (ATCC CRL-1690) cells were obtained from the American
Type Culture Collection (ATCC, Manassas, USA) and genotyped (Genolytic GmbH, Leipzig,
Germany) to confirm their identity prior to the experiments. Cells were propagated in 250 ml
culture flasks (Sarstedt AG & Co., Nümbrecht, Germany) using 10 ml of standard culture
medium (SCM) consisting of DMEM (Dulbecco’s Modified Eagle Medium) with 4.5 g/l glu-
cose, and without pyruvate (Life Technologies, Darmstadt, Germany), supplemented with 10%
fetal bovine serum (FBS superior, Biochrom, Berlin, Germany), 2 mMGlutaMAX (Life Tech-
nologies) and Penicillin-Streptomycin (Life Technologies) at 37˚C and 5% CO2 in humidified
air in an incubator.
Reporter gene construction
The human PDK4 promoter (-3968/+319 bp relative to the transcription start site) was
obtained by PCR (polymerase chain reaction) employing the GoTaq Long PCRMaster Mix
(Promega, Mannheim, Germany) using genomic DNA extracted from T98G cells (QIAamp
DNAmini Kit, Qiagen) as template using the following primers: hPDK4_(-)3968: 5’-CAT
GGC GGG ATC CTT TCT TAT GGG CTG C-3’; (forward) and hPDK4_(+)319: 5’-CGC
CTC CAT GGT GAC GCC CAC CC-3’ (reverse). hPDK4_(-)3968 was designed containing
a BamHI recognition site and hPDK4_(+)319 containing an NcoI recognition site (both under-
lined in the primer sequences presented). These recognition sites allowed subcloning of the
amplification product into the reporter gene pT81_GauIII (containing the secreted luciferase
from Gaussia princeps [26]) after restriction digestion of both the PCR product and the vector.
In this way the reporter gene hPDK4_GauIII was obtained in which a ~4000 bp 5’-region
(-3986/+319) from the PDK4 gene controls the luciferase from Gaussia princeps with the
endogenous PDK4 start codon matching the start codon of the luciferase gene.
Reverse transcription–quantitative real time polymerase chain reaction
experiments
For the quantification of mRNA, RT-qPCR (reverse transcription–quantitative real time
polymerase chain reaction) experiments were carried out as described [24]. Briefly, 106 cells
were seeded into 100-mm cell culture dishes (TPP, Trasadingen, Switzerland) with 10 ml of
medium. After 24 hours of incubation, cells received fresh medium containing the compounds
to be tested. Cells were harvested 24 hours later and RNA was isolated using a miRNeasy mini
kit (Qiagen, Hilden, Germany) according to manufacturer’s instructions. The RNA was stored
at -80˚C until further use. 500 ng of RNA were used for reverse transcription employing the
ImProm-II Reverse Transcription System (Promega, Mannheim, Germany) according to
manufacturer’s instructions using random primer sets. DNA amplification was performed on
a Rotor-Gene 3000 system (Qiagen) employing SYBR Green (Maxima SYBR Green/ROX
qPCRMaster Mix, Thermo scientific). Copy numbers of individual mRNAs were determined
using linearized plasmid DNA (described in [24]) containing the corresponding target
Carnosine and PI3K/Akt/mTOR signaling
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sequence. Data analysis was performed using the Rotor-Gene 6 software, and data was pro-
cessed as described [24]. For reference, the transcript encoding the TATA-box binding protein
(TBP) was used. Primer sequences: PDK4_forward: 5’-CTG TGA TGG ATA ATT CCC-
3’; PDK4_reverse: 5’-GCC TTT AAG TAG ATG ATA GCA-3’; TBP_forward: 5’-TGA
CCT AAA GAC CAT TGC AC-3’; TBP_reverse: 5’-GCT CTG ACT TTA GCA CCT
GTT-3’.
Cell viability assays
For the determination of ATP production the CellTiter-Glo Assay (CTG) and for the determi-
nation of dehydrogenase activity the CellTiter-Blue Assay (CTB) were employed (all from
Promega, Mannheim, Germany) according to the instructions of the manufacturer, and as
described previously [27]. All measurements of luminescence and fluorescence were per-
formed using either a Mithras LB 940 Multimode Microplate reader (Berthold Technologies,
BadWildbad, Germany) or a Spectra Max M5 reader (Molecular Devices, Biberach,
Germany).
Transfection experiments
Transient transfection was performed using TurboFect transfection reagent (Thermo scien-
tific, Dreieich, Germany) according to manufacturer’s instructions. The ratio of DNA to
TurboFect employed was 2 μg DNA per 4 μl transfection reagent. For transfection, cells were
first seeded in 96-well plates at a density of 10,000 cells per well in 200 μl of medium. After
24 hours, old medium was removed and fresh medium containing the DNA/Polymer com-
plexes was added (100 μl with an equivalent of 25 ng DNA). Three hours later, medium was
exchanged and the cells received fresh medium with the supplements to be tested. Gaussia
luciferase activity was determined from the supernatant 24 hours after the start of the transfec-
tion as described before [26]. Briefly, cell supernatant (5 μl) was transferred into a well of a
white 96-well plate (Greiner bio-one, Frickenhausen, Germany). After an incubation of 20
minutes at room temperature, Gaussia luciferase activity was determined using a Mithras LB
940 Multimode reader (Berthold Technologies, BadWildbad, Germany) by injecting 50 μl of
luciferase assay reagent (20 mMMOPS (3-(N-morpholino)propanesulfonic acid); 0.75 M KBr;
5 mMMgCl2; 5 mM CaCl2; 1 mM EDTA (ethylenediaminetetraacetic acid); 10 μMCoelenter-
azine; pH 7.8) to the cell supernatant, followed by a 1.6 second delay until luminescence was
determined within a 0.5 s integral.
Western Blot analysis
Western Blot experiments were performed with cells cultivated at a density of 106 cells per
dish in 100-mm cell culture dishes for 24 hours in the presence of the test compounds. Briefly,
cells were washed twice with ice-cold washing buffer (137 mMNaCl; 5.4 mMHCl; 0.41 mM
MgSO4, 0.49 mMMgCl2; 0.126 mM CaCl2; 0.33 mMNa2HPO4; 0.44 mM KH2PO4; 2 mM
HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid); pH 7.4), and were then trans-
ferred to a 1.5 ml reaction vial using a cell scraper (TPP, Trasadingen, Switzerland), and 1 ml
of ice-cold washing buffer. Cells were collected by centrifugation (500xg; 4 min; 4˚C), and
resuspended in 150 μl of ice-cold RIPA buffer (50 mmol/l Tris (tris(hydroxymethyl)amino-
methane); 150 mmol/l NaCl; 1% Nonidet P40; 0.25% Natriumdesoxycholat; 0.1% SDS; pH 8.0)
containing a combination of protease inhibitors (0.025 mg/ml Aprotinin; 0.025 mg/ml Leu-
peptin; 2.5 mmol/l Benzamidin; 0.01 mg/ml Pepstatin A; 2.5 mmol/l phenylmethylsulfonyl-
fluorid), phosphatase inhibitors (PhosSTOP, Sigma) and 1 mmol/l DTT (Dithiothreitol). Cells
were sonified using a Bioruptor system (Diagenode, Seraing, Belgium) at highest energy
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setting using a “30 s on/ 30 s off” protocol for 7.5 min. After sonification debris was removed
by centrifugation (5500xg; 5 min; 4˚C) and the supernatant containing the proteins was trans-
ferred to fresh reaction vials. Proteins were either immediately used for Western blotting or
frozen at -80˚C for long term storage.
SDS-PAGE (sodium dodecyl sulfate–polyacrylamide gel electrophoresis) was performed
with 30 μg of protein per lane using a Mini-PROTEAN System (Bio-Rad, Munich, Germany).
For the detection of Akt, gels with a concentration of 12% acrylamide were used, and for the
detection of mTOR, gels with an acrylamide concentration of 6%. After electrophoresis, pro-
teins were transferred to PVDF (polyvinylidene difluoride) membranes (Low Fluorescence
Membrane Opti Blot, Abcam, Cambridge, GB) using a Mini Trans-Blot Cell (Bio-Rad). Then,
the membranes were incubated with antibodies diluted in TBST (Tris-buffered saline with
Polysorbate 20: 20 mM Tris, 134 mMNaCl, 0.1% Tween 20 and 2% (w/v) bovine serum albu-
min; pH 7.6) at the dilutions indicated below.
The primary antibodies used were: mouse anti-pan-AKT [Cell Signaling; #2920] 1:2000 in
TBST; rabbit anti-PSer473-AKT [Cell Signaling; #4058] 1:1000 in TBST; mouse-anti-mTOR
[Millipore; # 05–1564] 1:1000 in TBST; rabbit anti-PSer2448-mTOR [Cell Signaling; #2971]
1:1000 in TBST. The secondary antibodies employed (red fluorescent IRDye 680RD Goat anti-
Mouse and green fluorescent IRDye 800CWGoat anti-Rabbit; both diluted 1:5000 in TBST)
were purchased from LI-COR (LI-COR Biosciences, Lincoln, USA). Membranes were scanned
using an Odyssey Imaging System (LI-COR, Bad Homburg, Germany), and band intensities
were determined by the Image Studio 5 software (LI-COR).
Statistical analysis
Statistical analysis was carried out using SPSS (IBM, Armonk, USA; Version: 24.0.0.2 64-bit).
For multiple comparisons, a one-way ANOVA with the Games-Howell post hoc test was used.
A significance level of p<0.05 was considered to be significant. Relative data resulting from
two or more experiments or parameters (normalization to reference) with a separate mean
and standard deviation are presented using Gaussian error propagation as described before
[24]. For the comparison of data obtained from the densitometric analysis of different Western
Blot experiments, a least square method was employed in order to calculate means and stan-
dard deviations [28].
Results
PDK4 expression under the influence of carnosine, rapamycin and Ly-
294,002
In a first series of experiments, we asked whether the effect of carnosine on the expression of
PDK4 in U87 and T98G glioblastoma cells, that was described by Letzien et al. [24], can also
be detected using inhibitors of PI3K/Akt/mTOR signaling. Therefore, cells from the two lines
were exposed for 24 hours to carnosine (50 mM), the PI3K inhibitor Ly-294,002 (5 μM), the
mTORC1 inhibitor rapamycin (25 nM), and to combinations of the compounds. Then,
mRNA was isolated and subjected to RT-qPCR. The result of the experiment is presented in
Fig 1. The concentration of rapamycin employed in the experiments (25 nM) has been deter-
mined to result in a maximal effect on PDK4 expression in U87 cells, whereas that of Ly-
294,002 (5 μM) resulted in an increase of 60% compared to the maximal achievable effect at a
concentration of 10 μM in U87 cells (S1 Fig). The rational for using Ly-294,002 at a concentra-
tion of 5 μM instead of 10 μMwas based on suppliers information that the compound has an
IC50 of 0.5 μM/0.57 μM/0.97 μM for PI3Kα/δ/β (Selleckchem, Munich, Germany), but that
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the compound may also affect targets seemingly unrelated to the PI3K family with an
IC50>50 μM (Abcam). Therefore, we preferred to have a concentration as low as possible, but
resulting in a reproducible significant effect. As can be seen in Fig 1, carnosine significantly
increased the expression of PDK4 in both cell lines, but only in U87 cells a significant increase
is seen under the influence of rapamycin and Ly-294,002. Combining Ly-294,002 with carno-
sine resulted in a higher expression of PDK4, compared to expression with carnosine alone,
but only for U87 cells significance was confirmed (p<0.005). Although, the combination of
carnosine with rapamycin did also result in a higher expression, compared to that in carnosine
alone, this effect was not significant in both cell lines.
Expression of a PDK4 reporter gene under the influence of carnosine,
rapamycin and Ly-294,002
As rapamycin and Ly-294,002 were both able to increase expression of PDK4 in the two cell
lines investigated (although significance was only confirmed for U87), we wondered whether
carnosine exerts its effect on PDK4 expression via PI3/Akt/mTOR signaling. In order to prove
this hypothesis, reporter gene assays were performed. The experiments were based on the
observation that the effect of PI3K/Akt/mTOR signaling on expression of PDK4 is mediated
by elements in the 5’-upstream region of the gene, e.g. by binding sites for transcription factors
of the FOXO family [25]. Therefore, we asked whether the effect of carnosine is also mediated
by elements located in the promoter of the gene. To answer this question, a reporter gene was
constructed that covered a region from the human PDK4 gene (hPDK4) encompassing 3968
bp upstream from the transcriptional start point and 319 bp downstream of it, including the
start codon of hPDK4 controlling a luciferase gene with a secretion signal from Gaussia prin-
ceps. The construct designated “hPDK4_GauIII” was transfected into U87 and T98G cells.
After 3 hours of exposure to the DNA/transfection complexes, medium was exchanged and
the cells were exposed to carnosine (50 mM), rapamycin (25 nM) and Ly-294,002 (5 μM).
Twenty-four hours later, luciferase activity was determined from the supernatant. As
Fig 1. Influence of carnosine, rapamycin and Ly-294,002 on the expression of PDK4 and TBP in cells from the glioblastoma cell lines U87 and
T98G. Cells from the lines U87 and T98G were cultivated for 24 hours in the presence of carnosine (Car; 50 mM), rapamycin (Rapa; 25 nM), Ly-294,002
(Ly; 5 μM) or a combination of the compounds. Afterwards expression of PDK4 and TBP was measured and the fold change of expression under the
influence of the compounds was determined. Asterisks above the columns indicate a significantly increased expression under the influence of the test
compound compared to untreated control cells and the asterisks at the lines connecting columns indicate significant differences between the connected
columns: ns: not significant; �: p<0.05; ��: p<0.005; ���: p<0.0005.
https://doi.org/10.1371/journal.pone.0218972.g001
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reference, cells were also transfected with the reporter gene “pT81_GauIII” used for the con-
struction of “hPDK4_GauIII” which only contained a minimal promoter from the thymidine
kinase of Herpes simplex. The result of a corresponding experiment is presented in Fig 2. The
experiment demonstrates a significant response of the PDK4 reporter gene to the presence of
rapamycin in both cell lines. In the presence of Ly-294,002, we also observed increased expres-
sion in both cell lines but statistical significance could only be confirmed for U87 cells. Regard-
ing expression of the corresponding control vector, no statistically significant influence of
carnosine, rapamycin, and Ly-294,002 was obtained. In the presence of carnosine, the reporter
gene and the control plasmid exhibited a comparable reduced expression in U87 cells (statisti-
cally significant only for the reporter gene) and no response in cells from the line T98G. Note:
The negative response in the presence of carnosine, which becomes significant in U87 cells
transfected with the reporter gene, is a result of reduced viability under the influence of the
dipeptide (compare Fig 3). Therefore, we conclude that carnosine’s effect on expression of the
endogenous PDK4 gene is independent from an interaction of transcription factors within the
tested cis-elements and also different from the effects exhibited by rapamycin and Ly-294,002.
Cell viability under the influence of carnosine, rapamycin and Ly-294,002
As the reporter gene assay performed indicated a strong influence of carnosine on viability of
cells from the line U87, which was not observed in the presence of rapamycin and Ly-294,002,
we decided to study the effect of the three compounds on viability in more detail. Therefore,
Fig 2. Expression of a reporter gene with human PDK4 5’-region after exposure to different compounds. The
reporter gene hPDK4_GauIII with the 5’-region from the human PDK4 promoter and the control vector pT81_GauIII
were transfected into U87 and T98G cells. Cells were exposed to carnosine (Car; 50 mM), rapamycin (Rap; 25 nM), Ly-
294,002 (Ly; 5 μM) or to vehicle control (Con) and luciferase activity was determined after 24 hours of incubation (6
independent wells). �: p<0.05; ��: p<0.005, and ���: p<0.0005.
https://doi.org/10.1371/journal.pone.0218972.g002
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U87 and T98G cells were cultivated in 96-well plates and exposed to carnosine (50 mM), rapa-
mycin (25 nM) and Ly-294,002 (5 μM). Twenty-four hours later, cell viability was determined
measuring ATP in cell lysates using the CellTiter-Glo assay and dehydrogenase activity using
the CellTiterBlue assay. The result of an experiment in which 5000 cells per well were used is
presented in Fig 3. As can be seen, carnosine had a significant effect on viability of both cell
lines as determined by ATP production (Fig 3a) and dehydrogenase activity (Fig 3b). The
determination of ATP in cell lysates did not show an influence of rapamycin on viability, but
the determination of dehydrogenase activity clearly indicated that rapamycin affects dehydro-
genase activity as a measure of viability, which is more prominent in cells from the line T98G
than in cells from the line U87. Analyzing effects by combination of carnosine with the other
Fig 3. Viability of U87 and T89G cells under the influence of carnosine, rapamycin and Ly-294,002. Cells from the lines U87 and T98G were cultivated for 24
hours in the presence of carnosine (Car; 50 mM), rapamycin (Rap; 25 nM), Ly-294,002 (Ly; 5 μM) or vehicle control (contr). Then, the amount of ATP in cell
lysates (left panels) and dehydrogenase activities (right panels) as a measure of cell viability were determined. Upper panels show the influence of each compound
on viability compared to untreated cells. In the lower panels the effect of rapamycin and Ly-294,002 on the viability of cells treated in combination with carnosine
(cells treated with carnosine only set as 100%) is shown. Mean and standard deviation are presented from 8 independently treated wells for each condition.
�: p<0.05; ��: p<0.005, and ���: p<0.0005.
https://doi.org/10.1371/journal.pone.0218972.g003
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compounds (Fig 3c/3d), a significant reduction of viability compared to cells treated with
carnosine alone was detected by combination with rapamycin in both cell lines but only
regarding dehydrogenase activity. Interestingly, dehydrogenase activity was increased in U87
cells treated with Ly-294,002 and carnosine compared to carnosine alone, and we identified a
reduction of dehydrogenase activity in T98G cells combining Ly-294,002 with carnosine rela-
tive to cells treated with carnosine alone, which was not significant.
Phosphorylation of Akt and mTOR under the influence of carnosine,
rapamycin and Ly-294,002
The experiments presented in the preceding paragraphs indicated that carnosine’s effect on
PDK4 expression is different from that of rapamycin and Ly-294,002. To finally analyze
whether PI3K/Akt/mTOR pathway signaling in U87 and T98G cells is affected at the level of
Akt and mTOR phosphorylation, when the cells are exposed to carnosine and the inhibitors,
we performedWestern Blot experiments. Therefore, U87 and T98G cells were cultivated for
24 hours in the presence of carnosine (50 mM), rapamycin (25 nM) and Ly-294,002 (5 μM),
and combinations of the compounds. Then, proteins were extracted, subjected to SDS-PAGE
andWestern Blotting was performed with antibodies directed against mTOR and Akt and
their phosphorylated forms. In Fig 4 representative Blots and a densitometric analysis from six
(U87), and three (T98G) independent experiments with each pair of antibodies are presented.
Whereas rapamycin was able to reduce mTOR phosphorylation in both cell lines, Ly-294,002
did affect phosphorylation of mTOR only in T98G cells but not in U87 cells. Most importantly,
carnosine had no effect on phosphorylation of mTOR. Analyzing the phosphorylation of Akt
we did not detect an effect of rapamycin on its phosphorylation, but a significant one by Ly-
294,002 in both cell lines. Interestingly, carnosine significantly reduced phosphorylation of
Akt in cells from the line U87 but not in T98G.
Discussion
Here, we investigated, whether carnosine has an influence on the PI3K/Akt/mTOR pathway.
Ample laboratory studies suggest that this pathway is vital to the growth and survival of cancer
cells, including glioblastoma with hyperactivated PI3K/Akt/mTOR [7]. In our experiments,
the PI3Kα/δ/β inhibitor Ly294,002 significantly inhibited phosphorylation of Akt in T98G and
U87 cells, but an effect on phosphorylation of mTOR after 24 hours of treatment was only
detected in T98G and not in U87 cells. More importantly, we found no indication of reduced
viability after treatment with Ly294,002 in both cell lines. This appears to be in contrast to
results obtained by others [29]. These authors observed enhanced survival of nude mice with
intracranially implanted U87 cells after oral administration of the pan-class I PI3K inhibitor
NVP-BKM120 (buparsilib; 5 times a week for a total of 20 treatments). In addition, they also
detected enhanced apoptosis, as detected by Annexin V staining, in cultured U87 cells after 72
hour treatment with NVP-BKM120 [29]. We assume that it may be that the 24-hour incuba-
tion period employed in our experiments is too short to see effects of PI3K inhibition on
tumor cell viability. This assumption is supported by data obtained with the glioblastoma cell
lines LN229 and U251, which did significantly respond to 10 μM Ly294,002 only when they
were incubated in its presence for more than one day [30]. It also should be noted that other
authors point out that in the range of 4 to 8 μM Ly294,002 does not discernibly affect cell cycle
progression, at least in U251 MG glioblastoma cells [31]. Carnosine, which also reduced phos-
phorylation of Akt in U87 cells, although not as strong as Ly294,002, had a strong effect on via-
bility already after 24-hour exposure. We currently do not know why phosphorylation of Akt
under the influence of carnosine is not observed in T98G cells. However, it has to be taken
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into account, that the status of phosphorylation is also dependent on the activity of phospha-
tases and other mechanisms such as subcellular localization (for a recent review see [32]).
Rapamycin (also known as Sirolimus) did reduce phosphorylation of mTOR in both cell
lines, as it had to be expected, but it had no effect on viability as determined by ATP in cell
lysates. Measuring dehydrogenase activity, a minor effect of rapamycin on viability was
detected in U87 cells. In T98G cells the effect of rapamycin was comparable to the effect of car-
nosine, when measuring dehydrogenase activity. From these data, we conclude that the anti-
neoplastic effect of carnosine is certainly not mediated via an effect on PI3K, and also unlikely
to be mediated via mTOR. However, as demonstrated by the data presented in Fig 3, a small
combinatorial effect of carnosine and rapamycin can be observed in both cell lines with regard
to dehydrogenase activity, and not with regard to the amount of ATP in cell lysates.
The influence of Ly294,002 and rapamycin on PDK4 expression is known to be mediated by
5’-elements in the PDK4 gene, which we confirmed by our reporter gene assay. As carnosine
did not increase the expression of the reporter gene, this observation supports the assumption
resulting from the viability assays, that carnosine must mediate its physiological effects
without influencing PI3K/Akt/mTOR in the glioblastoma cells used. At this point it may be
Fig 4. Phosphorylation of mTOR and Akt under the influence of carnosine, rapamycin and Ly-294,002. Cells from
the lines U87 and T98G were incubated in the presence of carnosine (Car; 50 mM), rapamycin (Rap; 25 nM), Ly-
294,002 (Ly; 5 μM) or vehicle control or a combination of the compounds. Proteins were isolated, subjected to
SDS-PAGE andWestern Blotting was performed using antibodies for mTOR and mTOR phosphorylation at serine
2448 (mTOR and p-mTOR; left) and antibodies against Akt and Akt phosphorylation at serine 473 (Akt and p-Akt
right). In the lower part, representative blots are presented in which the total amount of each signaling molecule is
detected by red fluorescence and its corresponding phosphorylated form by green fluorescence. Below the combined
bands are shown (merged) in yellow. Actin served as loading control (green fluorescence). A densitometry analysis
from six (U87) and three (T98G) independent experiments was performed with each set of the two primary antibodies.
Data is presented as “relative phosphorylation”, indicating the ratio of the signal obtained with the phospho-specific
antibody compared to the signal with the antibody direct against total protein of the factor under the influence of a
compound, compared to this ratio in untreated control cells (set as 1). Statistical significance was calculated by one-
way ANOVA with the Games-Howell post hoc test: �: p<0.05; ��: p<0.005, and ���: p<0.0005.
https://doi.org/10.1371/journal.pone.0218972.g004
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hypothesized that elements which were not present in our reporter gene, such as intronic or 3’-
elements, could be responsible for the induction of the PDK4 gene under the influence of car-
nosine. In fact, we just recently demonstrated that the effect of carnosine on PDK4 expression
is linked to epigenetic mechanisms [33]. At this point it is also interesting to note, that a recent
report, comparing PDK4 mRNA expression under the influence of carnosine and L-histidine
in 21 primary glioblastoma cultures and 10 glioblastoma cell lines, revealed that no correlation
exists between increased mRNA expression and the compounds influence on viability [34].
As already outlined in the introduction, there is evidence, that carnosine’s effect on tumor
cell viability is accompanied by effects on signal transduction and on tumor cell metabolism.
However, the question remains, whether the effects on signal transduction detected in other
tumor models, as outlined in the introduction, are resulting from a direct effect on a single
transduction molecule or on a receptor. In fact, we recently demonstrated that increased
expression of PDK4 is accompanied by epigenetic regulation [33], and the possibility cannot
be ruled out that the primary target of carnosine is an unknown Histone Deacetylase. In that
case, the observed changes in signal transduction may be a secondary response. As carnosine
is able to react non-enzymatically with aldehydes [35], one could also imagine that its primary
target is a metabolite, such as an aldehyde of the glycolytic pathway, which might explain its
effect on ATP production from glucose [17]. Any influence on metabolism will in turn also
feed-back on signal transduction [36].
Although, carnosine’s primary targets have still not been revealed, we consider it worth to
further investigate them, as understanding carnosine’s mode of action could pave the way to the
discovery of novel therapeutic interventions. In this context, it should be emphasized, that the
present investigation demonstrates, that tumors, which do not or less respond to drugs targeting
pathways, such as the PI3K/Akt/mTOR pathway, are still sensitive to carnosine. This could
offer the opportunity for new strategies for the treatment of tumors in general and glioblastoma
in particular, that are resistant to currently employed drugs. However, these interventions may
include the design of novel drugs, targeting the primary targets of carnosine, as we are aware,
that the concentrations employed in the in vitro experiments in the present study may not be
reached in a patient by oral administration of the dipeptide. On the other hand, dose response
studies demonstrated that lower concentrations are also effective [14,24], especially after pro-
longed incubation [16]. In addition, the great advantage of carnosine is, that it is a naturally
occurring compound, which has already been used for the treatment of other diseases, without
having side-effects [37–39]. In addition, we just recently demonstrated that the dipeptide does
not decrease the viability of fibroblasts [16], and does even have neuroprotective effects [40].
Supporting information
S1 Fig. Relative PDK4 expression after exposure to different concentrations of rapamycin
and Ly-294,002. Cells from the line U87 were cultivated at a density of 106 cells per culture
plate and exposed for 24 hours to different concentrations of rapamycin and Ly-294,002. The
fold of enhancement of PDK4 mRNA expression was calculated from the relative expression
of PDK4 (compared to the expression of mRNA encoding TBP) and compared to the corre-
sponding control cells treated with vehicle.
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In summary, we have shown that inhibition of the PI3K/Akt/mTORC1 pathway also induces 
the expression of the PDK4 gene in glioblastoma cells. However, carnosine’s influence on 
PDK4 mRNA expression was independent from this pathway and possibly also independent 
from any other transcription factor binding within the ~ 4000 bp long 5’-upstream region of 
the human PDK4 gene. Aside from a reduction of Akt phosphorylation in U87 cells, the 
dipeptide did not affect mTORC1 or Akt phosphorylation in glioblastoma cells. As carnosine 
reduced cell viability of glioblastoma cells which were resistant to treatment with Ly-294,002 
and rapamycin, we conclude that the PI3K/Akt/mTORC1 pathway is of less importance for 
the anti-neoplastic effect of the dipeptide.  
Further studies should address the identification of signalling pathways which are influenced 
by carnosine in different cancer cells equally. Indeed, previous studies suggested different 
signalling molecules to be associated with carnosine’s effect. Among them are HIF (Forsberg 
et al. 2015), prohibitin-1 which controls the expression of mitochondrial proteins (Cheng et al. 
2019), the oncogene c-myc (Bao et al. 2018) and Erk1/2 (Rybakova et al. 2013). 
Unfortunately, the published observations are sometimes controversial, as for example in the 
case of HIF. There are reports demonstrating increased HIF signalling (cervix carcinoma 
cells (Ditte et al. 2014)) under the influence of carnosine whereas other reports show 
decreased HIF signalling (colon cancer cells (Iovine et al. 2014)). Hence, care has to be 
taken transferring observations of carnosine’s action on cancer cell signalling from one 
cancer model to another.  
 
2.3 The influence of carnosine on epigenetic regulation in glioblastoma 
cells  
 
As outlined in the preceding chapter, we ruled out that increased expression of PDK4 mRNA 
under the influence of carnosine is mediated by the interaction of transcription factors within 
the promoter region of the gene and known upstream signalling pathways controlling their 
activity. As it was known that PDK4 mRNA expression is also controlled by microRNAs 
(Deng et al. 2018) we also investigated whether carnosine induces PDK4 mRNA expression 
via microRNAs. Therefore, a reporter gene containing the 3’- untranslated region (binding 
sites for microRNAs) of the PDK4 mRNA was employed. This experiment did not reveal an 
effect of carnosine on reporter gene expression. Therefore, we next focussed on the 
possibility that carnosine may affect histone acetylation as it was previously demonstrated 
that PDK4 expression can also be controlled by epigenetic mechanisms, such as DNA 
methylation (Barrès et al. 2012) or histone acetylation (Kwon et al. 2006). First, we compared 
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the effect of different histone deacetylase inhibitors, including trichostatin A which was shown 
to induce PDK4 expression (Kwon et al. 2006), with the dipeptides effect on PDK4 mRNA 
expression. In addition, we performed chromatin immunoprecipitation experiments to analyse 
the acetylation of lysine residues of PDK4 promoter associated histones under the influence 
of carnosine. We also tested whether carnosine may reduce glioblastoma cell viability by an 
effect on histone acetylation. Therefore, the dipeptides effect on cell viability was compared 
to that of other histone deacetylase inhibitors on viability. In addition, an analysis of a 
potential general effect of carnosine on histone acetylation was investigated by Western blot.  
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Abstract
Carnosine (β-alanyl-L-histidine) affects a plethora of signaling pathways and genes in different biological systems. Although 
known as a radical scavenger, not all of these effects can simply be ascribed to its chemical nature. As previous experiments 
pointed towards the possibility that carnosine affects epigenetic regulation via histone acetylation, we investigated this 
hypothesis using the glioblastoma cell lines U87 and T98G in which carnosine’s anti-neoplastic effect is accompanied by 
increased expression of pyruvate dehydrogenase kinase 4. Viability and expression of PDK4 was analyzed after incubation in 
carnosine and different histone deacetylase inhibitors (HDACi) using cell-based assays and qRT-PCR. In addition, chromatin 
immunoprecipitation (ChIP) experiments were performed and the global influence of carnosine on histone H3 acetylation was 
analyzed by Western blot. Carnosine as well as the HDACi used increased expression of PDK4. In addition, all compounds 
reduced cell viability, although differences were observed with regard to magnitude and required concentrations. ChIP 
analysis revealed increased acetylation of histone H3 in the PDK4 promoter of U87 and T98G cells (~ 1.3- and ~ 1.7-fold, 
respectively) 6 h after the addition of carnosine (50 mM) followed by increased expression of PDK4 mRNA. Western blots 
did not detect a general increase of H3 acetylation at a genome-wide scale under the influence of carnosine. Our experiments 
for the first time demonstrate that carnosine influences epigenetic regulation via increased histone acetylation.
Keywords Glioblastoma · Histone deacetylase · Chromatin immune precipitation
Introduction
Carnosine (β-alanyl-L-histidine) was first described by 
Gulewitsch and Amiradzibi (Gulewitsch and Amiradzibi 
1900) more than 100 years ago. It is a naturally occurring 
dipeptide which is especially abundant in human skeletal 
muscle. In gastrocnemius, for example, basal concentra-
tions of 7.2 ± 2.5, 7.2 ± 1.6 and 7.3 ± 1.6 mM (each from 
a group of 10 volunteers) have been reported (Blancquaert 
et al. 2017). Since its discovery, different physiological roles 
have been considered (for review, see Boldyrev et al. 2013). 
Many functions described such as its pH-buffering poten-
tial (Smith 1938), its potential to chelate metal ions (Baran 
2000) or the aspect that it has a role as a scavenger of radical 
oxygen species (Kohen et al. 1988) are based on the assump-
tion that the dipeptides’ functions are simply based on their 
chemical properties. After the discovery that carnosine also 
has anti-neoplastic effects (for review, see Gaunitz and Hip-
kiss 2012 and Hipkiss and Gaunitz 2014), several groups 
identified different influences of the dipeptide on molecular 
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mechanisms that point towards specific effects on signal 
transduction, gene expression and metabolism. Briefly, there 
is evidence that carnosine affects a number of signaling mol-
ecules and pathways including HIF (Iovine et al. 2014), Akt/
mTOR/p70S6 K (Zhang et al. 2014), STAT3 (Wang et al. 
2013), MAPK (Kulebyakin et al. 2012) and KRAS signal-
ing (Iovine et al. 2011). It also affects the transcription of a 
number of genes including RUNX2/Cbfa1 (Ito-Kato et al. 
2004), pyruvate dehydrogenase kinase 1 and 4 (PDK1/4) 
and glucokinase (Letzien et al. 2014) and it interferes with 
glycolytic production of ATP in tumor cells (Oppermann 
et al. 2016). Some of the observations may be retraceable to 
carnosine’s effect on radical oxygen species (ROS), such as 
it was suggested for KRAS and MAPK signaling. In addi-
tion, effects on signaling in turn affect gene expression and 
influence metabolism (or vice versa). However, there is a 
growing body of evidence that the dipeptide exerts its physi-
ological functions by more sophisticated mechanisms than 
simply by detoxifying ROS. This assumption is underlined 
by the fact that the enantiomer D-carnosine, which shares the 
chemical properties of L-carnosine, fails to provoke some of 
the effects observed under L-carnosine, such as the rejuvena-
tion of fibroblasts in vitro (McFarland and Holliday 1994). 
The multitude of the responses observable in single cells, 
tissues and organisms points towards the possibility that car-
nosine’s primary molecular target is high in the hierarchy of 
signaling or that the physiological mechanism affected is of 
such a general importance that its modulation results in a 
plethora of biological effects.
Among the best described effects of carnosine on gene 
expression is the enhancement of mRNA expression of 
PDK4 in cells derived from glioblastoma (Letzien et al. 
2014), which is a tumor of the central nervous system. The 
regulation of PDK4 mRNA expression has been studied 
since many years and several pathways and transcription fac-
tors modulating its expression have been described. Within 
a ~ 850-bp-long 5′-promoter region, functional transcription 
factor-binding sites for glucocorticoids, transcription factors 
from the FOXO family, retinoic acid receptors, estrogen-
related receptors, SP1 and p300/CBP have been identified 
(Kwon and Harris 2004). In addition, there is evidence that 
regulation controlled by these binding sites can be influenced 
by PGC-1α and PPARα (Araki et al. 2007), by PPAR-δ (Bar-
rès et al. 2012) and by PPARγ (Way et al. 2001). It has also 
been shown that PDK4 mRNA is induced in the presence of 
the histone deacetylase inhibitor trichostatin A (TSA) (Kwon 
et al. 2006) and driven down by promoter methylation at 
a single cytosine residue located within a non-CpG site in 
its promoter (Barrès et al. 2012). In addition, influences on 
expression by miRNAs were described (Han et al. 2016). As 
reporter gene assays performed with reporter genes either 
carrying a ~ 4000-bp-long 5′-region (− 3986/+ 319) from the 
human PDK4 gene or a ~ 3700-bp-long 3′-end from the gene 
did not reveal any effect of carnosine on their expression 
(Supplement 1), we hypothesized that enhanced expression 
of the endogenous PDK4 gene may result from an effect 
of carnosine on histone acetylation of the PDK4 promoter 
which may not be detectable by the plasmid-based reporter 
genes used in our experiments. To test this hypothesis, we 
compared the effect of carnosine on viability and on expres-
sion of PDK4 in U87 and T98G glioblastoma cells with the 
effect of different histone deacetylase (HDAC) inhibitors 
using qRT-PCR and cell-based assays. Finally, we analyzed 
PDK4 histone acetylation at the promoter of the gene by 
chromatin immunoprecipitation (ChIP).
Materials and methods
Reagents
Carnosine was kindly provided by Flamma (Flamma s.p.a. 
Chignolo d’Isola, Italy) and β-alanyl-L-alanine was pur-
chased from Bachem (Bubendorf, Switzerland). If not 
stated otherwise all chemicals were purchased from Sigma-
Aldrich (Taufkirchen, Germany) and Carl Roth (Karlsruhe, 
Germany).
Cell culture
U87 and T98G cells were obtained from the ATCC (Manas-
sas, USA) and genotyped (Genolytic GmbH, Leipzig, Ger-
many) to confirm their identity. Cells were propagated in 
250-ml culture flasks (Sarstedt AG & Co., Nümbrecht, 
Germany) using 10 ml of DMEM/4.5 g/l glucose, without 
pyruvate (Life Technologies, Darmstadt, Germany) supple-
mented with 10% fetal bovine serum (FBS superior, Bio-
chrom, Berlin, Germany), 2 mM GlutaMAX (Life Technol-
ogies) and Penicillin–Streptomycin (Life Technologies) at 
37 °C and 5%  CO2 in humidified air in an incubator.
qRT‑PCR experiments
qRT-PCR experiments were carried out as described (Letz-
ien et al. 2014). Briefly,  106 cells were seeded in 10-mm cell 
culture dishes (TPP, Trasadingen, Switzerland) with 10 ml 
of medium. After 24 h of incubation, cells received fresh 
medium containing the compounds to be tested. Cells were 
harvested at the times specified in each experiment and RNA 
was isolated using a miRNeasy mini kit (Qiagen, Hilden, 
Germany) according to the manufacturer’s instructions. 
The RNA was stored at − 80 °C until further use. 500 ng 
of RNA was used for reverse transcription employing the 
ImProm-II™ Reverse Transcription System (Promega, Man-
nheim, Germany) according to the manufacturer’s instruc-
tions using random primer sets. DNA amplification was 
67
Carnosine influences transcription via epigenetic regulation as demonstrated by enhanced…
1 3
performed on a Rotor-Gene 3000 system (Qiagen) employ-
ing SYBR Green (Maxima SYBR Green/ROX qPCR Master 
Mix, Thermo Scientific, Dreieich, Germany). Copy num-
bers of individual mRNAs were determined using linearized 
plasmid DNA (described in Letzien et al. 2014) contain-
ing the corresponding target sequence. Data analysis was 
performed using the Rotor-Gene 6 software and the data 
were processed as described (Letzien et al. 2014). Primer 
sequences used: PDK4_forward: 5′-CTG TGA TGG ATA 
ATT CCC-3′; PDK4_reverse: 5′-GCC TTT AAG TAG ATG 
ATA GCA-3′; TBP_forward: 5′-TGA CCT AAA GAC CAT 
TGC AC-3′; TBP_reverse: 5′-GCT CTG ACT TTA GCA 
CCT GTT-3′; β-actin_forward: 5′-CCG GGA CCT GAC 
TGA CTA CCT-3′; β-actin_reverse: 5′-CCT AGA AGC 
ATT TGC GGT GGA-3′. TATA box-binding protein (TBP) 
was used as reference gene in Fig. 4 for normalizing expres-
sion of PDK4 and β-actin under the influence of carnosine 
as it is not affected by carnosine. However, we identified an 
effect of trichostatin A (TSA) on TBP expression. There-
fore, when TSA was used (Fig. 3), β-actin, which was not 
effected by TSA, was used as reference gene to normalize 
PDK4 expression.
Cell‑based assays
Viability was determined by measuring ATP in cell lysates 
using the CellTiter-Glo Assay and by the determination 
of dehydrogenase activity using the CellTiter-Blue Assay 
(all from Promega, Mannheim, Germany) according to the 
instructions of the manufacturer and as described previously 
(Gaunitz and Heise 2003). All measurements of lumines-
cence and fluorescence were performed using either a Mith-
ras LB 940 Multimode Microplate reader (Berthold Tech-
nologies, Bad Wildbad, Germany) or a Spectra Max M5 
reader (Molecular Devices, Biberach, Germany).
Chromatin immunoprecipitation
For chromatin immunoprecipitation, four culture flasks were 
used for each condition tested. Briefly, 5 × 106 cells were 
seeded in culture flasks (250 ml) in 10 ml of medium. After 
19 h, cells received fresh medium with or without 50 mM 
carnosine. After 3, 6, 9, 12, 15, 18, 21 and 24 h of incuba-
tion, cells from one flask (with or without carnosine) were 
harvested for the determination of cell number and for the 
analysis of PDK4 mRNA expression. Cells from the remain-
ing flasks (three treated with carnosine and three without 
carnosine) were used for ChIP analysis. To each flask 20 ml 
fresh serum-free culture medium with 0.5% formaldehyde 
was added after the old medium was removed. After 10-min 
incubation at room temperature, glycine was added to a final 
concentration of 125 mM. After 5 min at room tempera-
ture, medium was removed and the flasks were transferred 
to ice. Now, cells were washed three times with 20 ml ice-
cold phosphate-buffered saline (PBS; Gibco Thermo Fisher 
Scientific) and finally 1 ml of PBS with a protease inhibi-
tor cocktail was added (aprotinin: 10 µg/ml; benzamidine: 
2.5 mM; leupeptin: 10 µg/ml; pepstatin A: 10 µg/ml, phe-
nylmethylsulfonyl fluoride (PMSF): 2.5 mM; dithiothreitol 
(DTT): 1 mM). Now, cells were mechanically removed using 
a cell scraper (TPP, Trasadingen, Switzerland) and trans-
ferred into 2 ml reaction vials. To transfer all cells, the last 
step was repeated with another 1 ml PBS with inhibitor cock-
tail. Then the suspensions were centrifuged (700×g; 4 °C; 
5 min) and after removal of medium, the pellets were stored 
at − 80 °C if not directly processed further. For shearing, 
pellets were dissolved in SDS lysis buffer (10 mM EDTA; 
1% SDS (sodium dodecyl sulfate); 50 mM Tris/HCl; pH 8.1) 
containing protease inhibitors in the concentrations given 
above. The amount of SDS lysis buffer was adjusted to have 
20 × 106 cells (as estimated from the culture flask that was 
used to determine the cell number) in 1 ml of buffer. Suspen-
sions were then distributed into 1.5 ml reaction vials (each 
with 150 µl suspension) and sonicated for 4 cycles (30 s 
on/30 s off) using a Bioruptor (Diagenode, Liège, Belgium) 
set at high intensity. Then, suspensions were centrifuged 
(10,000×g; 4 °C; 10 min) and the supernatants from cells 
treated with each condition were collected in one vial. After 
success of fragmentation was confirmed by gel electropho-
resis of a small sample (fragmentation size 500–1200 bp), 
comparable amounts of DNA were obtained from cells under 
each condition, using a Nano Drop 1000 (ThermoFisher 
Scientific), 800 µl of fragmented DNA was mixed with 
1200 µl of ChIP-Dilution Buffer (1.2 mM EDTA; 167 mM 
NaCl; 16.7 mM Tris/HCl; 0.01% SDS; 1.1% Triton X-100; 
pH 8.1) containing protease inhibitors as stated above. An 
aliquot of the mixture (10 µl) was stored at − 20 °C to be 
used as “input sample” and 500 µl was transferred to new 
1.5-ml reaction vials. One vial (with 500 µl) received 2 µl 
of rabbit IgG (#2729; Cell Signaling Technologies, Dan-
vers, USA) for negative control and one vial received 10 µl 
anti-acetyl-histone H3 antibody directed against acetyl K9, 
K14, K18, K23, and K27 (ab47915; Abcam, Cambridge, 
UK). The vials were incubated at 4 °C overnight using a 
tube rotator (SB3 Rotator; Cole-Parmer Ltd; Staffordshire; 
UK) and the next day ChIP-Grade Protein G Magnetic Beads 
(30 µl; Cell Signaling Technology) were added to each vial. 
Tubes were again continuously mixed for 2 h at 4 °C using 
the tube rotator before the beads were collected for 3 min 
using a magnetic stand. Then the supernatant was carefully 
removed and the pellets were washed three times with 1 ml 
of low-salt buffer (2 mM EDTA; 150 mM NaCl; 0.1% SDS; 
20 mM Tris/HCl; 1.1% Triton X-100; pH 8.1) for 5 min at 
4 °C using the rotator. After the last collection and removal 
of residual low-salt buffer 1 ml of high-salt buffer (2 mM 
EDTA; 350 mM NaCl; 0.1% SDS; 20 mM Tris/HCl; 1.1% 
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Triton X-100; pH 8.1) was added and the beads were again 
incubated for 5 min at 4 °C using the rotator. After the final 
removal of the high-salt buffer, ChIP-elution buffer (150 µl; 
1% SDS; 100 mM  NaHCO3) was added to each pellet and to 
the pre-thawed 10 µl of “input sample”. Pellets dissolved in 
ChIP-elution buffer were incubated for 30 min at 65 °C and 
1200 rpm using a thermomixer. Finally, the magnetic beads 
were collected using a magnetic stand (3 min) before super-
natants were transferred to 1.5-ml reaction vials. To each 
supernatant and the “input sample”, 6 µl of NaCl solution 
(5 M) was added before overnight incubation at 65 °C and 
700 rpm using a thermomixer. After overnight incubation, 
1 µl of RNase A (10 mg/ml), 2 µl of Proteinase K (20 mg/
ml), 4 µl EDTA (0.5 M) and 17 µl of Tris/HCl (0.5 M; pH 
7.4) were added to each vial and incubation proceeded for 
3 h at 37 °C and 800 rpm in a thermomixer. Finally, DNA 
for PCR was extracted using a PCR-extraction Kit (Qiagen). 
Then, qRT-PCR was performed using “ChIP-primers” for 
PDK4 and β-actin with the following primer sequences: 
ChiP_PDK4 forward: 5‘-TCA CTG GAA CTT GGA AAC 
GC-3‘;ChiP_PDK4_reverse: 5‘-TCC GTG GTC ACC GTG 
CC-3‘;ChiP_β-actin_forward: 5‘-GGC CAC TTA GAA GTC 
GCA GGA 3‘-3‘;ChiP_β-actin_reverse: 5‘-GGC TGG GCG 
TGA CTG TT -3‘.
To calculate the relative change of histone acetylation 
(for β-actin in triplicate and for PDK4 expression in quintu-
plicate), measurements were normalized to the signal of the 
corresponding input sample.
Western blot analysis
Western blot experiments were performed with cells cul-
tivated at a density of  106 cells per dish in 10-cm culture 
dishes. For total protein isolation, cells were washed twice 
with ice-cold washing buffer (137 mM NaCl, 5.4 mM HCl, 
0.41  mM  MgSO4, 0.49  mM  MgCl2, 0.126  mM  CaCl2, 
0.33 mM  Na2HPO4, 0.44 mM  KH2PO4, 2 mM HEPES, pH 
7.4) and finally collected in 1 ml of washing buffer. After a 
centrifugation (5 min, 500×g, 4 °C), cells were suspended 
in 150 µl of ice-cold RIPA buffer (50 mM Tris, 150 mM 
NaCl, 0.25% sodium deoxycholate, 0.1% SDS, 1% Nonidet 
P40) supplemented with PhosSTOP and a protease inhibitor 
cocktail (0.025 g/L aprotinin, 0.025 g/L leupeptin, 0.01 g/L 
pepstatin A, 1 mM dithiothreitol, 2.5 mM phenylmethylsul-
fonylfluoride and 2.5 mM benzamidine). After 10 min of 
incubation on ice, cells were lysed by sonification (Biorup-
tor, Diagenode, Seraing, Belgium; settings: power: high, 
interval: 0.5, time: 7 min), the debris removed by centrifu-
gation (5500×g at 4 °C for 5 min) and the supernatant was 
transferred into new 1.5-ml reaction tubes. The protein con-
centration was determined using the Pierce 660 nm assay 
reagent according to the manufacturer’s instructions. Pro-
teins were stored at − 80 °C or immediately used for SDS 
polyacrylamide gel electrophoresis (SDS-PAGE). For his-
tone isolation, cells were washed three times with ice-cold 
histone extraction buffer (5 mM sodium butyrate in phos-
phate-buffered saline; pH 7.4). After addition of 1 ml histone 
extraction buffer, cells were transferred to a 1.5-ml reaction 
vial using a cell scraper. Cells were collected by centrifuga-
tion (500×g; 5 min; 4 °C) and resuspended in 100 µl of ice-
cold Triton buffer (histone extraction buffer containing 0.5% 
Triton X-100; 2 mM PMSF and 0.02%  NaN3). After minc-
ing by ten strokes using a 1-ml Dounce tissue grinder with 
PTFE pestle (Wheaton/Fisher Scientific), cells were put on 
ice for 10 min. Then, the lysate was centrifuged (10,000×g; 
10 min; 4 °C) and the pellet was washed once with 50 µl of 
ice-cold Triton buffer, followed by a second centrifugation 
step (10,000×g; 10 min; 4 °C). The pellet was resuspended 
in 25 µl 0.2 N HCl and the solution was incubated overnight 
at 4 °C and 950 rpm using a thermomixer. The next day, 
debris was pelleted by centrifugation (10,000×g; 10 min; 
4 °C) and the supernatant was transferred to a 1.5-ml reac-
tion vial. After the determination of their concentration, 
proteins were stored at − 20 °C or immediately used for 
SDS-PAGE. SDS-PAGE was performed according to stand-
ard protocols using a Mini-PROTEAN® System (Bio-Rad, 
Munich, Germany). A concentration of 12% acrylamide was 
used to separate proteins and a concentration of 20% to sepa-
rate histone extracts. After electrophoresis, proteins were 
transferred to PVDF membranes (Low-Fluorescence Mem-
brane 0.2 µm, Biozym, Oldendorf, Germany) using a Mini 
Trans-Blot® Cell (Bio-Rad). The membrane was blocked 
using  Odyssey® Blocking Buffer for 1 h at room tempera-
ture. Then, the membranes were incubated with antibodies 
diluted 1:1000 in TBST (20 mM Tris, 134 mM NaCl, 0.1% 
Tween 20). The primary antibodies used were mouse anti-
PDK4 (Abcam; ab110336), rabbit anti-GAPDH (1:5000; 
Cell Signaling; #2118), mouse anti-histone H3 (Cell Sign-
aling; #3638) and rabbit anti-acetyl-histone H3 (Abcam; 
ab47915). The secondary antibodies employed (red fluores-
cent  IRDye® 680RD Goat anti-Mouse and green fluorescent 
 IRDye® 800CW Goat anti-Rabbit; both diluted 1:5000 in 
TBST) were purchased from LI-COR (LI-COR Biosciences, 
Lincoln, USA). Membranes were scanned using an Odys-
sey Imaging System (LI-COR, Bad Homburg, Germany) 
and band intensities were determined by the Image Studio 
5 software (LI-COR).
Determination of oxygen consumption rate
For the determination of the oxygen consumption rate 
(OCR), 2500 cells were seeded in 80 µl of medium in an 
XF96 cell culture microplate (Seahorse Bioscience, Bill-
erica, MA). After 19 h, cells received fresh medium con-
taining 20 or 50 mM carnosine or vehicle control. After 
additional 24 h of incubation, cells were washed twice with 
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Seahorse XF DMEM medium containing 4.5 g/L glucose 
and 2 mM L-glutamine and OCR was determined in the same 
medium using an XF96 Extracellular Flux Analyzer accord-
ing to the instructions of the manufacturer. After comple-
tion of the assay, cells were lysed in 20 µl of lysis buffer 
(77.05 mM  K2HPO4, 22.9 mM  KH2PO4, 1 mM dithiothrei-
tol, 0.2% Triton X-100, pH 7.8) and the amount of protein 
was determined using the Pierce 660-nm assay.
Statistical analysis
One-way and two-way ANOVA analyses with post hoc 
Tukey test have been performed using OriginPro 2017GS 
(OriginLab Corporation, Northampton, USA). When appli-
cable, an unpaired Student’s t test with unequal variances 
was performed using the algorithms implemented in Excel 
(Microsoft, Richmond, USA). Relative data resulting from 
two or more experiments or parameters (normalization to 
reference) with a separate mean and standard deviation are 
presented using Gaussian error propagation as described 
before (Letzien et al. 2014).
Results
PDK4 mRNA expression in U87 cells 
under the influence of carnosine and different HDAC 
inhibitors
Previous experiments demonstrated that PDK4 mRNA 
expression is increased when cells from the glioblastoma 
cell line U87 are exposed to carnosine (Letzien et al. 2014). 
As we hypothesized that this effect is mediated via increased 
histone acetylation, we compared the effect of carnosine on 
PDK4 mRNA expression with the effect of other known 
HDAC inhibitors. For the experiment, U87 cells were incu-
bated for 24 h in the presence of carnosine (Car; 50 mM), 
belinostat (Bel; 4 µM), valproate (Val; 4 mM), TSA (1.6 µM) 
or SAHA (4 µM). In addition, we also included resveratrol 
(Res; 100 µM) in our experiments although it is not a clas-
sical HDAC inhibitor, but was also shown to affect histone 
acetylation (Venturelli et al. 2013). In Fig. 1, expression of 
PDK4 mRNA under the influence of the compounds is pre-
sented. All compounds significantly increased expression 
of PDK4 mRNA compared to untreated control cells. The 
greatest increase was obtained with carnosine (4.3 ± 0.7-fold; 
p < 0.005) followed by belinostat (2.9 ± 0.2-fold; p < 0.0005), 
TSA (2.5 ± 0.1-fold; p < 0.0005), valproate (2.2 ± 0.0-fold; 
p < 0.0005), SAHA (2.1 ± 0.2-fold; p < 0.0005) and resvera-
trol (1.7 ± 0.2-fold; p < 0.0005). In addition, statistical analy-
sis revealed that expression under the influence of carnosine 
was significantly strongly increased compared to any other 
HDACi (p < 0.05–p < 0.005) at the concentrations employed 
in the experiment. At this point, it may also be interesting 
to note that none of the compounds had a significant effect 
on the expression of the reference gene β-actin (data not 
shown).
Viability of U87 glioblastoma cells 
under the influence of carnosine and different HDAC 
inhibitors
Next, we asked whether the HDAC inhibitors used in the 
previous experiments have an effect on viability comparable 
to that described for carnosine (Letzien et al. 2014). There-
fore, U87 cells were incubated for 24 and 48 h in the pres-
ence of the compounds used in the previous experiment. In 
Fig. 2, the result of the determination of cell viability is pre-
sented and statistical significance is indicated by a pairwise 
statistical analysis using Student’s t test comparing cells 
treated with a compound to untreated cells. As can be seen, 
carnosine at a concentration of 50 mM significantly reduced 
viability after 24 and 48 h of incubation (all: p < 0.0005) and 
all compounds employed inhibited tumor cell viability after 
48-h exposure and at the highest concentration employed 
aside from valproate when measuring dehydrogenase activ-
ity after 48 h. Although the high variation of response to the 
different concentrations employed and the inhibitors used 
makes it difficult to compare the effect of carnosine on any 
Fig. 1  PDK4-mRNA expression in U87 cells incubated in the pres-
ence of different compounds after 24-h exposure. U87 cells were 
exposed to carnosine (Car; 50 mM), belinostat (Bel; 4 µM), valproate 
(Val; 4  mM), TSA (1.6  µM), SAHA (4  µM) or resveratrol (Res; 
100  µM) and the relative level of expression of PDK4 mRNA was 
determined after 24 h of incubation from five individually treated cul-
tures for each compound. The increase of PDK4 mRNA expression 
under the influence of the test compounds was calculated in relation 
to PDK4 mRNA expression in untreated control cells and statistically 
analyzed by pairwise comparison of treated cells to untreated control 
cells using Student’s t test. **p < 0.005; ***p < 0.0005
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other HDACi, it is obvious that all HDAC inhibitors nega-
tively influenced tumor cell viability as does carnosine.
Expression of PDK4 mRNA in U87 cells combining 
different concentrations of carnosine and TSA 
indicates that both compounds have common 
molecular targets
Next, we performed an experiment exposing cells to the 
HDAC inhibitor TSA together with carnosine for 24 h. We 
hypothesized that in case both compounds exert their effect on 
PDK4 mRNA expression by the same mechanism (e.g., his-
tone acetylation) no additive effect of a compound should be 
visible when the other compound already shows a maximum 
effect. The result of a corresponding experiment is presented 
in Fig. 3. As can be seen, at a concentration of 20 mM carnos-
ine, expression of PDK4 mRNA can significantly be increased 
with increasing concentrations of TSA (for p values, refer to 
Fig. 3), whereas at a concentration of 50 mM carnosine, an 
increase in the concentration of TSA from 0.8 to 1.6 μM does 
not result in a further significant increase in expression (Fig. 3, 
left panel). In addition, PDK4 mRNA expression at a concen-
tration of 0, 0.4 and 0.8 μM TSA can be further increased by 
increasing concentrations of carnosine (for p values, refer to 
the figure), whereas at a concentration of 1.6 μM, TSA expres-
sion is not significantly different between 20 mM carnosine 
and 50 mM carnosine. This observation points towards the 
possibility that carnosine and TSA may in fact affect PDK4 
mRNA expression via a common mechanism.
Fig. 2  Viability of U87 cells incubated in the presence of differ-
ent compounds after 24- and 48-h exposure. Cells from the line U87 
were cultivated in the presence of 50 mM carnosine, belinostat (1, 2 
or 4 µM), valproate (1, 2, 4 mM), TSA (0.8 and 1.6 µM), SAHA (1, 2 
or 4 µM) or resveratrol (25, 50 or 100 µM). For control, cells received 
fresh medium without any compound. After 24 (upper panels) and 
48  h (lower panels), viability was determined by measuring the 
amount of ATP in cell lysates (left panels) and by determining dehy-
drogenase activities (right panels). The values obtained were normal-
ized to those obtained analyzing cells treated without supplement set 
as 100%. All experiments were performed in sextuplicate and the 
means and standard deviations are presented. Statistical analysis was 
determined by pairwise comparison of cells treated with compound 
at the indicated concentration to untreated cells using Student’s t test: 
*p < 0.05; **p < 0.005; ***p < 0.0005
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Chromatin immune precipitation identifies 
increased histone acetylation of the PDK4 promoter 
after exposure to carnosine followed by enhanced 
mRNA expression
The experiments described in the preceding chapters 
pointed towards the possibility that the effect of carno-
sine on PDK4 expression may be caused by increased 
histone acetylation. To test this notion, we decided to 
investigate the acetylation of PDK4 promoter-associated 
histones by chromatin immunoprecipitation (ChIP) using 
U87 and T98G cells treated with 50 mM carnosine. As 
acetylation is known to be a highly dynamic process, we 
performed the experiments with cells incubated for 3, 
6, 12, 18 and 24 h. In addition, we also determined the 
amount of mRNA encoding PDK4 by qRT-PCR after 3, 6, 
9, 12, 15, 18, 21 and 24 h of incubation in the presence or 
absence of 50 mM carnosine. The result of the experiment 
is presented in Fig. 4. For control, we also determined 
the amount of mRNA encoding β-actin as well as histone 
acetylation of the corresponding gene. As can be seen in 
Fig. 4, we identified increased acetylation of PDK4-asso-
ciated histones at 6-h exposure in both cell lines, followed 
by an increase in mRNA expression. This demonstrates 
that exposure to carnosine results in enhanced histone 
acetylation at the PDK4 promoter followed by induction 
of its expression. In addition, no statistically different 
expression of β-actin was observed under the influence of 
carnosine in T98G cells and only a small but significant 
reduction of β-actin mRNA expression (as revealed by 
two-way Anova) was seen in U87 cells after 9- (p < 0.05) 
and 21-h exposure (p < 0.0005).
Histone acetylation under the influence of carnosine 
and Trichostatin A determined by Western blot 
of histone extracts
The experiments of the preceding section indicated that car-
nosine does increase histone acetylation of the PDK4 gene 
and there was no indication of enhanced histone acetylation 
of the gene encoding β-actin. We now asked whether we could 
detect a general influence on histone acetylation under the 
influence of carnosine as it is the case with HDACs such as 
TSA or valproate for which acetylation of H3 can be detected 
in Western blots (He et al. 2014). For the experiment, U87 and 
T98G cells were incubated for 6 h in the presence of 50 mM 
carnosine or 1.6 µM TSA and Western blots using antibodies 
directed against histone 3 and against histone H3 acetylated 
at K9; K14; K18; K23 and K27 were performed. Representa-
tive Western blots are presented in Fig. 5. Whereas a strong 
increase in the amount of acetylated H3 was detectable in the 
presence of TSA in both cell lines, the amount of detectable 
acetylation of H3 was even slightly reduced in the presence 
of carnosine, although the effect was in no case significant 
as deduced by one-way ANOVA. This demonstrates that the 
effect of carnosine on histone acetylation is obviously different 
from TSA which has a broad-spectrum inhibiting class I and 
class II deacetylases in mammals.
Discussion
Since its discovery, many different physiological functions 
have been ascribed to carnosine. With the advent of mod-
ern techniques allowing the analysis of signal transduction 
Fig. 3  PDK4-mRNA expression in U87 cells incubated in the pres-
ence of carnosine and TSA after 24-h exposure. U87 cells were 
exposed to different concentrations of carnosine (Car: 20, 50  mM) 
and TSA (0.4, 1.6  µM). After 24  h, the increase of PDK4 mRNA 
expression under the influence of the test compounds was analyzed 
by the comparison of expression in the presence of the compounds 
to expression in untreated control cells (all in quintuplicate). Pair-
wise statistical analysis was performed by Student’s t test. *p < 0.05; 
**p < 0.005; ***p < 0.0005. n.s.: not significant
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pathways and gene expression profiles, it became evident 
that the broad range of different physiological and pharma-
cological observations made are also reflected by a broad 
range of cellular responses. The high pleiotropy of effects 
observed and the fact that different biological models 
respond differently to the dipeptide already led to the notion 
that carnosine may have specific functions aside from effects 
based on its chemical nature, e.g., having buffer or metal-
chelating capacity.
Previous experiments performed in our group identi-
fied an increase in mRNA expression of PDK4 under the 
influence of carnosine. Analyzing the known regulatory 
mechanisms responsible for increased PDK4 expres-
sion by reporter gene assays, including interactions in the 
5′-upstream and the 3′-downstream region, we were not able 
to identify interactions with transcription factors or miRNAs 
with regulatory sequences of the PDK4 gene as responsible 
for the effect of carnosine on endogenous PDK4 expression 
(Supplemental Fig. 1). As it was known that PDK4 mRNA 
expression can also be increased by increased histone acety-
lation (Kwon et al. 2006) we asked whether carnosine may 
be able to influence histone acetylation.
The results presented for the first time provide evidence 
that carnosine influences the acetylation of histones. The 
acetylation of lysine residues in core histones by histone 
acetyl transferases (HATs) neutralizes the positive charge 
of side chains, promoting a less dense chromatin structure 
which allows transcriptional activation, whereas deacetyla-
tion by HDACs promotes a less relaxed state, inhibiting tran-
scription (Kuo and Allis 1998). The ChIP assay described in 
the present manuscript is in good agreement with the notion 
that carnosine does in fact influence histone 3 acetylation at 
least within the PDK4 promoter. However, it appears that 
the effect of carnosine on acetylation is different from that 
of other classical HDAC inhibitors. We could clearly dem-
onstrate increased histone acetylation of the PDK4 promoter 
Fig. 4  PDK4 and β-actin mRNA expression in relation to histone 
acetylation of their corresponding genes after treatment with carno-
sine. Cells from the lines U87 (left panels) and T98G (right panels) 
were incubated in the absence and presence of carnosine. ChIP anal-
ysis and expression analysis of mRNA encoding PDK4 and β-actin 
were performed before the addition of carnosine (0  h control) and 
after 3, 6, 9, 12, 15, 18, 21 and 24 h of incubation. The upper panels 
show the relative mRNA expression of cells treated with carnosine 
and of untreated control cells (in fold, relative to the level of expres-
sion before the addition of carnosine). qRT-PCR of β-actin was per-
formed in triplicate and of PDK4 expression in quintuplicate. Stars 
in the upper panels indicate significant differences (as determined 
by pairwise Student’s t test between treated and untreated cells at 
each individual time point) in the expression mRNA either encoding 
β-actin or PDK4. *p < 0.05; **p < 0.005; ***p < 0.0005
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by ChIP, but no general effect on histone 3 acetylation in 
Western blots, which we observed under the influence of 
TSA. General effects have also been described for SAHA 
(Xu et al. 2014), belinostat [previously known as PXD101 
(Mackay et al. 2010)] and valproate (Chavez-Blanco et al. 
2005). At this point it should also be taken into account that 
we cannot rule out the possibility that instead of inhibiting 
HDACs carnosine may positively influence the activity of 
HATs, although its anti-neoplastic effect points towards its 
function as an inhibitor of deacetylation (Cohen et al. 2011). 
However, this is highly speculative and further experiments 
will be required to resolve the exact mechanisms by which 
carnosine influences histone acetylation. The same holds 
true for the question whether carnosine may directly interact 
with a histone-modifying enzyme or whether its effect is of 
secondary nature, e.g., influencing the NAD/NADH ratio or 
the supply with acetyl-CoA.
Although the focus of our work was to analyze whether 
carnosine affects histone acetylation, we also wondered 
whether increased expression of PDK4 influences pyruvate 
dehydrogenase activity and in turn mitochondrial oxidative 
phosphorylation. By performing Western blot analysis we 
were not able to detect PDK4 protein expression in U87 cells 
independent of whether cells were treated with carnosine 
or not. In T98G cells, PDK4 protein was detectable, but 
no change in PDK4 protein expression under the influence 
of carnosine was observed (Supplement 2 a). In addition, 
when we analyzed the oxygen consumption rate (OCR) of 
U87 and T98G cells by a Seahorse XF analyzer, we did 
not see a change in the OCR after 24 h of incubation in the 
presence of 20 or 50 mM carnosine (Supplement 2b). This 
obvious discrepancy between protein expression and mRNA 
expression and the absence of an effect of carnosine on the 
OCR after 24-h exposure to the dipeptide raise the interest-
ing question of whether the tumor cells are able to prevent 
enhanced protein expression of PDK4 by a mechanism that 
counteracts the enhanced expression of mRNA encoding 
PDK4. As the activity of a reporter gene, which contained 
the 3′UTR of the PDK4 gene, was not influenced by carno-
sine (Supplemental Fig. 1), we rule out the possibility that a 
miRNA is responsible for the effect.
An interesting question that also has to be asked is 
whether the high concentrations of carnosine (up to 50 mM) 
used in our experiments do reflect physiological doses. This 
is certainly not the case although it is difficult to tell which 
concentrations are reached at a specific site in an organism. 
It should also be kept in mind that cell culture experiments 
are always far away from the physiological situation and can 
only help to get an idea of which mechanism is affected in an 
individual. With regard to carnosine, the situation is espe-
cially difficult as carnosine administered to humans is prone 
to rapid degradation by serum carnosinase. On the other 
hand, it has been discussed that there must be some kind 
of depot where carnosine is protected from degradation. In 
experiments with volunteers that orally ingested carnosine, 
it was demonstrated that the dipeptide is secreted with the 
urine even 5 h after ingestion. At this time the concentra-
tions in serum are already below the detection level (Gard-
ner et al. 1991). Therefore, a certain tissue may be able to 
pick up significant amounts of carnosine, accumulating the 
dipeptide in amounts much higher as supposed by measuring 
serum concentrations. At this point it should also be noted 
that we currently rule out the possibility that osmotic effects 
are responsible for the effects observed, as dipeptides such 
as β-Ala-L-Ala (also at a concentration of 50 mM) do not 
influence viability of tumor cells (Supplement 3).
In conclusion, under the experimental condition used 
by our group, we could for the first time demonstrate that 
carnosine influences histone acetylation which could well 
be one key to understand the multiple and different effects 
carnosine has in different model systems, tissues and organ-
isms. It would be highly interesting to investigate which 
other genes in addition to PDK4 are activated by histone 
acetylation under the influence of carnosine. This could, 
for example, be done by ChIP followed by next-generation 
sequencing. In addition, the question how transcription is 
influenced under physiological concentrations of carnosine 
and in other tissues and whether in other tissues enhanced 
expression of PDK4 mRNA may be followed by enhanced 
protein expression and changes of PDH enzyme activity 
should be answered.
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In summary, we have shown that carnosine induces the mRNA expression of the PDK4 gene 
by increasing acetylation of PDK4-promoter associated histones. To our knowledge, this is 
the first report demonstrating that the dipeptide is able to affect transcription by an epigenetic 
mechanism. As a general effect on histone acetylation by the dipeptide, as determined by 
Western blot, was not detected, we concluded that carnosine does not conduct its effects like 
a classical histone deacetylase inhibitor such as trichostatin A. This notion was supported by 
determining cell viability. In these experiments only one out of five histone deacetylase 
inhibitors could mimic carnosine’s effect on viability. 
In further studies it has to be evaluated whether carnosine’s effect on histone acetylation 
may affect the expression of other genes. These investigations could potentially reveal clues 
understanding mechanisms responsible for carnosine’s other effects, such as those on 
ageing, on the mitigation of symptoms of neurological disorders and on wound healing (see 
1.3 Carnosine in health and disease). 
 
2.4 The influence of carnosine on glioblastoma cell metabolism 
 
Previously, our group demonstrated that carnosine inhibits glycolytic ATP production in 
glioblastoma (Renner et al. 2010a) which was confirmed also in other tumour entities (Bao et 
al. 2018; Shen et al. 2014). However, the mechanisms behind carnosine’s effect on glucose 
metabolism are far from being understood. In the study of Oppermann et al. (Oppermann et 
al. 2016a) we investigated the response of glioblastoma cells, when glucose supply is 
reduced or glycolysis is bypassed via substitution of glucose by pyruvate. For these 
experiments we omitted the use of foetal bovine serum which influences metabolic fluxes in 
an undefined manner, as serum contains more than 2000 different compounds (Psychogios 
et al. 2011). By determining L-lactate, methylglyoxal which arises by non-enzymatic 
elimination of phosphate from GA3P and DHAP, and its detoxification product D-lactate, we 
analysed how different glucose concentrations or pyruvate in medium contribute to the 
glycolytic flux. Furthermore, the amount of ATP in cell lysates was determined to monitor 
energy balance of glioblastoma cells after treatment. In order to investigate how metabolites 
are affected by different supply of glucose, we analysed the associated metabolic changes 
using gas chromatography coupled to mass spectrometry (GC-MS).  
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Background: Tumor cells are highly dependent on glucose even in the presence of oxygen. This concept called
the Warburg effect is a hallmark of cancer and strategies are considered to therapeutically exploit the phenomenon
such as ketogenic diets. The success of such strategies is dependent on a profound understanding of tumor
cell metabolism. With new techniques it is now possible to thoroughly analyze the metabolic responses to the
withdrawal of substrates and their substitution by others. In the present study we used gas chromatography
coupled to mass spectrometry (GC-MS) to analyze how glioblastoma brain tumor cells respond metabolically
when glucose is withdrawn and substituted by pyruvate.
Methods: Glioblastoma brain tumor cells were cultivated in medium with high (25 mM), medium (11 mM) or low (5.
5 mM) glucose concentration or with pyruvate (5 mM). After 24 h GC-MS metabolite profiling was performed.
Results: The abundances of most metabolites were dependent on the supply of glucose in tendency but not in a
linear manner indicating saturation at high glucose. Noteworthy, a high level of sorbitol production and release was
observed at high concentrations of glucose and high release of alanine, aspartate and citrate were observed when
glucose was substituted by pyruvate. Intermediates of the TCA cycle were present under all nutritional conditions
and evidence was found that cells may perform gluconeogenesis from pyruvate.
Conclusions: Our experiments reveal a high plasticity of glioblastoma cells to changes in nutritional supply which
has to be taken into account in clinical trials in which specific diets are considered for therapy.
Keywords: Cancer, Glucose, Pyruvate, Metabolite profiling, Glioblastoma, Warburg effect
Background
In many studies published in recent years the analysis
of tumors predominately focused on gene and protein
expression as well as on signal transduction in order to
draw conclusions about the biology of cancer. Compared
to the high amount of literature focusing on these topics
much less has been investigated with regard to cancer cell
metabolism despite the fact that the peculiarities of energy
metabolism in tumors have already been investigated at
the beginning of the last century [1].
The most prominent feature of tumor cell metabolism
is the so-called Warburg effect which describes a strong
dependence on glycolytic production of ATP accompanied
by the conversion of pyruvate to lactate even in the pres-
ence of oxygen (aerobic glycolysis). In his article from
1956 which was a translation of a lecture delivered in
1955, Warburg still proposed that “respiration” (OxPhos)
must be irreversibly injured in cancer cells [2]. Although
the concept has been refined, it is still common sense that
in many cancer cell lines as well as in solid tumors the
production of lactate is more pronounced than the pro-
duction of pyruvate. Pyruvate accounts for 60–75 % of the
metabolic consumption of external glucose whereas the
production of acetyl-CoA from pyruvate accounts for ~10
to 25 % of the glycolytic flux [3, 4]. At this point it should
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also be kept in mind that only a fraction of the acetyl-CoA
produced from pyruvate is used for the production of
ATP [3, 4].
Aerobic glycolysis is still considered to be a hallmark
of cancer [5] and up to now no breakthrough thera-
peutic strategy exploiting this potential Achilles heel of
cancer has been developed. Aside from research on
drugs that could possibly be used for a “metabolic ther-
apy” (for review see [6]), several authors and clinicians
focused on the development of diets especially high in
fat and low in carbohydrates. These so-called ketogenic
diets were considered having beneficial effects by forcing
cells to utilize fatty acids as their primary energy source
[7–10]. Aside from the increasing amount of data imply-
ing that the ketogenic diet is an effective adjuvant cancer
therapy (for a summary of current mouse models and
clinical trials see [11]), the underlying mechanisms
might be more complex involving also anti-angiogenic,
anti-inflammatory and pro-apoptotic processes [12].
However, it is without question that the development of
successful strategies targeting tumor-specific metabol-
ism requires a thorough understanding of the under-
lying mechanisms, especially of the mechanisms that
enable tumor cells to switch from one substrate to an-
other under defined dietary constraints. Unfortunately,
up to now, most investigations focused on proteins re-
quired for the glycolytic flux and much research has
been committed to the analysis of their activity [6, 13].
In addition, a number of transcription factors and path-
ways involved in the up-regulation of the corresponding
genes have frequently been identified to be aberrantly
regulated in cancer such as c-Myc, Hif-1α or mTOR
[14]. Much less research has been done on the metabo-
lites and their concentration as the available methods
have been cumbersome and mostly out of fashion. With
the advent of improved technologies such as liquid or
gas chromatography (GC) coupled to mass spectrometry
(MS) the biochemical analysis of pathway fluxes and
changes of single metabolite concentrations under dif-
ferent physiological conditions became possible in an
elegant and precise manner.
In the present work we used GC coupled to MS to
analyze the metabolic response of glioblastoma cells to
the presence of different concentrations of glucose and
in a situation when glucose is substituted by pyruvate.
Glioblastoma is the most aggressive and most frequent
primary brain tumor in adults with a median survival
after biopsy and standard therapy of only 14.6 months
[15]. As previous experiments pointed towards the im-
portance of glycolysis for the survival of cells derived
from this highly malignant tumor and the possibility that
pyruvate may become important under conditions of
impaired glycolysis [16], we analyzed metabolite abun-
dances under different concentrations of glucose and in
medium in which glucose was substituted by pyruvate.
In addition, we omitted medium supplements commonly
used such as fetal bovine serum or glutamine which
significantly influence metabolic fluxes and in the case
of serum in an even undefined manner.
Methods
Chemicals and reagents
If not stated otherwise all chemicals were purchased
from Sigma-Aldrich (Taufkirchen, Germany).
Cell culture
U87 cells were originally obtained from the ATCC
(Manassas, USA) and cultured in 250 mL culture flasks
(Sarstedt AG & Co., Nümbrecht, Germany) using
DMEM/25 mM glucose, without pyruvate (Life Tech-
nologies, Darmstadt, Germany) supplemented with
10 % fetal bovine serum (FBS superior, Biochrom,
Berlin, Germany), 2 mM GlutaMAX and antibiotics
(Life Technologies) at 37 °C and 5 % CO2 in humidi-
fied air in an incubator. In order to confirm identity
over long culture periods, cells were genotyped by STR
analysis at the Genolytic GmbH (Leipzig, Germany)
using a PowerPlex® 21 System (Promega, Mannheim,
Germany) and cells were confirmed as the U87MG cell
line from the ATCC [17]. For starvation experiments,
U87 cells were seeded in 6-well plates (TPP, Trasadigen,
Switzerland) at a density of 106 cells per well in 2 mL full
supplemented DMEM (10 % FBS, GlutaMAX, antibiotics)
and incubated for 3 h before receiving fresh medium
(1 mL) without a carbon source and without GlutaMAX
and FBS (DMEM [0]). Cells were incubated for 20 h be-
fore replacing the culture medium with medium (1 mL)
containing either different concentrations of glucose or
medium without glucose but pyruvate at a concentration
of 5 mM.
Determination of extracellular lactate
After incubation, media were collected for lactate deter-
mination and cells were lysed in 200 μL lysis buffer
(77 mM K2HPO4, 23 mM KH2PO4, 0.2 % TritonX-100,
pH 7.8) and the protein content was determined using
the Pierce 660 nm Protein Assay (Thermo Scientific,
Braunschweig, Germany). For D-lactate determination
collected medium (100 μL) was evaporated to dryness
and dissolved in H2Odd (25 μL). For the determination
of L-lactate, H2Odd (20 μL) was added to collected
medium (5 μL). Then, prepared samples (20 μL) were
incubated in the wells of a black 96 well plate (Greiner
Bio One, Frickenhausen, Germany) in the presence of
enzyme mix (224 μL) consisting of 430 mM glycine,
340 mM hydrazine sulfate, 5 mM NAD and 10 U L-
lactate dehydrogenase (Megazyme, Wicklow, Ireland)
(pH 9) for L-lactate and 490 mM glycine, 200 mM
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hydrazine sulfate, 1 mM DETAPAC, 5 mM NAD and
100 U D-lactate dehydrogenase (pH 9.2) for D-lactate
(Megazyme) (final concentration for all formulations) for
90 min at room temperature. Production of NADH was
observed by fluorometric detection (excitation/ emission
= 340/ 460 nm) using a SpectraMax M5 Microplate
Reader (Molecular Devices, Biberach, Germany) [18].
A standard curve was prepared using 0.375 to 10 μg
D/L-lactate.
Determination of free MGO
U87 cells were seeded as described above. After 20 h in
medium without a carbon source and without serum,
cells received fresh medium (1 mL) supplemented with
the compounds to be tested. After 24 h of incubation,
cells were washed with ice cold washing buffer (1 mL of
100 mM Tris/HCl, pH 8.0) and then 70/30 methanol/
H2O (v/v; 430 μL) containing 1.16 mM O-(2,3,4,5,6-pen-
tafluorobenzyl)hydroxylamine (PFBHA) was instantly
added to each well. After shaking for 10 min at room
temperature, the plates were placed on a shaking incuba-
tor at 40 °C for 1 h derivatization. Afterwards, the solu-
tion was transferred into a 1.5 mL reaction vial. Then,
9 M H2SO4 (10 μL) and cyclohexane (200 μL) was added
to each sample. The solution was vortex mixed, followed
by a brief centrifugation. The upper organic phase was
transferred into a clean conical glass insert. This extrac-
tion procedure was performed three times in total. The
collected extract was evaporated to dryness using a gen-
tle stream of air, analytes were dissolved in cyclohexane
(60 μL) containing suberic acid dimethyl ester as internal
standard (cyclohexane: internal standard = 10000:1, v/v)
and analyzed by GC-MS.
GC-MS analysis of intracellular MGO samples
Free MGO from cell extracts was analyzed on an Agilent
6890 N gas chromatograph equipped with a 7683 Series
auto sampler and a 30-m J&W Fisher DB-35 ms capillary
column (250-μm I.D. and 0.25 μm film) coupled with a
5973 N mass selective detector (all modules and columns
from Agilent Technologies, Waldbronn, Germany). Sam-
ples (2 μL) were injected at 250 °C in splitless mode with
helium as carrier gas with a flow rate of 1 mL/min. Initial
GC oven temperature was set to 50 °C, held for 2 min,
then increased at a rate of 15 °C/ min up to 320 °C and
held for 10 min. The electron impact ionization source
operated at 230 °C, 70 eV and a scan range of m/z 50 to
550. For MGO quantitation, the peak area of m/z 181 of
the corresponding derivative was integrated.
Metabolic profiling via GC-MS
For the determination of extracellular metabolites,
medium (10 μL) was collected from each well and im-
mediately frozen at –80 °C until further use. For the
determination of intracellular metabolites, cells were
briefly washed with pre-cooled (4 °C) washing buffer on
ice. Immediately after washing, pre-cooled (-20 °C) metha-
nol (1 mL) was added to each well and metabolites were
extracted for 24 h on an orbital shaker at 8 °C. Then, the
extracts were transferred to 1.5 mL reaction vials and add-
itional pre-cooled (4 °C) methanol (500 μL) was used to
rinse the remaining metabolites from each well and
combined with the extract. Samples were evaporated to
dryness using a speed vac (Maxi-Dry Lyo, Heto-Holten,
Allerød, Denmark) and stored at -80 °C until further use.
Derivatization and GC-MS analyses were performed as
described previously [19]. Data evaluation was carried
out using AMDIS 2.71 [20] for peak picking and cre-
ation of a customer library of detected peaks. Quantita-
tion with Xcalibur 1.4 (Thermo Scientific) was based
on the integration of selective mass traces. Tentative
identifications were achieved by spectra comparison
with NIST14 (National Institute of Standards and
Technologies [NIST], Gaithersburg, USA) and a cus-
tomer library of reference spectra under consideration
of related Kovac retention time indices [21]. Metabolite
profiling experiments were repeated once with a similar
result, whereas representative data is presented. If not
stated otherwise, the abundance of a metabolite is de-
fined by the peak area determined from the selected
ion chromatogram of an experiment normalized to
total cellular protein (μg).
Statistical analysis
Student’s t-test was performed using the algorithm im-
plemented in Excel (Version: 14.0.7128.5000; Microsoft,
Redmond, USA) (unpaired two-sample test with unequal
variances). Principal component analysis was performed
using the Excel add-in Multibase package (Numerical
Dynamics, Japan). All experiments were carried out in
6-tuplicate.
Results
D-lactate, L-lactate and MGO production at different
concentrations of glucose and supply of pyruvate
In order to investigate how different concentrations of
glucose in the medium contribute to the glycolytic flux
in U87 glioblastoma cells, we determined the production
of L-lactate in medium with different concentrations of
glucose and in the presence of 5 mM pyruvate instead of
glucose. In addition, we also determined the production of
methylglyoxal (MGO) and D-lactate. MGO arises by non-
enzymatic elimination of phosphate from glyceraldehyde-
3-phosphate and dihydroxyacetone phosphate, two inter-
mediates of glycolysis, and is finally converted to D-lactate
by the glyoxalase system [22]. We expected to get a more
comprehensive picture of the glycolytic flux than just by
the determination of L-lactate, which only appears as long
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as glycolytic produced pyruvate is not used for the pro-
duction of acetyl-CoA. For the experiment, cells were
cultivated for 20 h in the absence of glucose and pyruvate
in medium which did not contain any glutamine source or
fetal bovine serum. Then, fresh medium was added con-
taining 25, 11 and 5.5 mM glucose or 5 mM pyruvate
without glucose, followed by incubation for 24 h. The used
concentrations of glucose are commonly employed in cell
culture experiments. With regard to physiological concen-
trations, 5 mM has to be considered as a physiological
blood concentration at starvation and 11 mM as the
blood concentration after a meal, whereas 25 mM is
only reached in diabetic conditions. Blood concentra-
tions of pyruvate are supposed to be around 0.05 mM
(0.44 mg/100 ml) in fasted individuals [23]. The ra-
tional to use an almost 100-fold higher concentration is
based on control experiments in which we determined
that at this concentration (5 mM) the relative ATP con-
centration is saturated and was comparable to that ob-
tained with all three concentrations of glucose used
(Additional file 1: Figure S1). Finally, media were collected
for the determination of extracellular D- and L-lactate. In
addition, the intracellular MGO was determined from the
cells and normalized to the total extracted protein.
As can be seen in Fig. 1, there was no significant dif-
ference neither in L/D-lactate production nor in MGO
production between cells either incubated in the pres-
ence of 25 mM or 11 mM glucose. This may indicate
that there was almost the same glycolytic flux at both
concentrations of glucose. Only when the concentration
of glucose was further decreased down to 5.5 mM, a
significant reduction was detected in the production of
L-lactate (fold change to: 0.74 ± 0.08; p < 0.05) which was
very low in the absence of glucose and the presence of
pyruvate (fold change to: 0.06 ± 0.02; p < 0.0005). Al-
though a significant reduction of MGO was observed at
a concentration of 5.5 mM glucose compared to higher
glucose concentrations (fold change in 5.5 compared to
25 mM glucose: 0.71 ± 0.09; p < 0.005) the abundance of
MGO was almost equal to the one measured in the
absence of glucose (fold change in 5 mM pyruvate
compared to 25 mM glucose: 0.63 ± 0.09; p < 0.005)
indicating that the highly reactive MGO is a poor in-
dicator of the glycolytic flux. The same holds true for
D-lactate although compared to MGO it was strongly
reduced in the absence of glucose (fold change in
5 mM pyruvate compared to 25 mM glucose: 0.12 ±
0.09; p < 0.005).
Metabolites in glioblastoma cells at different supply with
glucose and pyruvate
In order to analyze how metabolites are affected by a
different supply of glucose we analyzed the associated
metabolic changes using GC-MS profiling. Therefore,
U87 cells were cultivated as described in the previous
section and after 24 h of incubation the intra-and extra-
cellular metabolites were extracted, derivatized and ana-
lyzed by GC-MS. After automated peak deconvolution
by AMDIS, 194 peaks were manually selected and
quantified using Xcalibur. Finally, 106 metabolites were
identified by comparison of mass spectra and Kovac
retention time indices with mass spectral libraries. The
resulting relative intracellular abundances are presented
in Fig. 2 as logarithmically transformed fold-changes
compared to the samples obtained from the cells treated
with 25 mM glucose.
Among the most prominent changes associated with a
reduced supply of glucose was an expected reduction in
the amount of different mono- and disaccharides and
sugar phosphates that already became prominent when
the concentration of glucose was reduced from 25 mM
to 11 mM. In contrast to the results obtained with the
analysis of MGO and lactate in the previous section, the
metabolic profile of 11 mM glucose samples was more
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Fig. 1 D-Lactate, L-lactate and MGO production at different concentrations of glucose and in medium containing pyruvate. U87 cells were cultivated
in the presence of 5.5 mM, 11 mM, 25 mM glucose or 5 mM pyruvate in the absence of glucose. After 24 h intracellular MGO (a) as well as extracellular
D-lactate (b) and L-lactate (c) were determined. All experiments have been conducted in 6-tuplicate and statistical significance was determined
by Student’s t-test with: *: p < 0.05; **: p < 0.005; ***: p < 0.0005; ns: not significant
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similar to 5.5 mM glucose than to 25 mM glucose
samples, which was confirmed by multivariate analysis
(Additional file 2: Figure S2). Possibly, this may be re-
lated to the fact that the glycolytic flux appeared to
enter saturation from 11 mM glucose supplement on.
A complete overview of the metabolites detected and
quantified and their relation to other metabolites is
depicted in Fig. 3 (for an extended version see Add-
itional file 3: Figure S3). Based on the data presented
in Fig. 3, a number of different features of tumor me-
tabolism in U87 cells under different nutritional sup-
ply was analyzed and is presented in the following
paragraphs.
Glucose and the glycolytic flux
As can be seen in Fig. 3 the intracellular abundance of
glucose increases with increased supply, but does not
follow it in a linear manner as the intracellular abun-
dance of glucose was more than 5 times higher at an
extracellular concentration of 25 mM than at 11 mM.
We presume that the transport of glucose is mainly car-
ried out by GLUT1 as this is the main transporter in
brain [24] and we found its mRNA to be ~ 25 times
more abundantly expressed than that encoding GLUT3
or GLUT4 whereas mRNA encoding GLUT2 was almost
not present in the U87 cells used in the experiment
(Additional file 4: Figure S4a). As the Km of GLUT1 for
averageaverage
average average average
average
log
2
average
averageaverage average
dihydroxyacetone-phosphate
Fig. 2 Comparative metabolic profiling of U87 cells cultivated in the presence of glucose and pyruvate. Fold changes (log2-transformed) of
intracellular metabolite abundances are indicated with regard to the highest concentration of glucose employed (25 mM; set to log2(1) = 0)
for glucose concentrations of 11 mM (11 Glc), 5.5 mM (5.5 Glc) or for medium without glucose containing 5 mM pyruvate instead (Pyr).
Identified metabolites were grouped in dependence on their metabolic role: TCA: metabolites associated with the tricarboxylic acid cycle;
lipid synthesis: metabolites associated with lipid synthesis; glycolysis: glycolytic metabolites; nucleobase/nucleotides; monosaccharides;
disaccharides; sugar phosphates; amino acids; amino acid metabolism: metabolites associated with amino acid metabolism; other: other
metabolites not unequivocally associated with the other pathways indicated. The average of the fold changes from the metabolites in each
group is indicated as “average”
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glucose is around 1.5 mM, uptake should already be sat-
urated at the lowest concentration of glucose (5.5 mM).
Consequently, phosphorylation to glucose-6-phosphate
becomes important for a continuous uptake of glucose.
This phosphorylation should be catalyzed by hexokinase
2 and hexokinase 1 which at the level of the mRNA is
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Fig. 3 Metabolic pathway of U87 cells profiling data. A combined metabolic pathway is presented, including glycolysis, the pentose-phosphate
pathway, the TCA cycle and branched chain amino acid degradation. Intracellular metabolite abundances (Fig. 2) are shown as bar diagrams
depicting the relative abundance which is the: ratio between the abundance of a metabolite (the peak area) normalized to total protein (μg)
compared to the abundance at 25 mM glucose (normalized to protein) set as 1. Direct reactions without intermediates are presented as straight
lines and reactions involving several steps are presented as dotted lines. Metabolites which were not determined are labeled in Grey. All experiments
have been conducted in 6-tuplicate and statistical significance was determined by Student’s t-test with: *: p < 0.05; **: p < 0.005; ***: p < 0.0005.
An extended version of the figure including extracellular metabolite concentrations is available in the (Additional file 2: Figure S2). Abbreviations:
GA3P: glyceraldehyde-3-phosphate; DHAP: dihydroxyacetone phosphate; Glu: glutamate; aKG: α-ketoglutarate
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three times stronger expressed than isoform 2 as re-
vealed by qRT-PCR (Additional file 4: Figure S4b). At
this point, it is interesting to note, that in normal brain
tissue hexokinase 2 is only negligibly expressed and its
expression in glioblastoma was already considered to
contribute to the Warburg effect and the malignity of
the tumor [25].
When glucose in the medium was reduced from
25 mM to 11 mM the abundances of intracellular
glucose (fold change to: 0.22 ± 0.19; p < 0.0005) and
glucose-6-phosphate (fold change to: 0.24 ± 0.16; p <
0.05) were significantly reduced. In the case of
fructose-6-phosphate (fold change to: 0.72 ± 0.42) and
glyceraldehyde-3-phosphate (fold change to: 0.9 ± 0.13)
only weak and non-significant effects were observed.
A further reduction of glucose supply to 5.5 mM did
also not significantly reduce fructose-6-phosphate
(fold change to: 0.5 ± 0.29) and 2-phospho-glycerate
(fold change to: 0.84 ± 0.35), but we observed a signi-
ficant reduction in intracellular glucose (fold change
to: 0.15 ± 0.02; p < 0.0005), glucose-6-phosphate (fold
change to: 0.12 ± 0.08; p < 0.05) and glyceraldehyde-3-
phosphate (fold change to: 0.82 ± 0.13; p < 0.05). Com-
paring glucose concentrations 11 mM and 5.5 mM in
medium, no significant changes of the aforementioned
metabolites were detected. Therefore, it has to be
assumed that the glycolytic flux downstream from
glucose-6-phosphate is similar under the different
external glucose concentrations. As the amount of
ribose-5-phosphate was also not significantly affected
by different concentrations of extracellular glucose it
may be assumed that the pentose-phosphate pathway
has the same activity at all concentrations of glucose,
although we observed a significant reduction of
erythrose-4-phosphate comparing its amounts at
25 mM glucose and 5.5 mM (fold change to: 0.57 ±
0.11; p < 0.05).
Fructose and sorbitol
Aside from a steep raise of the intracellular abundances
of glucose and glucose-6-phosphate when the extra-
cellular concentration of glucose was increased from
11 mM to 25 mM, we also observed a significant raise
in the abundances of intracellular sorbitol (fold change
to: 2.86 ± 0.98; p < 0.005) and fructose (fold change to:
7.69 ± 9.46; p < 0.005). Moreover, raising glucose con-
centrations from 5.5 mM to 11 mM in medium also re-
sulted in a significant enhancement of sorbitol
abundances (fold change to: 2.69 ± 0.62; p < 0.05). Inter-
estingly, sorbitol produced by the cells was significantly
released into the extracellular medium whereas the
extracellular abundance of fructose did not follow its
enhanced intracellular production (Additional file 3:
Figure S3).
Glucose and the tricarboxylic acid cycle
The data presented in Fig. 3 shows that the abun-
dance of intracellular lactate (fold change in 5.5
mM compared to 25 mM glucose: 0.65 ± 0.13; p <
0.05) followed in tendency the abundance of
glyceraldehyde-3-phosphate (fold change in 5.5 com-
pared to 25 mM glucose: 0.82 ± 0.13; p < 0.05) which
is the metabolite at the entry of the second (three
carbon) part of the glycolytic pathway. Although this
appears to be in accordance with the Warburg effect,
we also observed a significant reduction (fold change)
in 5.5 mM glucose compared to 25 mM glucose in
the amounts of citrate (0.57 ± 0.17; p < 0.05), malate
0.61 ± 0.12; p < 0.005) and α-ketoglutarate (0.71 ±
0.18). This clearly indicates that at a high glucose
concentration (25 mM), glucose-derived pyruvate is
metabolized by the TCA cycle.
Metabolic flux under substitution of glucose by pyruvate:
lactate and metabolites associated with the TCA cycle
When glucose was substituted by pyruvate a strong in-
crease of the intracellular amount of pyruvate was ob-
served (5 mM pyruvate compared to 25 mM glucose:
9.85 ± 4.54; p < 0.05) which clearly indicates that the
compound is readily taken up by the tumor cells. The
high intracellular amount of pyruvate was not accom-
panied by a corresponding raise of intracellular lactate.
As the formation of lactate requires NADH +H+, that
in the presence of a glycolytic flux is produced by the
conversion of glyceraldehyde-3-phosphate to glycerate
1,3-bisphosphate, a lack of reduced NADH may be the
reason for the non-appearance of increased lactate pro-
duction in the absence of glucose. We also observed a
significantly higher abundance of the TCA cycle metab-
olites citrate (1.67 ± 0.52; p < 0.05), α-ketoglutarate
(1.76 ± 0.59; p < 0.05), succinate (2.60 ± 0.56; p < 0.005)
and malate (2.42 ± 0.46; p < 0.005) following the higher
abundance of intracellular pyruvate when glucose was
substituted by pyruvate (fold change in cells exposed to
5 mM pyruvate compared to cells exposed to 25 mM
glucose). Therefore, pyruvate in the absence of glucose
can obviously be metabolized by the TCA cycle and it
has to be expected that at least two mitochondrial
NADH +H+ producing steps (from isocitrate to α-
ketoglutarate and from α-ketoglutarate to succinyl-
CoA) are active. Provided that we found no evidence of
enhanced production of lactate in the absence of glu-
cose and high levels of intracellular pyruvate, these
reduction equivalents are most likely used for the
production of ATP by OxPhos rather than shuttled
out of the mitochondria. An intensive use of pyruvate
for the production of ATP under the extracellular
concentrations employed (5 mM) is also in accord-
ance to the observation that at this concentration
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ATP production was comparable to the production in
medium containing glucose (Additional file 1: Figure S1).
We also observed a significantly higher abundance
of extracellular citrate when glucose was substituted
by pyruvate (5 mM pyruvate compared to 25 mM
glucose: 2.01 ± 0.33; p < 0.05). Most likely this citrate
originates in the mitochondria by the reaction of
acetyl-CoA with oxaloacetate. Under normal condi-
tions this reaction precedes the export of citrate
which is then cleaved by cytosolic ATP/citric acid
lyase in order to provide acetyl-CoA for lipid synthe-
sis by the cytosolic lipid acid synthase. It may be pre-
sumed that in the absence of glucose not enough
NADPH for lipid synthesis is available which can be
gained from the pentose-phosphate pathway or from
the conversion of malate to pyruvate by malic enzyme
[EC 1.1.1.40] [26]. This notion is in contrast to the
fact that the amount of ribose-5-phosphate was still
high in the absence of glucose and the presence
of pyruvate. On the other hand, the high abundance
of malate in the presence of high concentrations of
pyruvate may indicate that its conversion to pyruvate
by malic enzyme and the associated production of
NADPH is impaired.
Metabolic flux under substitution of glucose by pyruvate:
gluconeogenesis
As pointed out in the introduction several metabolites
from the glycolytic pathway are building blocks required
for growth and proliferation of tumor cells. Therefore,
the question was whether a substitution of glucose by
pyruvate contributes to gluconeogenesis sufficient for
their supply. As demonstrated in Fig. 3, abundances of
2-phosphoglycerate (fold change to: 0.24 ± 0.24) and
fructose-6-phosphate (fold change to: 0.29 ± 0.16) were
obviously reduced, whereas reduction of abundances in
glyceraldehyde-3-phosphate (fold change to: 0.34 ± 0.1;
p < 0.0005), glycerol-3-phosphate (fold change to: 0.38 ±
0.06; p < 0.005) and erythrose-4-phosphate (fold change
to: 0.31 ± 0.1; p < 0.05) was detected as statistically
significant when glucose was substituted by pyruvate
(comparing cells exposed to 5 mM pyruvate to cells ex-
posed to 25 mM glucose). Interestingly, the abundance
of ribose-5-phosphate did not appear to be affected in a
comparable manner as the aforementioned metabolites
of the glycolytic pathway when glucose was substituted
by pyruvate. This may indicate that the gluconeogenic
pathway is active in the absence of glucose and the
presence of pyruvate [27].
Metabolic flux under substitution of glucose by pyruvate:
amino acids
Substituting glucose with pyruvate resulted in a strong
increase of alanine (significant fold change to: 4.33 ± 2.01;
p < 0.05) which is most likely catalyzed by the trans-
amination of pyruvate supplied in high amounts in the
medium. A second prominent effect was a strong raise
in the concentration of aspartate (significant fold
change to: 15.09 ± 1.62; p < 0.0005). As aspartate is
mainly synthesized by a transamination reaction from
oxaloacetate it has to be assumed that under our ex-
perimental conditions more oxaloacetate was produced
by pyruvate carboxylase than is needed for anaplerosis
and gluconeogenesis. As both amino acids are released
in significantly higher amounts into the medium (ala-
nine: fold change to: 3.51 ± 0.32; p < 0.0005; aspartate
fold change to: 9.6 ± 5.63; p < 0.05), the cells seem to
continuously loose amino groups. Although speculative,
we presume that the observed increase in the amounts of
branched chain keto acids (BCKA) such as α-keto-
isocaproate (4-Methyl-2-oxopentanoate) (fold change
compared to 25 mM glucose intracellular: 2.27 ± 1.19;
extracellular: 2.18 ± 0.13; p < 0.0005), α-keto-β-methylvale-
rate ((S)-3-Methyl-2-oxopentanoate) (fold change com-
pared to 25 mM glucose intracellular: 1.76 ± 1.09;
extracellular: 1.53 ± 0.1; p < 0.0005) and of α-keto-
isovalerate (3-Methyl-2-oxobutanoate) (fold change
compared to 25 mM glucose intracellular: 2.07 ± 1.13;
extracellular: 1.69 ± 0.09; p < 0.0005) may indicate that
the amino groups originate from transamination reac-
tions catalyzed by branched-chain amino acid (BCAA)
aminotransferase [EC:2.6.1.42] using L-leucine, L-
isoleucine and L-valine as substrates (Additional file 3:
Figure S3). This notion is supported by the observation
that BCAAs are a major source of amino groups for
transamination reactions in the brain [28].
Discussion
The central aim of this study was to obtain a more com-
prehensive understanding of the metabolic contribution
of glucose and pyruvate in tumor cells. In accordance
with the concept of Krall and Christofk [21], who
pointed out that metabolic mechanisms that are im-
perative for tumor growth may be uncovered by sub-
jecting tumor cells to nutrient limitations [29], we used
different concentrations of glucose in our experiments
and we also substituted glucose by pyruvate. The ra-
tional to use pyruvate to replace glucose goes back to
the observation that cancer cells proliferate rapidly in
the presence of exogenous pyruvate [30]. It was also
demonstrated that exogenous pyruvate is required to
sustain proliferation of both cancer and non-cancer
cells that cannot utilize oxygen [31]. In this work the
authors also propose that exogenous pyruvate may be
released by tumor adjacent cells. Although, to our
knowledge there is no experimental confirmation that
non-tumor cells can release pyruvate into the tumor
microenvironment, the high expression of monocarboxylate
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transporters (which transport lactate and pyruvate) in
many tumors has led to the assumption that tumor cells
may use these transporters for the uptake of metabolically
important molecules [30].
Analyzing the dependence of the abundance of glyco-
lytic intermediates from glucose we found no strict
linear correlation between the extracellular supply of
glucose and the abundance of glycolytic intermediates,
but there was a general tendency that most metabolites
of the glycolytic and associated pathways are more
abundant at a higher concentration of glucose than at a
lower concentration.
An interesting observation is the high increase in the
abundance of sorbitol in the medium.
The polar character of sorbitol usually should prevent
its release by diffusion, which in the case of diabetes
results in the so-called diabetic cataract [32]. As intra-
cellular sorbitol does induce osmotic stress [33] it is
tempting to speculate whether tumor cells may have
acquired mechanisms for the effective removal of
sorbitol such as the sorbitol permease described to be
present in the rabbit papillary epithelial cell line PAP-
HT25 [34]. In conclusion, we consider that the high
level of sorbitol produced under conditions of high
glucose supply and especially the ability to release
this metabolite should be studied in more detail
as it may be a possible unique target for therapeutic
intervention.
Our data clearly demonstrates that at a glucose
concentration of 25 mM glycolytically derived pyruvate
is metabolized by the TCA cycle. This may at a first
glace appear to be in contrast to the Warburg effect
but is in agreement with its present day understanding.
As pointed out by DeBerardinis et al. [35], the reduc-
tion of substrate oxidation by glioblastoma and other
tumor cells can simply be secondary to the metabolic
activities needed for biosynthesis rather than being an
impairment of oxidative metabolism. At this point it
has to be taken into account that the TCA cycle also
delivers acetyl-CoA which is required for lipid biosyn-
thesis. In fact, using the paediatric glioma cell line
SF188 DeBerardinis et al. [35] could demonstrate that
10 % of total glucose metabolism is utilized for the bio-
synthesis of fatty acids and nucleotides as well as for other
processes such as glycosylation.
In conclusion, our data demonstrates that in human
U87 glioblastoma cells, pyruvate derived from glucose
can be shuttled into the TCA cycle as previously dem-
onstrated for paediatric glioma cells [35], A549 lung
carcinoma cells [4] and rat C6 glioma cells [3]. From
our data we cannot estimate the percentage of glucose
entering the TCA cycle as we did not use isotopically
labeled glucose. This will be the next step in future ex-
periments in which we will also investigate how other
energy-rich metabolites such as ketone bodies can be
utilized as substrates for glioma cell metabolism.
More experiments are required to solve the interest-
ing question whether the high extracellular concentra-
tion of citrate, under the withdrawal of glucose and its
substitution by pyruvate, indicates that the cell pro-
duces more citrate than needed for the production of
fatty acids or whether the conversion of citrate to
acetyl-CoA and oxaloacetate is impaired as this would
finally prevent tumor cell proliferation. The high
amount of citrate released into the medium also raises
a question about anaplerosis: it should be kept in
mind that the removal of citrate and other metabolites
from the TCA cycle that are used as precursors for
biosynthetic reactions outside the mitochondria, re-
quires anaplerotic reactions that refill the pool of pre-
cursor molecules. In glioblastoma and other
transformed cell lines, glutamine is the preferred ana-
plerotic precursor when it is supplied by the medium,
contributing up to 90 % to the oxaloacetate pool [35].
As in our experiments glutamine is not supplied with
the medium, the synthesis of oxaloacetate via pyruvate
carboxylase becomes important and may compensate
the loss of glutamine-dependent anaplerosis, which is
a mechanism previously proposed by Cheng et al. who
investigated glioblastoma growth under deprivation of
glutamine [36]. A high flux of pyruvate through the
pyruvate carboxylase reaction is also in agreement
with the assumption that the cells perform gluconeo-
genesis when glucose is substituted by pyruvate in
order to provide ribose-5-phosphate (or other metabo-
lites of the glycolytic pathway). At this point it is also
interesting to note that gluconeogenesis in tumor cells
under low glucose conditions has also been reported
in lung cancer cells [27] although in this study glu-
tamine served as substrate for the gluconeogenic
pathway.
Conclusions
Overall the data in the present study demonstrates that
i) there is no strict correlation between the extracellu-
lar supply of glucose and abundance of glycolytic inter-
mediates, ii) sorbitol is highly produced and released
into the medium under high glucose supply, iii) U87
cells metabolize a significant amount of glucose derived
pyruvate in the mitochondria and iv) gluconeogenesis
is most likely activated when glucose is substituted by
pyruvate. These observations suggest a high plasticity
of glioblastoma cells to changes in nutritional supply
which should be taken into account with regard to the
prescription of special diets for the treatment of tumor
patients or when considering to use specific inhibitors
of glycolysis.
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Additional files
Additional file 1: Figure S1. Relative intracellular ATP concentration at
different concentrations of glucose and pyruvate. U87 cells were seeded
at a density of 5000 cells per well in 96 well microplates and received
medium without a carbon source and without GlutaMAX and FBS for
20 h. Then, fresh medium was added containing different concentrations
of glucose (5.5 mM, 11 mM and 25 mM), pyruvate (1 mM, 2.5 mM, 5 mM,
10 mM and 20 mM) or without any carbon source (0 mM). 24 h later the
relative intracellular ATP concentration was determined by the CellTiterGlo
Assay (for method description see Additional file 5: Methods). Results
are represented as mean and standard deviation of 6 independently
measured wells compared to the signal of 25 mM glucose set to 1.
Statistical significance was determined by Student’s t-test with: *: p <
0.05; **: p < 0.005; ***: p < 0.0005; ns: not significant. (TIF 949 kb)
Additional file 2: Figure S2. Multivariate analysis of metabolite profiles.
Principal component analysis (PCA) of metabolite profiles from U87 cells
cultivated in the presence of 5.5 mM (5.5 Glc), 11 mM (11 Glc), 25 mM
glucose (25 Glc) or 5 mM pyruvate in the absence of glucose (Pyr) for
24 h. 25 Glc and Pyr appear clearly separated from each other, whereas
11 Glc and 5.5 Glc have a similar profile separated from 25 Glc and Pyr.
PC1 includes 34.7 % of variability (responsible for separation of Pyr), PC2
16.2 % (differences between the glucose treated cells). n = 6 for each
condition, all identified metabolites were included (n = 106). (TIF 69 kb)
Additional file 3: Figure S3. Extended metabolic pathway of U87 cells
profiling data. A combined metabolic pathway is presented, including
glycolysis, the pentose-phosphate pathway, the TCA cycle and the
branched chain amino acid degradation with the subcellular
localization (mitochondrial, cytoplasm and extra cellular—methodically it
can only be distinguished between intra- and extracellular metabolites).
Intracellular metabolite abundances (Fig. 2) are shown as bar diagrams
depicting the ratio between the abundance of a metabolite (the peak area)
normalized to total protein (μg) compared to the abundance at 25 mM
glucose (normalized to protein) set to 1. The consumption of
extracellularly present metabolites was determined by the comparison
of signals obtained from medium without cells to those after incubation
with cells. Thus, a value of 0 indicates the same abundance of a metabolite
in medium with and without cells (no consumption) and a value of -1
indicates that the metabolite is completely consumed. Abundances of
metabolites released from the cells are expressed as the abundance of a
metabolite in medium after incubation compared to its abundance in
medium with 25 mM glucose set to 1. All experiments have been conducted
in 6-tuplicate and statistical significance was determined by Student’s t-test
with: *: p < 0.05; **: p < 0.005; ***: p < 0.0005. The statistical analysis for
intracellular and released metabolites was performed by comparing the
abundance of a metabolite in an experiment (11 mM or 5 mM glucose
or 5 mM pyruvate) to the abundance in 25 mM glucose. For consumed
metabolites, each metabolite’s abundance was compared to its abundance
in medium without cells. Direct reactions are presented as straight lines and
reactions involving several steps are presented as dotted lines. Metabolites
which were not determined are labeled Grey. Abbreviations: GA3P:
glyceraldehyde-3-phosphate; DHAP: dihydroxyacetone phosphate; Glu:
glutamate; aKG: α-ketoglutarate; PEP: phosphoenolpyruvate. (JPG 3880 kb)
Additional file 4: Figure S4. mRNA expression of glycolytic genes in
U87 cells. Expression of mRNA encoded by the genes GLUT1/2/3/4
(glucose transporters 1/2/3/4) (a) and HK1/2 (hexokinase 1/2) (b) in U87
cells as revealed by qRT-PCR (for method description see Additional file
5). The relative expression was determined using standard curves
normalized to the expression of TATA box binding protein (TBP). (TIF 655 kb)
Additional file 5: Methods. (DOCX 16 kb)
Abbreviations
aKG: α-ketoglutarate; BCAA: Branched-chain amino acid; BCKA: Branched
chain keto acids; DHAP: Dihydroxyacetone phosphate; GA3P: Glyceraldehyde-
3-phosphate; GC-MS: Gas chromatography coupled to mass spectrometry;
Glc: Glucose; Glu: Glutamate; MGO: Methylglyoxal; NIST: National Institute
of Standards and Technologies; PCA: Principal component analysis;
PEP: Phosphoenolpyruvate; PFBHA: O-(2,3,4,5,6-pentafluorobenzyl)
hydroxylamine; Pyr: Pyruvate; TCA: Tricarboxylic acid
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In summary, our experiments demonstrate that glioblastoma cells exhibit a high metabolic 
flexibility which enables adjustments to maintain cell growth under restricted conditions. As 
inhibition of glycolytic flux appeared not to be accompanied by reduced intracellular ATP, we 
conclude that glioblastoma cells shift metabolism in response to reduced supply with 
glucose.  
After we demonstrated that glioblastoma cells can metabolise pyruvate, we further 
investigated the hypothesis of Holliday and McFarland regarding the attenuation of 
carnosine’s anti-neoplastic effect by pyruvate (Holliday and McFarland 1996). In their study 
carnosine selectively eliminated cervix carcinoma cells from a co-culture with fibroblasts 
which was attenuated by the presence of 1 mM pyruvate. The authors assumed that 
treatment with carnosine reduces the production of pyruvate from glucose and therefore 
inhibits the ATP produced by glycolysis, TCA cycle and subsequent oxidative 
phosphorylation (OxPhos). Hence, the supplementation of pyruvate could reverse this effect 
by increasing aerobic ATP production (Holliday and McFarland 1996). In the study of 
Oppermann et al. (Oppermann et al. 2016b) we investigated whether the anti-neoplastic 
effect of carnosine can be antagonised by ATP production via OxPhos fuelled by pyruvate. 
To do that, we tested the influence of carnosine on glioblastoma cell viability after pre-
starvation and the availability of only glucose, galactose or pyruvate during cultivation. With 
this strategy, we expected to minimize possible unintended effects from serum which is 
present during long term cultivation and contains compounds of undefined nature. To 
investigate the significance of aerobe metabolism of pyruvate when this compound is added 
to the medium to attenuate carnosine’s growth inhibiting effect, we used the inhibitors 2,4-
dinitrophenol (DNP) and CPI-613. The latter is a lipoate analogue which blocks the entry of 
pyruvate into the TCA cycle by inducing PDKs which in turn inhibit the PDC via 
phosphorylation (Zachar et al. 2011). DNP inhibits mitochondrial ATP production by 
uncoupling electron transport from phosphorylation without affecting oxygen uptake (Loomis 
and Lipmann 1948).  
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ABSTRACT
Here we analyzed whether the anti-neoplastic effect of carnosine, which 
inhibits glycolytic ATP production, can be antagonized by ATP production via 
oxidative phosphorylation fueled by pyruvate. Therefore, glioblastoma cells were 
cultivated in medium supplemented with glucose, galactose or pyruvate and in the 
presence or absence of carnosine. CPI-613 was employed to inhibit the entry of 
pyruvate into the tricarboxylic acid cycle and 2,4-dinitrophenol to inhibit oxidative 
phosphorylation. Energy metabolism and viability were assessed by cell based assays 
and histochemistry.
ATP in cell lysates and dehydrogenase activity in living cells revealed a strong 
reduction of viability under the influence of carnosine when cells received glucose or 
galactose but not in the presence of pyruvate. CPI-613 and 2,4-dinitrophenol reduced 
viability of cells cultivated in pyruvate, but no effect was seen in the presence of 
glucose. No effect of carnosine on viability was observed in the presence of glucose 
and pyruvate even in the presence of 2,4-dinitrophenol or CPI-613.
In conclusion, glioblastoma cells produce ATP from pyruvate via the tricarboxylic 
acid cycle and oxidative phosphorylation in the absence of a glycolytic substrate. In 
addition, pyruvate attenuates the anti-neoplastic effect of carnosine, even when ATP 
production via tricarboxylic acid cycle and oxidative phosphorylation is blocked. We 
also observed an inhibitory effect of carnosine on the tricarboxylic acid cycle and a 
stimulating effect of 2,4-dinitrophenol on glycolytic ATP production.
INTRODUCTION
The anti-neoplastic effect of carnosine has been 
described for a number of tumor derived cells in vitro 
including gastric [1, 2], colon [3], ovarian [4] and brain 
cancer cells [5]. In addition, effects were demonstrated 
in vivo [6, 7] and the number of examples is still increasing 
(for reviews see [8, 9, 10]). The primary molecular targets 
responsible for carnosine’s action on tumor cells are still 
not known. Although, its influence on glycolytic ATP 
production, recognized to be crucial for tumor cell energy 
metabolism, has been suggested by previous experiments 
[11]. The dependence of tumor cells on glycolysis is 
known as the so-called Warburg effect. It describes that 
ATP production in cancer cells is frequently dependent 
on glycolysis resulting in the production of lactate even 
in the presence of oxygen. In normoxic conditions non-
tumor cells produce ATP by oxidative phosphorylation 
(OxPhos) using reduction equivalents derived from the 
metabolization of pyruvate entering the tricarboxylic 
acid (TCA) cycle (for reviews see [12, 13]). The 
Warburg effect has originally been attributed to defects 
in the mitochondria of cancer cells. According to current 
knowledge this only holds true for a minority of tumors 
[14]. More recent data point towards variants of glycolytic 
enzymes that may specifically be expressed in tumors such 
as pyruvate kinase M2 [15]. Unfortunately, this knowledge 
has up to now not resulted in the development of new 
therapeutic strategies to fight cancer. Thus, a thorough 
investigation of the inhibitory effect of carnosine on 
tumor cell specific ATP production will greatly help to 
develop new strategies which can exploit the Warburg 
effect. This is especially pertinent for malignancies, for 
those chances of recovery are poor under present-day 
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treatment strategies. Tumor cells may adapt to changes 
in nutritional supply by switching metabolic fluxes and/
or become fed by compounds supplied by neighbor cells 
[16]. Hence a possible inhibition of glycolysis, attenuated 
by metabolic adaptation, has to be taken into account 
(for recent reviews see [17, 18]). More than 20 years 
ago, Holiday and McFarland suggested that carnosine’s 
anti-neoplastic effect might be inhibited by the presence 
of pyruvate [19]. As carnosine inhibits glycolytic ATP 
production [11] the most straight interpretation of the 
observation of Holiday and McFarland would be a tumor 
cell switch to OxPhos when glycolysis is inhibited and 
pyruvate is supplied. Therefore, we analyzed the response 
of tumor cell viability measuring ATP in cell lysates and 
dehydrogenase activities (NAD(P)H) in living cells. 
We used cells from human glioblastoma (GBM) which 
is the most common primary tumor of the adult brain 
[20]. According to the classification of the world health 
organization (WHO), GBM is one of the most malignant 
diffuse astrocytic tumors and classified as WHO grade IV 
[21]. Currently, the median overall survival of patients 
receiving standard therapy after surgery of the tumor 
is 14.6 month [22]. Consequently, there is urgent need 
to develop alternative treatment strategies. These may 
include a metabolic intervention at the level of glycolysis 
as glucose is the central metabolic fuel of this tumor. Our 
experiments were mainly performed with cells cultivated 
in the presence of glucose. We also tested galactose 
as a nutritional substitute for glucose in a first series of 
experiments. The cells were cultivated in the absence and 
presence of carnosine and we analyzed the influence of 
pyruvate on carnosine’s anti-neoplastic effect. In order to 
determine the influence of the TCA cycle and of OxPhos 
the experiments were also performed in the absence and 
presence of inhibitors for the pyruvate dehydrogenase 
complex and for ATP production by OxPhos. In addition, 
we established a protocol in which the cells were pre-
starved in the absence of glucose, glutamine and serum. 
Effects from the presence of compounds the cells were 
exposed to during long term cultivation were thus avoided. 
This appeared to be especially important with regard to 
serum that was omitted throughout the experiments 
because it contains compounds of undefined nature.
RESULTS
Viability, amount of ATP and NAD(P)H 
production in glioblastoma cells cultivated 
in glucose, galactose or pyruvate under the 
influence of serum and GlutaMax
In previous experiments, in which the anti-neoplastic 
effect of carnosine on glioblastoma cells was analyzed, a 
high variation of viability was encountered [23]. Comparing 
eight independent experiments, in which the effect of 
50 mM carnosine in U87 cells after 24 hours of incubation 
was determined, we found a reduction of ATP in cell 
lysates between 44% and 89% (75 ± 15%; data not shown) 
compared to the untreated control. In these experiments 
cells received medium supplemented with carnosine after 
they had been grown in medium with 4.5 g/L glucose, 10% 
FBS and 2 mM GlutaMax. Therefore, it cannot be ruled 
out that the effect of carnosine on ATP production was 
concealed by intracellular metabolites, contributing to ATP 
production, downstream of carnosine’s target.
This question was addressed by firstly investigating 
the viability of cells cultivated for 24 hours in medium 
without the supplements glucose, GlutaMax and FBS. 
The result of one representative experiment is presented 
in Figure 1. In addition, we investigated whether galactose 
and pyruvate are able to substitute glucose. As can be seen 
in Figure 1, only the absence of FBS from the culture 
medium prominently decreased viability as revealed by 
reduced dehydrogenase activity and ATP in cell lysates. 
Additionally, no signs of apoptosis or necrosis were 
observed. Galactose as well as pyruvate could substitute 
glucose to a large extent. More importantly, the viability 
of cells that were cultivated in the absence of glucose, 
galactose or pyruvate did not severely differ from that 
of cells cultivated in the presence of the nutrients or did 
exhibit morphological change (data not shown). The 
experiment indicates an influence of FBS on viability 
and demonstrates that a 24 hour starvation in the absence 
of glucose, galactose or pyruvate had only minor effects 
on viability. The determination of lactate dehydrogenase 
release into the medium, as a marker of necrotic loss of 
membrane integrity, did not reveal cell death by necrosis 
(data not shown). Further experiments with cells cultivated 
without glucose, galactose or pyruvate and without FBS 
and GlutaMax prior to the addition of carnosine were 
hence decided.
Viability, amount of ATP and NAD(P)H 
production of pre-starved glioblastoma cells 
under the influence of carnosine and different 
nutrients
The cultivation of cells for 24 hours in the 
absence of FBS, GlutaMax and the specified nutrients 
did not result in a pronounced reduction of viability. 
Therefore, experiments with carnosine were performed 
with cells pre-cultivated for 20 hours in the absence of 
the aforementioned supplements. This avoids effects 
which could flaw the experiments as described in the 
introduction. Cells from the glioblastoma cell line 
U87 were transferred to 96-well plates at a density 
of 5000 cells per well, seeded for 3 hours in fully 
supplemented medium and then cultivated in the absence 
of glucose, galactose or pyruvate and without FBS and 
GlutaMax for 20 hours. Then, fresh medium was added 
containing glucose, galactose, pyruvate or without any 
of these compounds and supplemented with or without 
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50 mM carnosine. Twenty-four and forty-eight hours later 
viability was determined by measuring ATP in cell lysates 
and dehydrogenase activity in living cells. As can be seen 
in Figure 2A, cells cultivated in glucose, galactose and 
pyruvate exhibited a comparable amount of ATP in cell 
lysates after 24 and 48 hours in the absence of carnosine. 
Whereas carnosine strongly reduced viability in cells 
cultivated in the presence of glucose and galactose (down 
to 3.6 ± 5.6% at 48 hours), but not in those cells incubated 
in the presence of pyruvate (94.0 ± 15.5% at 48 hours). 
This demonstrates strong inhibition of the glycolytic ATP 
production by carnosine. In addition, it indicates that the 
tumor cells can compensate insufficient production of 
ATP by glycolysis by fueling pyruvate into the TCA cycle 
resulting in ATP production by OxPhos. As there was a 
distinctively measurable amount of ATP in cell lysates of 
cells cultivated without any supplement and in the absence 
of carnosine (47.3 ± 42.9% at 24 hours + 20 hours of 
starvation and 29.3 ± 31.7% at 48 hours + 20 hours of 
starvation compared to cells in the presence of glucose), 
but not in the presence of carnosine (0.2 ± 0.1% at 44 
and 68 hours of total starvation time), this ATP may be 
generated from metabolites that are present even after 
44 and 68 hours of starvation. This ATP production, 
however, is clearly inhibited by carnosine. Comparing 
the production of NAD(P)H in living cells (Figure 2B) 
it becomes obvious that pyruvate does not completely 
substitute galactose or glucose. The glycolytic production 
of redox equivalents appears to be higher than that from 
pyruvate, but this may be caused by a rapid mitochondrial 
metabolization of TCA cycle derived redox equivalents. 
The minor difference between production of NAD(P)H 
in medium containing pyruvate with or without carnosine 
may indicate that there are still metabolites present which 
account for the production of NAD(P)H. Moreover, this 
notion is substantiated by the observation that there is 
still some NAD(P)H production in medium containing 
either glucose or galactose and carnosine. It also has to 
be taken into account that the CellTiter-Blue assay also 
measures the production of reduced reduction equivalents 
from other dehydrogenases aside from the glyceraldehyde-
3-phosphate dehydrogenase reaction. However, as the 
production of NAD(P)H is higher in medium containing 
pyruvate than in the medium without any supplement there 
is an obvious production of NAD(P)H via pyruvate. As 
revealed in Figure 7 and Table 1 no necrosis does occur in 
cells treated with carnosine in the presence of pyruvate.
Viability and the amount of ATP in glioblastoma 
cells in the presence of the pyruvate 
dehydrogenase inhibitor CPI-613
The experiments presented in Figure 2 demonstrate 
that cells from the line U87 are viable in the absence of 
a glycolytic substrate, when pyruvate is present. This 
indicates that the cells can produce ATP from pyruvate 
via the TCA cycle and OxPhos in the absence of glucose, 
which we just recently demonstrated by the analysis of 
metabolic profiles, determined by gas chromatography 
coupled to mass spectrometry (GC-MS) [24]. Hence, it 
Figure 1: Amount of ATP in cell lysates and NAD(P)H production in cells from the line U87 under different culture 
conditions. Cells from the line U87 were cultivated for 20 hours at a density of 5000 cells per well in 96-well microplates in DMEM standard 
culture medium before they received fresh medium with different supplements: FBS: fetal bovine serum, 10%; Glx: GlutaMax, 2 mM; Glu/
Gal/Pyr: glucose, galactose, pyruvate: each 25 mM; 0: no Glu/Gal/Pyr. 24 hours later the CellTiter-Glo assay (measuring ATP in cell lysates, 
left part of the panel) and the CellTiter-Blue assay (measuring NAD(P)H production, right part of the panel) were employed to assess cell 
viability. Signals obtained from cells cultivated in 25 mM glucose, 10% FBS and 2 mM GlutaMax were set as 100%. Results are presented as 
mean and standard deviation of 6 wells. Statistical significance was determined by Student’s t-test with: *p < 0.05; **p < 0.005; ***p < 0.0005.
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was asked whether the flux of metabolites through the 
TCA cycle can antagonize the effect of carnosine on 
ATP production. Therefore, the pyruvate dehydrogenase 
inhibitor CPI-613 was used to block the initial step that 
converts pyruvate to acetyl-CoA fueling the TCA cycle 
[25]. CPI-613 is a lipoic acid analog which activates the 
lipoate-responsive regulatory phosphorylation of the E1α 
pyruvate dehydrogenase subunit and was shown to be 
selective for tumor cells in culture [25]. The experiments 
were performed with cells from the glioblastoma lines 
LN405 and T98G in addition to U87 in order to analyze 
a cell line dependent difference. For the experiment, 
cells from the three lines were pre-starved for 20 hours 
as described above, before they received medium with 
either 25 mM glucose or 5 mM pyruvate and different 
concentrations of CPI-613 for 24 hours. A concentration of 
5 mM pyruvate was chosen, as experiments revealed that 
this concentration is sufficient for the maximum amount 
of ATP determined in cell lysates in the presence of 
50 mM carnosine (Supplementary Data S1). As shown in 
Figure 3, the amount of ATP in cell lysates in the presence 
of CPI-613 was progressively reduced with increasing 
concentrations of the inhibitor when pyruvate was 
supplied as nutrient. This supports the notion that pyruvate 
can be metabolized by the TCA cycle and that OxPhos 
is not impaired in these cells. Furthermore, cells from 
the lines U87 and LN405 did not show any significant 
change in the amount of ATP in the presence of glucose 
and CPI-613, whereas ATP of cells from the line T98G 
was strongly reduced. This demonstrates that T98G cells 
are dependent on the TCA cycle and OxPhos. At this point 
it is interesting to note, that in the absence of glucose, 
pyruvate does differently contribute to the amount of ATP 
(in the absence of the inhibitor) in the three lines (data not 
shown in the graph): Whereas ATP in U87 and T98G cells 
is not significantly different between cells either supplied 
with glucose or pyruvate (glucose to pyruvate in U87: 
100 ± 15.1% and 120.2 ± 31%, in T98G: 100 ± 12.4% 
and 83 ± 28.6%), pyruvate does less efficiently contribute 
to ATP in cells from the line LN405 (glucose to pyruvate: 
100 ± 14.3% and 39 ± 13%; p < 0.005).
Viability and amount of ATP in glioblastoma 
cells under the influence of carnosine in the 
presence of glucose and glucose plus pyruvate 
The experiments in the previous sections 
demonstrated that the production of ATP via pyruvate is 
possible in glioblastoma cells (although not required when 
glucose is abundant - at least in cells from the lines U87 
and LN405), but may become important in the absence of 
glucose. To consider using carnosine’s capacity to block 
the glycolytic flux from glucose in tumor cells for the 
treatment of human tumors, it had to be asked whether the 
anti-neoplastic effect of the dipeptide may be attenuated 
by pyruvate. Therefore, cells from the glioblastoma lines 
U87, LN405 and T98G were incubated in the presence of 
either glucose (25 mM) or a mixture of glucose (25 mM) 
and pyruvate (5 mM) and in the absence and presence 
of different concentrations of carnosine determined to 
equal an inhibitory concentration of IC20, IC50 and 
IC80 (see Supplementary Data S2). The data presented in 
Figure 2: Amount of ATP in cell lysates and NAD(P)H production in the line U87 under the influence of glucose, 
galactose or pyruvate and carnosine after pre-starvation. Cells from the line U87 were seeded at a density of 5000 cells per well 
in 96-well microplates and were incubated for 20 hours in medium without glucose, galactose or pyruvate and without FBS and GlutaMax. 
After 20 hours, medium was substituted for medium with different supplements: glucose (Glu), galactose (Gal), pyruvate (Pyr): 25 mM, 
no supplement (0); and with or without 50 mM carnosine. 24 and 48 hours later CellTiter-Glo and CellTiter-Blue assays were employed to 
determine ATP in cell lysates and NAD(P)H production in intact cells. In order to compare the effects of glucose, galactose and pyruvate 
in the presence and absence of carnosine, results are grouped into data sets with regard to the amount of ATP in cell lysates (A) and 
dehydrogenase activity (B). Results are represented as mean and standard deviation of 6 wells from three independent experiments for 
each condition normalized to signals recorded from cells cultivated in the presence of glucose and the absence of carnosine (set as 100%). 
Statistical significance was determined by Student’s t-test with: *p < 0.05; **p < 0.005; ***p < 0.0005.
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Figure 4 demonstrates that in all three lines the inhibitory 
effect of carnosine on cell viability in the presence of 
glucose is strongly attenuated by the addition of pyruvate. 
Only at the highest concentration of carnosine (IC80) a 
significantly reduced amount of ATP in the presence of 
glucose and pyruvate is observed. In fact, cells from the 
line U87 grown in the presence of glucose and 50 mM 
carnosine exhibit an almost complete loss of viability after 
a 24 hour exposure to the dipeptide. Cells, which received 
pyruvate in addition, were as healthy as cells cultivated 
in the absence of carnosine (Figure 7; Table 1). At this 
point it also has to be noted that the amount of ATP in 
the presence of glucose and pyruvate compared to glucose 
alone was ~2-fold higher in LN405 and comparable in 
U87 cells (1.3-fold higher). The amount of ATP in cells 
from the line T98G was ~10-fold higher in the presence 
of pyruvate and glucose compared to glucose alone. This 
underscores that ATP production from pyruvate via the 
Table 1: Cell viability in the presence of different nutritional compounds and inhibitors
Glucose Pyruvate Glucose + Pyruvate
Control 94.30 ± 4.56% 98.54 ± 0.29% 98.63 ± 1.38%
Carnosine 0.00 ± 0.00% 99.25 ± 0.54% 95.58 ± 2.03%
CPI-613 93.79 ± 3.40% 27.41 ± 11.15% 99.18 ± 0.04%
Carnosine + CPI-613 0.47 ± 0.47% 2.72 ± 0.81% 98.37 ± 0.81%
DNP 97.13 ± 0.71% 21.06 ± 3.03% 96.48 ± 3.84%
Carnosine + DNP 1.65 ± 2.32% 1.95 ± 2.29% 98.03 ± 1.34%
Number of viable cells in the presence of different nutrients and inhibitors as determined by Calcein AM/PI staining from the 
experiments depicted in Figure 5 to 7 expressed in % of cells stained with Calcein AM compared to the total number of cells.
Figure 3: Amount of ATP in cell lysates of cells from the lines U87, T98G and LN405 under the influence of the 
pyruvate dehydrogenase inhibitor CPI-613. Cells were seeded at a density of 5000 cells per well in 96-well microplates before 
they received medium without glucose, galactose or pyruvate and without FBS and GlutaMax. 20 hours later fresh medium was added 
with different concentrations of CPI-613 (0 µM, 10 µM, 25 µM, 50 µM) in the presence of either glucose (Glu; 25 mM) or pyruvate (Pyr; 
5 mM). 24 hours later ATP amount in cell lysates was determined using the CellTiter-Glo assay. ATP amount in cell lysates in the absence 
of inhibitor was set as 100%. Results are represented as mean and standard deviation of 6 wells for each condition. Statistical significance 
was determined by Student’s t-test with: **p < 0.005 and ***p < 0.0005.
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TCA cycle significantly contributes to ATP production in 
cells from the line T98G, but also demonstrates that ATP 
can also be produced by OxPhos in the other cell lines. 
Comparing this data to the results in the preceding section, 
this reveals a different response of cells to the supply with 
nutrients. Cells from the line T98G exhibit much higher 
amounts of ATP when both glucose and pyruvate are 
supplied than with either nutrient alone. This indicates 
that in these cells excessive ATP production by OxPhos 
also drives glycolytic ATP production - most likely via 
regeneration of NAD+, resulting in an overall synergistic 
effect on total ATP production in these cells.
Amount of ATP and viability of U87 
glioblastoma cells in the presence of glucose and 
pyruvate under the influence of carnosine and 
CPI-613
The experiments presented in Figure 4 indicated that 
pyruvate attenuates the inhibitory effect of carnosine on 
ATP production and viability in cells cultivated in glucose 
alone. As ATP production from pyruvate requires its entry 
into the TCA cycle, we asked whether the combined block 
of glycolysis by carnosine and of pyruvate dehydrogenase 
by CPI-613 does completely block ATP production in 
U87 cells. The result of a corresponding experiment is 
presented in Figure 5. This experiment demonstrates 
that the combination of carnosine and CPI-613 almost 
completely blocks ATP production in the presence of either 
glucose (1.5 ± 0.2%) or pyruvate alone (5.9 ± 5.1%). The 
viability of cells as determined by Calcein AM/PI staining 
was reduced to 0.5 ± 0.5% (glucose) and to 2.7 ± 0.8% 
(pyruvate) (see Figure 7 and Table 1). CPI-613 alone did 
only slightly reduce the amount of ATP determined in the 
presence of glucose (91.1 ± 6.5%; p < 0.05) and viability 
determined by Calcein AM/PI was 93.8 ± 3.4% compared 
to 94.3 ± 4.6% in the absence of CPI-613. When cells 
cultivated in pyruvate received CPI-613 alone, the amount 
of ATP was reduced from 126 ± 21% to 48 ± 10% and 
cell viability determined by Calcein AM/PI was reduced 
from 98.5 ± 0.3% to 27.4 ± 11.2% (p < 0.02; Figure 7; 
Table 1). Therefore, the cells were still able to produce 
some ATP and were not completely killed during the 24 
hours incubation time. Most importantly, although viability 
was strongly reduced when only glucose or only pyruvate 
were supplied in the presence of carnosine and CPI-613, 
viability in the presence of both, glucose and pyruvate, 
was completely restored (98.4 ± 0.8%). Correspondingly, 
ATP production was restored, although significantly lower 
amounts were detected (77.1 ± 5.3%; p < 0.0005) than in 
cells cultivated in the presence of glucose and pyruvate 
without the inhibitors (112.5 ± 19.9%).
Figure 4: Amount of ATP in cell lysates of the lines U87, T98G and LN405 under the influence of different concentrations 
of carnosine in the presence of glucose and glucose plus pyruvate. Cells were seeded at a density of 5000 cells per well in 96-well 
microplates and received medium without glucose, galactose or pyruvate and without FBS and GlutaMax. After 20 hours, fresh medium was 
added with either glucose (Glu; 25 mM) or a mixture of 25 mM glucose and 5 mM pyruvate (Glu+Pyr) and cell line dependent inhibitory 
concentrations of carnosine (see Supplementary Data S2). 24 hours later the amount of ATP in cell lysates was determined using the 
CellTiter-Glo assay. The amount of ATP in the absence of carnosine was set as 100%. Results are represented as mean and standard deviation 
of 6 wells for each condition. Statistical significance was determined by Student’s t-test with: *p < 0.05; **p < 0.005; ***p < 0.0005.
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Viability and amount of ATP in U87 
glioblastoma cells in the presence of glucose and 
pyruvate under the influence of carnosine and 
2,4-dinitrophenol
The experiments in the previous section revealed 
that the combination of carnosine and CPI-613 in the 
presence of pyruvate and glucose does not kill the 
cells. This observation is in contrast to the notion that 
pyruvate’s attenuation of the inhibitory effect of carnosine 
is dependent on ATP production from pyruvate via TCA 
cycle and OxPhos. However, as we observed viable cells 
in the presence of pyruvate alone and CPI-613 (27.4 ± 
11.2%) and also a significant amount of ATP in cell lysates 
(48 ± 10%) (Figure 5), we decided to block ATP production 
additionally at the level of OxPhos using 2,4-dinitrophenol 
(DNP). DNP inhibits mitochondrial ATP production by 
uncoupling electron transport from phosphorylation [26]. 
In the experiment in Figure 6 cells from the line U87 
were incubated with combinations of carnosine, DNP, 
glucose and pyruvate. In cells fed with glucose, DNP did 
not reduce the amount of ATP (122 ± 7.9% compared to 
100 ± 9% in cells without the inhibitor). The viability 
determined by Calcein AM/PI was 97.1 ± 0.7% compared 
to 94.3 ± 4.6% (without DNP) (Figure 7; Table 1). Cells 
fed with pyruvate exhibited a strong reduction of ATP 
when incubated in the presence of DNP (0.5 ± 0.1% 
compared to cells in the absence of the inhibitor 138.5 
± 9%). The viability determined by Calcein AM/PI was 
reduced from 98.5 ± 0.3% to 21.1 ± 3% (Figure 7; Table 
1). This demonstrates that DNP completely blocks ATP 
production from pyruvate, but also shows that a fraction of 
cells is able to survive at least after 24 hours of exposure 
to DNP. Therefore, it is tempting to speculate that survival 
of some cells is independent from ATP production. Cells 
cultivated in glucose only exhibited a strong reduction of 
ATP when cultivated in carnosine (0.8 ± 0.2%; Figure 6) 
as already shown in Figure 5. Cells receiving pyruvate 
as nutrient exhibited a comparable amount of ATP in the 
presence of carnosine (95.5 ± 11.1%) as cells cultivated 
in glucose without it (100 ± 9.1%). As also seen in 
Figure 5 and Figure 2A, cells receiving pyruvate produced 
more ATP in the absence of inhibitors than cells cultivated 
in glucose (138.5 ± 9%). As the addition of carnosine 
always reduces ATP production in the presence of pyruvate 
alone, carnosine does obviously also inhibit mitochondrial 
ATP production, although to a lesser extent than it effects 
glycolytic ATP production. Most importantly, in the 
presence of both, pyruvate and glucose, the amount of ATP 
determined in the presence of carnosine and DNP (103.7 
± 7.0%) was comparable to that of cells grown in glucose 
without any inhibitor (100 ± 9.1%). In addition, viability 
determined by Calcein AM/PI was 98.0 ± 1.3% (Figure 7; 
Table 1). This demonstrates that the attenuation of the anti-
neoplastic effect of carnosine by pyruvate is independent 
from the production of ATP via the TCA cycle and OxPhos. 
DISCUSSION
We investigated how the anti-neoplastic effect of 
carnosine is influenced by the nutritional supply of tumor 
cells and how glycolysis, the TCA cycle and OxPhos 
Figure 5: Amount of ATP in cell lysates of the line U87 under the influence of carnosine and CPI-613. Cells from the line 
U87 were seeded at a density of 5000 cells per well in 96-well microplates and received medium without glucose, galactose or pyruvate 
and without GlutaMax and FBS for 20 hours. Then, fresh medium was added with 25 mM glucose, 5 mM pyruvate or a combination of 
both nutrients. In addition, cells received 50 mM carnosine and/or 50 µM CPI-613. 24 hours later the amount of ATP in cell lysates was 
determined. Results are represented as mean and standard deviation of 6 wells for each condition normalized to cells cultivated in the 
presence of glucose (set as 100%). Statistical significance was determined by Student’s t-test with: *p < 0.05; ***p < 0.0005.
96
Oncotarget8www.impactjournals.com/oncotarget
contribute to tumor cell survival. It was previously 
shown that pyruvate inhibits the anti-neoplastic effect of 
carnosine [19]. We were thus interested to study, whether 
this can also be seen in glioblastoma tumor cells and 
whether the production of ATP via TCA cycle and OxPhos 
are responsible for this effect.
The results of the experiments presented in Figure 5 
to Figure 7 and in Table 1 are summarized and interpreted 
in Figure 8. In (A1) of Figure 8 the situation is depicted 
in which glucose is supplied as the only nutrient and 
in the absence of inhibitors. In this case the amount of 
ATP determined in cell lysates is set as 100% and living 
cells are illustrated by the green color. Adding carnosine 
(A2) results in a complete loss of ATP production and the 
cells are dead as shown by Calcein AM/PI staining. In 
accordance with our previously published data [5] no signs 
of apoptosis were detected and cells obviously died due to 
necrosis. Neither CPI-613 (A3) nor DNP (A4) decrease 
viability in the presence of glucose. Therefore, viability 
in the presence of glucose is almost independent from 
mitochondrial ATP production. However, adding CPI-613 
to cells cultivated in glucose results in a small loss of ATP 
(A3 compared to A1), indicating that a small amount of 
pyruvate produced by glycolysis is used for mitochondrial 
ATP production. The slightly enhanced production of 
ATP in the presence of DNP (A4) demonstrates enhanced 
glycolytic production of ATP, when OxPhos is blocked 
by DNP. A comparable, recent observation by Bhatt et 
al. describes a rise of glycolytic ATP production in the 
cerebral glioma cell line BMG-1 and other cells when 
they were treated with DNP [27]. The addition of CPI-
613 (A5) or DNP (A6) to cells in the presence of glucose 
and carnosine results in the same loss of ATP and viability 
as in (A2). When pyruvate is the only nutrient, ATP is 
even higher than in the presence of glucose alone (B1 
compared to A1). Therefore, U87 cells can efficiently use 
pyruvate for ATP synthesis in the absence of glucose. A 
significant drop (p < 0.05) of ATP is observed when cells 
cultivated in pyruvate received carnosine (B2 compared 
to B1 and B5 compared to B3). Hence, carnosine 
does also inhibit mitochondrial ATP production. This 
inhibition is less pronounced than that on glycolysis and 
it is in agreement with recent observations of Shen and 
co- workers et al.  These authors showed that carnosine 
is able to inhibit mitochondrial ATP-linked respiration in 
gastric cancer cells [1]. In addition, we have previously 
demonstrated that carnosine enhances the expression of 
pyruvate dehydrogenase kinase 4 (PDK4) [23], although, 
in further experiments (which were done in the presence 
of FBS and GlutaMax) we did not detect a change of 
pyruvate dehydrogenase activity under the influence 
of carnosine (unpublished data). Another result is the 
apparent incomplete inhibition of ATP production by CPI-
613 when pyruvate is supplied, but glucose is absent (B3). 
This observation of the experiments presented in Figure 5 
(and repetitions of it) is in contrast to the data presented 
in Figure 3 in which a concentration of 50 µM CPI-613 
severely diminished the amount of ATP. It is tempting to 
speculate that this variation in the quantitative effect of 
CPI-613 on ATP is associated with the effect of CPI-613 
Figure 6: Amount of ATP in cell lysates of the line U87 under the influence of carnosine and 2,4-dinitrophenol (DNP). 
Cells from the line U87 were seeded at a density of 5000 cells per well in 96-well microplates and received medium without glucose, 
galactose or pyruvate and without GlutaMax and FBS for 20 hours. Then, fresh medium was added with 25 mM glucose, 5 mM pyruvate or 
a combination of both nutrients. In addition, cells received 50 mM carnosine and/or 0.5 mM DNP. 24 hours later the amount of ATP in cell 
lysates was determined. Results are represented as mean and standard deviation of 6 wells for each condition normalized to cells cultivated in 
the presence of glucose (set as 100%). Statistical significance was determined by Student’s t-test with: *p < 0.05; **p < 0.005; ***p < 0.0005.
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on 2-oxoglutarate dehydrogenase. This would also 
disrupt mitochondrial metabolism [28], dependent on the 
current status of the oxidative defense systems of the cell. 
Moreover, the lipoate derivative CPI-613 could possibly 
also inhibit other mitochondrial enzyme complexes 
that require lipoate as coenzyme, e.g. the branched-
chained alpha-ketoacid dehydrogenase complex [29]. 
However, these interpretations are speculative and CPI-
613 at a concentration of 50 µM may simply not always 
completely block the pyruvate dehydrogenase activity. In 
fact, as demonstrated in the experiments of Zachar et al. 
[25], the IC50 for most of the cell lines tested was in the 
range between 120 and 280 µM. Despite the fact, their 
experiments are difficult to compare, as the authors used 
additional media supplements. In the presence of DNP 
(B4) the pyruvate supplied in the medium is not able to 
contribute to ATP production. Although, almost no ATP 
was determined in cell lysates (0.58 ± 0.06%; compared 
to pyruvate without inhibitor), up to 21% of the cells were 
still alive (Figure 7, yellow color in Figure 8, Table 1). 
Therefore, a strict correlation between ATP and viability 
has to be questioned. Nevertheless, full ATP production is 
important for 100% survival. It also has to be noted that 
the cells stained by Calcein AM had a severely changed 
morphology, indicating that they were also dying (data 
not shown). No cells are stained by Calcein AM in the 
presence of pyruvate and DNP when carnosine was added 
(B6 compared to B4). This indicates that carnosine also 
inhibits other biochemical pathways required for survival 
even in the absence of ATP production. This supports the 
Figure 7: Viability of U87 cells under the influence of carnosine in the presence of glucose, pyruvate, carnosine (Car), 
2,4-dinitrophenol (DNP) and CPI-613 (CPI). U87 cells were seeded at a density of 5000 cells per well in 96-well microplates and 
received medium without glucose, galactose or pyruvate and without FBS and GlutaMax. After 20 hours, fresh medium was added with 
either glucose (25 mM), pyruvate (5 mM) or both nutrients and in addition cells received carnosine (50 mM), CPI-613 (50 µM) or DNP 
(0.5 mM) or mixtures of these supplements. After 24 hours living cells were stained using Calcein AM (green) and dead cells were stained 
using propidium iodide (red). Fluorescence images were captured by microscopy. Scale bars: 200 µm. For quantification see Table 1.
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notion that carnosine does in fact have pleiotropic effects 
[30]. The restoration of viability and ATP production 
in the experiments (C5) and (C6) whereby glucose and 
pyruvate are combined, demonstrates that exogenous 
pyruvate attenuates or even inhibits the effect of carnosine 
on glycolytic breakdown of glucose. We currently do 
not know at which step carnosine inhibits the glycolytic 
breakdown of glucose. This would require a detailed 
metabolomics study, and corresponding follow-up 
experiments, e.g. Western Blots, qRT-PCR and enzyme 
assays. Pyruvate could possibly restore NAD+ which is 
consumed in the glycolytic step from glyceraldehyde-3-
phosphate to 1,3-bisphosphoglycerate. This presupposes 
that carnosine reduces the availability of NAD+. In that 
case, the concentrations of glycolytic triose phosphates 
(glyceraldehyde-3-phosphate and dihydroxyacetone-
phosphate) will increase. In turn, the concentration of 
methylglyoxal will increase, which would result in protein 
and mitochondrial dysfunction [31]. This can explain the 
anti-neoplastic effects that cannot solely be attributed to the 
impairment of ATP production. However, this assumption 
is in contrast to the observation that carnosine inhibits the 
Figure 8: Overview of the results from the experiments presented in Figure 5 to Figure 7 and Table 1. A1 to A6 depict 
the experiments in the presence of glucose (Glu), B1 to B6 the experiments in the presence of pyruvate (Pyr) and C1 to C6 those with 
both, glucose and pyruvate. The numbers below denote the amount of ATP determined in cell lysates under each condition (rounded to be 
presented in intervals of 5). Colors denote: red: cells are dead; green: cells were alive; yellow: viable cells were detectable (20 to 30%; 
compare Table 1). Car denotes the use of carnosine, CPI denotes the use of CPI-613 and DNP the use of 2,4-dinitrophenol. The thickness 
of the arrows indicates the estimated flux of metabolites. For further details refer to the text.
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deleterious effects accompanied by enhanced production 
of methylglyoxal [32]. In addition, carnosine’s abatement 
on senescence and increase of life-span in normal cells 
and healthy organisms argue against the assumption that 
carnosine has a general effect on the availability of NAD+ 
[33]. Hence, the hypothesis that carnosine reduces the 
availability of NAD+ will only make sense if the effect 
is tumor-cell specific. A second possibility is a reduced 
availability of pyruvate from the glycolytic breakdown of 
glucose under the influence of carnosine. This will also 
suppress the regeneration of NAD+ for ongoing glycolysis. 
It is known that carnosine does react with aldehydes [34], 
or as other histidine containing dipeptides, with carbonyl 
groups in general [35]. Therefore, it may react with one or 
several metabolites in the glycolytic pathway. However, 
as pyruvate attenuates the effect of carnosine even at a 
concentration ten times lower than that of the dipeptide, a 
competitive inhibition by pyruvate appears to be unlikely. 
Although the mechanisms by which pyruvate restores 
tumor cell viability in the presence of carnosine remain 
unknown, the hypothesis can be excluded that pyruvate 
inhibits the anti-neoplastic effect of carnosine by increased 
mitochondrial production of ATP [19].
Our data may appear to diminish the hope 
that carnosine could be used as an anti-cancer drug. 
Nevertheless, it should be taken into account that 
carnosine’s effect on glycolysis is one aspect of its anti-
neoplastic activity [36]. Results obtained with other cancer 
models demonstrated that carnosine does also influence 
signal transduction pathways such as HIF-1alpha [37] or 
Akt/mTOR/p70S6K [2]. In addition, effects on manganese 
superoxide dismutase and cyclin B1 expression have been 
reported [38]. At this point, it should be noted that previous 
experiments demonstrated that carnosine has long term 
effects on tumor cell growth in vitro [5] and in vivo [7] 
even in the presence of pyruvate and FBS. In conclusion, 
the results presented bear the challenge to enhance the 
anti-neoplastic effect of the dipeptide by an inhibition of 
mechanisms which attenuate its inhibition of glycolysis.
MATERIALS AND METHODS
Reagents
Unless otherwise stated, all chemicals were 
purchased from Sigma Aldrich (Taufkirchen, Germany) 
including the carnosine employed in this study (Cat.-Nr.: 
C9625/ Lot: BCBK4678V).
Long-term cell culture
All cells were propagated in 250 ml culture flasks 
(Sarstedt AG & Co., Nümbrecht, Germany) using 10 ml of 
standard culture medium (SCM: DMEM / 4.5 g/l glucose, 
without pyruvate (Life Technologies, Darmstadt, Germany) 
supplemented with 10% fetal bovine serum (FBS 
superior, Biochrom, Berlin, Germany), 2 mM GlutaMax 
(Life Technologies) and Penicillin-Streptomycin (Life 
Technologies)) at 37°C and 5% CO
2
 in humidified air in an 
incubator. The human glioblastoma multiforme (GBM) cell 
lines T98G and U87 were obtained from ATCC (Manassas, 
USA) and the line LN405 from the German collection of 
microorganisms and cell cultures (DSMZ, Braunschweig, 
Germany). All cells were genotyped (Genolytic GmbH, 
Leipzig, Germany) and their identity confirmed.
Cell culture experiments
For the experiments, cells were used from culture 
flasks at 70 to 90% confluency. Cells were first washed 
with 6 ml of Hanks (without Ca2+ / Mg2+: 137 mM 
NaCl; 5.4 mM KCl; 0.33 mM Na
2
HPO
4
 × 2 H
2
0; 0.44 
mM KH
2
PO
4
; 2 mM Hepes (pH 7.4)) and then detached 
for 5 min in an incubator at 37°C using 2 ml Accutase 
(Life Technologies). Then, pre-warmed SCM (4 ml) 
was added and the cells were transferred to a centrifuge 
tube and collected by centrifugation (5 min; 125 × g). 
After aspiration of old medium, fresh SCM was added 
and 0.5x106 cells were equally spread in 10 ml of SCM 
into new culture flasks (250 ml). After 72 hours cells 
were again harvested as described above and seeded at a 
density of 5000 cells per well in 96-well plates (µClear, 
Greiner Bio One, Frickenhausen, Germany) in SCM 
for 3 hours before they received fresh medium without 
glucose, galactose or pyruvate and without GlutaMax and 
FBS. Then cells were incubated for 20 or 24 hours (see 
individual experiment) before they received new medium 
with the supplements indicated in each experiment.
Cell-based assays
For the determination of the amount of ATP in 
cell lysates the CellTiter-Glo Assay (CTG), for the 
determination of NAD(P)H production the CellTiter-Blue 
Assay (CTB) and for the determination of extracellular 
lactate dehydrogenase (LDH) activity (measuring loss 
of membrane integrity due to necrosis) the CytoTox-
ONE Assay (all from Promega, Mannheim, Germany) 
were employed according to the instructions of the 
manufacturer and as described previously [39]. Briefly, 
the CellTiter-Glo Assay was performed by adding 100 µl 
of the CellTiter-Glo Assay reagent to the cells cultivated 
in 100 µl medium. Cells were lysed within the solution for 
10 minutes and then luminescence was recorded using a 
Mithras LB 940 Multimode Microplate reader (Berthold 
Technologies, Bad Wildbad, Germany). The CellTiter-
Blue assay was started by adding 20 µl of CellTiter-Blue 
reagent to the cells cultivated in 100 µl of medium. Ninety 
minutes later fluorescence was recorded at an excitation 
wavelength of 560 nm and an emission wavelength of 590 
nm using a Spectra Max M5 reader (Molecular Devices, 
Biberach, Germany). At this point it may also be important 
to note that the presence of test compounds in the medium 
did not interfere with the assays (data not shown).
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Live cell imaging and cell counting
In order to determine viability at the microscopic 
level viable cells were stained with Calcein AM 
(Invitrogen, Darmstadt, Germany) and dead cells with 
propidium iodide (PI). Briefly, a mixture containing 20 
µM Calcein AM and 120 µM propidium iodide (5 µl) was 
added to cells cultivated in 100 µl culture medium in a 
well of a 96-well plate (µClear black, Greiner Bio One). 
After an incubation of 10 minutes at 37°C, fluorescence 
images were captured using a Leica DM IRBE inverted 
fluorescence microscope (Leica microsystems, Wetzlar, 
Germany). Cells were counted using ImageJ scripts [40] 
and cell viability was determined by comparing the total 
cell number of cells to the number of living cells stained by 
Calcein AM and dead cells stained with propidium iodide.
Statistical analysis
For the determination of mean and standard 
deviation as well as statistical significance by student’s 
t-test (unpaired two-sample test with unequal variances) 
of single experiments the algorithms implemented in 
Excel (Microsoft, Richmond, USA) were used. Data 
obtained from more than one experiment were processed 
as followed: Raw data of each independent experiment 
was normalized by the sum of all corresponding data 
points [41]. Then, the mean and the standard deviation 
of all normalized data points for each condition were 
calculated and statistical significance determined by the 
algorithms implemented in Excel. For the calculation of 
inhibitory concentration (IC) data points were fitted to the 
Boltzmann function to plot a sigmoidal curve using Origin 
8 (OriginLab Corporation, Northampton, USA).
ACKNOWLEDGMENTS
We gratefully acknowledge the technical assistance 
of Rainer Baran-Schmidt and we like to thank Dr. Hans-
Heinrich Foerster from the Genolytic GmbH (Leipzig, 
Germany) for genotyping and confirmation of cell identity. 
We also thank Berthold Technologies (Bad Wildbad, 
Germany) for providing a Mithras LB 940 Multimode 
Microplate Reader.
CONFLICTS OF INTEREST
The authors declare that they have no potential 
conflicts of interest.
REFERENCES
 1. Shen Y, Yang J, Li J, Shi X, Ouyang L, Tian Y, Lu J. 
Carnosine inhibits the proliferation of human gastric cancer 
SGC-7901 cells through both of the mitochondrial respiration 
and glycolysis pathways. PLoS ONE. 2014; 9:e104632.
 2. Zhang Z, Miao L, Wu X, Liu G, Peng Y, Xin X, Jiao B, 
Kong X. Carnosine Inhibits the Proliferation of Human 
Gastric Carcinoma Cells by Retarding Akt/mTOR/p70S6K 
Signaling. J Cancer. 2014; 5:382–389.
 3. Iovine B, Iannella ML, Nocella F, Pricolo MR, Baldi MR, 
Bevilacqua MA. Carnosine inhibits KRas-mediated HCT-
116 proliferation by affecting ATP and ROS production. 
Cancer Lett. 2011; 315:122–128.
 4. Mikuła-Pietrasik J, Książek K. L-Carnosine Prevents 
the Pro-cancerogenic Activity of Senescent Peritoneal 
Mesothelium Towards Ovarian Cancer Cells. Anticancer 
Res. 2016; 36:665–671.
 5. Renner C, Seyffarth A, Garcia de Arriba S, Meixensberger J, 
Gebhardt R, Gaunitz F. Carnosine Inhibits Growth of Cells 
Isolated from Human Glioblastoma Multiforme. Int J Pept 
Res Ther. 2008; 14:127–135.
 6. Nagai K, Suda T. Antineoplastic effects of carnosine 
and beta-alanine--physiological considerations of its 
antineoplastic effects. J Physiol Soc Jpn. 1986; 48:741–747.
 7. Renner C, Zemitzsch N, Fuchs B, Geiger KD, Hermes M, 
Hengstler J, Gebhardt R, Meixensberger J, Gaunitz F. 
Carnosine retards tumor growth in vivo in an NIH3T3-
HER2/neu mouse model. Mol Cancer. 2010; 9:2.
 8. Gaunitz F, Hipkiss AR. Carnosine and cancer: a perspective. 
Amino Acids. 2012; 43:135–142.
 9. Hipkiss AR, Gaunitz F. Inhibition of tumour cell growth by 
carnosine: some possible mechanisms. Amino Acids. 2014; 
46:327–337.
10. Gaunitz F, Oppermann H, Hipkiss AR. Carnosine and 
Cancer. In: V. R. Preedy (ed.). Imidazole Dipeptides, pp. 
372–392. Cambridge. 2015.
11. Renner C, Asperger A, Seyffarth A, Meixensberger J, 
Gebhardt R, Gaunitz F. Carnosine inhibits ATP production in 
cells from malignant glioma. Neurol Res. 2010; 32:101–105.
12. Bensinger SJ, Christofk HR. New aspects of the Warburg 
effect in cancer cell biology. Semin Cell Dev Biol. 2012; 
23:352–361.
13. Koppenol WH, Bounds PL, Dang CV. Otto Warburg‘s 
contributions to current concepts of cancer metabolism. Nat 
Rev Cancer. 2011; 11:325–337.
14. Frezza C, Gottlieb E. Mitochondria in cancer: Not just 
innocent bystanders. Semin Cancer Biol. 2009; 19:4–11.
15. Christofk HR, Vander Heiden MG, Harris MH, 
Ramanathan A, Gerszten RE, Wei R, Fleming MD, 
Schreiber SL, Cantley LC. The M2 splice isoform of 
pyruvate kinase is important for cancer metabolism and 
tumour growth. Nature. 2008; 452:230–233.
16. Sousa CM, Biancur DE, Wang X, Halbrook CJ, Sherman 
MH, Zhang L, Kremer D, Hwang RF, Witkiewicz AK, 
Ying H, Asara JM, Evans RM, Cantley LC et al. Pancreatic 
stellate cells support tumour metabolism through autophagic 
alanine secretion. Nature. 2016; 536:479–483.
17. Hay N. Reprogramming glucose metabolism in cancer: can 
it be exploited for cancer therapy? Nat Rev Cancer. 2016; 
16:635–649.
101
Oncotarget13www.impactjournals.com/oncotarget
18. Asgari Y, Zabihinpour Z, Salehzadeh-Yazdi A, Schreiber F, 
Masoudi-Nejad A. Alterations in cancer cell metabolism: 
the Warburg effect and metabolic adaptation. Genomics. 
2015; 105:275–281.
19. Holliday R, McFarland GA. Inhibition of the growth of 
transformed and neoplastic cells by the dipeptide carnosine. 
Br J Cancer. 1996; 73:966–971.
20. Ostrom QT, Gittleman H, Fulop J, Liu M, Blanda R, 
Kromer C, Wolinsky Y, Kruchko C, Barnholtz-Sloan JS. 
CBTRUS Statistical Report: Primary Brain and Central 
Nervous System Tumors Diagnosed in the United States in 
2008–2012. Neuro-Oncology. 2015; 17 Suppl 4:iv1-iv62.
21. Louis DN, Perry A, Reifenberger G, Deimling A von, 
Figarella-Branger D, Cavenee WK, Ohgaki H, Wiestler OD, 
Kleihues P, Ellison DW. The 2016 World Health 
Organization Classification of Tumors of the Central 
Nervous System: a summary. Acta Neuropathologica. 2016; 
131:803–820.
22. Stupp R, Mason WP, van den Bent,M. J., Weller M, Fisher B, 
Taphoorn MJB, Belanger K, Brandes AA, Marosi C, 
Bogdahn U, Curschmann J, Janzer RC, Ludwin SK et al. 
Radiotherapy plus concomitant and adjuvant temozolomide 
for glioblastoma. New England Journal of Medicine. 2005; 
352:987–996.
23. Letzien U, Oppermann H, Meixensberger J, Gaunitz F. 
The antineoplastic effect of carnosine is accompanied by 
induction of PDK4 and can be mimicked by L-histidine. 
Amino Acids. 2014.
24. Oppermann H, Ding Y, Sharma J, Bernd-Paetz M, 
Meixensberger J, Gaunitz F, Birkemeyer C. Metabolic 
response of glioblastoma cells associated with glucose 
withdrawal and pyruvate substitution as revealed by GC-
MS. Nutrition & Metabolism. 2016.
25. Zachar Z, Marecek J, Maturo C, Gupta S, Stuart SD, 
Howell K, Schauble A, Lem J, Piramzadian A, Karnik S, 
Lee K, Rodriguez R, Shorr R et al. Non-redox-active lipoate 
derivates disrupt cancer cell mitochondrial metabolism and 
are potent anticancer agents in vivo. J Mol Med (Berl). 
2011; 89:1137–1148.
26. Loomis WF, Lipmann F. Reversible inhibition of the 
coupling between phosphorylation and oxidation. J Biol 
Chem. 1948; 173:807.
27. Bhatt AN, Chauhan A, Khanna S, Rai Y, Singh S, Soni R, 
Kalra N, Dwarakanath BS. Transient elevation of glycolysis 
confers radio-resistance by facilitating DNA repair in cells. 
BMC Cancer. 2015; 15:335.
28. Stuart SD, Schauble A, Gupta S, Kennedy AD, Keppler BR, 
Bingham PM, Zachar Z. A strategically designed small 
molecule attacks alpha-ketoglutarate dehydrogenase in tumor 
cells through a redox process. Cancer Metab. 2014; 2:4.
29. Fujiwara K, Takeuchi S, Okamura-Ikeda K, Motokawa Y. 
Purification, characterization, and cDNA cloning of lipoate-
activating enzyme from bovine liver. J Biol Chem. 2001; 
276:28819–28823.
30. Boldyrev AA, Aldini G, Derave W. Physiology and 
pathophysiology of carnosine. Physiol Rev. 2013; 93: 
1803–1845.
31. Hipkiss AR. Aging, Proteotoxicity, Mitochondria, 
Glycation, NAD and Carnosine: Possible Inter-
Relationships and Resolution of the Oxygen Paradox. Front 
Aging Neurosci. 2010; 2:10.
32. Hipkiss AR, Chana H. Carnosine protects proteins against 
methylglyoxal-mediated modifications. Biochem Biophys 
Res Commun. 1998; 248:28–32.
33. Hipkiss AR. NAD(+) and metabolic regulation of age-
related proteoxicity: A possible role for methylglyoxal? Exp 
Gerontol. 2010; 45:395–399.
34. Xie Z, Baba SP, Sweeney BR, Barski OA. Detoxification 
of aldehydes by histidine-containing dipeptides: From 
chemistry to clinical implications. Enzymology and 
Molecular Biology of Carbonyl Metabolism 16. 2013; 
202:288–297.
35. Vistoli G, Colzani M, Mazzolari A, Maddis DD, Grazioso G, 
Pedretti A, Carini M, Aldini G. Computational approaches 
in the rational design of improved carbonyl quenchers: 
focus on histidine containing dipeptides. Future Med Chem. 
2016; 8:1721–1737.
36. Hipkiss AR, Gaunitz F. Inhibition of tumour cell growth by 
carnosine: some possible mechanisms. Amino Acids. 2013.
37. Iovine B, Guardia F, Irace C, Bevilacqua MA. l-carnosine 
dipeptide overcomes acquired resistance to 5-fluorouracil 
in HT29 human colon cancer cells via downregulation of 
HIF1-alpha and induction of apoptosis. Biochimie. 2016; 
127:196–204.
38. Rybakova YS, Kalen AL, Eckers JC, Fedorova TN, 
Goswami PC, Sarsour EH. Increased manganese superoxide 
dismutase and cyclin B1 expression in carnosine-induced 
inhibition of glioblastoma cell proliferation. Biomed Khim. 
2015; 61:510–518.
39. Gaunitz F, Heise K. HTS compatible assay for antioxidative 
agents using primary cultured hepatocytes. Assay.Drug Dev.
Technol. 2003; 1:469–477.
40. Schneider CA, Rasband WS, Eliceiri KW. NIH Image to 
ImageJ: 25 years of image analysis. Nat Methods. 2012; 
9:671–675.
41. Degasperi A, Birtwistle MR, Volinsky N, Rauch J, Kolch 
W, Kholodenko BN. Evaluating strategies to normalise 
biological replicates of Western blot data. PLoS ONE. 2014; 
9:e87293.
102
Publications 
103 
 
In summary, we confirmed the hypothesis that carnosine inhibits glycolysis, possibly by 
affecting one or more steps between the breakdown of glucose to pyruvate. Furthermore, we 
showed that the attenuation of the anti-neoplastic effect of carnosine by pyruvate is not 
performed by switching from aerobe glycolysis to oxidative phosphorylation for ATP 
production. 
In order to get a more detailed view into the mechanisms responsible for the effect of 
carnosine on glycolysis further experiments were performed. As Hipkiss and co-workers 
demonstrated that carnosine prevents protein glycation induced by DHAP (Hipkiss et al. 
1995) and as the dipeptide is in general able to react with ketones (Hipkiss 2000), it was 
suggested that the depletion of DHAP by carnosine could be responsible for its effect on 
glycolytic ATP production (Boldyrev et al. 2013; Holliday and McFarland 2000). In our next 
study (Oppermann et al. 2019d) we therefore analysed the influence of carnosine on the 
abundances of glycolytic intermediates and the corresponding connected metabolic 
pathways such as the PPP and the TCA cycle (see Figure 3) in three glioblastoma cell lines. 
To do that, we employed the GC-MS method previously used by us to investigate the central 
carbon metabolism of glioblastoma cells (Oppermann et al. 2016a). In addition, we used 
mass spectrometry to identify possible reaction products of metabolites and carnosine and 
we analysed whether we could also detect a direct influence on OxPhos by the dipeptide by 
measuring the oxygen consumption rate.  
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1  | INTRODUC TION
In	 1900,	 Gulewitsch	 and	 Amiradžibi	 characterized	 the	 first	 natu‐
rally occurring dipeptide carnosine (β‐alanyl‐l‐histidine), which was 
isolated	from	Liebig's	meat	extract.1 In human skeletal muscle, car‐
nosine	 reaches	 a	median	 concentration	of	 about	20.0	±	4.7	mmol	
per kg dry weight.2 Albeit human brain tissue contains more homo‐
carnosine (0.16 mmol per kg dry weight3) than carnosine, the latter 
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Abstract
Objectives: Carnosine	(β‐alanyl‐l‐histidine) is a naturally occurring dipeptide that se‐
lectively	inhibits	cancer	cell	growth,	possibly	by	influencing	glucose	metabolism.	As	
its	precise	mode	of	action	and	its	primary	targets	are	unknown,	we	analysed	carnos‐
ine's	effect	on	metabolites	and	pathways	in	glioblastoma	cells.
Materials and methods: Glioblastoma	cells,	U87,	T98G	and	LN229,	were	treated	with	
carnosine, and metabolites were analysed by gas chromatography coupled with mass 
spectrometry.	Furthermore,	mitochondrial	ATP	production	was	determined	by	ex‐
tracellular	flux	analysis	and	reaction	products	of	carnosine	were	investigated	using	
mass spectrometry.
Results: Carnosine	decreased	the	intracellular	abundance	of	several	metabolites	in‐
dicating	a	reduced	activity	of	the	pentose	phosphate	pathway,	the	malate-aspartate	
shuttle and the glycerol phosphate shuttle. Mitochondrial respiration was reduced in 
U87	and	T98G	but	not	in	LN229	cells,	independent	of	whether	glucose	or	pyruvate	
was	used	as	substrate.	Finally,	we	demonstrate	non-enzymatic	reaction	of	carnosine	
with	dihydroxyacetone	phosphate	and	glyceraldehyde-3-phosphate.	However,	gly‐
colytic	flux	from	glucose	to	l-lactate	appeared	not	to	be	affected	by	the	reaction	of	
carnosine with the metabolites.
Conclusions: Carnosine	 reacts	non-enzymatically	with	glycolytic	 intermediates	 re‐
ducing	the	activity	of	the	pentose	phosphate	pathway	which	is	required	for	cell	pro‐
liferation.	Although	the	activity	of	the	malate-aspartate	and	the	glycerol	phosphate	
shuttle	appear	to	be	affected,	reduced	mitochondrial	ATP	production	under	the	influ‐
ence	of	the	dipeptide	is	cell-specific	and	appears	to	be	independent	of	the	effect	on	
the shuttles.
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is	 found	with	higher	concentrations	 (2.2	mmol	per	kg	dry	weight4) 
in	the	olfactory	bulb.	In	the	human	body,	carnosine	levels	are	con‐
trolled	 by	 three	 genes.	 Human	 serum	 carnosinase	 (CNDP1)	 and	
cytosolic	non-specific	dipeptidase	(CNDP2)	degrade	the	dipeptide,	
whereas	carnosine	synthase	1	(CARNS1),	which	is	highly	expressed	
in	skeletal	muscle,	catalyses	the	formation	of	carnosine	from	β‐ala‐
nine and l‐histidine.5	Surprisingly,	although	the	dipeptide	is	known	
since more than 100 years, its physiological role has not completely 
been	 resolved.	 Among	 the	 physiological	 functions	 described	 are	
pH-buffering,	chelation	of	heavy	metal	ions,	scavenging	of	reactive	
oxygen	species,	protection	 from	advanced	glycation	end-products	
and	 protection	 from	 lipid	 peroxidation-related	 cell	 damage	 (for	
a comprehensive review see Boldyrev et al6).	 In	 1986,	 Nagai	 and	
Suda	demonstrated	 that	 carnosine	 aside	 from	 “normal”	 physiolog‐
ical	 functions	 inhibits	 tumour	 growth	 in	 a	 mouse	 in	 vivo	 model.7 
We	 and	 other	 groups	 confirmed	 this	 anti-neoplastic	 effect	 using	
different	types	of	cancer	models,	 including	glioblastoma,	 in	vivo8,9 
and in vitro.10‐13	 Since	 the	anti-neoplastic	effect	has	been	studied	
in	more	 detail,	 a	 number	 of	 possibly	 involved	 signalling	 pathways	
have	been	suggested.	Some	reports	point	towards	an	 inhibition	of	
Akt phosphorylation 12,14	and	HIF-1α signalling,10 and G1 and G2/M 
cell cycle arrest has been detected.15,16	Furthermore,	we	and	others	
reported that carnosine inhibits glucose‐dependent ATP production 
in glioblastoma cells.11,17	However,	the	mechanisms	responsible	for	
carnosine's	 anti-neoplastic	 effect	 are	 far	 from	 being	 understood.	
Additionally,	 a	primary	 target	has	not	been	 identified	which	espe‐
cially	 pertains	 to	 carnosine's	 effect	 on	 glucose	metabolism.	Here,	
we	analysed	the	metabolic	profiles	of	tumour	cells	treated	with	or	
without	carnosine	in	order	to	reveal	whether	primary	targets	of	the	
dipeptide	can	be	identified.
We	decided	to	use	glioblastoma	cells	in	our	study	as	this	is	the	
most	 frequent	malignant	 tumour	of	 the	human	brain18 with an in‐
cident	 of	 3.21	 new	 cases	 per	 100	 000	 inhabitants	 in	 the	 United	
States.	 Under	 standard	 therapy	 consisting	 of	maximal	 safe	 resec‐
tion	of	 the	 tumour,	 radiotherapy	and	adjuvant	chemotherapy	with	
temozolomide,	median	survival	of	patients	 is	only	12-15	months.19 
Thus,	there	is	an	urgent	need	for	additional	therapeutic	options	to	
treat	 this	 highly	malignant	 tumour	 of	 the	 central	 nervous	 system.	
Understanding	the	mechanisms	by	which	carnosine	exerts	its	anti-
neoplastic	effect	 could	well	pave	 the	way	 for	 the	development	of	
new therapeutic options.
2  | MATERIAL S AND METHODS
2.1 | Chemicals and reagents
If	not	stated	otherwise,	all	chemicals	were	purchased	from	Sigma-
Aldrich.	Carnosine	was	kindly	provided	by	Flamma	S.p.A.
2.2 | Cell culture
U87,	 T98G	 and	 LN229	 cells	 were	 originally	 obtained	 from	 the	
ATCC	 and	 cultured	 in	 T-75	 culture	 flasks	 (Sarstedt	 AG	 &	 Co.)	
in	 DMEM/25	 mM	 glucose,	 without	 pyruvate	 (Thermo	 Fisher	
Scientific),	supplemented	with	10%	foetal	bovine	serum	(FBS	supe‐
rior, Biochrom), 2 mM l‐alanyl‐l‐glutamine and antibiotics (Thermo 
Fisher	Scientific)	(further	designated	as	“culture	medium”)	at	37°C	
and	5%	CO2	in	humidified	air	in	an	incubator.	In	order	to	confirm	
identity	 over	 long	 culture	periods,	 cells	were	 genotyped	by	STR	
analysis	 at	 the	 Genolytic	 GmbH	 using	 a	 PowerPlex®	 21	 System	
(Promega)	and	cells	were	confirmed	as	the	U87MG	cell	 line	from	
the	ATCC.20
2.3 | Growth rate determination
About	150	000	cells	were	 seeded	 in	 culture	medium	 (5	mL)	 in	nine	
T-25	 culture	 flasks	 (Sarstedt).	 After	 24	 hours	 of	 incubation,	 cells	 in	
three	 flasks	were	detached	using	StemPro	Accutase	 (Thermo	Fisher	
Scientific)	and	cells	were	counted.	Then,	remaining	cells	were	washed	
once	with	Hank's	balanced	salt	solution	(HBSS;	2	mL;	137	mM	NaCl,	
5.4	mM	HCl,	 0.41	mM	MgSO4,	 0.49	mM	MgCl2,	 0.126	mM	CaCl2, 
0.33	mM	Na2HPO4,	 0.44	mM	KH2PO4,	 2	mM	HEPES,	 pH	 7.4),	 fol‐
lowed	by	an	incubation	time	of	72	hours	in	DMEM	(1	mL)	containing	
25	mM	 glucose,	 2	mM	 l-alanyl-l-glutamine,	N2	 supplement	 (further	
designated	DMEM	N2)	and	supplemented	with	or	without	50	mM	car‐
nosine. Then, cells were detached and counted, and the doubling time 
was calculated.
2.4 | Determination of l‐lactate production rate
About 106	cells	were	seeded	in	culture	medium	(2	mL)	per	well	into	
6-well	plates.	After	24	hours	of	incubation,	cells	were	washed	once	
with	HBSS	(1	mL)	and	then	further	 incubated	with	DMEM	N2	and	
supplemented	with	or	without	50	mM	carnosine.	After	0,	3,	6,	12,	
24	and	32	hours,	medium	(5	µL)	was	collected	and	stored	at	−80°C	
until	 further	 use.	 l-lactate	was	 determined	 as	 described	 before.21 
Absolute	 amounts	 of	 l‐lactate were calculated using a standard 
curve, and l‐lactate production rate was determined by calculating 
the l-lactate	production	between	three	and	six	hours	of	incubation.	
In	order	to	validate	the	significance	of	the	data	obtained,	repeated	
measures	one-way	ANOVA	was	performed	using	all	time	points.
2.5 | Determination of glucose uptake rate
A	total	of	10	000	cells	were	seeded	in	culture	medium	(200	µL)	in	96-
well	 plates	 (µClear,	Greiner	 Bio-One).	 After	 24	 hours	 of	 incubation,	
cells	were	washed	once	with	HBSS	 (200	µL)	and	 then	 further	 incu‐
bated	with	DMEM	N2	and	supplemented	with	or	without	50	mM	car‐
nosine	for	6	hours.	Then,	DMEM	(30	µL)	containing	Hoechst	33	342	
(10	ng/mL;	Thermo	Fisher	Scientific)	was	added	to	each	well	and	cells	
were	counted	using	a	Celigo	Imaging	Cytometer	(Nexcelom	Bioscience	
LLC)	after	an	incubation	for	30	minutes	at	37°C.	Afterwards,	cells	were	
washed	once	with	HBSS	(100	µL)	and	further	incubated	in	the	pres‐
ence	of	1	mM	2-desoxy-d-glucose	for	10	minutes.	Formed	2-desoxy-
d‐glucose‐6‐phosphate was determined using the glucose uptake Glo 
assay	(Promega)	according	to	the	manufactures	recommendations.
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2.6 | Metabolic profiling via GC‐MS
Metabolic	profiling	was	performed	as	described	previously.21	Briefly,	
106	cells	were	seeded	in	culture	medium	(2	mL)	per	well	into	6-well	
plates.	After	24	hours	of	 incubation,	 cells	were	washed	once	with	
HBSS	(1	mL)	and	then	further	incubated	with	DMEM	N2	(1	mL),	sup‐
plemented	with	0,	12.5,	25	or	50	mM	carnosine.	After	 incubation	
(see	 individual	 experiments	 for	 details),	 cell	 supernatants	 (10	 µL)	
were	 collected	 from	 each	 well	 and	 immediately	 frozen	 at	 –80°C	
until	further	use.	For	the	determination	of	intracellular	metabolites,	
cells	 were	 placed	 on	 ice	 and	 briefly	 washed	 with	 ice-cold	 HBSS.	
Immediately	after	washing,	 ice-cold	methanol	 (1	mL)	was	added	to	
each	well	and	metabolites	were	extracted	for	24	hours	on	an	orbital	
shaker	at	8°C.	Then,	extracts	were	collected	and	wells	were	rinsed	
once	with	methanol.	Afterwards,	samples	were	evaporated	to	dry‐
ness	using	a	speed	vac	 (Maxi-Dry	Lyo,	Heto-Holten)	and	stored	at	
−80°C	until	further	use.	Derivatization,	gas	chromatography	coupled	
with	mass	spectrometry	(GC-MS)	analysis	and	data	evaluation	were	
performed	 as	 described	 before.21,22	 If	 not	 stated	 otherwise,	 the	
abundance	of	a	metabolite	is	defined	by	the	peak	area	determined	
from	the	selected	ion	chromatogram	of	an	experiment	normalized	to	
total	cellular	protein	(µg).
2.7 | Quantification of glyceraldehyde‐3‐
phosphate and dihydroxyacetone phosphate
In	 order	 to	 investigate	 a	 possible	 reaction	 of	 carnosine	with	 glyc‐
eraldehyde-3-phosphate	 (GA3P)	 and	 dihydroxyacetone	 phosphate	
(DHAP),	GA3P	(625	µM)	or	DHAP	(625	µM)	was	incubated	at	37°C	
for	4	hours	in	the	presence	of	0,	0.625,	1.25,	6.25	or	62.5	mM	car‐
nosine	 in	 triethanolamine	 buffer	 (50	 mM	 triethanolamine;	 5	 mM	
MgCl2;	 pH	7.6;	 total	 volume:	 75	µL).	 Then,	 the	 amounts	 of	GA3P	
or	DHAP	were	quantified	according	to	Bergmeyer.23	Briefly,	1.5	µL	
of	NADH	solution	(20	mM)	was	added	to	each	reaction	and	the	ini‐
tial	extinction	at	340	nm	was	determined.	Afterwards,	enzyme	mix	
(3.5	µL)	was	added	to	detect	GA3P	(1	U/µL	triosephosphate	isomer‐
ase;	 0.085	 U/µL	 glycerol-3-phosphate	 dehydrogenase	 diluted	 in	
triethanolamine	buffer)	or	DHAP	(0.085	U/µL	glycerol-3-phosphate	
dehydrogenase,	diluted	in	triethanolamine	buffer).	After	an	incuba‐
tion	of	30	minutes	at	37°C,	extinction	at	340	nm	was	determined	
and	the	absolute	amounts	of	GA3P	and	DHAP	were	calculated	using	
a standard curve.
2.8 | MS‐based analysis of carnosine 
reaction products
In	order	to	identify	a	possible	reaction	product	of	carnosine	and	
GA3P, GA3P (7.5 mM) was incubated in the presence or absence 
of	carnosine	 (7.5	mM)	 in	NH4
+/CH3COO
−	buffer	 (5	mM,	pH	7.6)	
for	 4	 hours	 at	 37°C.	 Then,	 the	 reaction	 mixture	 was	 diluted	
1:12.5	 in	 30%	 acetonitrile/H2O	 and	 analysed	 by	 flow	 injection	
analysis	 on	 an	 ESI-TOF	 micrOTOF	 (Bruker	 Daltonik)	 in	 posi‐
tive	mode	 (negative	mode	 for	GA3P	detection)	with	 an	Agilent	
1100	 AS	 autosampler	 and	 otofControl	 3.4	 and	 HyStar	 3.2-LC/
MS.	 Injection	 was	 performed	 with	 the	 following	 parameters:	
nebulizer	 (26.1	psi),	dry	gas	flow	(6	L/min),	dry	gas	temperature	
(220°C),	injection	volume	(5	µL),	flow	rate	(0.1	mL/min)	and	elu‐
ent	 (methanol	 containing	 0.1%	 formic	 acid).	Mass	 selective	 de‐
tector	 was	 used	 with	 the	 following	 settings:	 mass	 range	 m/z 
50-1500,	capillary	exit	100	V,	skimmer	1	50	V,	hexapole	1	23	V,	
hexapole	RF	70	Vpp,	skimmer	2	23	V,	 lens	1	transfer	70	µs	and	
lens	1	pre-pulse	storage	8	µs.
2.9 | Determination of oxygen consumption rate 
(OCR) and extracellular acidification rates (ECAR)
For	the	determination	of	the	OCR	and	the	ECAR,	10	000	cells	were	
seeded	in	80	µL	of	culture	medium	in	an	XF96	cell	culture	micro‐
plate	 (Seahorse	 Bioscience).	 After	 19	 hours,	 cells	 were	 washed	
once	with	HBSS	 (1	mL)	 and	 then	 further	 incubated	with	DMEM	
(80	µL)	containing	25	mM	glucose,	2	mM	l‐alanyl‐l-glutamine,	N2	
supplement	and	0	or	50	mM	carnosine.	After	additional	6	hours	of	
incubation,	cells	were	washed	twice	with	HBSS,	 followed	by	1	h	
incubation	at	37°C	 in	180	µL	of	Seahorse	XF	DMEM	containing	
25 mM glucose and 2 mM l‐alanyl‐l‐glutamine and 0 or 50 mM 
carnosine,	 or	 180	µL	HBSS	 containing	25	mM	glucose	or	 5	mM	
pyruvate and supplemented with 0 or 50 mM carnosine. Then, 
Seahorse	XF	Cell	Mito	Stress	Test	was	performed	using	an	XF96	
Extracellular	Flux	Analyzer	according	to	the	manufacturer.	Briefly,	
after	 baseline	determination,	OCR	was	determined	 after	 the	 se‐
quential	addition	of	oligomycin	A,	FCCP	and	rotenone/antimycin	
A	(each	1	µM).	After	the	final	measurement,	Seahorse	XF	DMEM	
(30	µL)	containing	Hoechst	33342	(10	ng/mL)	was	added	to	each	
well	 and	 cells	 were	 counted	 using	 a	 Celigo	 Imaging	 Cytometer	
after	 an	 incubation	 of	 30	minutes	 at	 37°C.	 Data	were	 analysed	
using	the	Seahorse	Wave	Desktop	Software;	OCR	is	reported	as	
unit nanomole per minute and 106	cells,	and	ECAR	is	reported	as	
unit mpH per minute and 103 cells.
2.10 | Statistical analysis
Statistical	 analysis	 was	 carried	 out	 using	 SPSS	 (IBM;	 Version:	
24.0.0.2	64-bit).	False	discovery	rate	(FDR)	was	calculated	accord‐
ing to Benjamini and Hochberg.24	 For	 pairwise	 comparisons,	 a	 t	
test	was	performed.	For	multiple	comparisons,	a	one-way	ANOVA	
with the Games‐Howell post hoc test was used. Principal com‐
ponent	 analysis	 (data	were	 normalized	 to	 untreated	 control	 and	
auto‐scaled) and metabolite pathway analysis (settings: Over 
Representation Analysis: Hypergeometric Test; Pathway Topology 
Analysis:	 Relative-betweenness	 Centrality;	 Pathway	 Database:	
Homo	sapiens	The	Small	Molecule	Pathway	Database)	were	per‐
formed	 using	MetaboAnalyst.25	 If	 not	 stated	 otherwise,	 experi‐
ments	were	carried	out	in	6-tuplicate	(independent	experiments)	
and	data	are	presented	as	mean	±	standard	deviation.	Non-over‐
lapping	confidence	intervals	(CI	95%),	P-value	<	.05	or	FDR	<	0.05	
were	presumed	to	be	statistically	significant.
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3  | RESULTS
3.1 | Carnosine affects metabolic pathways 
connected to glycolysis
Previous	 studies	 indicated	 that	 carnosine	 affects	 cancer	 cell	me‐
tabolism	 by	 influencing	 the	 glycolytic	 pathway.11,26 As neither 
its	mode	of	action	nor	 targets	of	carnosine	were	known,	we	em‐
ployed	a	targeted	method	using	GC-MS	to	study	metabolites	and	
pathways	 connected	 to	 glycolysis.	 Therefore,	 U87	 glioblastoma	
cells	 were	 treated	 with	 FBS-free	 medium	 containing	 different	
concentrations	of	carnosine	(0,	12.5,	25	and	50	mM),	followed	by	
metabolite	extraction	and	GC-MS	analysis	after	6	hours	of	incuba‐
tion.	First,	we	asked	whether	the	dipeptide	has	a	general	effect	on	
cancer	cell	metabolism.	Performing	a	principal	component	analysis	
(Figure	 1A),	we	 observed	 a	 significantly	 different	metabolic	 pro‐
file	already	at	a	concentration	of	12.5	mM	carnosine.	Increasing	its	
concentrations	for	treatment	resulted	in	an	even	better	separation	
compared	 to	 the	 control	 cells,	 but	 confidence	 intervals	of	 scores	
between	 cells	 treated	with	 different	 concentrations	 of	 carnosine	
overlap,	 indicating	 a	 similarity	 between	metabolic	 profiles	 under	
carnosine	treatment.	 In	order	to	distinguish	between	cell-specific	
and	general	effects	of	 the	dipeptide,	we	also	analysed	 intra-	and	
extracellular	metabolites	 in	 the	 glioblastoma	 cell	 lines	 T98G	 and	
LN229	treated	with	50	mM	carnosine	for	6	hours.	Similar	to	U87	
cells,	treatment	of	T98G	and	LN229	cells	resulted	in	a	clear	sepa‐
ration	 in	principal	component	analysis	 (Figure	1B,C).	Next,	we	 in‐
vestigated	which	metabolic	pathways	are	affected	by	the	dipeptide	
using	MetaboAnalyst.	Therefore,	abundances	of	 intra-	and	extra‐
cellular	metabolites	of	cells	 treated	with	0	and	50	mM	carnosine	
were	compared	by	using	a	t	test	(for	each	cell	line	individually)	and	
metabolites	whose	abundances	exhibited	an	FDR	<	0.05	were	sub‐
jected	to	a	pathway	analysis	(Figure	1D).
The	 metabolite	 set	 enrichment	 analysis	 revealed	 effects	 on	
several pathways, such as glycine and serine metabolism and lysine 
degradation	with	different	probability	 among	 the	 cell	 lines.	More	
important,	 four	 pathways,	 namely	 pentose	 phosphate	 pathway	
(PPP), malate‐aspartate shuttle, glycerol phosphate shuttle and 
Warburg	effect	 (summarizes	glycolysis,	PPP	and	citric	 acid	cycle),	
were	significantly	(P	<	.05)	enriched	in	all	three	cell	lines	after	car‐
nosine	treatment.	The	relative	intracellular	abundances	of	the	de‐
tected	 metabolites	 of	 the	 corresponding	 pathways	 are	 shown	 in	
Figure	1F	 (for	 the	complete	 results	of	 the	metabolic	profiling	 see	
Figure	S1).
The	influence	of	carnosine	on	the	PPP	is	highly	interesting,	as	this	
pathway	plays	a	critical	role	for	proliferation,	providing	5-phosphori‐
bosyl	diphosphate	for	DNA	and	RNA	biosynthesis.27 In accordance, 
treatment	with	 50	mM	 carnosine	 significantly	 increased	 the	 dou‐
bling	time	of	U87,	T98G	and	LN229	glioblastoma	cells	(Figure	1E).
In	addition,	the	influence	of	carnosine	on	the	glycerol	phosphate	
shuttle	and	the	malate-aspartate	shuttle	suggests	an	 inhibitory	ef‐
fect	of	carnosine	on	cellular	redox	homeostasis,	as	the	malate-aspar‐
tate	shuttle	contributes	~20%	to	the	total	 respiratory	rate,	and	 its	
inhibition	leads	to	reduced	production	of	glutamate	from	glucose.28
3.2 | Carnosine inhibits mitochondrial respiration 
independent of the malate‐aspartate and the glycerol 
phosphate shuttle
Our	 results	 suggest	 an	 inhibitory	 effect	 of	 carnosine	 on	 the	 glyc‐
erol phosphate shuttle and the malate‐aspartate shuttle which are 
required	for	mitochondrial	ATP	production.	Hence,	we	investigated	
the	 influence	 of	 carnosine	 on	 mitochondrial	 respiration	 using	 a	
Seahorse	 XF	 analyser.	 In	 this	 experiment	 (Figure	 2A,C,E;	 see	 also	
Figure	S2),	 treatment	with	50	mM	carnosine	 significantly	 reduced	
the	ATP-linked	oxygen	 consumption	 rate	 (OCR)	of	U87	and	T98G	
cells	 but	 not	 that	 of	 LN229	 cells	 (assayed	 in	 DMEM	 containing	
25 mM glucose and 2 mM l‐alanyl‐l‐glutamine). Although reduced 
ATP-linked	OCR	in	U87	and	T98G	is	in	agreement	with	the	assump‐
tion	that	it	is	caused	by	the	dipeptide's	influence	on	the	aforemen‐
tioned	shuttles,	the	observation	made	in	LN229	argues	against	this	
idea.	Therefore,	we	determined	the	OCR	in	HBSS	with	pyruvate	as	
the	only	substrate,	as	mitochondrial	ATP	production	from	pyruvate	
is	 independent	 of	 the	 malate-aspartate	 shuttle	 and	 the	 glycerol	
phosphate shuttle.29	As	seen	in	Figure	2B,D,F,	ATP-linked	OCR	was	
significantly	higher	 in	 the	presence	of	5	mM	pyruvate	 than	 in	 the	
presence	of	25	mM	glucose	 in	all	 three	cell	 lines.	More	 important,	
we	also	observed	reduced	ATP-linked	OCR	under	 the	 influence	of	
pyruvate	in	U87	and	T98G	but	not	in	LN229	(for	the	complete	analy‐
sis	of	data	obtained	from	the	Seahorse	experiments	see	Figure	S3).	
Therefore,	 we	 conclude	 that	 carnosine's	 impact	 on	 mitochondrial	
respiration	is	cell-specific	and	not	necessarily	dependent	on	its	influ‐
ence on the shuttle systems.
3.3 | Glucose consumption and l‐lactate production
In	 view	 of	 the	 observation	 that	 the	 abundances	 of	 DHAP	 and	
GA3P	 (Figure	 1F)	 are	 reduced	 under	 the	 influence	 of	 the	
F I G U R E  1   Impact	of	carnosine	on	glioblastoma	cell	metabolism.	Principal	component	analysis	of	the	metabolic	profiles	obtained	from	(A)	
U87	cells	treated	for	6	h	with	0	mM	(red),	12.5	mM	(green),	25	mM	(blue)	or	50	mM	(cyan)	carnosine	(Car)	and	(B)	T98G	and	(C)	LN229	cells	
treated	for	6	h	with	0	mM	(red),	50	mM	(green)	Car.	D,	Pathway	analysis	using	metabolites	whose	abundances	were	significantly	(FDR	<	0.05)	
changed	by	50	mM	Car.	Bold	line	indicates	a	P-value	=	.05.	E,	Doubling	time	of	U87,	T98G	and	LN229	cells	treated	with	or	without	50	mM	
Car	(n	=	3).	F,	Significantly,	changed	abundances	of	metabolites	which	belong	to	the	metabolic	pathways	shown	in	(D).	Data	are	presented	
as	fold-change	compared	to	0	mM	Car	(n	=	6).	2PG,	2-phosphoglycerate;	3PG,	3-phosphoglycerate;	aKg,	α‐ketoglutarate; Asp, aspartate; 
Cit,	citrate;	DHAP,	dihydroxyacetone	phosphate;	E4P,	erythrose-4-phosphate;	F6P,	fructose-6-phosphate;	Fum,	fumarate;	G3P,	glycerol-3-
phosphate;	G6P,	glucose-6-phosphate;	GA3P,	glyceraldehyde-3-phosphate;	Glc,	glucose;	Gln,	glutamine;	Glu,	glutamate;	Lac,	lactate;	Mal,	
malate;	R5P,	ribose-5-phosphate;	Suc,	succinate.	Level	of	significance	is	indicated	as:	***P	<	.0005;	**P	<	.005;	*P	<	.05	vs.	0	mM	Car
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dipeptide,	we	wondered	whether	the	flux	from	glucose	to	l‐lac‐
tate	 is	 also	 affected.	 Therefore,	we	determined	 glucose	uptake	
rate	 (Figure	3A)	and	l-lactate	production	rate	 (Figure	3B)	under	
the	influence	of	50	mM	carnosine.	As	can	be	seen	in	Figure	3A,B,	
uptake	 of	 2-desoxy-d-glucose	 was	 significantly	 reduced	 only	
in	 LN229	 cells	 and	 l-lactate	 production	 significantly	 reduced	
only	in	T98G	cells	(repeated	measures	one-way	ANOVA	over	all	
time points: P	=	.065,	.0026	and	.055	for	U87,	T98G	and	LN229,	
respectively).
3.4 | Carnosine reduces the intracellular 
abundance of GA3P by a direct reaction 
with the metabolite
Next,	we	investigated	whether	reaction	of	carnosine	with	DHAP	
and	GA3P	may	be	responsible	for	their	decreased	abundance	in	the	
presence	of	the	dipeptide.	Therefore,	both	triose	phosphates	were	
incubated	 in	 vitro	 in	 the	 presence	 of	 the	 dipeptide	 (Figure	 4A).	
We	observed	that	equimolar	concentrations	of	carnosine	resulted	
F I G U R E  2  Carnosine	inhibits	
mitochondrial ATP production in U87 
and	T98G	cells.	Determination	of	the	
ATP-linked	oxygen	consumption	rate	
(OCR)	in	(A)	U87,	(C)	T98G	or	(E)	LN229	
cells treated with or without 50 mM 
carnosine	(Car)	for	6	h	in	the	presence	
of	DMEM	with	25	mM	glucose	(Glc)	and	
2 mM l‐alanyl‐l‐glutamine (Ala‐Gln). 
Determination	of	the	ATP-linked	oxygen	
consumption	rate	(OCR)	in	(B)	U87,	
(D)	T98G	or	(F)	LN229	cells	in	HBSS	
containing 25 mM Glc or 5 mM pyruvate 
(Pyr)	as	the	only	energy	source	after	6	h	
treatment	with	0	or	50	mM	Car	(n	=	6-10).	
Level	of	significance	is	indicated	as:	
***P	<	.0005;	**P	<	.005;	*P < .05; ns: 
P > .05
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in	a	1.3-fold	reduction	of	the	GA3P	concentration,	and	a	ten-fold	
higher	concentration	of	 the	dipeptide	 resulted	 in	a	36.5-fold	 re‐
duction	 of	GA3P.	We	 also	 observed	 a	 reduced	 concentration	 of	
DHAP	 in	 the	 presence	 of	 carnosine,	 but	 a	 1.1-fold	 reduction	 of	
DHAP	 required	 a	 ten-fold	 molar	 excess	 of	 carnosine.	 This	 indi‐
cates	 that	 a	 non-enzymatic	 reaction	 of	 carnosine	 with	 GA3P	 is	
responsible	for	the	reduced	abundance	of	the	triose	phosphates.	
To	confirm	a	reaction	of	carnosine	with	GA3P,	mass	spectrometry	
was	performed	which	detected	two	peaks	with	a	mass	of	379.1011	
and	 401.0829	 (Figure	 4D,E)	 referring	 to	 a	 reaction	 product	 of	
GA3P	 and	 carnosine	 ionized	 with	 H+	 or	 Na+ (calculated mass: 
379.1013	and	401.0833,	 respectively).	 Interestingly,	we	also	de‐
tected	the	reaction	product	of	methylglyoxal	(MGO)	and	carnosine	
(Figure	4F,G),	which	was	identified	by	the	exact	mass	of	281.1264	
(H+	ionization;	calculated	mass:	281.1244)	and	303.1036	(Na+ ioni‐
zation;	calculated	mass:	303.1064).
4  | DISCUSSION
The naturally occurring dipeptide carnosine reduces tumour 
growth in vivo8,9 and in vitro.10‐13 However, as pointed out in the 
introduction,	neither	the	exact	mechanisms	behind	this	observa‐
tion	 nor	 the	 primary	 targets	 of	 carnosine	 have	 been	 identified.	
Using	mass	spectrometry,	we	detected	that	carnosine	non-enzy‐
matically reacts with GA3P in vitro similar to its previously de‐
scribed	 reaction	 with	 methylglyoxal.30 As we also see reduced 
intracellular	abundances	of	GA3P	and	DHAP	in	cultured	cells,	we	
presume	 this	 reaction	 to	 be	 responsible	 for	 the	 reduced	 abun‐
dances	of	these	triose	phosphates.	Surprisingly,	the	reduced	abun‐
dance	of	these	metabolites	was	not	unequivocally	accompanied	by	
a decreased glucose uptake rate or by a decreased lactate release 
rate.	Although	one	has	to	note	that	a	precise	determination	of	the	
glycolytic	flux	would	require	more	powerful	methods,	such	as	13C-
based	metabolic	flux	analysis,	this	is	an	indication	that	the	overall	
glycolytic	flux	is	not	decreased	by	the	presence	of	the	dipeptide.	
More	 importantly,	 the	 reduced	 abundances	 of	GA3P	 and	DHAP	
are	 accompanied	 by	 reduced	 abundances	 of	metabolites	 associ‐
ated with the PPP, the glycerol phosphate shuttle and the malate‐
aspartate	shuttle.	The	PPP	is	especially	important	for	tumour	cells	
as	 it	provides	nucleotides	 for	nucleic	acid	synthesis	and	NADPH	
required	for	fatty	acid	synthesis	and	scavenging	of	reactive	oxy‐
gen	species	(for	review	see31).	Therefore,	a	decreased	activity	of	
this	pathway	will	 impair	proliferation	and	defence	against	oxida‐
tive	stress,	and	it	has	been	discussed	that	the	PPP	could	be	in	fact	
a	potential	target	for	cancer	therapy.32
In	previous	 investigations,	the	anti-neoplastic	of	carnosine	was	
shown to be associated with decreased ATP production. However, 
there	have	been	different	reports	either	pointing	towards	an	effect	
on glycolysis, mitochondrial respiration or on both, depending on 
the cell type investigated.11,15,17,18	 As	we	observed	 a	 reduction	of	
metabolites	of	the	malate-aspartate	shuttle	and	the	glycerol	phos‐
phate	shuttle	 in	all	 three	cell	 lines,	 it	 is	 straightforward	 to	assume	
that	this	observation	is	responsible	for	reduced	mitochondrial	ATP	
production	as	these	pathways	deliver	cytosolic	NADH	to	mitochon‐
drial	oxidation.	However,	using	pyruvate	as	substrate,	only	cells	from	
the	lines	U87	and	T98G	responded	to	the	presence	of	the	dipeptide	
with	reduced	ATP-linked	OCR	but	not	cells	from	the	line	LN229.	As	
LN229	cells	do	not	 respond	with	 reduced	ATP	production	even	 in	
the	presence	of	glucose	(Figure	S3),	aside	from	a	predicted	impair‐
ment	of	 the	 shuttles,	we	assume	 that	 the	 shuttles	may	also	be	of	
less	importance	for	ATP	production	in	U87	and	T98G	cells.	In	addi‐
tion,	the	cell-specific	response	of	mitochondrial	ATP	production	to	
the	presence	of	carnosine	is	highly	interesting,	pointing	towards	the	
possibility	 of	 a	 tumour-specific	 reactivity.	 A	 cell-specific	 response	
was also reported by Bao et al17 who demonstrated that carnosine 
inhibits	the	enzymatic	activity	of	electron	transport	chain	complexes	
in	HeLa	 cells	 but	 not	 in	 SiHa	 cells.	 Therefore,	 future	work	 should	
carefully	evaluate	 in	which	cells	carnosine	affects	ATP-linked	OCR	
to	 reveal	 the	mechanisms	 behind	 this	 phenomenon.	 Nonetheless,	
carnosine	 impairs	 proliferation	 in	 all	 three	 lines	 examined.	 This	 in	
turn indicates that decreased mitochondrial ATP production is not 
as	important	for	the	anti-neoplastic	effect	of	the	dipeptide	as	a	de‐
creased	activity	of	the	PPP.
F I G U R E  3   Influence	of	carnosine	on	
glucose uptake and l‐lactate production. 
A,	Cells	were	treated	with	or	without	
50	mM	carnosine	(Car)	for	6	h.	Then,	
2-desoxy-d‐glucose (2DG) uptake 
was	determined	as	a	measure	for	the	
glucose	uptake	rate	(n	=	6).	B,	Cells	
were treated with or without 50 mM 
Car	and	extracellular	l‐lactate was 
determined	after	3	and	6	h	to	calculate	
l-lactate	production	rate	(n	=	6).	Level	of	
significance	is	indicated	as:	***P < .0005; 
**P < .005; ns: P > .05
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Up to now, several suggestions have been made on how car‐
nosine	 may	 influence	 tumour	 cell	 growth	 (for	 a	 review	 see33). A 
recent	 report	 analysing	 a	 potential	 role	 of	 the	 PI3K/Akt/mTOR	
signalling pathway in U87 and T98G cells demonstrated that the 
inhibitory	 effect	 of	 carnosine	 is	 independent	 of	 this	 pathway,	 al‐
though	 cells	 from	 the	 line	U87	 exhibited	 a	 decreased	 phosphory‐
lation	of	Akt	under	 the	 influence	of	 the	dipeptide.14	Whether	 the	
effect	on	Akt	is	caused	by	the	influence	of	carnosine	on	metabolites	
F I G U R E  4  Carnosine	reacts	with	glyceraldehyde-3-phosphate.	A,	Carnosine	(Car)	non-enzymatically	reacts	with	glyceraldehyde-3-
phosphate	(GA3P)	and	dihydroxyacetone	phosphate	(DHAP)	(4	h	of	incubation;	n	=	3).	Mass	spectrometric	analysis	of	reaction	products	
of	carnosine	with	GA3P	and	methylglyoxal	(MGO).	Intensity	of	(B)	GA3P,	(C)	car,	(D,	E)	GA3P-Car,	(F,	G)	MGO-Car.	Numbers	indicate	the	
corresponding m/z
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or	mitochondrial	respiration	 is	difficult	to	resolve	as	these	 interac‐
tions	are	highly	complex	 (for	 review	see34). At this point, it should 
also	be	emphasized	that	care	has	to	be	taken	to	compare	the	dipep‐
tide's	effect	on	different	cancer	cell	types.	Whereas	in	glioblastoma	
cells	no	effect	on	mTOR	signalling	was	detected,14 Zhang et al re‐
ported	 an	 inhibitory	 effect	 on	 mTOR/p70S6K-signalling	 in	 gastric	
carcinoma.12	As	increased	GA3P	levels	lead	to	activation	of	mTOR,35 
a	reduction	of	GA3P	could	be	responsible	for	an	 inhibitory	effect.	
To	 solve	 the	 riddle	why	glioblastoma	cells	behave	differently	with	
regard	 to	mTOR	signalling	would	 require	 further	 investigations	on	
how	phosphorylation/dephosphorylation	 of	mTOR	 is	 controlled	 in	
different	 cells.	 However,	 both	 observations	 taken	 together	 argue	
against	the	notion	that	mTOR	is	a	direct	target	of	carnosine,	pointing	
towards an upstream target such as GA3P.
As	it	is	reported	that	carnosine	suppresses	HIF-1α signalling,10,36 
it	is	also	tempting	to	speculate	that	inhibition	of	this	pathway,	which	
controls	the	expression	of	glycolytic	enzymes,	is	responsible	for	the	
effects	observed	in	this	study.	However,	there	are	also	reports	that	
the	dipeptide	may	increase	HIF-1α activity accompanied by reduced 
tumour	growth	and	extracellular	acidification.37 In order to resolve 
whether	 HIF-1α	 signalling	 is	 involved	 in	 carnosine's	 anti-neoplas‐
tic	effect	 certainly	 requires	 further	 investigations.	At	 this	point,	 it	
should	also	be	noted	that	the	influence	of	metabolites	on	signalling	
is	still	far	from	being	understood.38
Our observation that all three lines responded to the presence 
of	carnosine	with	decreased	activity	of	the	PPP	and	with	decreased	
proliferation	when	supplied	with	glucose	is	in	agreement	with	more	
recent	 interpretations	of	 the	Warburg	effect.	Warburg's	observa‐
tion	 that	 cancer	 cells	 exhibit	 a	high	 rate	of	 glycolysis	 even	 in	 the	
presence	 of	 oxygen	 (aerobic	 glycolysis)	 has	 long	 been	 debated.	
Today,	the	most	accepted	interpretation	trying	to	explain	this	phe‐
nomenon	 is	 that	 aerobic	 glycolysis,	 despite	 its	 low	 efficiency	 in	
ATP yield per molecule glucose, strongly supports macromolecular 
synthesis	(for	review	see39).	Therefore,	the	reduced	abundances	of	
metabolites	such	as	GA3P,	DHAP,	E4P	or	R5P	can	be	interpreted	as	
a	direct	effect	of	carnosine	on	the	Warburg	effect.	Noteworthy,	our	
results	also	demonstrate	that	the	cells	from	all	three	lines	are	able	
to	produce	ATP	in	the	presence	of	pyruvate	and	in	the	absence	of	
glucose	confirming	that	mitochondria	are	not	defective	in	their	abil‐
ity	to	carry	out	oxidative	phosphorylation	(OXPHOS).	However,	as	
carnosine	interferes	with	OXPHOS	in	U87	and	T98G	cells	but	not	in	
LN229	cells,	mitochondrial	physiology	may	be	different	in	different	
cells.	This	can	even	be	the	case	within	one	tumour.	Janiszewska	et	
al,	 for	example,	demonstrated	 that	especially	glioblastoma	cancer	
stem	cells	strongly	appear	to	be	dependent	on	OXPHOS	but	not	on	
glycolysis.40 As there is now emerging evidence that cancer cells 
can	 acquire	 a	high	metabolic	 plasticity	by	 their	 hybrid	 glycolysis/
OXPHOS	phenotype,41 and it is interesting that carnosine is able 
to	interfere	with	both	pathways.	Hence,	our	observations	strongly	
demand	 further	 research	 into	 carnosine's	 effect	 on	 OXPHOS,	
as metabolic plasticity may be associated with metastasis and 
therapy‐resistance.
Considering	 using	 carnosine	 for	 the	 therapy	 of	 glioblastoma	 or	
other	types	of	cancer,	 the	question	has	to	be	answered	whether	 in‐
tracellular	concentrations	of	carnosine	could	be	reached	that	are	able	
to	inhibit	the	PPP	by	reaction	with	GA3P.	The	experiments	presented	
in	Figure	4A	demonstrate	 that	 a	 concentration	of	>1	mM	carnosine	
should	be	reached	to	reduce	the	available	amount	of	GA3P	to	<50%.	
This	is	at	least	in	the	range	of	carnosine	concentrations	determined	in	
kidney	tissue	of	CN1	transgenic	mice	which	were	supplemented	with	a	
bolus	of	200	mg	carnosine.42	In	these	experiments,	carnosine	concen‐
trations	reached	~0.5	mmol/kg	8	hours	after	supplementation.	More	
interestingly, the authors could also demonstrate that in mice receiving 
a	CN1	inhibitor,	tissue	concentrations	increased	~7-fold,	which	is	an	in‐
teresting	aspect	considering	carnosine	as	a	therapeutic.	In	this	context,	
one	should	also	be	aware	that	in	the	experiments	of	Qiu	et	al,42 car‐
nosine was supplemented only once and tissue concentrations were 
determined 8 hours later. However, in a clinical set‐up carnosine might 
be	supplemented	repeatedly.	As	demonstrated	by	the	experiments	of	
Blancquaert	et	al,43	daily	administration	of	the	carnosine	moieties	β‐al‐
anine and l‐histidine over 23 days results in a continuous increase in 
muscle carnosine concentrations. This observation points towards the 
possibility	that	the	dipeptide's	tissue	concentration	might	continuously	
be	increased	after	repeated	supplementation	during	cancer	therapy.
In	 conclusion,	 our	 investigation	 demonstrates	 that	 carnosine's	
anti-neoplastic	effect	is	accompanied	by	reduced	abundances	of	sev‐
eral metabolites associated with glycolysis and pathways dependent 
on	it.	We	suggest	that	a	non-enzymatic	reaction	of	GA3P	with	the	di‐
peptide	is	responsible	for	its	reduced	abundance	that	in	turn	leads	to	
a	decreased	activity	of	the	pentose	phosphate	pathway	required	for	
proliferation.	However,	we	also	observed	an	 inhibitory	effect	on	mi‐
tochondrial	ATP	production	which	is	cell-specific	and	independent	of	
carnosine's	effect	on	glycolytic	metabolites.
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In summary, our results suggest that carnosine’s effect on glioblastoma cell viability mainly 
results from a non-enzymatic reaction of the dipeptide with GA3P that in turn diminishes the 
supply of precursors for the biosynthesis of macromolecules, e.g. via the PPP. In fact, the 
PPP has already been considered to have a vital role in tumorigenesis (Patra and Hay 2014).  
At this point it is interesting to add that using mass spectrometry we observed that the 
identified carnosine-GA3P adduct exhibited only a minor abundance (signal) compared to the 
carnosine-methylglyoxal adduct. This indicates that GA3P-carnosine is an intermediate and 
not the end-product of carnosine dependent GA3P reduction. Using nuclear magnetic 
resonance spectroscopy, we observed that the dipeptide reduces the amounts of GA3P 
without being consumed. Further analysis revealed that carnosine catalyses the degradation 
of GA3P to methylglyoxal (unpublished results). Interestingly, the dipeptide also catalyses 
the oligomerisation of methylglyoxal (Weigand et al. 2018) which could be a subsequent 
reaction and possibly explains the detection of the carnosine-methylglyoxal adduct in our 
experiments. More important, the observation that carnosine can act as a catalyser opens a 
new aspect of the molecular properties of the dipeptide and deserves further investigation. 
 
2.5 Carnosine’s effect on Glioblastoma cell viability and migration 
 
Infiltration and formation of metastasis is in addition to rapid growth a hallmark of cancer 
(Hanahan and Weinberg 2011). Especially gliomas grow highly infiltrative and glioma cells 
can be found throughout the whole brain (Sahm et al. 2012). According to the “go or growth” 
hypothesis, cancer cells either exhibit a proliferative or an invasive phenotype (Hatzikirou et 
al. 2012). Therefore, a drug that inhibits cancer cell proliferation, such as carnosine, could 
possibly induce invasion which is accompanied with a poor prognosis for patients 
(Evdokimova et al. 2009). Therefore, we investigated carnosine’s influence on glioblastoma 
cell migration with a newly developed cell co-culture model (Oppermann et al. 2018). In our 
model, glioblastoma cells were seeded inside of a cloning ring and patient-derived fibroblasts 
were placed outside of the ring. After removal of the ring, co-cultures were cultivated in the 
presence or absence of carnosine over four weeks. In order to assess glioblastoma colony 
formation, an immunofluorescent staining was employed to distinguished fibroblasts from 
glioblastoma cells. This allowed us to investigate the infiltrative growth of glioblastoma cells 
in a non-neoplastic cell layer.  
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Background
Isocitrate dehydrogenase (IDH)-wildtype glioblastoma 
is the most malignant brain tumor of the adult brain 
and designated as Grade IV tumor by the World Health 
Organization (WHO) [1]. All tumors used in this study 
were IDH1R132H-non-mutant glioblastoma of elderly 
patients and, for reasons of simplicity, will further be 
referred to as GBM. Aside from a high mitotic activity 
and its ability to vascularize, GBM, as all diffuse glioma, 
has a high potential to infiltrate into intact brain tis-
sue which makes it virtually impossible for the surgeon 
to completely remove the tumor. Cells able to migrate 
within intact tissue are considered to be the main cause 
of tumor recurrence which is generally observed within 
6–9 month after surgery and standard therapy [2]. There-
fore, any therapeutic approach has to consider that it 
may not be enough to inhibit the proliferation of cells, 
but should although prevent their spreading into intact 
tissue. Moreover, as Giese et  al. [3] pointed out already 
more than 20  years ago, proliferation and migration 
appear to be mutually exclusive behaviors. The con-
cept of a dichotomy of proliferation/migration has been 
observed by many groups and has coined the term “go 
or grow” [4]. Having this dichotomy in mind it is impor-
tant that a substance that inhibits proliferation does not 
at the same time trigger migration and invasive behavior. 
This is the case for the dipeptide l-carnosine (β-alanyl-
l-histidine). This naturally occurring dipeptide has been 
discovered in 1900 by Gulewitsch and Amiradzibi [5]. 
Aside from a number of physiological roles attributed 
to it, such as pH-buffering or the chelation of metal ions 
(for review see [6]), it is discussed as a potential drug for 
the treatment of tumors (for reviews see [7, 8]). After the 
first observations made by Nagai and Suda [9] and the 
rediscovery of its anti-neoplastic effect by Holliday and 
McFarland [10], carnosine’s anti-tumor effect has been 
shown in vitro for a variety of cells derived from different 
tumors. This, for instance, includes gastric cancer cells 
[11], colon cancer cells [12] and, with special emphasis 
to this work, cells derived from glioblastoma [13]. Unfor-
tunately, the exact mechanisms by which the dipeptide 
exerts its anti-neoplastic effect are still unknown but 
appear to be pleiotropic and dependent on the tumor 
cells investigated (for review see [14]).
Although previous experiments pointed towards the 
possibility that carnosine also reduces migration and 
infiltration via inhibition of Matrix Metalloproteinase-9 
in SK-Hep-1 hepatoma cells [15] and in oxygen–glucose 
deprived reactive rat astrocytes [16] tumor cell inva-
sion in these experiments was determined using trans 
well chamber assays, which cannot answer the question 
whether migration into tissue or a layer of cells will also 
be inhibited by the dipeptide. The same is the case with 
recently published experiments performed with HCT-
116 human colon cancer cells which also indicated that 
the invasion ability of these cells is significantly inhibited 
already at a concentration 0.5 mM carnosine [17]. There-
fore, we analyzed the infiltrative capacity of IDH-wildtype 
glioblastoma cells in the presence of carnosine in a newly 
developed co-culture model. In our model glioblastoma 
cells were seeded inside a cloning ring placed in the well 
of a 12 well plate, seeding patient-derived fibroblasts out-
side the cloning rings. The rings were removed after the 
cells had attached to the culture dishes and the cells were 
incubated for different periods of time in the absence and 
presence of different concentrations of carnosine. Finally, 
the infiltrative potential of the tumor cells was analyzed 
by determining the number of colonies formed within 
the fibroblast layer and the area they covered.
Materials and methods
Reagents
Unless stated otherwise, all chemicals were purchased 
from Sigma Aldrich (Taufkirchen, Germany). Carnosine 
was kindly provided by Flamma (Flamma s.p.a. Chignolo 
d’Isola, Italy).
Cell lines and primary cell cultures
The GBM cell line T98G, negative for IDH1R132H-muta-
tion and O-6-methylguanine-DNA methyltransferase 
(MGMT) promoter methylation, was obtained from the 
ATCC, genotyped using a PowerPlex 21 System (Pro-
mega; Mannheim; Germany) by the Genolytic GmbH 
(Leipzig, Germany) and authenticated by comparison to 
data at the ATCC and the DSMZ. T98G cells were used 
at passage 5–7 after genotyping and authentication. Both, 
primary GBM cultures and primary fibroblast cultures 
were established from tissue samples obtained during 
standard surgery performed at the Neurosurgery Depart-
ment of the University Hospital Leipzig during 2015 and 
2016. All patients provided written informed consent 
according to the German laws as confirmed by the local 
committee. When possible, one primary GBM cell cul-
ture and one primary fibroblast culture was established 
from tissue samples obtained from each patient (Addi-
tional file 1: Table S1). All GBM samples were diagnosed 
and have been approved by the Neuropathology Depart-
ment of the Leipzig University Hospital. IDH 1 status 
has been determined using immunohistochemistry and 
pyrosequencing, MGMT promoter methylation status 
was determined using nucleic acid amplification followed 
by pyrosequencing.
For cultivation, tissue specimens from the tumor, 
from galea or from periost were cut into approximately 
1  mm3 large pieces and then separately placed into 
25 mm2 culture flasks (TPP, Trasadingen, Switzerland) 
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until tumor cells or fibroblasts grew out. When more 
than 90% confluence was reached specimens were 
removed and primary cell cultures were transferred 
into 75  mm2 culture flasks (TPP) for further cultiva-
tion. Cell cultures were maintained in high glucose 
DMEM (4.5  g glucose/ml) supplemented with 2  mM 
Glutamax™, 1% penicillin/streptomycin (all from 
Gibco Life Technologies, now Thermo Fisher Scien-
tific, Darmstadt, Germany) and 10% FBS (Biochrom 
GmbH, Berlin, Germany), further referred to as 
“standard medium”, and kept in incubators (37  °C, 5% 
 CO2/95% air).
Cell viability assays
For cell viability assays, cells were counted and seeded 
into sterile 96-well plates (µClear, Greiner Bio One, 
Frickenhausen, Germany) at a density of 5000 cells/well 
in 200  µl standard medium. After 24  h of cultivation 
(37 °C, 5%  CO2/95% air) the medium was aspirated and 
fresh medium supplemented with or without carnosine 
was added (100 µl/well) and the cells were incubated for 
additional 48  h. Then, the CellTiter-Glo Luminescent 
Cell Viability Assay (CTG, Promega, Mannheim, Ger-
many) was employed to determine viable cells by meas-
uring ATP in cell lysates and the CellTiter-Blue Cell 
Viability Assay (CTB, Promega) was used to quantify 
the cell’s metabolic capacity in living cells. All assays 
were carried out according to manufacturer’s protocols. 
Luminescence and fluorescence were measured using a 
SpectraMax M5 multilabel reader (Molecular Devices, 
Biberach, Germany).
Co‑cultivation of GBM cells and fibroblasts (ring‑cultures)
When cells reached more than 90% confluence in 
75  cm2 cell culture flasks they were detached using 
accutase (Thermo Fisher), counted and diluted for 
co-cultivation. The ring-cultures were established in 
12-well plates. Therefore, sterile cloning rings (steel, 
6  mm inner; 8  mm outer diameter, Hartenstein, Wür-
zburg, Germany) usually used for the isolation of 
clones, were placed in the middle of each well divid-
ing it into an inner-ring and an outer-ring part. Then, 
2500 tumor cells suspended in standard medium 
(112 µl) were seeded inside the ring. Afterwards, 50,000 
fibroblasts (in 658  µl standard medium) were seeded 
outside of the ring  (Additional file  2: Figure S1). Co-
cultures with cloning rings were incubated for 4  h 
(37 °C, 5%  CO2/95% air) before the rings were carefully 
removed using sterile forceps. Medium was exchanged 
immediately after ring removal containing various 
concentrations of carnosine. On the following days 
medium was exchanged twice a week.
Carnosine co‑culture experiments
Carnosine was diluted in 0.7% NaCl solution and car-
nosine experiments were performed with concentra-
tions of 0 mM, 10 mM, 25 mM, 50 mM and 75 mM. All 
ring-culture experiments were prepared as described 
above. Control experiments with T98G cells inside the 
ring and without fibroblasts in the outer part were kept 
for over 2 weeks. Ring co-cultures with T98G and fibro-
blasts (P0385) and with GBM cells and fibroblasts of the 
same patient (P0383 with P0385 and P0431 with P0433) 
were cultivated for 4 weeks. Throughout cultivation, cell 
growth and dissemination were monitored by bright field 
microscopy. After 4 weeks all co-cultures were fixated in 
4.5% paraformaldehyde and stored in 1% sodium azide 
solution at 4 °C until microscopic analysis.
Immunostaining
Immunofluorescent staining was carried out to discrimi-
nate between tumor cells and fibroblasts using anti-
fibroblast TE-7 (CBL271, Merck Millipore, Darmstadt, 
Germany), anti-nestin (AB5922, Merck Millipore) and 
secondary antibodies (ab6563, ab150081, abcam, Cam-
bridge, UK). Briefly, for the detection of TE-7 the fixated 
co-cultures were permeabilized with 0.1% TritonX-100 
at room temperature (RT) for 5 min. After blocking with 
10% goat serum for 15 min, samples were incubated 
with anti-fibroblast TE-7 primary antibodies (dilution 
1:100) at 5 °C overnight, washed with TBS (20 mM Tris, 
134 mM NaCl) and subsequently incubated with the sec-
ondary antibody (1:250; ab6563) for 45  min at RT. For 
the detection of nestin, fixated cell cultures were per-
meabilized with 0.1% TritonX-100 in TBS for 1 h at RT, 
blocked for 15 min with 10% goat serum and then incu-
bated with an anti-nestin antibody (dilution 1:250) for 1 h 
at RT. Afterwards, cultures were washed with TBS and 
incubated with a dilution of secondary antibody (1:250; 
ab150081) for 45  min at RT. Finally, nuclei were coun-
terstained with DAPI (4  µg/ml) and cell cultures were 
preserved in 10% sodium azide solution at 4  °C until 
microscopy.
Microscopy
For microscopic analysis a Zeiss Axiovert 200M micro-
scope (Zeiss, Oberkochen, Germany) equipped with a 
motorized stage (Märzhäuser, Wetzlar, Germany) with 
MosaiX software and by means of a CCD camera (Zeiss 
MRC) connected to an AxioVision 4.8.2 image analysis 
system (Zeiss) was used to create tile pictures. Each tile 
picture is composed of 285 single microscopic images 
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taken at a magnification of 50 and represents a whole 
well of a 12-well plate. As denoted in the figure legend to 
Fig. 2 ImageJ images in this figure have been graphically 
enhanced for representation purposes using the Corel 
Draw Graphics Suite 2017 (Corel Corporation, Ottawa, 
Canada).
Quantitative and statistical analysis
The number of colonies in ring co-culture experiments 
was determined using ImageJ after a color threshold and 
a common pixel size were defined. All pictures used for 
the analysis were taken at the same magnification and 
had the same size. Statistical analysis was performed 
using the algorithm for t-test implemented in Microsoft 
Excel 2010.
Results
Viability of patient derived fibroblasts and GBM cells 
under the influence of carnosine
In order to figure out how fibroblasts isolated from 
patients who underwent surgery for GBM do respond to 
the presence of carnosine, 11 primary fibroblast cultures 
derived from galea or periost were exposed to different 
concentrations of carnosine. Viability was determined by 
measuring the amount of ATP in cell lysates and by the 
analysis of metabolic activity, as reflected by dehydroge-
nase activity. In order to compare the effect of the dipep-
tide on fibroblasts, we performed the same experiment 
with 9 primary GBM cell cultures derived from patients 
and cells from the GBM cell line T98G. All cells were 
seeded at a density of 5000 cells into the wells of 96-well 
plates and exposed to carnosine for 48  h. The result of 
the experiment is presented in Fig. 1. At a concentration 
of 50 mM carnosine, the amounts of ATP and the meta-
bolic activity in fibroblasts were significantly reduced 
compared to untreated control cells (metabolic activity: 
89.4% ± 7.53, p < 0.005; ATP: 96.6% ± 5.08%. p < 0.05). 
We also observed a significant reduction of metabolic 
activity in primary GBM cells treated with 50  mM car-
nosine (compared to untreated control: 79.7% ± 18.51%, 
p < 0.05). However, although the amounts of ATP were 
decreased at 50  mM carnosine (87.8% ± 16.35% com-
pared to the untreated control) this effect was not sig-
nificant (p = 0.056). Increasing the concentration of 
carnosine to 75  mM leads to a significant reduction 
of metabolic activity and a decrease in the amounts of 
ATP in both, primary GBM cells (metabolic activity: 
61.2% ± 18.96, p < 0.0005; ATP: 71.5% ± 19.68%. p < 0.005) 
and fibroblasts (metabolic activity: 81.5% ± 12.03, 
p < 0.0005; ATP: 88.4% ± 5.07%. p < 0.005) compared to 
the untreated control. Furthermore, in the presence of 
75 mM carnosine, viability of primary GBM cells was sig-
nificantly stronger reduced than in fibroblasts (metabolic 
activity: p < 0.05; ATP: p < 0.05).
Please also note, that for statistical analysis data 
obtained from experiments with the cell line T98G were 
excluded.
Outgrowth of cells from a ring culture 
without co‑cultivated fibroblasts
Next, we asked how carnosine influences the growth of 
glioblastoma cells over a longer period of time when they 
start to grow after being seeded inside of a cloning ring 
and removal of it in the absence of other cells. There-
fore, 2500 cells from the glioblastoma cell line T98G 
were seeded inside a cloning ring placed in a 12-well 
plate. Four hours later the rings were removed and the 
cells were allowed to grow for 2  weeks in the absence 
and presence of carnosine (10 mM, 25 mM, 50 mM and 
75  mM). Medium was exchanged twice a week. After 
fixation of cells, 285 tiled images were taken from each 
well for each concentration employed (in quadruplicate) 
and the area covered by tumor cells was determined 
using ImageJ. The result of the experiment is presented 
in Fig. 2. As can be seen, the tumor cell covered area is 
continuously decreasing with increasing concentrations 
of carnosine although the effect becomes significant only 
at a concentration of 50 mM carnosine. At a concentra-
tion of 75  mM carnosine, no tumor cells were remain-
ing on the plates, demonstrating that this concentration 
Fig. 1 Viability of patient derived fibroblasts and primary 
glioblastoma cells under the influence of carnosine. Fibroblast 
cell cultures (11) and primary GBM cell cultures (9) were exposed 
for 48 h to different concentrations of carnosine (0, 50 or 75 mM). 
Viability was determined by measuring the amount of ATP in cell 
lysates (a) and by assessing metabolic activity (b). Each dot within 
the boxplots represents the mean obtained from six measurements 
of an individual cell culture. For comparison, the grey-colored dots 
(depicted by arrows) indicate the results obtained from experiments 
with the cell line T98G which was used for co-culture experiments. 
Statistical significance using data obtained from 11 fibroblast cultures 
and 9 primary GBM cultures was determined using Student’s t-test 
with: *p < 0.05; **p < 0.005; ***p < 0.0005
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does not only inhibit proliferation but also eliminates the 
tumor cells when exposed to the dipeptide for 2 weeks. 
In conclusion, the experiment demonstrates that the cells 
do survive for 2 weeks when seeded at a density of 2500 
cells inside a cloning ring and are incubated at carnosine 
concentrations of 50 mM or below.
Fluorescent discrimination of tumor cells and fibroblasts 
in co‑culture
In order to perform co-culture experiments with GBM 
cells and fibroblasts, we had to establish a method by 
which both types of cells can be discriminated. Using 
patient derived fibroblasts (P0385) and primary glio-
blastoma cells (P0383) we were able to discriminate both 
types of cells using an antibody directed against nestin 
(Fig.  3). Although both types of cells were detected by 
the anti-nestin specific antibody, staining was signifi-
cantly more intense on GBM cells allowing discrimina-
tion between both types of cells as demonstrated by the 
images presented in Fig. 3.
Unfortunately, discrimination between fibroblasts and 
cells from the glioblastoma cell line T98G was not pos-
sible using the nestin-specific antibody. We found a solu-
tion, using an anti-body directed against TE-7 which 
stains an unknown antigen specific for fibroblasts [18]. 
As demonstrated in Fig.  4 the TE-7 specific anti-body 
did also stain the nuclei of T98G cells, but did not detect 
antigen in their cytoplasm. Therefore, counterstaining 
with DAPI (color-coded in red) and TE-7 (color-coded in 
green) results in a yellow color of T98G nuclei and fibro-
blasts appear in green (cytosol) with red nuclei. At this 
point it should also be noted that the TE-7 specific anti-
body did also stain cells in primary GBM cultures which 
is the reason why this antibody had not been used for co-
cultures with primary cells.
Colony formation of T98G tumor cells in ring culture 
with fibroblasts under the influence of carnosine
Next we asked whether T98G cells seeded inside a 
cloning ring can migrate into a surrounding layer of 
Fig. 2 Outgrowth of T98G cells under the influence of carnosine. 
T98G cells were seeded inside a cloning ring placed in a 12-well 
plate. Rings were removed after 4 h and cells were allowed to 
grow in the presence of 0, 10, 25, 50 and 75 mM carnosine. After 
14 days, images were taken and the area covered by tumor cells was 
determined. The mean and standard deviation of the covered area 
from four independent wells for each concentration are presented 
in a. A statistical significant reduction was only seen at 50 mM 
carnosine (*) and at a concentration of 75 mM carnosine no tumor 
cells were left on the plates. In the lower part of the panel examples 
of images are presented that were used for data analysis (b without 
carnosine; c 10 mM; d 25 mM and e 50 mM carnosine). #2 presents 
the corresponding ImageJ processed pictures (Note: for presentation 
purposes the pictures shown have been vectorized and image 
enhanced using Corel Draw Graphic Suite 2017)
Fig. 3 Nestin staining of patient derived GBM cells and fibroblasts in ring co-culture. The figure shows staining of a co-culture of fibroblasts (P0385) 
with GBM cells (P0383) with DAPI (a), a nestin-specific antibody (b) and the merged image (c). GBM cells are presented in bright green at the right 
side of the image. Scale bar: 300 µm
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fibroblasts and whether migration and development of 
tumor cell colonies inside the fibroblast layer is influ-
enced by carnosine. Therefore, ring co-cultures were 
established with T98G cells inside the cloning ring and 
fibroblasts (P0375) outside of it. After removal of the 
ring, cells first have to migrate towards each other filling 
the gap left after ring removal. As presented in Fig. 5 cells 
are migrating to fill the gap within 4–11 days. As can be 
seen, both, fibroblasts (right side) and T98G cells are able 
to migrate towards each other, filling the gap between 
day 4 and day 11 in the absence of carnosine. In the pres-
ence of 50 mM carnosine migration is impaired in both 
types of cells as shown in the image taken after 4  days. 
At day 11 the gap gets filled, too, but it seems that mainly 
fibroblasts are located in the previous gap (Note: This 
experiment resembles a classical scratch assay). In a fol-
lowing series of experiments ring co-cultures of T98G 
cells and fibroblasts (P0375) incubated for 4 weeks in dif-
ferent concentrations of carnosine (0, 10, 25 and 50 mM) 
were fixated and stained with DAPI and the TE-7 specific 
antibody. After fluorescence microscopy the number of 
colonies formed by T98G cells and the area occupied by 
tumor cells was analyses using ImageJ. In Fig. 6a example 
fluorescence images of cultures and their corresponding 
ImageJ derived images are presented as well as the result 
of the determination of area occupancy (Fig. 6b) and the 
measurement of the number of colonies formed (Fig. 6c). 
As can be seen, the size of the area occupied by tumor 
cells and the number of colonies are decreasing with 
increasing concentrations of carnosine. In the absence 
of carnosine tumor cells occupied 13.5% ± 3.5% of the 
plate. Already in the presence of 10 mM carnosine area 
occupancy was significantly decreased to 7.7% ± 2.5% 
(p < 0.05) and diminished further by increasing con-
centrations of carnosine (25  mM: 6.0% ± 3.0%, p < 0.05; 
50  mM: 3.1% ± 3.3%, p < 0.0005). In addition, the num-
ber of colonies decreased with increasing concentrations 
from 80.8 ± 46.8 colonies in the absence of carnosine to 
46.6 ± 24.4 colonies (10 mM; not significant), 28.8 ± 24.0 
(25  mM, p < 0.05) and to 1.5 ± 0.8 colonies (50  mM, 
p < 0.05). This clearly demonstrates that carnosine inhib-
its the potential of T98G cells to infiltrate the fibroblast 
layer.
Fig. 4 TE-7 staining of T98G cells and fibroblasts in mono-, co- and in ring co-culture. The figure shows staining in mono cultures of fibroblasts 
(P0375) with DAPI (a), with a TE-7-specific antibody (e) and the merged image (i) and the corresponding images of staining of T98G cells (b, f, j). 
Images c, g and k were taken from a co-culture of both cells and d, h and f shows an image of a ring culture at low magnification. Fibroblasts 
appear with green staining in the cytoplasm and red nuclei, whereas T98G cells are presented by their yellow stained nuclei in the merged images. 
Scale bars a–c, e–g, i–k 30 µm, d, h, i 120 µm
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Fig. 5 Cells migrating into the gap after removal of the cloning ring in a co-culture of T98G cells and fibroblasts. T98G cells (2500) were placed 
inside the cloning ring and fibroblasts (P0375; 50.000) outside of it. Migration of cells into the gap left after removal of the cloning ring 3, 4 and 
11 days after ring removal with fibroblasts on the right side and T98G cells to the left as detected by bright field microscopy is presented. In the 
upper panel cultures were incubated in medium without carnosine and in the lower panel in medium containing 50 mM carnosine. Scale bar: 
30 µm
Fig. 6 Colony formation of T98G cells in a fibroblast layer in the presence of different concentrations of carnosine. T98G cells (2500) were placed 
inside the cloning ring and fibroblasts (P0375; 50.000) outside of it. The ring was removed 4 h later and after 4 weeks of cultivation in the presence 
of different concentrations of carnosine the cultures were fixated and stained with DAPI and a TE-7 specific antibody. Fluorescence images are 
presented in the upper part of panel a and pictures generated by ImageJ for the determination of area occupancy and the number of colonies 
formed is presented in the lower part. On the right side of the graph, area occupancy (b 100% equals the whole well area) and the number of 
tumor cell colonies formed (c) is presented. Statistical significance using data obtained from 8 to 10 independently treated cultures for each 
concentration of carnosine was determined using Student’s t-test with: *p < 0.05; ***p < 0.0005
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Colony formation of primary glioblastoma cells in ring 
culture with fibroblasts under the influence of carnosine
In order to verify that the effect of carnosine is not 
restricted to a cell line but can also be seen with tumor 
cells derived from a patient, we also performed ring co-
culture experiments with two patient-derived tumor 
cell cultures (P0383 and P0431) and fibroblasts from the 
same patient (P0385 and P0433, respectively). Again, 
tumor cells were seeded inside the cloning ring and 
fibroblasts outside of it. After 4  weeks of cultivation 
cells were stained with DAPI and a nestin-specific anti-
body and analyzed using ImageJ. Surprisingly, we did 
not detect colony formation inside the fibroblast layer 
even in the absence of carnosine. On the other hand, the 
tumor occupied area was significantly reduced already 
at a concentration of 10 mM carnosine. As the two pri-
mary cultured glioblastoma cells occupied different areas 
in the absence of carnosine, we set the area occupied in 
the absence of carnosine for each cell culture as 100% in 
order to compare the effect of carnosine and to deter-
mine an average. We found a reduction of the occupied 
area to 68.1% ± 11.3% (p < 0.05) at a concentration of 
10 mM carnosine, to 70.6% ± 3.1% (p < 0.0005) at 25 mM 
and to 18.7% ± 3.0% (p < 0.0005) at 50 mM. Comparable 
to the experiments with T98G cells and fibroblasts pre-
sented in Fig. 6, the space previously occupied by tumor 
cells becomes occupied by the fibroblasts. (For compari-
son: setting the occupied area to 100% in the experiment 
with T98G cells the reduction is 57.0% ± 18.5% at 10 mM, 
44.4% ± 22.2% at 25  mM and 23.0% ± 24.4% at 50  mM 
carnosine).
Discussion
As outlined in the introduction, we and others have 
shown that the naturally occurring dipeptide carnosine 
inhibits the growth of cancer cells in  vitro and in  vivo 
[14], whereas beneficial effects have been observed in 
cultured human fibroblasts [19]. Using a colorimetric 
assay (tetrazolium compound [3-(4,5-dimethylthiazol-
2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-
2H-tetrazolium, inner salt; MTS]) and human dermal 
fibroblasts, Ansurudeen et al. also demonstrated a greater 
number of viable cells in the presence of 50 mM carno-
sine after 24  h incubation [20]. Unfortunately, it is not 
traceable whether the fibroblasts used by Ansurudeen 
et  al. were from juvenile foreskin or from adult skin. In 
addition, the experiments performed by Holliday and 
McFarland were done by using a fibroblast cell line estab-
lished from human foreskin of a newborn male (HFF-1) 
and a second cell line established from lung tissue of a 
male at 14 weeks gestation (MRC-5). Considering using 
carnosine for the treatment of elderly patients the ques-
tion had to be answered whether fibroblasts isolated 
from adults or even senescent patients may behave differ-
ent to fibroblasts isolated from fetal or newborn human 
tissue. In our experiments presented in Fig. 1 we did not 
see a measurable beneficial effect of carnosine on fibro-
blast viability, although it is interesting to note, that 
fibroblasts cultivated in 50  mM carnosine appeared to 
be rejuvenated compared to fibroblasts cultivated in the 
absence of carnosine in accordance to the observations 
of McFarland and Holiday [21]. We also did not see any 
correlation between age of the patient, the tissue of ori-
gin or gender, though it has to be realized that the num-
ber of samples may be too low for such an analysis and 
most of our patients have been of comparable age. More 
importantly, a prolonged cultivation of fibroblasts as in 
the co-culture experiments demonstrates that the fibro-
blasts are alive and able to occupy the space left by dying 
glioblastoma cells even under the highest concentration 
of carnosine employed (50 mM). It is also very interest-
ing to note that we observed complete cell death of T98G 
tumor cells in long term culture incubating the cells at 
a concentration of 75  mM carnosine (Fig.  2). In previ-
ous experiments, cells were usually kept in the presence 
of carnosine for 24, 48 or 96 h [13] but not for 2 weeks. 
This is interesting, as shorter exposure times in previous 
experiments resulted in reduced proliferation but not 
complete elimination of tumor cells. Which processes 
are responsible for reduced tumor cell proliferation are 
under the influence of carnosine are still unknown [14]. 
However, it is an interesting question whether the pro-
cesses which reduce proliferation after short term expo-
sure may finally lead to cell death when the tumor cells 
are exposed to carnosine for a longer period of time.
In order to discriminate tumor cells from fibroblasts in 
ring co-culture experiments several markers were tested 
including glial fibrillary acidic protein (GFAP) which did 
also stained fibroblasts in accordance with observations 
made by others [22]. We finally identified that nestin-
staining was suitable to discriminate primary cultured 
tumor cells from patient-derived fibroblasts. Nestin is a 
class VI intermediate filament protein and a marker for 
neural stem cells. In addition, it has been reported as a 
cancer stem cell-specific marker [23] and a recent meta-
analysis performed by Lv et  al. [24] demonstrated that 
increased expression of nestin is positively associated 
with higher histological grade in glioma patients. This 
analysis also indicated that patients with higher nes-
tin expression are prone to recurrence and glioma cell 
infiltration into intact brain tissue. Surprisingly, in our 
ring co-culture experiments T98G cells, which did not 
express nestin, as previously reported by other investiga-
tors [25, 26], gave rise to many colonies in the surround-
ing fibroblast layer which was not the case when primary 
cultures with a high expression of nestin were cultivated 
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with fibroblasts. Although speculative, one interpretation 
could be that the primary cultures we used were of very 
early passages (Passage 1 and 5) and not as rapidly grow-
ing as T98G cells which is also reflected by their higher 
resistance towards carnosine (Fig. 1) as carnosine exerts 
its action mainly on metabolic highly active tumor cells 
[27]. Nonetheless, the results presented in Fig.  6 clearly 
demonstrate that colony formation is significantly inhib-
ited when invasively grown glioblastoma cells are treated 
with carnosine. In the last years, a so-called “go or grow 
concept” has been discussed, assuming that prolifera-
tion and migration are mutually exclusive phenomena 
in cancer cells [4]. Studies confirming this hypothesis 
are for example observations made in breast cancer cell 
lines in which overexpression of Homeobox Protein C9 
(HOXC9) resulted in increased invasiveness but at the 
same time inhibited proliferation [28]. Another exam-
ple is the observation that enforced expression of Y-box 
binding protein-1 (YB-1) in non-invasive breast epithe-
lial cells induces an epithelial–mesenchymal transition 
(EMT) resulting in an enhanced metastatic potential 
but at the same time reduces proliferation [29]. Unfortu-
nately, the exact mechanisms and down-stream targets 
responsible for either proliferation or invasion mediated 
by HOXC9 or YB-1 signaling are still unknown. More 
importantly, our results demonstrate that carnosine does 
not inversely influence proliferation and invasion. Up to 
now, the mechanisms responsible for the dipeptides anti-
proliferative effect, which has been confirmed in several 
studies with different types of cancer cells [11–13, 30] 
are still not understood. With regard to carnosine’s effect 
on migration and invasion it has been discussed that it 
involves regulation of matrix metalloproteinases (MMPs) 
[15], but more experiments are certainly needed to prop-
erly address this question.
Conclusions
This study demonstrates that carnosine’s anti-prolifer-
ative effect is not accompanied by increased invasion as 
suggested by the so-called “go-or-grow” concept. In fact, 
the dipeptide can inhibit tumor cell migration, which is 
especially important for the treatment of highly infiltrat-
ing and metastasizing tumors such as IDH-wildtype glio-
blastoma. In addition, the co-culture model presented is 
a valuable alternative to the commonly used scratch or 
Boyden chamber assays.
Additional files
Additional file 1: Table S1. Patients and patient derived cell cultures.
Additional file 2. Setup of ring-cultures.
Abbreviations
CTB: CellTiter-Blue Cell Viability Assay; CTG : CellTiter-Glo Luminescent Cell Via-
bility Assay; GBM: IDH1R132H-non-mutant glioblastoma; GFAP: glial fibrillary 
acidic protein; HOXC9: Homeobox Protein C9; IDH: isocitrate dehydrogenase; 
MGMT: O-6-methylguanine-DNA methyltransferase; MTS: 3-(4,5-dimethylthia-
zol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner 
salt; YB-1: Y-box binding protein-1; WHO: World Health Organization.
Authors’ contributions
JD performed most of the experiments with contributions of HO and KP. MM 
and CE assisted at microscopy and immuno-histochemistry. WM and CE per-
formed the pathologic classification of tumors. JM did the surgery and revised 
the manuscript. HO, JD and FG designed the experiments and contributed 
conceptually. HO and FG coordinated the experiments. JD and FG mainly 
wrote the manuscript but all authors contributed to its writing. All authors 
read and approved the final manuscript.
Author details
1 Department of Neurosurgery, University Hospital Leipzig, Liebigstraße 20, 
04103 Leipzig, Germany. 2 Medical Faculty, Paul-Flechsig-Institute of Brain 
Research, University of Leipzig, Leipzig, Germany. 3 Department of Neuropa-
thology, University Hospital Leipzig, Leipzig, Germany. 
Acknowledgements
We like to thank Flamma [Flamma s.p.a. Chignolo d’Isola, Italy (http://www.
flamm agrou p.com)] for the generous supply with very high quality carnosine 
for all of our experiments. In addition, we like to thank Dr. Hans-Heinrich 
Foerster from the Genolytic GmbH (Leipzig, Germany) for genotyping and 
confirmation of cell identity and last not least Mr. Rainer Baran-Schmidt for 
technical assistance.
Competing interests
The authors declare that they have no competing interests.
Availability of data and materials
All data generated or analyzed during this study are included in this published 
article.
Consent for publication
All authors have read and approved of its submission to Cancer Cell 
International.
Ethics approval and consent to participate
All patients provided written informed consent to participate according to the 
German laws as confirmed by the local committee.
Funding
No funding has been received. We acknowledge support from the German 
Research Foundation (DFG) and Leipzig University within the program of 
Open Access Publishing.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in pub-
lished maps and institutional affiliations.
Received: 17 April 2018   Accepted: 4 August 2018
References
 1. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK. WHO classification of 
tumours of the central nervous system. 4th ed. Lyon: International 
Agency for Research on Cancer; 2016.
 2. Mallick S, Benson R, Hakim A, Rath GK. Management of glioblastoma after 
recurrence: a changing paradigm. J Egypt Natl Cancer Inst. 2016;28:199–
210. https ://doi.org/10.1016/j.jnci.2016.07.001.
 3. Giese A, Loo MA, Tran N, Haskett D, Coons SW, Berens ME. Dichotomy of 
astrocytoma migration and proliferation. Int J Cancer. 1996;67:275–82. 
124
Page 10 of 10Oppermann et al. Cancer Cell Int  (2018) 18:111 
•
 
fast, convenient online submission
 
•
  
thorough peer review by experienced researchers in your field
• 
 
rapid publication on acceptance
• 
 
support for research data, including large and complex data types
•
  
gold Open Access which fosters wider collaboration and increased citations 
 
maximum visibility for your research: over 100M website views per year •
  
At BMC, research is always in progress.
Learn more biomedcentral.com/submissions
Ready to submit your research  ?  Choose BMC and benefit from: 
https ://doi.org/10.1002/(SICI)1097-0215(19960 717)67:2%3c275 :AID-IJC20 
%3e3.0.CO;2-9.
 4. Hatzikirou H, Basanta D, Simon M, Schaller K, Deutsch A. ‘Go or grow’: the 
key to the emergence of invasion in tumour progression? Math Med Biol. 
2012;29:49–65. https ://doi.org/10.1093/imamm b/dqq01 1.
 5. Gulewitsch W, Amiradzibi S. Ueber das Carnosin, eine neue organische 
Base des Fleischextraktes. Ber Dtsch Chem Ges. 1900;33:1902–3.
 6. Boldyrev AA, Aldini G, Derave W. Physiology and pathophysiology of 
carnosine. Physiol Rev. 2013;93:1803–45. https ://doi.org/10.1152/physr 
ev.00039 .2012.
 7. Gaunitz F, Hipkiss AR. Carnosine and cancer: a perspective. Amino Acids. 
2012;43:135–42. https ://doi.org/10.1007/s0072 6-012-1271-5.
 8. Hipkiss AR, Gaunitz F. Inhibition of tumour cell growth by carnosine: 
some possible mechanisms. Amino Acids. 2014;46:327–37.
 9. Nagai K, Suda T. Antineoplastic effects of carnosine and beta-alanine—
physiological considerations of its antineoplastic effects. J Physiol Soc 
Jpn. 1986;48:741–7.
 10. Holliday R, McFarland GA. Inhibition of the growth of transformed and 
neoplastic cells by the dipeptide carnosine. Br J Cancer. 1996;73:966–71.
 11. Shen Y, Yang J, Li J, Shi X, Ouyang L, Tian Y, Lu J. Carnosine inhibits the 
proliferation of human gastric cancer SGC-7901 cells through both 
of the mitochondrial respiration and glycolysis pathways. PLoS ONE. 
2014;9:e104632. https ://doi.org/10.1371/journ al.pone.01046 32.
 12. Iovine B, Oliviero G, Garofalo M, Orefice M, Nocella F, Borbone N, et al. The 
anti-proliferative effect of L-carnosine correlates with a decreased expres-
sion of hypoxia inducible factor 1 alpha in human colon cancer cells. 
PLoS ONE. 2014;9:e96755. https ://doi.org/10.1371/journ al.pone.00967 55.
 13. Renner C, Seyffarth A, de Arriba S, Meixensberger J, Gebhardt R, Gaunitz 
F. Carnosine inhibits growth of cells isolated from human glioblastoma 
multiforme. Int J Pept Res Ther. 2008;14:127–35. https ://doi.org/10.1007/
s1098 9-007-9121-0.
 14. Gaunitz F, Oppermann H, Hipkiss AR. Carnosine and cancer. In: Preedy VR, 
editor. Imidazole dipeptides. Cambridge: The Royal Society of Chemistry; 
2015. p. 372–92.
 15. Chuang C-H, Hu M-L. L-Carnosine inhibits metastasis of SK-Hep-1 cells by 
inhibition of matrix metaoproteinase-9 expression and induction of an 
antimetastatic gene, nm23-H1. Nutr Cancer. 2008;60:526–33. https ://doi.
org/10.1080/01635 58080 19117 87.
 16. Ou-Yang L, Liu Y, Wang B-Y, Cao P, Zhang J-J, Huang Y-Y, et al. Carnosine 
suppresses oxygen–glucose deprivation/recovery-induced proliferation 
and migration of reactive astrocytes of rats in vitro. Acta Pharmacol Sin. 
2018;39:24–34. https ://doi.org/10.1038/aps.2017.126.
 17. Lai P-Y, Hsieh S-C, Wu C-C, Hsieh S-L. ID: 1029 Effects of carnosine on 
regulation of migration and invasion in human colorectal cancer cells. 
Biomed Res Ther. 2017;4:104. https ://doi.org/10.15419 /bmrat .v4iS.305.
 18. Goodpaster T, Legesse-Miller A, Hameed MR, Aisner SC, Randolph-
Habecker J, Coller HA. An immunohistochemical method for identifying 
fibroblasts in formalin-fixed, paraffin-embedded tissue. J Histochem 
Cytochem. 2008;56:347–58. https ://doi.org/10.1369/jhc.7A728 7.2007.
 19. Holliday R, McFarland GA. A role for carnosine in cellular maintenance. 
Biochemistry (Mosc). 2000;65:843–8.
 20. Ansurudeen I, Sunkari VG, Grünler J, Peters V, Schmitt CP, Catrina S-B, et al. 
Carnosine enhances diabetic wound healing in the db/db mouse model 
of type 2 diabetes. Amino Acids. 2012;43:127–34. https ://doi.org/10.1007/
s0072 6-012-1269-z.
 21. McFarland GA, Holliday R. Further evidence for the rejuvenating effects 
of the dipeptide L-carnosine on cultured human diploid fibroblasts. Exp 
Gerontol. 1999;34:35–45.
 22. Hainfellner JA, Voigtländer T, Ströbel T, Mazal PR, Maddalena AS, Aguzzi 
A, Budka H. Fibroblasts can express glial fibrillary acidic protein (GFAP) 
in vivo. J Neuropathol Exp Neurol. 2001;60:449–61.
 23. Neradil J, Veselska R. Nestin as a marker of cancer stem cells. Cancer Sci. 
2015;106:803–11. https ://doi.org/10.1111/cas.12691 .
 24. Lv D, Lu L, Hu Z, Fei Z, Liu M, Wei L, Xu J. Nestin expression is associated 
with poor clinicopathological features and prognosis in glioma patients: 
an association study and meta-analysis. Mol Neurobiol. 2017;54:727–35. 
https ://doi.org/10.1007/s1203 5-016-9689-5.
 25. Kurihara H, Zama A, Tamura M, Takeda J, Sasaki T, Takeuchi T. Glioma/
glioblastoma-specific adenoviral gene expression using the nestin gene 
regulator. Gene Ther. 2000;7:686–93. https ://doi.org/10.1038/sj.gt.33011 
29.
 26. Hong X, Chedid K, Kalkanis SN. Glioblastoma cell line-derived spheres in 
serum-containing medium versus serum-free medium: a comparison of 
cancer stem cell properties. Int J Oncol. 2012;41:1693–700. https ://doi.
org/10.3892/ijo.2012.1592.
 27. Oppermann H, Schnabel L, Meixensberger J, Gaunitz F. Pyruvate attenu-
ates the anti-neoplastic effect of carnosine independently from oxidative 
phosphorylation. Oncotarget. 2016;7:85848–60. https ://doi.org/10.18632 /
oncot arget .13039 .
 28. Hur H, Lee J-Y, Yang S, Kim JM, Park AE, Kim MH. HOXC9 induces pheno-
typic switching between proliferation and invasion in breast cancer cells. 
J Cancer. 2016;7:768–73. https ://doi.org/10.7150/jca.13894 .
 29. Evdokimova V, Tognon C, Ng T, Ruzanov P, Melnyk N, Fink D, et al. Transla-
tional activation of snail1 and other developmentally regulated transcrip-
tion factors by YB-1 promotes an epithelial–mesenchymal transition. 
Cancer Cell. 2009;15:402–15. https ://doi.org/10.1016/j.ccr.2009.03.017.
 30. Zhang Z, Miao L, Wu X, Liu G, Peng Y, Xin X, et al. Carnosine inhibits the 
proliferation of human gastric carcinoma cells by retarding Akt/mTOR/
p70S6K signaling. J Cancer. 2014;5:382–9. https ://doi.org/10.7150/
jca.8024.
125
Publications 
126 
 
In summary, the experiments performed demonstrate that carnosine inhibits both colony 
formation and proliferation of glioblastoma cells. Thus, the anti-proliferative effect of 
carnosine is not accompanied by increased invasion as suggested by the “go or growth” 
concept. Furthermore, we also demonstrate that prolonged exposure to carnosine reduces 
glioblastoma growth also at lower concentrations (10 mM) than at those employed 
investigating the dipeptides anti-neoplastic effect in short term experiments (50 mM and 
higher) (Asperger et al. 2011; Iovine et al. 2012; Lee et al. 2018). Moreover, fibroblasts 
remained vital even in the presence of the highest carnosine concentration employed.  
 
2.6 Carnosine does not interfere with standard therapy for glioblastoma 
 
Considering using carnosine for the treatment of glioblastoma patients, possible interactions 
with the current standard therapy need to be taken into account. According to the European 
Association for Neuro-Oncology, treatment of newly diagnosed glioblastoma consist of 
microsurgical resection of the tumour followed by radiotherapy and adjuvant chemotherapy 
with TMZ ((Weller et al. 2014) and see 1.1 Glioblastoma). TMZ is a pro-drug which is 
dependent on pH non-enzymatically converted to 5-(3-methyltriazen-1-yl)imidazole-4-
carboxamide (MTIC). MTIC yields diazomethane which spontaneously produces a 
methyldiazonium cation leading to the formation of methyl adducts at the guanine residue of 
DNA (Bonmassar et al. 2013). Although carnosine exhibits potent pH puffer capabilities, it is 
unknown whether the dipeptide affects MTIC formation from TMZ. However, it was reported 
that carnosine mitigates genotoxicity induced by the alkylating agent cyclophosphamide 
(Naghshvar et al. 2012). The biological effect of IR is conducted by the formation of reactive 
oxygen and nitrogen species leading to DNA damage, changes in redox signalling and 
disruption of metabolic processes (Spitz and Hauer-Jensen 2014). As carnosine is capable 
of scavenging free radicals and has even been shown to attenuate IR induced damage 
(Guney et al. 2006), the dipeptide may attenuate the effect of IR which is indispensable for 
an improved outcome of glioblastoma patients (Laperriere et al. 2002). The study of Dietterle 
et al. (Dietterle et al. 2019) addresses the question whether carnosine attenuates the effects 
of IR and TMZ in glioblastoma. Therefore, we determined the influence of carnosine on cell 
viability in combination with IR and TMZ in primary glioblastoma cultures.  
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Aim: The naturally occurring dipeptide carnosine (CAR) has been considered for glioblastoma therapy. As
CAR also protects against ionizing irradiation (IR), we investigated whether it may counteract standard
therapy consisting of postsurgery IR and treatment with temozolomide (TMZ).Materials & methods: Four
isocitrate dehydrogenase-wildtype primary cell cultures were exposed to different doses of IR and differ-
ent concentrations of TMZ and CAR. After exposure, viability under the different conditions and combina-
tions of themwas determined. Results: All cultures responded to treatment with TMZ and IR with reduced
viability. CAR further decreased viability when TMZ and IR were combined. Conclusion: Treatment with
CAR does not counteract glioblastoma standard therapy. As the dipeptide also protects nontumor cells
from IR, it may reduce deleterious side effects of treatment.
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Isocitrate dehydrogenase (IDH)-wildtype glioblastoma (GBM) is a brain-derived tumor classified as WHO grade IV
based on histologic criteria, including high vascularization, high mitotic activity and invasion of adjacent brain
structures [1]. GBM is the most common of all malignant brain and other CNS tumors (47.7%) and accompanied
with very poor prognosis for patients (1-year survival: 39.7 ± 0.5%; 2-year survival: 17.2 ± 0.4%) [2]. Standard
treatment consists of microsurgical resection and adjuvant radiochemotherapy consisting of up to 60 Gray (Gy)
x-irradiation (IR) with concomitant temozolomide (TMZ) treatment followed by six cycles of the TMZ treatment
alone [3]. Although technical aspects of neurosurgery, including intraoperative magnetic resonance imaging [4],
mapping of brain functions [5] or awake craniotomy [6] have improved to provide maximum safe resection,
pharmacological therapy options remain poor [7]. In 2007, anti-angiogenic therapy with bevacizumab has been
approved for the treatment of recurrent GBM by the US FDA [8], yet meta-analysis did not show statistically
significant extension of overall survival [9]. Presently, the most promising new option to treat GBM are tumor-
treating fields that have shown to extent overall survival in large clinical trials by around 2–3 months [10] but are
not included into European guidelines for glioblastoma treatment until the present day [3]. As these new treatment
options are also far from being satisfying there is still urgent need to find new treatment strategies and compounds
that are able to selectively eliminate GBM tumor cells after surgical resection.
In a number of preclinical investigations, the naturally occurring dipeptide carnosine (CAR; β-alanyl-L-histidine)
was suggested as a potential new anticancer drug, also for the treatment of GBM [11]. The dipeptide was originally
discovered in 1900 by Gulewitsch and Amiradžibi [12], but its physiological role is still not fully understood. It has
been suggested that it has pH-buffering functions [13] and could act as a modulator of intracellular calcium [14]. It
is also able to act as a metal chelator [15], a scavenger of radical oxygen species [16], and as a protector against lipid
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Table 1. Primary cell cultures used for the experiments.
Culture label Gender Age at date of surgery in
years
MGMT promoter
methylation status (%)
IDH1-status (codon 132) IDH2-status (codon 172)
Number 1 Female 53 46% WT WT
Number 2 Male 69 10 WT WT
Number 3 Female 64 96% WT WT
Number 4 Male 60 96% WT WT
Gender (male/female) and age of the patient at surgery are indicated along with the MGMT promoter methylation status and the isocitrate dehydrogenase1/2 mutation status (all WT)
determined in the culture.
IDH: Isocitrate dehydrogenase; MGMT: O-6-methylguanine-DNA methyltransferase; WT: Wildtype.
peroxidation, hypochlorite anions and reactive nitrogen species [17]. As it exhibits antineoplastic effects in vitro and
in vivo against a range of cancer cells, including GBM [18], colon [19,20], gastric [21] and cervix carcinoma [22] cells,
it has been discussed as potential drug for the treatment of malignant diseases [23].
On the other hand, it is known since many years that the dipeptide has radioprotective properties [24–26]. In
fact, this effect could be exploited as suggested for the CAR-containing drug polaprezinc (Zeria Pharmaceutical
Co., Tokyo, Japan) [27] which has already been used in clinical trials [28]. However, it has to be asked whether the
radioprotective properties may become a problem when standard therapy of GBM including TMZ and especially
IR would be combined with CAR treatment.
Therefore, we investigated whether CAR interferes with standard therapy using four primary GBM cell cultures.
Materials & methods
Reagents
If not stated otherwise, all chemicals were purchased from Sigma-Aldrich (Taufkirchen, Germany), Merck (Darm-
stadt, Germany) or Carl Roth (Karlsruhe, Germany). CAR was kindly provided by Flamma s.p.a. (Chignolo d’Isola,
Italy).
Primary glioblastoma cell cultures
Primary GBM cultures were derived from tissue samples obtained during standard surgery performed at the
Department of Neurosurgery of the University of Leipzig Medical Center between 2005 and 2009 (Table 1).
Written informed consent from all patients was obtained according to the German laws as confirmed by the
local committee (144/08-ek). All samples were diagnosed at the Department of Neuropathology of the University
of Leipzig Medical Center. After cell cultures were established as described in detail before [29], cell suspensions
containing one million cells in 1 ml freezing medium (Dulbecco’s modified Eagle medium supplemented with 15%
fetal bovine serum and 10% dimethyl sulfoxide) were slowly cooled down to -80◦C (Nalgene Mr. Frosty, Thermo
Fisher Scientific, Darmstadt, Germany) and finally stored at -174◦C in liquid nitrogen (Air Liquide, Düsseldorf,
Germany).
For cultivation, cell suspensions were warmed up at room temperature and transferred into 75 mm2 culture flasks
(TPP, Trasadingen, Switzerland). Cell cultures were maintained in high glucose Dulbecco’s modified Eagle medium
(4.5 g glucose/l) supplemented with 1% penicillin/streptomycin, GlutaMax (both, Thermo Fisher Scientific)
and 10% fetal bovine serum (Biochrom GmbH, Berlin, Germany), further referred to as ‘standard medium,’
and kept in incubators (37◦C, 5% CO2/95% air), further referred to as ‘standard condition.’ After unfreezing,
IDH1/2 mutation status and O-6-methylguanine-DNA methyltransferase (MGMT) promoter methylation of
all cell cultures were determined using immunohistochemistry and pyrosequencing or nucleic acid amplification
followed by pyrosequencing (PyroMark Q24 System and the PyroMark Q24 CpG MGMT kit; Qiagen, Hilden,
Germany), respectively (Table 1).
Irradiation
A 150 kV x-ray machine (DARPAC 150-MC, RayTech) with a dose rate of 0.86 Gy/min was used for IR.
Cell-based assays
Primary GBM cells were seeded into 96-well plates (µClear, Greiner Bio One, Frickenhausen, Germany) at a
density of 2500 cells per well in 200 µl standard medium. After 24 h incubation, cells received fresh medium
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Figure 1. Viability of glioblastoma cells under the influence of irradiation, temozolomide and carnosine. Cells were treated with 4 or
8 Gy (left panels), 200 and 300 µM TMZ (central panels) and 10 and 20 mM CAR (right panels). Viability was determined by measuring ATP
in cell lysates (upper panels) or dehydrogenase activity in living cells (lower panels). Experiments have been performed in sextuplicate and
asterisks denote significance compared with untreated control cells as determined by one-way ANOVA with Games–Howell post hoc test
(*p < 0.05; **p < 0.005; ***p < 0.0005).
ANOVA: Analysis of variance; CAR: Carnosine; TMZ: Temozolomide.
containing the test compounds CAR and/or TMZ. IR was applied 24 h later and cell viability was assessed after
incubation for another 5 days under standard conditions (for details see single experiments).
In order to assess tumor cell viability, ATP in cell lysates and dehydrogenase activity in living cells were determined
using the CellTiter-Glo Luminescent Cell Viability Assay (CTG) and the CellTiter-Blue Cell Viability Assay
(CTB), respectively (both from Promega, Mannheim, Germany). Luminescence and fluorescence were measured
using SpectraMax M5 Microplate Reader (Molecular Devices, Biberach, Germany).
Statistical analysis
Statistical analysis was carried out using SPSS (IBM, NY, USA; version: 24.0.0.2 64-bit). For multiple comparisons,
a one-way analysis of variance (ANOVA) with Games–Howell post hoc test was used. p-values below 0.05 were
considered statistically significant.
Results
In a first series of experiments, we determined the effect of each compound and of IR on tumor cell viability in
four primary GBM cultures. Therefore, cells either received a single dose of 4 or 8 Gy, 200 or 300 µM TMZ and
10 or 20 mM CAR and cell viability was determined after 5 days. The results to the experiments are depicted in
Figure 1. Aside from a surprising slight significant increase of viability observed when cells from culture number
1 were exposed to 4 Gy (CTB: 112.2 ± 5.2%; CTG: 114.9 ± 22.9%; p > 0.05) all cultures responded to IR
with decreased viability, which was highly significant with both assays at 8 Gy (with the exception of culture
number 1 with regard to CTG). We also observed a reduction of viability at 4 Gy in all cultures except for culture
number 1 but statistical significance was not reached in all cases. Exposing the cells to 300 µM TMZ significantly
reduced viability in all cell cultures with both assays. At a concentration of 200 µM TMZ all cultures except
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Figure 2. Viability of glioblastoma cells under the influence of irradiation combined with carnosine. Cells were
treated with 4 Gy (left panels) or 8 Gy (right panels) in combination with 10 and 20 mM CAR. Viability was
determined by measuring ATP in cell lysates (upper panels) or dehydrogenase activity in living cells (lower panels).
Experiments have been performed in sextuplicate and asterisks denote significance compared with untreated control
cells as determined by one-way ANOVA with Games–Howell post hoc test: *p < 0.05; **p < 0.005; ***p < 0.0005.
CAR: Carnosine.
culture number 2 responded with reduced ATP in cell lysates. Although a response of this culture was seen with
regard to dehydrogenase activity, this culture in general exhibited a weak response towards TMZ. This is in fact
not surprising as this culture exhibited very low MGMT promoter methylation (Table 1) which confers resistance
toward TMZ [30]. At the concentrations employed, the effect of CAR on tumor cell viability was obvious and more
pronounced in the presence of 20 mM than in the presence of 10 mM CAR, although the effect did not reach
statistical significance in all cases. Only culture number 4 does appear to have a very low response to the presence
of the dipeptide.
Next, we combined CAR treatment with IR (Figure 2) or with TMZ treatment (Figure 3). In both figures,
statistical significance is depicted with regard to treatment with 4/8 Gy or 200/300 mM TMZ without CAR.
As can be seen in Figure 2, treatment with CAR further decreased viability of cells exposed to IR even in culture
number 1 which exhibited higher viability when exposed to 4 Gy alone. Almost no effect of CAR on irradiated
cells was seen in culture number 4 which is in agreement with the results presented in Figure 1. Analyzing the effect
of CAR on treatment with TMZ (Figure 3) all cultures responded to the presence of CAR with a further decrease
in viability when exposed to TMZ as revealed by the CTG assay. However, although the CTB also demonstrated a
tendency toward lower viability with increasing concentrations of CAR, this effect was weak and reached statistical
significance only in a few cases. More important, both experiments in Figures 2 & 3 demonstrate that CAR does
not counteract the effects of TMZ or IR on cell viability.
Finally, we asked whether CAR may counteract the effect of combined treatment with IR and TMZ, mimicking
glioblastoma standard therapy. Therefore, we applied 4 Gy together with 200 µM TMZ and compared viability
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Figure 3. Viability of glioblastoma cells under the influence of temozolomide combined with carnosine. Cells were
treated with 200 µM (left panels) or 300 µM TMZ (right panels) in combination with 10 and 20 mM CAR. Viability was
determined by measuring ATP in cell lysates (upper panels) or dehydrogenase activity in living cells (lower panels).
Experiments have been performed in sextuplicate and asterisks denote significance compared with untreated control
cells as determined by one-way ANOVA with Games–Howell post hoc test: *p < 0.05; **p < 0.005; ***p < 0.0005.
CAR: Carnosine; TMZ: Temozolomide.
of cells without CAR and with 20 mM CAR to untreated control cells (Figure 4). As can be seen, CAR had no
counter-effect on combined treatment with TMZ and IR but did even further decrease viability in all cell cultures.
The additional viability reduction was statistically significant in three of the four cultures employed (numbers 1–3).
Discussion
Although CAR appears to be a promising candidate for the treatment of different malignant diseases [23], including
GBM, one has to be aware that it is also able to protect against IR. Severin et al., who investigated the influence of
CAR (50–200 mg/kg/day for 20 days) on the survival of albino rats subjected to 5 Gy whole body IR, observed
an increased survival rate by 45–65% [24]. Comparable observations were made by other groups [25,26,31] and it
was suggested that CAR could be used to alleviate symptoms due to IR-induced lung injury in patients treated
for lung cancer [32]. Just recently, Doi et al. [28] collected data from clinical studies in which polaprezinc, an orally
bioavailable chelate composed of zinc and CAR, was applied together with IR therapy demonstrating potential
beneficial effects. As the biological effects of IR are mediated by the production of reactive oxygen and nitrogen
species [33], the well-described antioxidant activity of CAR [16] appears to be responsible for its IR-protective effects.
However, IR-induced production of reactive oxygen species in the tumor is required for the clinical efficiency of
IR. As demonstrated by Bairati et al. in the case of patients treated by radiation therapy for head and neck cancer,
supplementation of antioxidant vitamins can significantly increase mortality rates [34]. Therefore, it could not be
precluded, that the antineoplastic effects of CAR may be counteracted by protection against IR applied in the
course of cancer treatment. As demonstrated by the results presented in this manuscript, this does not seem to be
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Figure 4. Viability of glioblastoma cells under the influence of temozolomide combined with irradiation and of temozolomide plus
irradiation combined with carnosine. Cells were treated with 200 µM TMZ in combination IR 4 Gy and additionally with CAR (20 mM).
Viability was determined by measuring ATP in cell lysates (left panel) or dehydrogenase activity in living cells (right panel).
Experiments have been performed in sextuplicate and asterisks denote significance compared with untreated control cells as determined
by one-way ANOVA with Games–Howell post hoc test: *p < 0.05; **p < 0.005; ***p < 0.0005.
CAR: Carnosine; TMZ: Temozolomide.
the case. CAR, employed at concentrations of 10 and 20 mM, did neither counteract the effect of IR (4 and 8 Gy)
on GBM cell viability nor that of TMZ (200 and 300 µM). More important, CAR employed at a concentration of
20 mM together with TMZ and IR (200 µM and 4 Gy) did further decrease the viability of GBM cells compared
with cells treated only with a combination of TMZ and IR.
Regarding a potential therapeutic use of CAR, the question has to be answered whether the concentrations used
in our experiments are therapeutically feasible. In nonsupplemented humans, it reaches a median concentration
of about 20.0 ± 4.7 mmol/kg dry weight in skeletal muscle [35], but can be increased by 50% (soleus) by a
daily administration of the CAR moieties β-alanine and L-histidine over 23 days [36]. Although less abundant
in other tissues, Qui et al. demonstrated that in kidney tissue of CNDP1 transgenic mice supplemented with a
bolus of 200 mg CAR concentrations of approximately 0.5 mmol/kg were observed 8 h after supplementation [37].
More interesting, the authors could also demonstrate that in mice receiving a CN1 inhibitor, tissue concentrations
increased sevenfold, which is an interesting aspect considering CAR as a therapeutic. At this point, it is also
interesting to note that CAR appears to be nontoxic to nontumor cells even at concentrations up to 50 mM as
demonstrated already in 1994 by McFarland and Holiday [38]. In addition, aside from a rare and mild dysesthesia
reported after oral ingestion of CAR no other side effects have been described in a number of small clinical trials
supplementing CAR for the treatment of other diseases [39,40].
The next step that should be performed is to address, how cancer stem cells respond to combined treatment,
as these cells are generally more resistant to IR than their more mature progeny, exhibiting lower levels of reactive
oxygen species associated with increased expression of free radical scavenging systems [41]. In addition, experiments
should be performed to investigate whether the protective effects of CAR described in the literature could be
exploited for GBM standard therapy, protecting nontumor cells. These experiments could possibly be done with
ectopic GBM mouse models.
Conclusion
The experiments presented demonstrate that it seems to be safe to combine CAR with IR and TMZ for GBM
therapy and most likely also for other cancer therapies. As CAR was shown to protect animals from deleterious side
effects of IR and as up to now no deleterious side effects on nontumor cells have been observed, the dipeptide or
its zinc chelate could become a valuable supplement for the treatment of different malignancies.
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Future perspective
Deleterious side effects of ionizing IR caused by radiotherapy of cancer are a serious problem causing acute
and late morbidities. Up to now, most radioprotectors tested had limited success and also the FDA-approved
and currently used radioprotector amifostine, which has been used with success, has side effects such as allergic
reactions, hypotension, nausea and vomiting. CAR, which is long known to have radioprotective effects, is a
naturally occurring compound without known side effects. As it also has antineoplastic activity, the compound or
drugs derived from it, such as polaprezinc, may become a valuable adjuvant to radiotherapy not only in the case of
glioblastoma.
Executive summary
• Glioblastoma is the most common de novo brain malignancy and accompanied with very poor prognosis for
patients.
• Current standard therapy of glioblastoma consists of tumor removal by surgery, followed by radiotherapy
combined with temozolomide (TMZ) treatment.
• Median survival of patients undergoing standard therapy is poor with a 5-year survival rate of 5.5% after
diagnosis.
• The naturally occurring dipeptide carnosine (CAR) was shown to have antineoplastic effects in vitro and in vivo in
a number of animal and cell culture models, including glioblastoma.
• CAR is known to have radioprotective functions due to its ability to scavenge reactive oxygen and nitrogen
species.
• CAR does not counteract the effects of radiation or TMZ treatment in isocitrate dehydrogenase-wildtype
glioblastoma cell cultures.
• CAR further reduces cell viability when combined with radiation and TMZ treatment.
• CAR or drugs derived from it, such as polaprezinc, may become a valuable adjuvant to radiotherapy not only in
the case of glioblastoma.
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Glioblastoma is the most common primary malignancy of the human brain in adults. Despite 
patients undergo a harsh therapeutic regime consisting of microsurgical resection aiming at 
total gross resection of the tumour, radiotherapy and adjuvant chemotherapy with TMZ, only 
~17% of patients survive two years after diagnosis (Ostrom et al. 2018). Furthermore, side 
effects of the therapy, such as myelosuppression, nausea and alopecia, strongly affect the 
quality of life of patients (Davis 2016). Hence, new therapeutic approaches are urgently 
needed to improve outcome and quality of life of patients. Carnosine is a natural occurring 
dipeptide which was first isolated more than a century ago. Since its discovery several health 
promoting effects have been ascribed to carnosine, such as scavenging of reactive oxygen 
species, chelation of heavy metal ions, Ca2+ regulation and protection against advanced 
glycation end products and lipid peroxidation (see 1.3 Carnosine in health and disease). 
Therefore, the dipeptide or the carnosine containing drug polaprezinc has already been 
clinically evaluated for the mitigation of side effects of radio-/chemotherapy (Suzuki et al. 
2016; Yehia et al. 2019). Moreover, we and others demonstrated that carnosine inhibits 
proliferation and migration of cancer cells originating from different tissues ((Oppermann et 
al. 2018) and see 1.3.2 Carnosine and cancer). Understanding the molecular mechanisms of 
carnosine’s effects on tumour cells could pave the way for the design of new drugs exploiting 
the protective and anti-neoplastic effects of the dipeptide. Up to now, several suggestions 
have been made on how carnosine may inhibit tumour cell growth. Among them are the 
induction of cell cycle arrest at G1 (Huijie Jia et al. 2009) and G2/M (Rybakova et al. 2015), 
suppression of HIF (Iovine et al. 2014) and PI3K/Akt/mTORC1 (Zhang et al. 2014) signalling 
and inhibition of glycolytic (Renner et al. 2010a) and mitochondrial (Bao et al. 2018) ATP 
production. Despite those numerous reports, the mode of action of carnosine’s anti-
neoplastic effect has not been completely resolved. Especially, controversial observations 
made investigating different cancer cell types, for example the expression of HIF in colon 
(Iovine et al. 2014) and cervical (Ditte et al. 2014) cancer cells under the influence of the 
dipeptide, hamper the identification of carnosine’s primary target. In the present work we 
investigated carnosine’s impact on glioblastoma cell signalling and metabolism, in order to 
shed light into its mode of action. We demonstrated that carnosine’s anti-neoplastic effect 
does not correlate with its influence on PI3K/Akt/mTORC1 signalling in glioblastoma 
(Oppermann et al. 2019b). We suggest that its effect on transcription is in part mediated by 
influencing histone acetylation (Oppermann et al. 2019a). To our knowledge, the latter study 
for the first time demonstrated that carnosine induces gene expression by an epigenetic 
mechanism. Therefore, identifying further genes which expression is influenced by the 
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dipeptide, by combining chromatin immunoprecipitation with whole transcriptome 
sequencing, could potentially contribute to the understanding to carnosine’s anti-neoplastic 
and physiological effects. In order to examine the impact of carnosine on cell metabolism, we 
first investigated the metabolic plasticity of glioblastoma cells. With a metabolomics approach 
we showed that glioblastoma cells are using both glycolysis and mitochondrial respiration for 
energy production and are able to switch their metabolic program dependent on the supply of 
nutrients (Oppermann et al. 2016a). We disproved the theory that pyruvate attenuates the 
anti-neoplastic effect of carnosine by anaplerosis of TCA cycle intermediates and 
subsequent ATP generation via OxPhos (Holliday and McFarland 1996; Oppermann et al. 
2016b). More important, we proved the suggestion that carnosine reacts with the glycolytic 
intermediates GA3P and DHAP (Holliday and McFarland 2000). Moreover, this effect was 
accompanied with reduced amounts of PPP intermediates which suggests the inhibition of 
proliferation by retarding nucleotide biosynthesis, rather than only by inhibiting ATP 
production (Oppermann et al. 2019d). As carnosine more effectively reduces the amount of 
GA3P than that of DHAP, we suggest that the non-enzymatic reaction of carnosine with 
GA3P is of higher importance for its anti-neoplastic effect. In further studies the impact of this 
effect on non-neoplastic cells, such as erythrocytes which rely on glycolytic ATP production 
and NADPH generation via PPP, needs to be evaluated.  
Considering carnosine for the clinical application in glioblastoma therapy, we contributed to 
the pharmacological evaluation of the dipeptide. Carnosine is taken up by three different 
transporters of the POT family which mRNA expression is increased in glioblastoma tissue 
compared to normal brain tissue (Oppermann et al. 2019e). Furthermore, we demonstrated 
that cleavage of carnosine to L-histidine and β-alanine is not required to deploy its anti-
neoplastic effect. Consequently, delivery of intact carnosine to the target cells should be 
maximised for an optimal effect. Despite the observation that the dipeptide is effective as a 
drug when administered orally (Baraniuk et al. 2013; Mehrazad-Saber et al. 2018; Yehia et 
al. 2019), carnosine is rapidly degraded by CN1 which considerably reduces its tissue 
availability (Qiu et al. 2019)(Qiu et al. 2019). In order to overcome this obstacle, different 
approaches were suggested, including the co-administration of the CN1 inhibitor carnostatine 
(Qiu et al. 2019)(Qiu et al. 2019), development of CN1-resistant mimics of carnosine 
(Anderson et al. 2018)(Anderson et al. 2018) and intra-nasal administration of the dipeptide 
(Hipkiss et al. 2013)(Hipkiss et al. 2013). Despite these promising approaches for the clinical 
administration of carnosine, the impact and enrichment of carnosine in glioblastoma tissue 
relevant for patients can only be evaluated by a clinical trial. Keeping in mind that carnosine 
protects from IR induced damage (Guney et al. 2006), we tested whether the dipeptide may 
attenuate the effects of radiotherapy which is needed for an improved outcome of 
glioblastoma patients. Instead of attenuation, we could observe that carnosine further 
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decreased glioblastoma cell viability in combination with IR. The same observation was 
made, when carnosine was combined with TMZ or TMZ and IR (Dietterle et al. 2019). Hence, 
as carnosine amplifies the effect of glioblastoma standard therapy, rather than attenuating it, 
we conclude that treatment with the dipeptide will be safe for glioblastoma therapy. 
 
In conclusion, the natural occurring dipeptide carnosine inhibits proliferation and invasion of 
glioblastoma cells. We demonstrated for the first time that carnosine influences transcription 
via an epigenetic mechanism. Furthermore, we identified GA3P as a molecular target 
reacting non-enzymatically with the dipeptide resulting in decreased amounts of PPP 
intermediates. Important for the clinical application, we proved that in glioblastoma cells the 
dipeptide can be taken up by three different transporters and that the delivery of carnosine to 
the target cells does not require its degradation. Finally, the administration of carnosine does 
not negatively affect standard therapy in culture but even amplifies the effects of TMZ and IR. 
Therefore, we encourage the clinical evaluation of carnosine for the treatment of 
glioblastoma patients. 
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5 Appendix 
 
5.1 Eidesstattliche Erklärungen zur vorgelegten Habilitationsschrift 
 
 
Hiermit erkläre ich an Eides statt, 
 
1. dass die vorliegende Habilitationsordnung der Medizinischen Fakultät der Universität 
Leipzig anerkannt wird; 
 
2. dass die Habilitationsschrift in dieser oder ähnlicher Form an keiner anderen Stelle 
zum Zweck eines Graduierungsverfahrens vorgelegt wurde (ggf. eine Erklärung über 
frühere Habilitationsversuche unter Angabe von Ort, Zeit, Fakultät sowie Titel der 
Schrift); 
 
3. dass die Habilitationsschrift selbstständig verfasst und keine anderen als die 
angegebenen Quellen und Hilfsmittel benutzt wurden; 
 
4. dass die Einhaltung der „Satzung der Universität Leipzig zur Sicherung guter 
wissenschaftlicher Praxis“ in der Erstfassung vom 17. April 2015 Grundlage der 
Forschungstätigkeit war. 
 
 
 
 
 
 
 
 
 
 
 
 
.................................      ................................. 
Datum        Unterschrift 
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